US20200040083A1 - IL15/IL15Ralpha HETERODIMERIC Fc-FUSION PROTEINS - Google Patents

IL15/IL15Ralpha HETERODIMERIC Fc-FUSION PROTEINS Download PDF

Info

Publication number
US20200040083A1
US20200040083A1 US16/660,028 US201916660028A US2020040083A1 US 20200040083 A1 US20200040083 A1 US 20200040083A1 US 201916660028 A US201916660028 A US 201916660028A US 2020040083 A1 US2020040083 A1 US 2020040083A1
Authority
US
United States
Prior art keywords
seq
protein
polypeptide sequence
domain
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/660,028
Inventor
Matthew Bernett
Rumana Rashid
John Desjarlais
Rajat Varma
Christine Bonzon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xencor Inc
Original Assignee
Xencor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xencor Inc filed Critical Xencor Inc
Priority to US16/660,028 priority Critical patent/US20200040083A1/en
Publication of US20200040083A1 publication Critical patent/US20200040083A1/en
Assigned to XENCOR, INC. reassignment XENCOR, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BERNETT, MATTHEW, DESJARLAIS, JOHN, VARMA, Rajat, BONZON, CHRISTINE, RASHID, Rumana
Priority to US17/692,755 priority patent/US20220195048A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Definitions

  • IL-2 and IL-15 function in aiding the proliferation and differentiation of B cells, T cells, and NK cells.
  • IL-2 is also essential for regulatory T cell (Treg) function and survival.
  • Both cytokines exert their cell signaling function through binding to a trimeric complex consisting of two shared receptors, the common gamma chain ( ⁇ c; CD132) and IL-2 receptor B-chain (IL-2R ⁇ ; CD122), as well as an alpha chain receptor unique to each cytokine: IL-2 receptor alpha (IL-2R ⁇ ; CD25) or IL-15 receptor alpha (IL-15R ⁇ ; CD215).
  • cytokines are considered as potentially valuable therapeutics in oncology and IL-2 has been approved for use in patients with metastatic renal-cell carcinoma and malignant melanoma.
  • IL-2 has been approved for use in patients with metastatic renal-cell carcinoma and malignant melanoma.
  • IL-15 Currently there are no approved uses of recombinant IL-15, although several clinical trials are ongoing.
  • IL-2 presents several challenges as a therapeutic agent. First, it preferentially activates T cells that express the high affinity receptor complex, which depends on CD25 expression. Because Treg cells constitutively express CD25, they compete for IL-2 supplies with effector T cells, whose activation is preferred for oncology treatment. This imbalance has led to the concept of high dose IL-2. However, this approach creates additional problems because of IL-2-mediated toxicities such as vascular leak syndrome.
  • IL-2 is secreted primarily by activated T cells, while its receptors are located on activated T cells, Tregs, NK cells, and B cells.
  • IL-15 is produced on monocytes and dendritic cells and is primarily presented as a membrane-bound heterodimeric complex with IL-15R ⁇ present on the same cells. Its effects are realized through trans-presentation of the IL-15/IL-15R ⁇ complex to NK cells and CD8+ T cells expressing IL-2R ⁇ and the common gamma chain.
  • IL-15 As potential drugs, both cytokines suffer from a very fast clearance, with half-lives measured in minutes.
  • IL-15 by itself is less stable due to its preference for the IL-15R ⁇ -associated complex. It has also been shown that recombinantly produced IL15/IL15R ⁇ heterodimer can potently activate T cells. Nevertheless, a short half-life hinders favorable dosing.
  • the present invention solves this problem by providing novel IL15/IL15R ⁇ heterodimer Fc fusion proteins.
  • the present invention provides a heterodimeric protein comprising a) a first fusion protein comprising a first protein domain and a first Fc domain, wherein the first protein domain is covalently attached to the N-terminus of the first Fc domain using a first domain linker; b) a second fusion protein comprising a second protein domain and a second Fc domain, wherein the second protein domain is covalently attached to the N-terminus of the Fc domain using a seconddomain linker; wherein the first and the second Fc domains have a set of amino acid substitutions selected from the group consisting of S267K/L368D/K370S: S267K/LS364K/E357Q; S364K/E357Q: L368D/K370S; L368D/K370S: S364K; L368E/K370S: S364K; T411T/E360E/Q362E: D401K; L368D/K
  • the first protein domain is covalently attached to the N-terminus of the first Fc domain directly and without using the first domain linker and/or the second protein domain is covalently attached to the N-terminus of the second Fc domain directly and without using the second domain linker.
  • the heterodimeric protein comprises: (i) the first fusion protein having a polypeptide sequence of SEQ ID NOS 52, 412, 418, 430 and 436 (15902) and the second fusion protein having a polypeptide sequence of SEQ ID NOS 55, 76, 231, 237, 243, 249, 415, 427, 644, 732, 738, 744, 750, 756, 762, 768, 774, 780, 786, 792, 798, 804, 810, 816, 822, 828, 834, 840, 846, 884, 890, 896 and 902 (15908), (ii) the first fusion protein having a polypeptide sequence of SEQ ID NOS 52, 412, 418, 430 and 436 (15902) and the second fusion protein having a polypeptide sequence of SEQ ID NOS 421, 445 and 463 (15909), (iii) the first fusion protein having a polypeptide sequence of SEQ ID NOS 52,
  • the heterodimeric protein is selected from the group consisting of XENP20818, XENP20819, XENP21471, XENP21472, XENP21473, XENP21474, XENP21475, XENP21476, XENP21477, XENP22013, XENP22815, XENP22816, XENP22817, XENP22818, XENP22819, XENP22820, XENP22821, XENP22822, XENP22823, XENP22824, XENP22825, XENP22826, XENP22827, XENP22828, XENP22829, XENP22830, XENP22831, XENP22832, XENP22833, XENP22834, XENP23343, XENP23554,
  • the invention provides a heterodimeric protein comprising: a) a fusion protein comprising a first protein domain, a second protein domain, and a first Fc domain, wherein the first protein domain is covalently attached to the N-terminus of the second protein domain using a first domain linker, and wherein the second protein domain is covalently attached to the N-terminus of the first Fc domain using a second domain linker; b) a second Fc domain; wherein the first and the second Fc domains have a set of amino acid substitutions selected from the group consisting of S267K/L368D/K370S: S267K/LS364K/E357Q; S364K/E357Q: L368D/K370S; L368D/K370S: S364K; L368E/K370S: S364K; T411T/E360E/Q362E: D401K; L368D/K370S: S364K
  • the first fusion protein has a polypeptide sequence of SEQ ID NOS 64 and 466 (16478) and the Fc domain has a polypeptide sequence of SEQ ID NOS 68 and 470 (8924).
  • the heterodimeric protein can be XENP21478.
  • the invention provides a heterodimeric protein comprising: a) a fusion protein comprising a first protein domain and a first Fc domain, wherein the first protein domain is covalently attached to the N-terminus of the first Fc domain using a domain linker; b) a second Fc domain; and c) a second protein domain noncovalently attached to the first protein domain; wherein the first and the second Fc domains have a set of amino acid substitutions selected from the group consisting of S267K/L368D/K370S: S267K/LS364K/E357Q; S364K/E357Q: L368D/K370S; L368D/K370S: S364K; L368E/K370S: S364K; T411T/E360E/Q362E: D401K; L368D/K370S: S364K/E357L and K370S: S364K/E357Q, according
  • the heterodimer protein comprises: (i) the fusion protein having a polypeptide sequence of SEQ ID NOS 61, 71, 267, 433, 451, 473, 952 and 958 (16481), the second Fc domain having a polypeptide sequence of SEQ ID NOS 70, 75, 161, 166, 171, 472, 583, 588, 593, 598, 603, 608, 613, 618, 623, 628, 633, 638 and 643 (8793), and a second protein domain having a polypeptide sequence of SEQ ID NOS 69, 74, 87, 96, 121, 471, 479, 529, 531, 533, 535, 582, 587, 592, 642 and 667 (16484); (ii) the fusion protein having a polypeptide sequence of SEQ ID NO: 584 (17034), the second Fc domain having a polypeptide sequence of SEQ ID NOS 70, 75, 161, 166, 171, 47
  • the heterodimer protein can be selected from the group consisting of XENP21479, XENP22357, XENP22354, XENP22355, XENP22356, XENP22357, XENP22358, XENP22359, XENP22360, XENP22361, XENP22362, XENP22363, XENP22364, XENP22365, XENP22366, and XENP22637.
  • the invention provides a heterodimeric protein comprising: a) a first fusion protein comprising a first protein domain and a first Fc domain, wherein the first protein domain is covalently attached to the N-terminus of said first Fc domain using a domain linker; b) a second fusion protein comprising a second heavy chain comprising a second protein domain and a first second heavy chain comprising a second Fc domain, wherein the second protein domain is covalently attached to the C-terminus of the second Fc domain using a domain linker; c) a third protein domain noncovalently attached to the first protein domain of the first fusion protein; and d) a fourth protein domain noncovalently attached to the second protein domain of the second fusion protein, wherein the first and the second Fc domains have a set of amino acid substitutions selected from the group consisting of S267K/L368D/K370S: S267K/LS364K/E357Q; S364K/E3
  • the heterodimer protein comprises (i) the first fusion protein has a polypeptide sequence of SEQ ID NOS 84, 476 and 480 (17023) the second fusion protein has a polypeptide sequence of SEQ ID NOS 84, 476 and 480 (17023), the third protein domain has a polypeptide sequence of SEQ ID NOS 69, 74, 87, 96, 121, 471, 479, 529, 531, 533, 535, 582, 587, 592, 642 and 667 (16484), and the fourth protein domain has a polypeptide sequence of SEQ ID NOS 69, 74, 87, 96, 121, 471, 479, 529, 531, 533, 535, 582, 587, 592, 642 and 667 (16484) or (ii) the first fusion protein has a polypeptide sequence of SEQ ID NOS 179 and 651 (17581), the second fusion protein has a polypeptide sequence of SEQ
  • the invention provides a heterodimeric protein comprising: a) a first fusion protein comprising a first Fc domain and a first protein domain, wherein the first Fc domain is covalently attached to the N-terminus of the first protein domain using a domain linker; b) a second Fc domain, and c) a second protein domain noncovalently attached to the first protein domain of the first fusion protein; wherein the first and the second Fc domains have a set of amino acid substitutions selected from the group consisting of S267K/L368D/K370S: S267K/LS364K/E357Q; S364K/E357Q: L368D/K370S; L368D/K370S: S364K; L368E/K370S: S364K; T411T/E360E/Q362E: D401K; L368D/K370S: S364K/E357L and K370S: S364K; T4
  • the heterodimer protein comprises (i) the first fusion protein having a polypeptide sequence of SEQ ID NOS 92 and 663 (17603), the second Fc domain having a polypeptide sequence of SEQ ID NOS 95, 101, 194, 666, 676 and 1113 (8927), and the second protein domain having a polypeptide sequence of SEQ ID NOS 69, 74, 87, 96, 121, 471, 479, 529, 531, 533, 535, 582, 587, 592, 642 and 667 (16484); or ii) the first fusion protein having a polypeptide sequence of SEQ ID NOS 191 and 673 (17605), the second Fc domain having a polypeptide sequence of SEQ ID NOS 95, 101, 194, 666, 676 and 1113 (8927), and the second protein domain having a polypeptide sequence of SEQ ID NOS 123, 125, 127, 160, 165, 182, 186, 195, 5
  • the first and/or the second Fc domains can have an additional set of amino acid substitutions comprising Q295E/N384D/Q418E/N421D, according to EU numbering.
  • the first and/or the second Fc domains have an additional set of amino acid substitutions consisting of G236R/L328R, E233P/L234V/L235A/G236del/S239K, E233P/L234V/L235A/G236del/S267K, E233P/L234V/L235A/G236del/S239K/A327G, E233P/L234V/L235A/G236del/S267K/A327G and E233P/L234V/L235A/G236del, according to EU numbering.
  • the IL15 protein has a polypeptide sequence selected from the group consisting of SEQ ID NO:1 (full-length human IL15) and SEQ ID NO:2 (truncated human IL15), and the IL15R ⁇ protein has a polypeptide sequence selected from the group consisting of SEQ ID NO:3 (full-length human IL15R ⁇ ) and SEQ ID NO:4 (sushi domain of human IL15R ⁇ ).
  • the IL15 protein and the IL15R ⁇ protein have a set of amino acid substitutions or additions selected from the group consisting of E87C: D96/P97/C98; E87C: D96/C97/A98; V49C: S40C; L52C: S40C; E89C: K34C; Q48C: G38C; E53C: L42C; C42S: A37C; and L45C: A37C, respectively.
  • the present invention provides a heterodimeric protein selected from the group consisting of XENP20818, XENP20819, XENP21471, XENP21472, XENP21473, XENP21474, XENP21475, XENP21476, XENP21477, XENP21478, XENP21479, XENP21978, XENP22013, XENP22015, XENP22017, XENP22354, XENP22355, XENP22356, XENP22357, XENP22358, XENP22359, XENP22360, XENP22361, XENP22362, XENP22363, XENP22364, XENP22365, XENP22366, XENP22637, and XENP22639.
  • the present invention provides a heterodimeric protein selected from the group consisting of XENP20818, XENP20819, XENP21471, XENP21472, XENP21473, XENP21474, XENP21475, XENP21476, XENP21477, XENP22013, XENP22815, XENP22816, XENP22817, XENP22818, XENP22819, XENP22820, XENP22821, XENP22822, XENP22823, XENP22824, XENP22825, XENP22826, XENP22827, XENP22828, XENP22829, XENP22830, XENP22831, XENP22832, XENP22833, XENP22834, XENP23343, XEN
  • FIG. 1 depicts the structure of IL-15 in complex with its receptors IL-15R ⁇ (CD215), IL-15R ⁇ (CD122), and the common gamma chain (CD132).
  • FIGS. 2A-2B depict the sequences for IL-15 and its receptors.
  • FIG. 2A shows the sequences for human IL-15, human IL-15R ⁇ and human IL-15R ⁇ .
  • FIG. 2A shows the sequences for the human common gamma receptor.
  • FIGS. 3A-3E depict useful pairs of Fc heterodimerization variant sets (including skew and pI variants). On FIGS. 3D and 3E , there are variants for which there are no corresponding “monomer 2” variants; these are pI variants which can be used alone on either monomer.
  • FIG. 4 depict a list of isosteric variant antibody constant regions and their respective substitutions.
  • pI_( ⁇ ) indicates lower pI variants, while pI_(+) indicates higher pI variants.
  • pI_( ⁇ ) indicates lower pI variants, while pI_(+) indicates higher pI variants.
  • FIG. 5 depict useful ablation variants that ablate Fc ⁇ R binding (sometimes referred to as “knock outs” or “KO” variants). Generally, ablation variants are found on both monomers, although in some cases they may be on only one monomer.
  • FIGS. 6A-6E show a particularly useful embodiments of “non-cytokine” components of the invention.
  • FIG. 7 depicts a number of exemplary variable length linkers.
  • these linkers find use linking the C-terminus of IL-15 and/or IL-15R ⁇ (sushi) to the N-terminus of the Fc region.
  • these linkers find use fusing IL-15 to the IL-15R ⁇ (sushi).
  • FIGS. 8A-8E show the sequences of several useful IL-15/R ⁇ -Fc format backbones based on human IgG1, without the cytokine sequences (e.g., the Il-15 and/or IL-15R ⁇ (sushi)).
  • Backbone 1 is based on human IgG1 (356E/358M allotype), and includes C220S on both chain, the S364K/E357Q: L368D/K370S skew variants, the Q295E/N384D/Q418E/N421D pI variants on the chain with L368D/K370S skew variants and the E233P/L234V/L235A/G236del/S267K ablation variants on both chains.
  • Backbone 2 is based on human IgG1 (356E/358M allotype), and includes C220S on both chain, the S364K: L368D/K370S skew variants, the Q295E/N384D/Q418E/N421D pI variants on the chain with L368D/K370S skew variants and the E233P/L234V/L235A/G236del/S267K ablation variants on both chains.
  • Backbone 3 is based on human IgG1 (356E/358M allotype), and includes C220S on both chain, the S364K: L368E/K370S skew variants, the Q295E/N384D/Q418E/N421D pI variants on the chain with L368E/K370S skew variants and the E233P/L234V/L235A/G236del/S267K ablation variants on both chains.
  • Backbone 4 is based on human IgG1 (356E/358M allotype), and includes C220S on both chain, the D401K: K360E/Q362E/T411E skew variants, the Q295E/N384D/Q418E/N421D pI variants on the chain with K360E/Q362E/T411E skew variants and the E233P/L234V/L235A/G236del/S267K ablation variants on both chains.
  • Backbone 5 is based on human IgG1 (356D/358L allotype), and includes C220S on both chain, the S364K/E357Q: L368D/K370S skew variants, the Q295E/N384D/Q418E/N421D pI variants on the chain with L368D/K370S skew variants and the E233P/L234V/L235A/G236del/S267K ablation variants on both chains.
  • Backbone 6 is based on human IgG1 (356E/358M allotype), and includes C220S on both chain, the S364K/E357Q: L368D/K370S skew variants, Q295E/N384D/Q418E/N421D pI variants on the chain with L368D/K370S skew variants and the E233P/L234V/L235A/G236del/S267K ablation variants on both chains, as well as an N297A variant on both chains.
  • Backbone 7 is identical to 6 except the mutation is N297S.
  • Backbone 8 is based on human IgG4, and includes the S364K/E357Q: L368D/K370S skew variants, the Q295E/N384D/Q418E/N421D pI variants on the chain with L368D/K370S skew variants, as well as a S228P (EU numbering, this is S241P in Kabat) variant on both chains that ablates Fab arm exchange as is known in the art.
  • Backbone 9 is based on human IgG2, and includes the S364K/E357Q: L368D/K370S skew variants, the Q295E/N384D/Q418E/N421D pI variants on the chain with L368D/K370S skew variants.
  • Backbone 10 is based on human IgG2, and includes the S364K/E357Q: L368D/K370S skew variants, the Q295E/N384D/Q418E/N421D pI variants on the chain with L368D/K370S skew variants as well as a S267K variant on both chains.
  • Backbone 11 is identical to backbone 1, except it includes M428L/N434S Xtend mutations.
  • Backbone 12 is based on human IgG1 (356E/358M allotype), and includes C220S on both identical chain, the the E233P/L234V/L235A/G236del/S267K ablation variants on both identical chains.
  • Backbone 13 is based on human IgG1 (356E/358M allotype), and includes C220S on both chain, the S364K/E357Q: L368D/K370S skew variants, the P217R/P229R/N276K pI variants on the chain with S364K/E357Q skew variants and the E233P/L234V/L235A/G236del/S267K ablation variants on both chains.
  • any IL-15 and IL-15R ⁇ (sushi) pairs outlined herein including but not limited to IL-15/R ⁇ -heteroFc, ncIL-15/R ⁇ , scIL-15/R ⁇ , and dsIL-15/R ⁇ as schematically depicted in FIGS. 9A-9G , and FIGS. 39A-39D .
  • any IL-15 and/or IL-15R ⁇ (sushi) variants can be incorporated into these FIGS. 8A-8E backbones in any combination.
  • each of these backbones includes sequences that are 90%, 95%, 98% and 99% identical (as defined herein) to the recited sequences, and/or contain from 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional amino acid substitutions (as compared to the “parent” of the Figure, which, as will be appreciated by those in the art, already contain a number of amino acid modifications as compared to the parental human IgG1 (or IgG2 or IgG4, depending on the backbone). That is, the recited backbones may contain additional amino acid modifications (generally amino acid substitutions) in addition to the skew, pI and ablation variants contained within the backbones of this figure ( FIG. 8 ).
  • FIGS. 9A-9G depict several formats for the IL-15/R ⁇ -Fc fusion proteins of the present invention.
  • IL-15R ⁇ Heterodimeric Fc fusion or “IL-15/R ⁇ -heteroFc” ( FIG. 9A ) comprises IL-15 recombinantly fused to one side of a heterodimeric Fc and IL-15R ⁇ (sushi) recombinantly fused to the other side of a heterodimeric Fc.
  • the IL-15 and IL-15R ⁇ (sushi) may have a variable length Gly-Ser linker between the C-terminus and the N-terminus of the Fc region.
  • Single-chain IL-15/R ⁇ -Fc fusion or “scIL-15/R ⁇ -Fc” comprises IL-15R ⁇ (sushi) fused to IL-15 by a variable length linker (termed a “single-chain” IL-15/IL-15R ⁇ (sushi) complex or “scIL-15/R ⁇ ”) which is then fused to the N-terminus of a heterodimeric Fc-region, with the other side of the molecule being “Fc-only” or “empty Fc”.
  • Non-covalent IL-15/R ⁇ -Fc or “ncIL-15/R ⁇ -Fc” FIG.
  • FIG. 9C comprises IL-15R ⁇ (sushi) fused to a heterodimeric Fc region, while IL-15 is transfected separatedly so that a non-covalent IL-15/R ⁇ complex is formed, with the other side of the molecule being “Fc-only” or “empty Fc”.
  • Bivalent non-covalent IL-15/R ⁇ -Fc fusion or “bivalent ncIL-15/R ⁇ -Fc” ( FIG. 9D ) comprises IL-15R ⁇ (sushi) fused to the N-terminus of a homodimeric Fc region, while IL-15 is transfected separately so that a non-covalent IL-15/R ⁇ complex is formed.
  • Bivalent single-chain IL-15/R ⁇ -Fc fusion or “bivalent scIL-15/R ⁇ -Fc” comprises IL-15 fused to IL-15R ⁇ (sushi) by a variable length linker (termed a “single-chain” IL-15/IL-15R ⁇ (sushi) complex or “scIL-15/R ⁇ ”) which is then fused to the N-terminus of a homodimeric Fc-region.
  • Fc-non-covalent IL-15/R ⁇ fusion or “Fc-ncIL-15/R ⁇ ” FIG.
  • 9F comprises IL-15R ⁇ (sushi) fused to the C-terminus of a heterodimeric Fc region, while IL-15 is transfected separately so that a non-covalent IL-15/R ⁇ complex is formed, with the other side of the molecule being “Fc-only” or “empty Fc”.
  • Fc-single-chain IL-15/R ⁇ fusion or “Fc-scIL-15/R ⁇ ” FIG.
  • 9G comprises IL-15 fused to IL-15R ⁇ (sushi) by a variable length linker (termed a “single-chain” IL-15/IL-15R ⁇ (sushi) complex or “scIL-15/R ⁇ ”) which is then fused to the C-terminus of a heterodimeric Fc region, with the other side of the molecule being “Fc-only” or “empty Fc”.
  • a variable length linker termed a “single-chain” IL-15/IL-15R ⁇ (sushi) complex or “scIL-15/R ⁇ ”
  • FIG. 10 depicts sequences of XENP20818 and XENP21475, illustrative IL-15/R ⁇ -Fc fusion proteins of the “IL-15/R ⁇ -heteroFc” format, with additional sequences being listed as XENPs 20819, 21471, 21472, 21473, 21474, 21476, and 21477 in the sequence listing.
  • IL-15 and IL-15R ⁇ (sushi) are underlined, linkers are double underlined (although as will be appreciated by those in the art, the linkers can be replaced by other linkers, some of which are depicted in FIG. 7 ), and slashes (/) indicate the border(s) between IL-15, IL-15R ⁇ , linkers, and Fc regions.
  • FIG. 11 depicts sequences of XENP21478, an illustrative IL-15/R ⁇ -Fc fusion protein of the “scIL-15/R ⁇ -Fc” format, with additional sequences being listed as XENPs 21993, 21994, 21995, 23174, 23175, 24477, and 24480 in the sequence listing.
  • IL-15 and IL-15R ⁇ (sushi) are underlined, linkers are double underlined (although as will be appreciated by those in the art, the linkers can be replaced by other linkers, some of which are depicted in FIG. 7 ), and slashes (/) indicate the border(s) between IL-15, IL-15R ⁇ , linkers, and Fc regions.
  • FIGS. 12A-12B depict sequences of XENP21479, XENP22366 and XENP24348, illustrative IL-15/R ⁇ -Fc fusion proteins of the “ncIL-15/R ⁇ -Fc” format.
  • IL-15 and IL-15R ⁇ (sushi) are underlined, linkers are double underlined (although as will be appreciated by those in the art, the linkers can be replaced by other linkers, some of which are depicted in FIG. 7 ), and slashes (/) indicate the border(s) between IL-15, IL-15R ⁇ , linkers, and Fc regions.
  • FIG. 13 depicts sequences of XENP21978, an illustrative IL-15/R ⁇ -Fc fusion protein of the “bivalent ncIL-15/R ⁇ -Fc” format, with additional sequences being listed as XENP21979 in the sequence listing.
  • IL-15 and IL-15R ⁇ (sushi) are underlined, linkers are double underlined (although as will be appreciated by those in the art, the linkers can be replaced by other linkers, some of which are depicted in FIG. 7 ), and slashes (/) indicate the border(s) between IL-15, IL-15R ⁇ , linkers, and Fc regions.
  • FIG. 14 depicts sequences of an illustrative IL-15/R ⁇ -Fc fusion protein of the “bivalent scIL-15/R ⁇ -Fc” format.
  • IL-15 and IL-15R ⁇ (sushi) are underlined
  • linkers are double underlined (although as will be appreciated by those in the art, the linkers can be replaced by other linkers, some of which are depicted in FIG. 7 )
  • slashes (/) indicate the border(s) between IL-15, IL-15R ⁇ , linkers, and Fc regions.
  • FIG. 15 depicts sequences of XENP22637, an illustrative IL-15/R ⁇ -Fc fusion protein of the “Fc-ncIL-15/R ⁇ ” format, with additional sequences being listed as XENP22638 in the sequence listing.
  • IL-15 and IL-15R ⁇ (sushi) are underlined, linkers are double underlined (although as will be appreciated by those in the art, the linkers can be replaced by other linkers, some of which are depicted in FIG. 7 ), and slashes (/) indicate the border(s) between IL-15, IL-15R ⁇ , linkers, and Fc regions.
  • FIG. 16 depicts sequences of an illustrative IL-15/R ⁇ -Fc fusion protein of the “Fc-scIL-15/R ⁇ ” format.
  • IL-15 and IL-15R ⁇ (sushi) are underlined
  • linkers are double underlined (although as will be appreciated by those in the art, the linkers can be replaced by other linkers, some of which are depicted in FIG. 7 )
  • slashes (/) indicate the border(s) between IL-15, IL-15R ⁇ , linkers, and Fc regions.
  • FIGS. 17A-17E depict A) the IL-15/R ⁇ -Fc fusion protein format for XENP20818, the purity and homogeneity of XENP20818 as determined by B) SEC and C) CEF, D) the affinity of XENP20818 for IL-2R ⁇ as determined by Octet, and E) the stability of XENP20818 as determined by DSF
  • FIGS. 18A-18E depict A) the IL-15/R ⁇ -Fc fusion protein format for XENP21478, the purity and homogeneity of XENP21478 as determined by B) SEC and C) CEF, D) the affinity of XENP21478 for IL-2R ⁇ as determined by Octet, and E) the stability of XENP21478 as determined by DSF.
  • FIGS. 19A-19E depicts A) the IL-15/R ⁇ -Fc fusion protein format for XENP21479, the purity and homogeneity of XENP21479 as determined by B) SEC and C) CEF, D) the affinity of XENP21479 for IL-2R ⁇ as determined by Octet, and E) the stability of XENP21479 as determined by DSF.
  • FIGS. 20A-20C depict the induction of A) NK (CD56+/CD16+) cells, B) CD4+ T cells, and C) CD8+ T cells proliferation by illustrative IL-15/R ⁇ -Fc fusion proteins of the IL-15/R ⁇ -heteroFc format with different linker lengths based on Ki67 expression as measured by FACS.
  • FIGS. 21A-21C depict the induction of A) NK (CD56+/CD16+) cells, B) CD4+ T cells, and C) CD8+ T cells proliferation by illustrative IL-15/R ⁇ -Fc fusion proteins of the scIL-15/R ⁇ -Fc format (XENP21478) and the ncIL-15/R ⁇ -Fc format (XENP21479) based on Ki67 expression as measured by FACS.
  • FIG. 22 depicts enhancement of IL-2 secretion by illustrative IL-15/R ⁇ -Fc fusion proteins, an isotype control, and a bivalent anti-PD-1 antibody over PBS control in an SEB-stimulated PBMC assay.
  • FIG. 23 depicts the survival curve for PBMC-engrafted NSG mice following treatment with XENP20818 and recombinant IL-15.
  • FIG. 24 depicts the concentration of IFN ⁇ in serum of NSG mice on Day 7 after engraftment with human PBMCs and treatment with XENP20818 at the indicated concentrations.
  • FIGS. 25A-25C depict A) CD4+ T cell, B) CD8+ T cell, and C) CD45+ cell counts in whole blood of human PBMC-engrafted NSG mice 7 days after treatment with XENP20818 at the indicated concentrations.
  • FIG. 26 depicts a structural model of the IL-15/R ⁇ heterodimer showing locations of engineered disulfide bond pairs.
  • FIG. 27 depicts sequences for illustrative IL-15R ⁇ (sushi) variants engineered with additional residues at the C-terminus to serve as a scaffold for engineering cysteine residues.
  • FIG. 28 depicts sequences for illustrative IL-15 variants engineered with cysteines in order to form covalent disulfide bonds with IL-15R ⁇ (sushi) variants engineered with cysteines.
  • FIG. 29 depicts sequences for illustrative IL-15R ⁇ (sushi) variants engineered with cysteines in order to form covalent disulfide bonds with IL-15 variants engineered with cysteines.
  • FIGS. 30A-30C depict IL-15/R ⁇ heterodimers with and without engineered disulfide bonds between IL-15 and IL-15R ⁇ (sushi).
  • Non-covalent IL-15/R ⁇ heterodimer or “ncIL-15/R ⁇ heterodimer” comprises IL-15R ⁇ (sushi) and IL-15 transfected separately and non-covalently linked.
  • Disulfide-bonded IL-15/R ⁇ heterodimer or “dsIL-15/R ⁇ heterodimer” comprises IL-15R ⁇ (sushi) and IL-15 transfected separately and covalently linked as a result of engineered cysteines.
  • Single-chain IL-15/R ⁇ heterodimer or “scIL-15/R ⁇ Heterodimer” comprises IL-15R ⁇ (sushi) fused to IL-15 by a variable length Gly-Ser linker.
  • FIG. 31 depicts sequences of XENP21996, an illustrative ncIL-15/R ⁇ heterodimer. It is important to note that these sequences were generated using polyhistidine (Hisx6 or HHHHHH (SEQ ID NO: 1198)) C-terminal tags at the C-terminus of IL-15R ⁇ (sushi).
  • polyhistidine Hisx6 or HHHHHH (SEQ ID NO: 1198)
  • FIG. 32 depicts sequences of XENP22004, XENP22005, XENP22006, XENP22008, and XENP22494, illustrative dsIL-15/R ⁇ heterodimers, with additional sequences depicted as XENPs 22007, 22009, 22010, 22011, 22012, and 22493 in the sequence listing. It is important to note that these sequences were generated using polyhistidine (Hisx6 or HHHHHH (SEQ ID NO: 1198)) C-terminal tags at the C-terminus of IL-15R ⁇ (sushi).
  • polyhistidine Hisx6 or HHHHHH (SEQ ID NO: 1198)
  • FIG. 33 depicts the sequence for XENP22049, an illustrative scIL-15/R ⁇ Heterodimer. It is important to note that these sequences were generated using polyhistidine (Hisx6 or HHHHHH (SEQ ID NO: 1198)) C-terminal tags at the C-terminus of IL-15.
  • IL-15 and IL-15R ⁇ (sushi) are underlined, linkers are double underlined (although as will be appreciated by those in the art, the linkers can be replaced by other linkers, some of which are depicted in FIG. 7 ), and slashes (/) indicate the border(s) between IL-15, IL-15R ⁇ , and linker
  • FIG. 34 depicts the purity and homogeneity of illustrative IL-15/R ⁇ heterodimers with and without engineered disulfide bonds as determined by CEF.
  • FIG. 35 depicts the purity and homogeneity of illustrative IL-15/R ⁇ heterodimers with and without engineered disulfide bonds as determined by CEF.
  • FIG. 36 depicts the stability and melting temperatures of illustrative IL-15/R ⁇ heterodimers with and without engineered disulfide bonds as indicated by melting curves from DSF.
  • FIG. 37 depicts the stability and melting temperatures of illustrative IL-15/R ⁇ heterodimers with and without engineered disulfide bonds as indicated by melting curves from DSF.
  • FIG. 38 depicts the expression yield, molecular weight, predicted change in affinity between IL-15 and IL-15R ⁇ (sushi) as calculated by MOE software, melting temperature, and affinity for IL-2RB for IL-15/R ⁇ heterodimers with and without engineered disulfide bonds. Mutations are indicated in parentheses after the relevant monomer.
  • FIGS. 39A-39D depict additional formats for the IL-15/R ⁇ -Fc fusion proteins of the present invention with engineered disulfide bonds.
  • Disulfide-bonded IL-15/R ⁇ heterodimeric Fc fusion or “dsIL-15/R ⁇ -heteroFc” ( FIG. 39A ) is the same as “IL-15/R ⁇ -heteroFc”, but wherein IL-15R ⁇ (sushi) and IL-15 are further covalently linked as a result of engineered cysteines.
  • Disulfide-bonded IL-15/R ⁇ Fc fusion or “dsIL-15/R ⁇ -Fc” FIG.
  • FIG. 39B is the same as “ncIL-15/R ⁇ -Fc”, but wherein IL-15R ⁇ (sushi) and IL-15 are further covalently linked as a result of engineered cysteines.
  • Bivalent disulfide-bonded IL-15/R ⁇ -Fc or “bivalent dsIL-15/R ⁇ -Fc” is the same as “bivalent ncIL-15/R ⁇ -Fc”, but wherein IL-15R ⁇ (sushi) and IL-15 are further covalently linked as a result of engineered cysteines.
  • Fc-disulfide-bonded IL-15/R ⁇ fusion or “Fc-dsIL-15/R ⁇ ” is the same as “Fc-ncIL-15/R ⁇ ”, but wherein IL-15R ⁇ (sushi) and IL-15 are further covalently linked as a result of engineered cysteines.
  • FIGS. 40A-40B depicts sequences of XENP22013, XENP22014, XENP22015, and XENP22017, illustrative IL-15/R ⁇ -Fc fusion protein of the “dsIL-15/R ⁇ -heteroFc” format.
  • IL-15 and IL-15R ⁇ (sushi) are underlined
  • linkers are double underlined (although as will be appreciated by those in the art, the linkers can be replaced by other linkers, some of which are depicted in FIG. 7 )
  • slashes (/) indicate the border(s) between IL-15, IL-15R ⁇ , linkers, and Fc regions.
  • FIGS. 41A-41B depict sequences of XENP22357, XENP22358, XENP22359, XENP22684, and XENP22361, illustrative IL-15/R ⁇ -Fc fusion proteins of the “dsIL-15/R ⁇ -Fc” format. Additional sequences are depicted as XENPs 22360, 22362, 22363, 22364, 22365, and 22366 in the sequence listing. IL-15 and IL-15R ⁇ (sushi) are underlined, linkers are double underlined (although as will be appreciated by those in the art, the linkers can be replaced by other linkers, some of which are depicted in FIG. 7 ), and slashes (/) indicate the border(s) between IL-15, IL-15R ⁇ , linkers, and Fc regions.
  • FIG. 42 depicts sequences of XENP22634, XENP22635, and XENP22636, illustrative IL-15/R ⁇ -Fc fusion proteins of the “bivalent dsIL-15/R ⁇ -Fc” format. Additional sequences are depicted as XENP22687 in the sequence listing. IL-15 and IL-15R ⁇ (sushi) are underlined, linkers are double underlined (although as will be appreciated by those in the art, the linkers can be replaced by other linkers, some of which are depicted in FIG. 7 ), and slashes (/) indicate the border(s) between IL-15, IL-15R ⁇ , linkers, and Fc regions.
  • FIG. 43 depicts sequences of XENP22639 and XENP22640, illustrative IL-15/R ⁇ -Fc fusion proteins of the “Fc-dsIL-15/R ⁇ ” format.
  • IL-15 and IL-15R ⁇ (sushi) are underlined, linkers are double underlined (although as will be appreciated by those in the art, the linkers can be replaced by other linkers, some of which are depicted in FIG. 7 ), and slashes (/) indicate the border(s) between IL-15, IL-15R ⁇ , linkers, and Fc regions.
  • FIG. 44 depicts the purity and homogeneity of illustrative IL-15/R ⁇ -Fc fusion proteins with and without engineered disulfide bonds as determined by CEF.
  • FIGS. 45A-45C depict the induction of A) NK (CD56+/CD16+) cell, B) CD8+ T cell, and C) CD4+ T cell proliferation by illustrative IL-15/R ⁇ -Fc fusion proteins with and without engineered disulfide bonds based on Ki67 expression as measured by FACS.
  • FIG. 46 depicts the structure of IL-15 complexed with IL-15R ⁇ , IL-2RB, and common gamma chain. Locations of substitutions designed to reduce potency are shown.
  • FIGS. 47A-47C depict sequences for illustrative IL-15 variants engineered for reduced potency. Included within each of these variant IL-15 sequences are sequences that are 90%, 95%, 98%, and 99% identical (as defined herein) to the recited sequences, and/or contain from 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional amino acid substitutions. In a non-limiting example, the recited sequences may contain additional amino acid modifications such as those contributing to formation of covalent disulfide bonds as described in Example 2.
  • FIGS. 48A-48D depict sequences of XENP22821, XENP22822, XENP23554, XENP23557, XENP23561, XENP24018, XENP24019, XENP24045, XENP24051, and XENP24052, illustrative IL-15/R ⁇ -Fc fusion proteins of the “IL-15/R ⁇ -heteroFc” format engineered for lower potency.
  • Additional sequences are depicted as XENPs 22815, 22816, 22817, 22818, 22819, 22820, 22823, 22824, 22825, 22826, 22827, 22828, 22829, 22830, 22831, 22832, 22833, 22834, 23555, 23559, 23560, 24017, 24020, 24043, and 24048 in the sequence listing.
  • IL-15 and IL-15R ⁇ (sushi) are underlined
  • linkers are double underlined (although as will be appreciated by those in the art, the linkers can be replaced by other linkers, some of which are depicted in FIG. 7 )
  • slashes (/) indicate the border(s) between IL-15, IL-15R ⁇ , linkers, and Fc regions.
  • FIGS. 49A-49C depict sequences of XENP24015, XENP24050, XENP24475, XENP24476, XENP24478, XENP24479, and XENP24481, illustrative IL-15/R ⁇ -Fc fusion proteins of the “scIL-15/R ⁇ -Fc” format engineered for lower potency. Additional sequences are depicted as XENPs 24013, 24014, and 24016 in the sequence listing. IL-15 and IL-15R ⁇ (sushi) are underlined, linkers are double underlined (although as will be appreciated by those in the art, the linkers can be replaced by other linkers, some of which are depicted in FIG. 7 ), and slashes (/) indicate the border(s) between IL-15, IL-15R ⁇ , linkers, and Fc regions.
  • FIGS. 50A-50B depict sequences of XENP24349, XENP24890, and XENP25138, illustrative IL-15/R ⁇ -Fc fusion proteins of the “ncIL-15/R ⁇ -Fc” format engineered for lower potency.
  • IL-15 and IL-15R ⁇ (sushi) are underlined, linkers are double underlined (although as will be appreciated by those in the art, the linkers can be replaced by other linkers, some of which are depicted in FIG. 7 ), and slashes (/) indicate the border(s) between IL-15, IL-15R ⁇ , linkers, and Fc regions.
  • FIG. 51 depicts sequences of XENP22801 and XENP22802, illustrative ncIL-15/R ⁇ heterodimers engineered for lower potency. Additional sequences are depicted as XENPs 22791, 22792, 22793, 22794, 22795, 22796, 22803, 22804, 22805, 22806, 22807, 22808, 22809, 22810, 22811, 22812, 22813, and 22814 in the sequence listing. It is important to note that these sequences were generated using polyhistidine (Hisx6 or HHHHHH (SEQ ID NO: 1198)) C-terminal tags at the C-terminus of IL-15R ⁇ (sushi).
  • polyhistidine Hisx6 or HHHHHH (SEQ ID NO: 1198)
  • FIG. 52 depicts sequences of XENP24342, an illustrative IL-15/R ⁇ -Fc fusion protein of the “bivalent ncIL-15/R ⁇ -Fc” format engineered for lower potency.
  • IL-15 and IL-15R ⁇ (sushi) are underlined, linkers are double underlined (although as will be appreciated by those in the art, the linkers can be replaced by other linkers, some of which are depicted in FIG. 7 ), and slashes (/) indicate the border(s) between IL-15, IL-15R ⁇ , linkers, and Fc regions.
  • FIG. 53 depicts sequences of XENP23472 and XENP23473, illustrative IL-15/R ⁇ -Fc fusion proteins of the “dsIL-15/R ⁇ -Fc” format engineered for lower potency.
  • IL-15 and IL-15R ⁇ (sushi) are underlined, linkers are double underlined (although as will be appreciated by those in the art, the linkers can be replaced by other linkers, some of which are depicted in FIG. 7 ), and slashes (/) indicate the border(s) between IL-15, IL-15R ⁇ , linkers, and Fc regions.
  • FIGS. 54A-54C depict the induction of (A) NK cell, (B) CD8+(CD45RA ⁇ ) T cell, and (C) CD4+(CD45RA ⁇ ) T cell proliferation by variant IL-15/R ⁇ -Fc fusion proteins based on Ki67 expression as measured by FACS.
  • FIG. 55 depicts EC50 for induction of NK and CD8+ T cells proliferation by variant IL-15/R ⁇ -Fc fusion proteins, and fold reduction in EC50 relative to XENP20818.
  • FIGS. 56A-56C depict the gating of lymphocytes and subpopulations for the experiments depicted in FIGS. 59A-59D .
  • FIG. 56A shows the gated lymphocyte population.
  • FIG. 56B shows the CD3-negative and CD3-positive subpopulations.
  • FIGS. 57A-57C depict the gating of CD3+ lymphocyte subpopulations for the experiments depicted in FIGS. 59A-59D .
  • FIG. 57A shows the CD4+, CD8+ and ⁇ T cell subpopulations of the CD3+ T cells.
  • FIG. 57B shows the CD45RA( ⁇ ) and CD45RA(+) subpopulations of the CD4+ T cells.
  • FIG. 57C shows the CD45RA( ⁇ ) and CD45RA(+) subpopulation s of the CD8+ T cells.
  • FIGS. 58A-58B depict CD69 and CD25 expression before ( FIG. 58A ) and after ( FIG. 58B ) incubation of human PBMCs with XENP22821.
  • FIGS. 59A-59D depict cell proliferation in human PBMCs incubated for four days with the indicated variant IL-15/R ⁇ -Fc fusion proteins.
  • FIGS. 59A-C show the percentage of proliferating NK cells (CD3 ⁇ CD16+) ( FIG. 59A ), CD8+ T cells (CD3+CD8+CD45RA ⁇ ) ( FIG. 59B ) and CD4+ T cells (CD3+CD4+CD45RA ⁇ ) ( FIG. 59C ).
  • FIG. 59D shows the fold change in EC50 of various IL15/IL15R ⁇ Fc heterodimers relative to control (XENP20818).
  • FIGS. 60A-60D depict cell proliferation in human PBMCs incubated for three days with the indicated variant IL-15/R ⁇ -Fc fusion proteins.
  • FIGS. 60A-C show the percentage of proliferating CD8+(CD45RA ⁇ ) T cells (Figure A), CD4+(CD45RA ⁇ ) T cells ( FIG. 60B ), ⁇ T cells ( FIG. 60C ), and NK cells ( FIG. 60D ).
  • FIGS. 61A-61C depict the percentage of Ki67 expression on (A) CD8+ T cells, (B) CD4+ T cells, and (C) NK cells following treatment with additional IL-15/R ⁇ variants.
  • FIGS. 62A-62E depict the percentage of Ki67 expression on (A) CD8+(CD45RA ⁇ ) T cells, (B) CD4+(CD45RA ⁇ ) T cells, (C) ⁇ T cells, (D) NK (CD16+CD8 ⁇ ) cells, and (E) NK (CD56+CD8 ⁇ ) cells following treatment with IL-15/R ⁇ variants.
  • FIGS. 63A-63E depict the percentage of Ki67 expression on (A) CD8+(CD45RA ⁇ ) T cells, (B) CD4+(CD45RA ⁇ ) T cells, (C) ⁇ T cells, (D) NK (CD16+CD8 ⁇ ) cells, and (E) NK (CD56+CD8 ⁇ ) cells following treatment with IL-15/R ⁇ variants.
  • FIGS. 64A-64D depict the percentage of Ki67 expression on (A) CD8+ T cells, (B) CD4+ T cells, (C) ⁇ T cells and (D) NK (CD16+) cells following treatment with additional IL-15/R ⁇ variants engineered for decreased potency with different linker lengths.
  • FIGS. 65A-65D depict the percentage of Ki67 expression on (A) CD8+ T cells, (B) CD4+ T cells, (C) ⁇ T cells and (D) NK (CD16+) cells following treatment with additional IL-15/R ⁇ variants.
  • FIGS. 66A-66D depict gating of lymphocytes and subpopulations thereof for the experiments depicted in FIG. 67 .
  • FIG. 66A shows gating of the lymphocyte population.
  • FIG. 66B shows CD4+ and CD8+ T cells.
  • FIG. 66C shows the CD45RA and CD27 expressing subpopulations of CD4+ T cells.
  • FIG. 66D shows the CD45RA and CD27 expressing subpopulations of CD8+ T cells.
  • FIGS. 67A-67C depict STATS phosphorylation on A) CD8+ T cells (CD45RA ⁇ CD27 ⁇ ) and B) CD4+ T cells (CD45RA ⁇ CD27 ⁇ ) following incubation of PBMCs for 4 days with the indicated variant IL15/IL15R ⁇ -Fc fusion proteins at the indicated concentrations.
  • FIG. 67C shows the fold change in EC50 of various IL15/IL15R ⁇ Fc heterodimers relative to control (XENP20818).
  • FIG. 68 depicts IV-TV Dose PK of various IL-15/R ⁇ -Fc fusion proteins or controls in C57BL/6 mice at 0.1 mg/kg single dose.
  • FIG. 69 depicts the correlation of half-life vs NK cell potency.
  • FIG. 70 shows that CD45+ cell levels are predictive of disease.
  • FIGS. 71A-71B depict the enhancement of engraftment by variant IL-15/R ⁇ -Fc fusion proteins as indicated by CD45+ cell counts on Days A) 4 and B) 8.
  • FIGS. 72A-72C depict IFN ⁇ levels on Days (A) 4, (B) 7 and (C) 11 after treatment of NSG mice engrafted with human PBMCs with the indicated variant IL15/R ⁇ -Fc fusion proteins or control.
  • FIGS. 73A-73C depict CD45+ lymphocyte cell counts on Days (A) 4, (B) 7, and (C) 11 after treatment of NSG mice engrafted with human PBMCs with the indicated variant IL15/R ⁇ -Fc fusion proteins or control.
  • FIGS. 74A-74C depict NK cell (CD16+CD56+CD45RA+) counts on Days A) 4, B) 7 and C) 11 after treatment of NSG mice engrafted with human PBMCs with the indicated IL15/R ⁇ -Fc fusion proteins or control.
  • FIGS. 75A-75B depict CD8+ T cell (CD8+CD45RA+) counts on Days (A) 7 and (B) 11 after treatment of NSG mice engrafted with human PBMCs with the indicated IL15/R ⁇ -Fc fusion proteins or control.
  • FIGS. 76A-76B depict CD4+ T cell (CD4+CD45RA+) counts on Days A) 7 and B) 11 after treatment of NSG mice engrafted with human PBMCs with the indicated IL15/R ⁇ -Fc fusion proteins or control.
  • FIG. 77 depicts IFN ⁇ level on Days 4, 7, and 11 in serum of huPBMC engrafted mice following treatment with additional variant IL-15/R ⁇ -Fc fusion proteins.
  • FIGS. 78A-78C depict CD8+ T cell count on Days (A) 4, (B) 7, and (C) 11 in whole blood of huPBMC engrafted mice following treatment with additional variant IL-15/R ⁇ -Fc fusion proteins.
  • FIGS. 79A-79C depict CD4+ T cell count on Days (A) 4, (B) 7, and (C) 11 in whole blood of huPBMC engrafted mice following treatment with additional variant IL-15/R ⁇ -Fc fusion proteins.
  • FIGS. 80A-80C depict CD45+ cell count on Days (A) 4, (B) 7, and (C) 11 in whole blood of huPBMC engrafted mice following treatment with additional variant IL-15/R ⁇ -Fc fusion proteins.
  • FIGS. 81A-81C depict the body weight as a percentage of initial body weight of huPBMC engrafted mice on Days (A) 4, (B) 7, and (C) 11 following treatment with additional IL-15/R ⁇ variants. Each point represents a single NSG mouse. Mice whose body weights dropped below 70% initial body weight were euthanized. Dead mice are represented as 70%.
  • FIGS. 82A-82E depict lymphocyte counts after dosing cynomolgus monkeys with XENP20818.
  • FIGS. 82A-E respectively show the fold change in absolute count of CD56+ NK cells ( FIG. 82A ), CD16+ NK cells ( FIG. 82B ), ⁇ T cells (CD45RA+CD3+CD4 ⁇ CD8 ⁇ ) ( FIG. 82C ), CD8+ T cells ( FIG. 82D ), and CD4+ T cells ( FIG. 82E ).
  • FIGS. 83A-83E depict proliferation of CD56+ NK cells ( FIG. 83A ), CD16+NK cells ( FIG. 83B ), CD8+ T cells (CD45RA+) ( FIG. 83C ), CD8+ T cells (CD45RA ⁇ ) ( FIG. 83D ), and CD4+ T cells (CD45RA ⁇ ) ( FIG. 83E ) after dosing cynomolgus monkeys with XENP20818.
  • FIGS. 84A-84E depict lymphocyte counts after dosing cynomolgus monkeys with XENP22819.
  • FIGS. 84A-E respectively show the fold change in absolute count of CD56+ NK cells ( FIG. 84A ), CD16+ NK cells ( FIG. 84B ), ⁇ T cells (CD45RA+CD3+CD4 ⁇ CD8 ⁇ ) ( FIG. 84C ), CD8+ T cells ( FIG. 84D ), and CD4+ T cells ( FIG. 84E ).
  • FIGS. 85A-85E depict proliferation of CD56+ NK cells ( FIG. 85A ), CD16+NK cells ( FIG. 85B ), CD8+ T cells (CD45RA+) ( FIG. 85C ), CD8+ T cells (CD45RA ⁇ ) ( FIG. 85D ), and CD4+ T cells (CD45RA ⁇ ) ( FIG. 85E ) after dosing cynomolgus monkeys with XENP22819.
  • FIGS. 86A-86E depict lymphocyte counts after dosing cynomolgus monkeys with XENP22821.
  • FIGS. 86A-E respectively show the fold change in absolute count of CD56+ NK cells ( FIG. 86A ), CD16+ NK cells ( FIG. 86B ), ⁇ T cells (CD45RA+CD3+CD4 ⁇ CD8 ⁇ ) ( FIG. 86C ), CD8+ T cells ( FIG. 86D ), and CD4+ T cells ( FIG. 86E ).
  • FIGS. 87A-87E depict proliferation of CD56+ NK cells ( FIG. 87A ), CD16+NK cells ( FIG. 87B ), CD8+ T cells (CD45RA+) ( FIG. 87C ), CD8+ T cells (CD45RA ⁇ ) ( FIG. 87D ), and CD4+ T cells (CD45RA ⁇ ) ( FIG. 87E ) after dosing cynomolgus monkeys with XENP22821.
  • FIGS. 88A-88E depict lymphocyte counts after dosing cynomolgus monkeys with XENP22822.
  • FIGS. 88A-E respectively show the fold change in absolute count of CD56+ NK cells ( FIG. 88A ), CD16+ NK cells ( FIG. 88B ), ⁇ T cells (CD45RA+CD3+CD4 ⁇ CD8 ⁇ ) ( FIG. 88C ), CD8+ T cells ( FIG. 88D ), and CD4+ T cells ( FIG. 88E ).
  • FIGS. 89A-89E depict proliferation of CD56+ NK cells ( FIG. 89A ), CD16+NK cells ( FIG. 89B ), CD8+ T cells (CD45RA+) ( FIG. 89C ), CD8+ T cells (CD45RA ⁇ ) ( FIG. 89D ), and CD4+ T cells (CD45RA ⁇ ) ( FIG. 89E ) after dosing cynomolgus monkeys with XENP22822.
  • FIGS. 90A-90E depict lymphocyte counts after dosing cynomolgus monkeys with XENP22834.
  • FIGS. 90A-E respectively show the fold change in absolute count of CD56+ NK cells ( FIG. 90A ), CD16+ NK cells ( FIG. 90B ), ⁇ T cells (CD45RA+CD3+CD4 ⁇ CD8 ⁇ ) ( FIG. 90C ), CD8+ T cells ( FIG. 90D ), and CD4+ T cells ( FIG. 90E ).
  • FIGS. 91A-91E depict proliferation of CD56+ NK cells ( FIG. 91A ), CD16+NK cells ( FIG. 91B ), CD8+ T cells (CD45RA+) ( FIG. 91C ), CD8+ T cells (CD45RA ⁇ ) ( FIG. 91D ), and CD4+ T cells (CD45RA ⁇ ) ( FIG. 91E ) after dosing cynomolgus monkeys with XENP22834.
  • FIGS. 92A-92E depict lymphocyte counts after dosing cynomolgus monkeys with XENP23343.
  • FIGS. 92A-E respectively show the fold change in absolute count of CD56+ NK cells ( FIG. 92A ), CD16+ NK cells ( FIG. 92B ), ⁇ T cells (CD45RA+CD3+CD4 ⁇ CD8 ⁇ ) ( FIG. 92C ), CD8+ T cells ( FIG. 92D ), and CD4+ T cells ( FIG. 92E ).
  • FIGS. 93A-93E depict proliferation of CD56+ NK cells ( FIG. 93A ), CD16+NK cells ( FIG. 93B ), CD8+ T cells (CD45RA+) ( FIG. 93C ), CD8+ T cells (CD45RA ⁇ ) ( FIG. 93D ), and CD4+ T cells (CD45RA ⁇ ) ( FIG. 93E ) after dosing cynomolgus monkeys with XENP23343.
  • FIGS. 94A-94D depict sequences of XENP23343, XENP23504, XENP24113, XENP24301, XENP24306, and XENP24341, illustrative IL-15/R ⁇ -Fc fusion proteins of the “IL-15/R ⁇ -heteroFc” format with M428L/N434S substitutions.
  • IL-15 and IL-15R ⁇ (sushi) are underlined, linkers are double underlined (although as will be appreciated by those in the art, the linkers can be replaced by other linkers, some of which are depicted in FIG.
  • FIG. 94 D depicts sequences of XENP25938, an illustrative IL-15/R ⁇ -Fc fusion protein of the “scIL-15/R ⁇ -Fc” format with M428L/N434S substitutions.
  • FIG. 95 depicts sequences of XENP24383, an illustrative IL-15/R ⁇ -Fc fusion protein of the “ncIL-15/R ⁇ -Fc” format with M428L/N434S substitutions.
  • IL-15 and IL-15R ⁇ (sushi) are underlined, linkers are double underlined (although as will be appreciated by those in the art, the linkers can be replaced by other linkers, some of which are depicted in FIG. 7 ), and slashes (/) indicate the border(s) between IL-15, IL-15R ⁇ , linkers, and Fc regions.
  • FIG. 96 depicts sequences of XENP24346 and XENP24351, illustrative IL-15/R ⁇ -Fc fusion proteins of the “bivalent ncIL-15/R ⁇ -Fc” format with M428L/N434S substitutions.
  • IL-15 and IL-15R ⁇ (sushi) are underlined, linkers are double underlined (although as will be appreciated by those in the art, the linkers can be replaced by other linkers, some of which are depicted in FIG. 7 ), and slashes (/) indicate the border(s) between IL-15, IL-15R ⁇ , linkers, and Fc regions.
  • FIGS. 97A-97C depict the percentage of Ki67 expression on (A) human CD8+ T cells, (B) human CD4+ T cells and (C) human NK cells following treatment with IL-15/R ⁇ variants with M428L/N434S Fc mutations.
  • FIGS. 98A-98C depict the percentage of Ki67 expression on (A) cyno CD8+ T cells, (B) cyno CD4+ T cells and (C) cyno NK cells following treatment with IL-15/R ⁇ variants with M428L/N434S Fc mutations.
  • FIGS. 99A-99C depict CD4+ T cell count on (A) Day 4 and (B) Day 7 in whole blood and (C) Day 8 in spleen of huPBMC engrafted mice following treatment with additional variant IL-15/R ⁇ -Fc fusion proteins.
  • FIGS. 100A-100C depict CD8+ T cell count on (A) Day 4 and (B) Day 7 in whole blood and (C) Day 8 in spleen of huPBMC engrafted mice following treatment with additional variant IL-15/R ⁇ -Fc fusion proteins.
  • FIGS. 101A-101C depicts CD8+ T cell count on (A) Day 4 and (B) Day 7 in whole blood and (C) Day 8 in spleen of huPBMC engrafted mice following treatment with additional variant IL-15/R ⁇ -Fc fusion proteins.
  • FIGS. 102A-102F depict the body weight as a percentage of initial body weight of huPBMC engrafted mice on Days (A) ⁇ 2, (B) 1, (C) 5, (D) 8, and (E) 11 following treatment with additional IL-15/R ⁇ variants. Each point represents a single NSG mouse.
  • FIG. 102F depicts a time-course of body weight in huPBMC engrafted mice following treatment with the IL-15/R ⁇ variants.
  • FIGS. 103A-103C depict (A) CD8+ T cell, (B) CD4+ T cell, and (C) NK cell counts in cynomolgus monkeys after treatment with IL-15/R ⁇ variants on Day 1.
  • FIGS. 104A-104Z, 104AA-104AZ, and 104BA-104BL depicts sequences of the invention.
  • the CDRs are in bold, IL-15 and IL15-R ⁇ (sushi) are underlined, linkers are double underlined, and slashes (/) are between IL-15, IL15-R ⁇ (sushi), linkers, and Fc domains.
  • FIG. 105 depicts some preferred embodiments of the invention. “Xtend” versions contain the 428L/434S variants in the Fc domains of each monomer.
  • FIG. 106 depicts a list of engineered heterodimer-skewing (e.g. “steric heterodimerization”) Fc variants with heterodimer yields (determined by HPLC-CIEX) and thermal stabilities (determined by DSC). Not determined thermal stability is denoted by “n.d.”.
  • engineered heterodimer-skewing e.g. “steric heterodimerization”
  • Fc variants with heterodimer yields determined by HPLC-CIEX
  • thermal stabilities determined by DSC. Not determined thermal stability is denoted by “n.d.”.
  • ablation herein is meant a decrease or removal of activity.
  • “ablating Fc ⁇ R binding” means the Fc region amino acid variant has less than 50% starting binding as compared to an Fc region not containing the specific variant, with less than 70-80-90-95-98% loss of activity being preferred, and in general, with the activity being below the level of detectable binding in a Biacore assay.
  • the Fc monomers of the invention retain binding to the FcRn receptor.
  • ADCC antibody dependent cell-mediated cytotoxicity
  • ADCC antibody dependent cell-mediated cytotoxicity
  • the cell-mediated reaction wherein nonspecific cytotoxic cells that express Fc ⁇ Rs recognize bound antibody on a target cell and subsequently cause lysis of the target cell.
  • ADCC is correlated with binding to Fc ⁇ RIIIa; increased binding to Fc ⁇ RIIIa leads to an increase in ADCC activity.
  • many embodiments of the invention ablate ADCC activity entirely.
  • ADCP antibody dependent cell-mediated phagocytosis as used herein is meant the cell-mediated reaction wherein nonspecific cytotoxic cells that express Fc ⁇ Rs recognize bound antibody on a target cell and subsequently cause phagocytosis of the target cell.
  • modification herein is meant an amino acid substitution, insertion, and/or deletion in a polypeptide sequence or an alteration to a moiety chemically linked to a protein.
  • a modification may be an altered carbohydrate or PEG structure attached to a protein.
  • amino acid modification herein is meant an amino acid substitution, insertion, and/or deletion in a polypeptide sequence.
  • the amino acid modification is always to an amino acid coded for by DNA, e.g., the 20 amino acids that have codons in DNA and RNA.
  • amino acid substitution or “substitution” herein is meant the replacement of an amino acid at a particular position in a parent polypeptide sequence with a different amino acid.
  • the substitution is to an amino acid that is not naturally occurring at the particular position, either not naturally occurring within the organism or in any organism.
  • the substitution E272Y refers to a variant polypeptide, in this case an Fc variant, in which the glutamic acid at position 272 is replaced with tyrosine.
  • a protein which has been engineered to change the nucleic acid coding sequence but not change the starting amino acid is not an “amino acid substitution”; that is, despite the creation of a new gene encoding the same protein, if the protein has the same amino acid at the particular position that it started with, it is not an amino acid substitution.
  • amino acid insertion or “insertion” as used herein is meant the addition of an amino acid sequence at a particular position in a parent polypeptide sequence.
  • ⁇ 233E or 233E designates an insertion of glutamic acid after position 233 and before position 234.
  • ⁇ 233ADE or A233ADE designates an insertion of AlaAspGlu after position 233 and before position 234.
  • amino acid deletion or “deletion” as used herein is meant the removal of an amino acid sequence at a particular position in a parent polypeptide sequence.
  • E233 ⁇ or E233#, E233( ) or E233del designates a deletion of glutamic acid at position 233.
  • EDA233 ⁇ or EDA233# designates a deletion of the sequence GluAspAla that begins at position 233.
  • variant protein or “protein variant”, or “variant” as used herein is meant a protein that differs from that of a parent protein by virtue of at least one amino acid modification.
  • Protein variant may refer to the protein itself, a composition comprising the protein, or the amino sequence that encodes it.
  • the protein variant has at least one amino acid modification compared to the parent protein, e.g. from about one to about seventy amino acid modifications, and preferably from about one to about five amino acid modifications compared to the parent.
  • the parent polypeptide for example an Fc parent polypeptide
  • the protein variant sequence herein will preferably possess at least about 80% identity with a parent protein sequence, and most preferably at least about 90% identity, more preferably at least about 95-98-99% identity.
  • Variant protein can refer to the variant protein itself, compositions comprising the protein variant, or the DNA sequence that encodes it.
  • antibody variant or “variant antibody” as used herein is meant an antibody that differs from a parent antibody by virtue of at least one amino acid modification
  • IgG variant or “variant IgG” as used herein is meant an antibody that differs from a parent IgG (again, in many cases, from a human IgG sequence) by virtue of at least one amino acid modification
  • immunoglobulin variant or “variant immunoglobulin” as used herein is meant an immunoglobulin sequence that differs from that of a parent immunoglobulin sequence by virtue of at least one amino acid modification
  • Fc variant or “variant Fc” as used herein is meant a protein comprising an amino acid modification in an Fc domain.
  • the Fc variants of the present invention are defined according to the amino acid modifications that compose them.
  • N434S or 434S is an Fc variant with the substitution serine at position 434 relative to the parent Fc polypeptide, wherein the numbering is according to the EU index.
  • M428L/N434S defines an Fc variant with the substitutions M428L and N434S relative to the parent Fc polypeptide.
  • the identity of the WT amino acid may be unspecified, in which case the aforementioned variant is referred to as 428L/434S.
  • substitutions are provided is arbitrary, that is to say that, for example, 428L/434S is the same Fc variant as M428L/N434S, and so on.
  • amino acid position numbering is according to the EU index.
  • the EU index or EU index as in Kabat or EU numbering scheme refers to the numbering of the EU antibody (Edelman et al., 1969, Proc Natl Acad Sci USA 63:78-85, hereby entirely incorporated by reference).
  • the modification can be an addition, deletion, or substitution.
  • substitutions can include naturally occurring amino acids and, in some cases, synthetic amino acids. Examples include U.S. Pat. No.
  • protein herein is meant at least two covalently attached amino acids, which includes proteins, polypeptides, oligopeptides and peptides.
  • the peptidyl group may comprise naturally occurring amino acids and peptide bonds, or synthetic peptidomimetic structures, i.e. “analogs”, such as peptoids (see Simon et al., PNAS USA 89(20):9367 (1992), entirely incorporated by reference).
  • the amino acids may either be naturally occurring or synthetic (e.g. not an amino acid that is coded for by DNA); as will be appreciated by those in the art.
  • homo-phenylalanine, citrulline, ornithine and noreleucine are considered synthetic amino acids for the purposes of the invention, and both D- and L-(R or S) configured amino acids may be utilized.
  • the variants of the present invention may comprise modifications that include the use of synthetic amino acids incorporated using, for example, the technologies developed by Schultz and colleagues, including but not limited to methods described by Cropp & Shultz, 2004, Trends Genet.
  • polypeptides may include synthetic derivatization of one or more side chains or termini, glycosylation, PEGylation, circular permutation, cyclization, linkers to other molecules, fusion to proteins or protein domains, and addition of peptide tags or labels.
  • residue as used herein is meant a position in a protein and its associated amino acid identity.
  • Asparagine 297 also referred to as Asn297 or N297
  • Asn297 is a residue at position 297 in the human antibody IgG1.
  • IgG subclass modification or “isotype modification” as used herein is meant an amino acid modification that converts one amino acid of one IgG isotype to the corresponding amino acid in a different, aligned IgG isotype.
  • IgG1 comprises a tyrosine and IgG2 a phenylalanine at EU position 296, a F296Y substitution in IgG2 is considered an IgG subclass modification.
  • non-naturally occurring modification is meant an amino acid modification that is not isotypic.
  • the substitution 434S in IgG1, IgG2, IgG3, or IgG4 (or hybrids thereof) is considered a non-naturally occurring modification.
  • amino acid and “amino acid identity” as used herein is meant one of the 20 naturally occurring amino acids that are coded for by DNA and RNA.
  • effector function as used herein is meant a biochemical event that results from the interaction of an antibody Fc region with an Fc receptor or ligand. Effector functions include but are not limited to ADCC, ADCP, and CDC.
  • IgG Fc ligand as used herein is meant a molecule, preferably a polypeptide, from any organism that binds to the Fc region of an IgG antibody to form an Fc/Fc ligand complex.
  • Fc ligands include but are not limited to Fc ⁇ RIs, Fc ⁇ RIIs, Fc ⁇ RIIIs, FcRn, Clq, C3, mannan binding lectin, mannose receptor, staphylococcal protein A, streptococcal protein G, and viral Fc ⁇ R.
  • Fc ligands also include Fc receptor homologs (FcRH), which are a family of Fc receptors that are homologous to the Fc ⁇ Rs (Davis et al., 2002, Immunological Reviews 190:123-136, entirely incorporated by reference).
  • Fc ligands may include undiscovered molecules that bind Fc. Particular IgG Fc ligands are FcRn and Fc gamma receptors.
  • Fc ligand as used herein is meant a molecule, preferably a polypeptide, from any organism that binds to the Fc region of an antibody to form an Fc/Fc ligand complex.
  • Fc gamma receptor any member of the family of proteins that bind the IgG antibody Fc region and is encoded by an Fc ⁇ R gene. In humans this family includes but is not limited to Fc ⁇ RI (CD64), including isoforms Fc ⁇ RIa, Fc ⁇ RIb, and Fc ⁇ RIc; Fc ⁇ RII (CD32), including isoforms Fc ⁇ RIIa (including allotypes H131 and R131), Fc ⁇ RIIb (including Fc ⁇ RIIb-1 and Fc ⁇ RIIb-2), and Fc ⁇ RIIc; and Fc ⁇ RIII (CD16), including isoforms Fc ⁇ RIIIa (including allotypes V158 and F158) and Fc ⁇ RIIIb (including allotypes Fc ⁇ RIIb-NA1 and Fc ⁇ RIIb-NA2) (Jefferis et al., 2002, Immunol Lett 82:57-65
  • An Fc ⁇ R may be from any organism, including but not limited to humans, mice, rats, rabbits, and monkeys.
  • Mouse Fc ⁇ Rs include but are not limited to Fc ⁇ RI (CD64), Fc ⁇ RII (CD32), Fc ⁇ RIII (CD16), and Fc ⁇ RIII-2 (CD16-2), as well as any undiscovered mouse Fc ⁇ Rs or Fc ⁇ R isoforms or allotypes.
  • FcRn or “neonatal Fc Receptor” as used herein is meant a protein that binds the IgG antibody Fc region and is encoded at least in part by an FcRn gene.
  • the FcRn may be from any organism, including but not limited to humans, mice, rats, rabbits, and monkeys.
  • the functional FcRn protein comprises two polypeptides, often referred to as the heavy chain and light chain.
  • the light chain is beta-2-microglobulin and the heavy chain is encoded by the FcRn gene.
  • FcRn or an FcRn protein refers to the complex of FcRn heavy chain with beta-2-microglobulin.
  • FcRn variants can be used to increase binding to the FcRn receptor, and in some cases, to increase serum half-life.
  • the Fc monomers of the invention retain binding to the FcRn receptor (and, as noted below, can include amino acid variants to increase binding to the FcRn receptor).
  • parent polypeptide as used herein is meant a starting polypeptide that is subsequently modified to generate a variant.
  • the parent polypeptide may be a naturally occurring polypeptide, or a variant or engineered version of a naturally occurring polypeptide.
  • Parent polypeptide may refer to the polypeptide itself, compositions that comprise the parent polypeptide, or the amino acid sequence that encodes it.
  • parent immunoglobulin as used herein is meant an unmodified immunoglobulin polypeptide that is modified to generate a variant
  • parent antibody as used herein is meant an unmodified antibody that is modified to generate a variant antibody. It should be noted that “parent antibody” includes known commercial, recombinantly produced antibodies as outlined below.
  • Fc or “Fc region” or “Fc domain” as used herein is meant the polypeptide comprising the constant region of an antibody excluding, in some instances, the first constant region immunoglobulin domain (e.g., CH1) or a portion thereof, and in some cases, part of the hinge.
  • an Fc can refer to the last two constant region immunoglobulin domains (e.g., CH2 and CH3) of IgA, IgD, and IgG, the last three constant region immunoglobulin domains of IgE and IgM, and the flexible hinge N-terminal to these domains.
  • Fc may include the J chain.
  • the Fc domain comprises immunoglobulin domains C ⁇ 2 and C ⁇ 3 (C ⁇ 2 and C ⁇ 3) and the lower hinge region between C ⁇ 1 (C ⁇ 1) and C ⁇ 2 (C ⁇ 2).
  • an Fc refers to a truncated CH1 domain, and CH2 and CH3 of an immunoglobulin.
  • the human IgG heavy chain Fc region is usually defined to include residues E216 or C226 or P230 to its carboxyl-terminus, wherein the numbering is according to the EU index as in Kabat.
  • amino acid modifications are made to the Fc region, for example to alter binding to one or more Fc ⁇ R receptors or to the FcRn receptor.
  • Fc fusion protein or “immunoadhesin” herein is meant a protein comprising an Fc region, generally linked (optionally through a linker moiety, as described herein) to a different protein, such as to IL-15 and/or IL-15R, as described herein.
  • two Fc fusion proteins can form a homodimeric Fc fusion protein or a heterodimeric Fc fusion protein with the latter being preferred.
  • one monomer of the heterodimeric Fc fusion protein comprises an Fc domain alone (e.g., an empty Fc domain) and the other monomer is an Fc fusion, comprising a variant Fc domain and a protein domain, such as a receptor, ligand or other binding partner.
  • position as used herein is meant a location in the sequence of a protein. Positions may be numbered sequentially, or according to an established format, for example the EU index for antibody numbering.
  • strandedness in the context of the monomers of the heterodimeric antibodies of the invention herein is meant that, similar to the two strands of DNA that “match”, heterodimerization variants are incorporated into each monomer so as to preserve the ability to “match” to form heterodimers.
  • steric variants that are “charge pairs” that can be utilized as well do not interfere with the pI variants, e.g. the charge variants that make a pI higher are put on the same “strand” or “monomer” to preserve both functionalities.
  • wild type or WT herein is meant an amino acid sequence or a nucleotide sequence that is found in nature, including allelic variations.
  • a WT protein has an amino acid sequence or a nucleotide sequence that has not been intentionally modified.
  • the heterodimeric proteins of the present invention are generally isolated or recombinant.
  • isolated when used to describe the various polypeptides disclosed herein, means a polypeptide that has been identified and separated and/or recovered from a cell or cell culture from which it was expressed. Ordinarily, an isolated polypeptide will be prepared by at least one purification step.
  • Recombinant means the proteins are generated using recombinant nucleic acid techniques in exogeneous host cells.
  • Percent (%) amino acid sequence identity with respect to a protein sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the specific (parental) sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. One particular program is the ALIGN-2 program outlined at paragraphs [0279] to [0280] of US Pub. No. 20160244525, hereby incorporated by reference.
  • invention sequence The degree of identity between an amino acid sequence of the present invention (“invention sequence”) and the parental amino acid sequence is calculated as the number of exact matches in an alignment of the two sequences, divided by the length of the “invention sequence,” or the length of the parental sequence, whichever is the shortest. The result is expressed in percent identity.
  • two or more amino acid sequences are at least 50%, 60%, 70%, 80%, or 90% identical. In some embodiments, two or more amino acid sequences are at least 95%, 97%, 98%, 99%, or even 100% identical.
  • Specific binding or “specifically binds to” or is “specific for” a particular antigen or an epitope means binding that is measurably different from a non-specific interaction. Specific binding can be measured, for example, by determining binding of a molecule compared to binding of a control molecule, which generally is a molecule of similar structure that does not have binding activity. For example, specific binding can be determined by competition with a control molecule that is similar to the target.
  • the present invention relates to heterodimeric Fc fusion proteins that include IL-15 and IL-15 receptor alpha (IL-15R ⁇ ) protein domains in different orientations.
  • the Fc domains can be derived from IgG Fc domains, e.g., IgG1, IgG2, IgG3 or IgG4 Fc domains, with IgG1 Fc domains finding particular use in the invention.
  • each chain defines a constant region primarily responsible for effector function.
  • Kabat et al. collected numerous primary sequences of the variable regions of heavy chains and light chains. Based on the degree of conservation of the sequences, they classified individual primary sequences into the CDR and the framework and made a list thereof (see SEQUENCES OF IMMUNOLOGICAL INTEREST, 5th edition, NIH publication, No. 91-3242, E. A. Kabat et al., entirely incorporated by reference).
  • the Kabat numbering system is generally used when referring to a residue in the variable domain (approximately, residues 1-107 of the light chain variable region and residues 1-113 of the heavy chain variable region) and the EU numbering system for Fc regions (e.g., Kabat et al., supra (1991)).
  • immunoglobulin domains in the heavy chain.
  • immunoglobulin (Ig) domain herein is meant a region of an immunoglobulin having a distinct tertiary structure.
  • the heavy chain domains including, the constant heavy (CH) domains and the hinge domains.
  • the IgG isotypes each have three CH regions. Accordingly, “CH” domains in the context of IgG are as follows: “CH1” refers to positions 118-220 according to the EU index as in Kabat.
  • CH2 refers to positions 237-340 according to the EU index as in Kabat
  • CH3 refers to positions 341-447 according to the EU index as in Kabat.
  • the pI variants can be in one or more of the CH regions, as well as the hinge region, discussed below.
  • Ig domain of the heavy chain is the hinge region.
  • hinge region or “hinge region” or “antibody hinge region” or “immunoglobulin hinge region” herein is meant the flexible polypeptide comprising the amino acids between the first and second constant domains of an antibody.
  • the IgG CH1 domain ends at EU position 220, and the IgG CH2 domain begins at residue EU position 237.
  • the antibody hinge is herein defined to include positions 221 (D221 in IgG1) to 236 (G236 in IgG1), wherein the numbering is according to the EU index as in Kabat.
  • the lower hinge is included, with the “lower hinge” generally referring to positions 226 or 230.
  • pI variants can be made in the hinge region as well.
  • the present invention provides different antibody domains.
  • the heterodimeric proteins of the invention comprise different domains, which can be overlapping as well. These domains include, but are not limited to, the Fc domain, the CH1 domain, the CH2 domain, the CH3 domain, the hinge domain, and the heavy constant domain (CH1-hinge-Fc domain or CH1-hinge-CH2-CH3).
  • the “Fc domain” includes the -CH2-CH3 domain, and optionally a hinge domain.
  • the Fc domain also includes a truncated CH1 domain.
  • a protein fragment e.g., IL-15 or IL-15R ⁇
  • it is the C-terminus of the IL-15 or IL-15R ⁇ construct that is attached to all or part of the hinge of the Fc domain; for example, it is generally attached to the sequence EPKSS (SEQ ID NO: 1204) which is the beginning of the hinge.
  • a protein fragment e.g., IL-15 or IL-15R ⁇
  • it is the C-terminus of the IL-15 or IL15R ⁇ construct that is attached to the CH1 domain of the Fc domain.
  • the C-terminus of the IL-15 or IL-15R ⁇ protein fragment is attached to the N-terminus of a domain linker, the C-terminus of which is attached to the N-terminus of a constant Fc domain (N-IL-15 or IL-15R ⁇ protein fragment-linker-Fc domain-C) although that can be switched (N-Fc domain-linker-IL-15 or IL-15R ⁇ protein fragment-C).
  • C-terminus of a first protein fragment is attached to the N-terminus of a second protein fragment, optionally via a domain linker
  • the C-terminus of the second protein fragment is attached to the N-terminus of a constant Fc domain, optionally via a domain linker.
  • a constant Fc domain that is not attached to a first protein fragment or a second protein fragment is provided.
  • a heterodimer Fc fusion protein can contain two or more of the exemplary monomeric Fc domain proteins described herein.
  • the linker is a “domain linker”, used to link any two domains as outlined herein together, some of which are depicted in FIG. 87 .
  • any suitable linker can be used, many embodiments utilize a glycine-serine polymer, including for example (GS)n (SEQ ID NO: 1199), (GSGGS)n (SEQ ID NO: 1200), (GGGGS)n (SEQ ID NO: 1203), and (GGGS)n (SEQ ID NO: 1201), where n is an integer of at least one (and generally from 0 to 1 to 2 to 3 to 4 to 5) as well as any peptide sequence that allows for recombinant attachment of the two domains with sufficient length and flexibility to allow each domain to retain its biological function.
  • strandedness as outlined below, charged domain linkers.
  • heterodimeric Fc fusion proteins contain at least two constant domains which can be engineered to produce heterodimers, such as pI engineering.
  • Other Fc domains that can be used include fragments that contain one or more of the CHL CH2, CH3, and hinge domains of the invention that have been pI engineered.
  • the formats depicted in FIGS. 9A-9G, and 39A-39D are heterodimeric Fc fusion proteins, meaning that the protein has two associated Fc sequences self-assembled into a heterodimeric Fc domain and at least one protein fragment (e.g., 1, 2 or more protein fragments).
  • a first protein fragment is linked to a first Fc sequence and a second protein fragment is linked to a second Fc sequence.
  • a first protein fragment is linked to a first Fc sequence, and the first protein fragment is non-covalently attached to a second protein fragment that is not linked to an Fc sequence.
  • the heterodimeric Fc fusion protein contains a first protein fragment linked to a second protein fragment which is linked a first Fc sequence, and a second Fc sequence that is not linked to either the first or second protein fragments.
  • the present invention provides heterodimeric Fc fusion proteins that rely on the use of two different heavy chain variant Fc sequences, that will self-assemble to form a heterodimeric Fc domain fusion polypeptide.
  • the present invention is directed to novel constructs to provide heterodimeric Fc fusion proteins that allow binding to one or more binding partners, ligands or receptors.
  • the heterodimeric Fc fusion constructs are based on the self-assembling nature of the two Fc domains of the heavy chains of antibodies, e.g., two “monomers” that assemble into a “dimer”.
  • Heterodimeric Fc fusions are made by altering the amino acid sequence of each monomer as more fully discussed below.
  • the present invention is generally directed to the creation of heterodimeric Fc fusion proteins which can co-engage binding partner(s) or ligand(s) or receptor(s) in several ways, relying on amino acid variants in the constant regions that are different on each chain to promote heterodimeric formation and/or allow for ease of purification of heterodimers over the homodimers.
  • heterodimerization variants amino acid variants that lead to the production of heterodimers are referred to as “heterodimerization variants”.
  • heterodimerization variants can include steric variants (e.g. the “knobs and holes” or “skew” variants described below and the “charge pairs” variants described below) as well as “pI variants”, which allows purification of homodimers away from heterodimers.
  • heterodimerization variants useful mechanisms for heterodimerization include “knobs and holes” (“KIH”; sometimes herein as “skew” variants (see discussion in WO2014/145806), “electrostatic steering” or “charge pairs” as described in WO2014/145806, pI variants as described in WO2014/145806, and general additional Fc variants as outlined in WO2014/145806 and below.
  • KH knocks and holes
  • skew electrostatic steering
  • charge pairs as described in WO2014/145806
  • pI variants as described in WO2014/145806
  • general additional Fc variants as outlined in WO2014/145806 and below.
  • embodiments of particular use in the present invention rely on sets of variants that include skew variants, that encourage heterodimerization formation over homodimerization formation, coupled with pI variants, which increase the pI difference between the two monomers.
  • pI variants can be either contained within the constant and/or Fc domains of a monomer, or domain linkers can be used. That is, the invention provides pI variants that are on one or both of the monomers, and/or charged domain linkers as well.
  • additional amino acid engineering for alternative functionalities may also confer pI changes, such as Fc, FcRn and KO variants.
  • amino acid variants can be introduced into one or both of the monomer polypeptides; that is, the pI of one of the monomers (referred to herein for simplicity as “monomer A”) can be engineered away from monomer B, or both monomer A and B change be changed, with the pI of monomer A increasing and the pI of monomer B decreasing.
  • the pI changes of either or both monomers can be done by removing or adding a charged residue (e.g., a neutral amino acid is replaced by a positively or negatively charged amino acid residue, e.g., glycine to glutamic acid), changing a charged residue from positive or negative to the opposite charge (e.g. aspartic acid to lysine) or changing a charged residue to a neutral residue (e.g., loss of a charge; lysine to serine.).
  • a charged residue e.g., a neutral amino acid is replaced by a positively or negatively charged amino acid residue, e.g., glycine to glutamic acid
  • changing a charged residue from positive or negative to the opposite charge e.g. aspartic acid to lysine
  • changing a charged residue to a neutral residue e.g., loss of a charge; lysine to serine.
  • this embodiment of the present invention provides for creating a sufficient change in pI in at least one of the monomers such that heterodimers can be separated from homodimers.
  • this can be done by using a “wild type” heavy chain constant region and a variant region that has been engineered to either increase or decrease its pI (wt A ⁇ +B or wt A ⁇ B), or by increasing one region and decreasing the other region (A+ ⁇ B ⁇ or A ⁇ B+).
  • a component of some embodiments of the present invention are amino acid variants in the constant regions that are directed to altering the isoelectric point (pI) of at least one, if not both, of the monomers of a dimeric protein by incorporating amino acid substitutions (“pI variants” or “pI substitutions”) into one or both of the monomers.
  • pI variants amino acid substitutions
  • pI substitutions amino acid substitutions
  • the number of pI variants to be included on each or both monomer(s) to get good separation will depend in part on the starting pI of the components. As is known in the art, different Fcs will have different starting pIs which are exploited in the present invention. In general, as outlined herein, the pIs are engineered to result in a total pI difference of each monomer of at least about 0.1 logs, with 0.2 to 0.5 being preferred as outlined herein.
  • the number of pI variants to be included on each or both monomer(s) to get good separation will depend in part on the starting pI of the components. That is, to determine which monomer to engineer or in which “direction” (e.g., more positive or more negative), the sequences of the Fc domains, and in some cases, the protein domain(s) linked to the Fc domain are calculated and a decision is made from there. As is known in the art, different Fc domains and/or protein domains will have different starting pIs which are exploited in the present invention. In general, as outlined herein, the pIs are engineered to result in a total pI difference of each monomer of at least about 0.1 logs, with 0.2 to 0.5 being preferred as outlined herein.
  • heterodimers can be separated from homodimers on the basis of size. As shown in the Figures, for example, several of the formats allow separation of heterodimers and homodimers on the basis of size.
  • heterodimerization variants including skew and purification heterodimerization variants
  • the possibility of immunogenicity resulting from the pI variants is significantly reduced by importing pI variants from different IgG isotypes such that pI is changed without introducing significant immunogenicity.
  • an additional problem to be solved is the elucidation of low pI constant domains with high human sequence content, e.g. the minimization or avoidance of non-human residues at any particular position.
  • a side benefit that can occur with this pI engineering is also the extension of serum half-life and increased FcRn binding. That is, as described in U.S. Ser. No. 13/194,904 (incorporated by reference in its entirety), lowering the pI of antibody constant domains (including those found in antibodies and Fc fusions) can lead to longer serum retention in vivo. These pI variants for increased serum half life also facilitate pI changes for purification.
  • the pI variants of the heterodimerization variants give an additional benefit for the analytics and quality control process of Fc fusion proteins, as the ability to either eliminate, minimize and distinguish when homodimers are present is significant. Similarly, the ability to reliably test the reproducibility of the heterodimeric Fc fusion protein production is important.
  • the present invention provides heterodimeric proteins, including heterodimeric Fc fusion proteins in a variety of formats, which utilize heterodimeric variants to allow for heterodimeric formation and/or purification away from homodimers.
  • the heterodimeric fusion constructs are based on the self-assembling nature of the two Fc domains, e.g., two “monomers” that assemble into a “dimer”.
  • these sets do not necessarily behave as “knobs in holes” variants, with a one-to-one correspondence between a residue on one monomer and a residue on the other; that is, these pairs of sets form an interface between the two monomers that encourages heterodimer formation and discourages homodimer formation, allowing the percentage of heterodimers that spontaneously form under biological conditions to be over 90%, rather than the expected 50% (25% homodimer A/A:50% heterodimer A/B:25% homodimer B/B).
  • the formation of heterodimers can be facilitated by the addition of steric variants. That is, by changing amino acids in each heavy chain, different heavy chains are more likely to associate to form the heterodimeric structure than to form homodimers with the same Fc amino acid sequences.
  • Suitable steric variants are included in in the FIG. 29 of U.S. Ser. No. 15/141,350, all of which is hereby incorporated by reference in its entirety, as well as in FIG. 84 .
  • knocks and holes referring to amino acid engineering that creates steric influences to favor heterodimeric formation and disfavor homodimeric formation can also optionally be used; this is sometimes referred to as “knobs and holes”, as described in U.S. Ser. No. 61/596,846, Ridgway et al., Protein Engineering 9(7):617 (1996); Atwell et al., J. Mol. Biol. 1997 270:26; U.S. Pat. No. 8,216,805, all of which are hereby incorporated by reference in their entirety.
  • the Figures identify a number of “monomer A-monomer B” pairs that rely on “knobs and holes”.
  • these “knobs and hole” mutations can be combined with disulfide bonds to skew formation to heterodimerization.
  • electrostatic steering An additional mechanism that finds use in the generation of heterodimers is sometimes referred to as “electrostatic steering” as described in Gunasekaran et al., J. Biol. Chem. 285(25):19637 (2010), hereby incorporated by reference in its entirety. This is sometimes referred to herein as “charge pairs”.
  • electrostatics are used to skew the formation towards heterodimerization. As those in the art will appreciate, these may also have an effect on pI, and thus on purification, and thus could in some cases also be considered pI variants. However, as these were generated to force heterodimerization and were not used as purification tools, they are classified as “steric variants”.
  • D221E/P228E/L368E paired with D221R/P228R/K409R e.g., these are “monomer corresponding sets”
  • C220E/P228E/368E paired with C220R/E224R/P228R/K409R e.g., these are “monomer corresponding sets”
  • the steric variants outlined herein can be optionally and independently incorporated with any pI variant (or other variants such as Fc variants, FcRn variants, etc.) into one or both monomers, and can be independently and optionally included or excluded from the proteins of the invention.
  • a list of suitable skew variants is found in FIG. 84 .
  • the pairs of sets including, but not limited to, S364K/E357Q: L368D/K370S; L368D/K370S: S364K; L368E/K370S: S364K; T411T/E360E/Q362E: D401K; L368D/K370S: S364K/E357L, K370S: S364K/E357Q and T366S/L368A/Y407V: T366W (optionally including a bridging disulfide, T366S/L368A/Y407V/Y349C: T366W/S354C).
  • the pair “S364K/E357Q: L368D/K370S” means that one of the monomers has the double variant set S364K/E357Q and the other has the double variant set L368D/K370S; as above, the “strandedness” of these pairs depends on the starting pI.
  • pI variants those that increase the pI of the protein (basic changes) and those that decrease the pI of the protein (acidic changes).
  • basic changes those that increase the pI of the protein
  • acidic changes those that decrease the pI of the protein
  • all combinations of these variants can be done: one monomer may be wild type, or a variant that does not display a significantly different pI from wild-type, and the other can be either more basic or more acidic. Alternatively, each monomer is changed, one to more basic and one to more acidic.
  • FIG. 30 of U.S. Ser. No. 15/141,350 Preferred combinations of pI variants are shown in FIG. 30 of U.S. Ser. No. 15/141,350, all of which are herein incorporated by reference in its entirety. As outlined herein and shown in the figures, these changes are shown relative to IgG1, but all isotypes can be altered this way, as well as isotype hybrids. In the case where the heavy chain constant domain is from IgG2-4, R133E and R133Q can also be used.
  • a preferred combination of pI variants has one monomer comprising 208D/295E/384D/418E/421D variants (N208D/Q295E/N384D/Q418E/N421D when relative to human IgG1) if one of the Fc monomers includes a CH1 domain.
  • the second monomer comprising a positively charged domain linker, including (GKPGS) 4 (SEQ ID NO: 1202).
  • the first monomer includes a CH1 domain, including position 208.
  • a preferred negative pI variant Fc set includes 295E/384D/418E/421D variants (Q295E/N384D/Q418E/N421D when relative to human IgG1).
  • mutations are made in the hinge domain of the Fc domain, including positions 221, 222, 223, 224, 225, 233, 234, 235 and 236. It should be noted that changes in 233-236 can be made to increase effector function (along with 327A) in the IgG2 backbone. Thus, pI mutations and particularly substitutions can be made in one or more of positions 221-225, with 1, 2, 3, 4 or 5 mutations finding use in the present invention. Again, all possible combinations are contemplated, alone or with other pI variants in other domains.
  • substitutions that find use in lowering the pI of hinge domains include, but are not limited to, a deletion at position 221, a non-native valine or threonine at position 222, a deletion at position 223, a non-native glutamic acid at position 224, a deletion at position 225, a deletion at position 235 and a deletion or a non-native alanine at position 236.
  • pI substitutions are done in the hinge domain, and in others, these substitution(s) are added to other pI variants in other domains in any combination.
  • mutations can be made in the CH2 region, including positions 274, 296, 300, 309, 320, 322, 326, 327, 334 and 339. Again, all possible combinations of these 10 positions can be made; e.g., a pI antibody may have 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 CH2 pI substitutions.
  • substitutions that find use in lowering the pI of CH2 domains include, but are not limited to, a non-native glutamine or glutamic acid at position 274, a non-native phenylalanine at position 296, a non native phenylalanine at position 300, a non-native valine at position 309, a non-native glutamic acid at position 320, a non-native glutamic acid at position 322, a non-native glutamic acid at position 326, a non-native glycine at position 327, a non-native glutamic acid at position 334, a non native threonine at position 339, and all possible combinations within CH2 and with other domains.
  • the mutations can be independently and optionally selected from position 355, 359, 362, 384, 389,392, 397, 418, 419, 444 and 447.
  • Specific substitutions that find use in lowering the pI of CH3 domains include, but are not limited to, a non native glutamine or glutamic acid at position 355, a non-native serine at position 384, a non-native asparagine or glutamic acid at position 392, a non-native methionine at position 397, a non native glutamic acid at position 419, a non native glutamic acid at position 359, a non native glutamic acid at position 362, a non native glutamic acid at position 389, a non native glutamic acid at position 418, a non native glutamic acid at position 444, and a deletion or non-native aspartic acid at position 447.
  • IgG1 is a common isotype for therapeutic antibodies for a variety of reasons, including high effector function.
  • the heavy constant region of IgG1 has a higher pI than that of IgG2 (8.10 versus 7.31).
  • IgG2 residues at particular positions into the IgG1 backbone By introducing IgG2 residues at particular positions into the IgG1 backbone, the pI of the resulting monomer is lowered (or increased) and additionally exhibits longer serum half-life.
  • IgG1 has a glycine (pI 5.97) at position 137
  • IgG2 has a glutamic acid (pI 3.22); importing the glutamic acid will affect the pI of the resulting protein.
  • pI 3.22 glutamic acid
  • a number of amino acid substitutions are generally required to significant affect the pI of the variant Fc fusion protein.
  • even changes in IgG2 molecules allow for increased serum half-life.
  • non-isotypic amino acid changes are made, either to reduce the overall charge state of the resulting protein (e.g., by changing a higher pI amino acid to a lower pI amino acid), or to allow accommodations in structure for stability, etc. as is more further described below.
  • the pI of each monomer can depend on the pI of the variant heavy chain constant domain and the pI of the total monomer, including the variant heavy chain constant domain and the fusion partner.
  • the change in pI is calculated on the basis of the variant heavy chain constant domain, using the chart in the FIG. 19 of US Publ. App. No. 2014/0370013.
  • which monomer to engineer is generally decided by the inherent pI of each monomer.
  • the pI variant decreases the pI of the monomer, they can have the added benefit of improving serum retention in vivo.
  • Fc amino acid modification In addition to pI amino acid variants, there are a number of useful Fc amino acid modification that can be made for a variety of reasons, including, but not limited to, altering binding to one or more Fc ⁇ R receptors, altered binding to FcRn receptors, etc.
  • the proteins of the invention can include amino acid modifications, including the heterodimerization variants outlined herein, which includes the pI variants and steric variants.
  • Each set of variants can be independently and optionally included or excluded from any particular heterodimeric protein.
  • Fc substitutions that can be made to alter binding to one or more of the Fc ⁇ R receptors.
  • Substitutions that result in increased binding as well as decreased binding can be useful.
  • ADCC antibody dependent cell-mediated cytotoxicity; the cell-mediated reaction wherein nonspecific cytotoxic cells that express Fc ⁇ Rs recognize bound antibody on a target cell and subsequently cause lysis of the target cell.
  • Fc ⁇ RIIb an inhibitory receptor
  • Amino acid substitutions that find use in the present invention include those listed in U.S. Ser. Nos. 11/124,620 (particularly FIG.
  • variants that find use include, but are not limited to, 236A, 239D, 239E, 332E, 332D, 239D/332E, 267D, 267E, 328F, 267E/328F, 236A/332E, 239D/332E/330Y, 239D, 332E/330L, 243A, 243L, 264A, 264V and 299T.
  • amino acid substitutions that increase affinity for Fc ⁇ RIIc can also be included in the Fc domain variants outlined herein.
  • the substitutions described in, for example, U.S. Ser. Nos. 11/124,620 and 14/578,305 are useful.
  • Fc substitutions that find use in increased binding to the FcRn receptor and increased serum half-life, as specifically disclosed in U.S. Ser. No. 12/341,769, hereby incorporated by reference in its entirety, including, but not limited to, 434S, 434A, 428L, 308F, 259I, 428L/434S, 259I/308F, 436I/428L, 436I or V/434S, 436V/428L and 259I/308F/428L.
  • Fc ⁇ R ablation variants or “Fc knock out (FcKO or KO)” variants.
  • Fc ⁇ R ablation variants or “Fc knock out (FcKO or KO)” variants.
  • Fc ⁇ R ablation variants for some therapeutic applications, it is desirable to reduce or remove the normal binding of the Fc domain to one or more or all of the Fc ⁇ receptors (e.g., Fc ⁇ R1, Fc ⁇ RIIa, Fc ⁇ RIIb, Fc ⁇ RIIIa, etc.) to avoid additional mechanisms of action. That is, for example, in many embodiments, particularly in the use of bispecific immunomodulatory antibodies desirable to ablate Fc ⁇ RIIIa binding to eliminate or significantly reduce ADCC activity such that one of the Fc domains comprises one or more Fc ⁇ receptor ablation variants.
  • ablation variants are depicted in FIG. 31 of U.S. Ser. No. 15/141,350, all of which are herein incorporated by reference in its entirety, and each can be independently and optionally included or excluded, with preferred aspects utilizing ablation variants selected from the group consisting of G236R/L328R, E233P/L234V/L235A/G236del/S239K, E233P/L234V/L235A/G236del/S267K, E233P/L234V/L235A/G236del/S239K/A327G, E233P/L234V/L235A/G236del/S267K/A327G and E233P/L234V/L235A/G236del, according to the EU index. It should be noted that the ablation variants referenced herein ablate Fc ⁇ R binding but generally not FcRn binding.
  • heterodimerization variants including skew and/or pI variants
  • skew and/or pI variants can be optionally and independently combined in any way, as long as they retain their “strandedness” or “monomer partition”.
  • all of these variants can be combined into any of the heterodimerization formats.
  • any of the heterodimerization variants, skew and pI are also independently and optionally combined with Fc ablation variants, Fc variants, FcRn variants, as generally outlined herein.
  • a monomeric Fc domain can comprise a set of amino acid substitutions that includes C220S/S267K/L368D/K370S or C220S/S267K/S364K/E357Q.
  • heterodimeric Fc fusion proteins can comprise skew variants (e.g., a set of amino acid substitutions as shown in FIGS. 1A-1C of U.S. Ser. No. 15/141,350, all of which are herein incorporated by reference in its entirety), with particularly useful skew variants being selected from the group consisting of S364K/E357Q: L368D/K370S; L368D/K370S: S364K; L368E/K370S: S364K; T411T/E360E/Q362E: D401K; L368D/K370S: S364K/E357L, K370S: S364K/E357Q, T366S/L368A/Y407V: T366W and T366S/L368A/Y407V/Y349C: T366W/S354C, optionally ablation variants, optionally charged domain linkers and the heavy chain comprises
  • the Fc domain comprising an amino acid substitution selected from the group consisting of: 236R, 239D, 239E, 243L, M252Y, V259I, 267D, 267E, 298A, V308F, 328F, 328R, 330L, 332D, 332E, M428L, N434A, N434S, 236R/328R, 239D/332E, M428L, 236R/328F, V259I/V308F, 267E/328F, M428L/N434S, Y436I/M428L, Y436V/M428L, Y436I/N434S, Y436V/N434S, 239D/332E/330L, M252Y/S254T/T256E, V259IN308F/M428L, E233P/L234V/L235A/G236del/S
  • a particular combination of skew and pI variants that finds use in the present invention is T366S/L368A/Y407V: T366W (optionally including a bridging disulfide, T366S/L368A/Y407V/Y349C: T366W/S354C) with one monomer comprises Q295E/N384D/Q418E/N481D and the other a positively charged domain linker.
  • the “knobs in holes” variants do not change pI, and thus can be used on either monomer.
  • the present invention provides heterodimeric Fc fusion proteins containing IL-15 and IL-15R ⁇ proteins.
  • the IL-15 complex can take several forms.
  • the IL-15 protein on its own is less stable than when complexed with the IL-15R ⁇ protein.
  • the IL-15R ⁇ protein contains a “sushi domain”, which is the shortest region of the receptor that retains IL-15 binding activity.
  • preferred embodiments herein include complexes that just use the sushi domain, the sequence of which is shown in the figures.
  • the IL-15 complexes generally comprises the IL-15 protein and the sushi domain of IL IL-15R ⁇ (unless otherwise noted that the full length sequence is used, “IL-15R ⁇ ”, “IL-15R ⁇ (sushi)” and “sushi” are used interchangeably throughout).
  • This complex can be used in three different formats. As shown in FIG. 9A , the IL-15 protein and the IL-15R ⁇ (sushi) are not covalently attached, but rather are self-assembled through regular ligand-ligand interactions. As is more fully described herein, it can be either the IL-15 domain or the sushi domain that is covalently linked to the Fc domain (generally using an optional domain linker).
  • FIG. 9B depicts the sushi domain as the N-terminal domain, although this can be reversed.
  • each of the IL-15 and sushi domains can be engineered to contain a cysteine amino acid, that forms a disulfide bond to form the complex as is generally shown in FIGS. 39A-39D , again, with either the IL-15 domain or the sushi domain being covalently attached (using an optional domain linker) to the Fc domain.
  • the human IL-15 protein has the amino acid sequence set forth in NCBI Ref. Seq. No. NP 000576.1 or SEQ ID NO:1. In some cases, the coding sequence of human IL-15 is set forth in NCBI Ref. Seq. No. NM_000585.
  • An exemplary IL-15 protein of the Fc fusion heterodimeric protein outlined herein can have the amino acid sequence of SEQ ID NO:2 or amino acids 49-162 of SEQ ID NO:1. In some embodiments, the IL-15 protein has at least 90%, e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO:2.
  • the IL-15 protein has the amino acid sequence set forth in SEQ ID NO:2 and the amino acid substitution N72D. In other embodiments, the IL-15 protein has the amino acid sequence of SEQ ID NO:2 and one or more amino acid substitutions selected from the group consisting of C42S, L45C, Q48C, V49C, L52C, E53C, E87C, and E89C. Optionally, the IL-15 protein also has an N72D substitution.
  • the IL-15 protein of the Fc fusion protein can have 1, 2, 3, 4, 5, 6, 7, 8 or 9 amino acid substitutions.
  • the amino acid substitution(s) may be isosteric substitutions at the IL-15:IL-2 ⁇ and IL-15:common gamma chain interface.
  • the human IL-15 protein has one or more amino acid substitutions selected from the group consisting of N1D, N4D, D8N, D30N, D61N, E64Q, N65D, Q108E, and any combination thereof.
  • the IL-15 protein has the amino acid substitution Q108E.
  • the IL-15 protein has 1, 2, 3, 4, 5, 6, 7, 8, or more amino acid substitutions.
  • the IL-15 protein can have a N1D, N4D, D8N, D30N, D61N, E64Q, N65D, or Q108E substitution.
  • the amino acid substitution can include N1D/D61N, N1D/E64Q, N4D/D61N, N4D/E64Q, D8N/D61N, D8N/E64Q, D61N/E64Q, E64Q/Q108E, N1D/N4D/D8N, D61N/E64Q/N65D, N1D/D61N/E64Q, N1D/D61N/E64Q/Q108E, or N4D/D61N/E64Q/Q108E.
  • the IL-15 protein has the amino acid substitutions D30N/E64Q/N65D.
  • the human IL-15 receptor alpha (IL-15R ⁇ ) protein has the amino acid sequence set forth in NCBI Ref. Seq. No. NP_002180.1 or SEQ ID NO:3.
  • the coding sequence of human IL-15R ⁇ is set forth in NCBI Ref. Seq. No. NM_002189.3.
  • An exemplary the IL-15R ⁇ protein of the Fc fusion heterodimeric protein outlined herein can comprise or consist of the sushi domain of SEQ ID NO:3 (e.g., amino acids 31-95 of SEQ ID NO:3), or in other words, the amino acid sequence of SEQ ID NO:4.
  • the IL-15R ⁇ protein has the amino acid sequence of SEQ ID NO:4 and an amino acid insertion selected from the group consisting of D96, P97, A98, D96/P97, D96/C97, D96/P97/A98, D96/P97/C98, and D96/C97/A98, wherein the amino acid position is relative to full-length human IL-15R ⁇ protein or SEQ ID NO:3.
  • amino acid(s) such as D (e.g., Asp), P (e.g., Pro), A (e.g., Ala), DP (e.g., Asp-Pro), DC (e.g., Asp-Cys), DPA (e.g., Asp-Pro-Ala), DPC (e.g., Asp-Pro-Cys), or DCA (e.g., Asp-Cys-Ala)
  • D e.g., Asp
  • P e.g., Pro
  • A e.g., Ala
  • DP e.g., Asp-Pro
  • DC e.g., Asp-Cys
  • DPA e.g., Asp-Pro-Ala
  • DPC e.g., Asp-Pro-Cys
  • DCA e.g., Asp-Cys-Ala
  • the IL-15R ⁇ protein has the amino acid sequence of SEQ ID NO:4 and one or more amino acid substitutions selected from the group consisting of K34C, A37C, G38C, 540C, and L42C, wherein the amino acid position is relative to SEQ ID NO:4.
  • the IL-15R ⁇ protein can have 1, 2, 3, 4, 5, 6, 7, 8 or more amino acid mutations (e.g., substitutions, insertions and/or deletions).
  • the IL-15 protein and IL-15R ⁇ protein are attached together via a linker.
  • the proteins are not attached via a linker.
  • the IL-15 protein and IL-15R ⁇ protein are noncovalently attached.
  • the IL-15 protein is attached to an Fc domain via a linker.
  • the IL-15 protein is attached to an Fc domain directly, such as without a linker.
  • the IL-15R ⁇ protein is attached to an Fc domain via a linker.
  • the IL-15R ⁇ protein is attached to an Fc domain directly.
  • a linker is not used to attach the IL-15 protein or IL-15R ⁇ protein to an Fc domain.
  • the linker is a “domain linker”, used to link any two domains as outlined herein together. While any suitable linker can be used, many embodiments utilize a glycine-serine polymer, including for example (GS)n (SEQ ID NO: 1199), (GSGGS)n (SEQ ID NO: 1200), (GGGGS)n (SEQ ID NO: 1203), and (GGGS)n (SEQ ID NO: 1201), where n is an integer of at least 0 (and generally from 0 to 1 to 2 to 3 to 4 to 5) as well as any peptide sequence that allows for recombinant attachment of the two domains with sufficient length and flexibility to allow each domain to retain its biological function.
  • GS glycine-serine polymer
  • useful linkers include (GGGGS) 0 or (GGGGS) 1 (SEQ ID NO: 14) or (GGGGS) 2 (SEQ ID NO: 15).
  • charged domain linkers can be used as discussed herein and shown in FIG. 7 .
  • the heterodimeric fusion proteins of the invention have two functional components: an IL-15/IL-15R ⁇ (sushi) component and an Fc component, both of which can take different forms as outlined herein and both of which can be combined with the other component in any configuration.
  • the first and the second Fc domains can have a set of amino acid substitutions selected from the group consisting of a) S267K/L368D/K370S: S267K/LS364K/E357Q; b) S364K/E357Q: L368D/K370S; c) L368D/K370S: S364K; d) L368E/K370S: S364K; e) T411T/E360E/Q362E: D401K; f) L368D/K370S: S364K/E357L and g) K370S: S364K/E357Q, according to EU numbering.
  • the first and/or the second Fc domains have an additional set of amino acid substitutions comprising Q295E/N384D/Q418E/N421D, according to EU numbering.
  • the first and/or the second Fc domains have an additional set of amino acid substitutions consisting of G236R/L328R, E233P/L234V/L235A/G236del/S239K, E233P/L234V/L235A/G236del/S267K, E233P/L234V/L235A/G236del/S239K/A327G, E233P/L234V/L235A/G236del/S267K/A327G and E233P/L234V/L235A/G236del, according to EU numbering.
  • the first and/or second Fc domains have 428L/434S variants for half life extension.
  • the heterodimeric fusion protein comprises two monomers.
  • the first monomer comprises (from N- to C-terminus) IL-15-optional domain linker-CH2-CH3, where the domain linker sometimes comprises all or part of the hinge.
  • the second monomer comprises the IL-15/R ⁇ (sushi) domain-optional domain linker-CH2-CH3, where the domain linker sometimes comprises all or part of the hinge.
  • a preferred embodiment utilizes the skew variant pair S364K/E357Q: L368D/K370S.
  • a preferred embodiment utilizes the IL-15 variant Q108E.
  • a preferred embodiment utilizes the IL-15 variant Q108E and the skew variant pair S364K/E357Q: L368D/K370S.
  • a preferred embodiment utilizes the IL-15 variant Q108E and the skew variant pair S364K/E357Q: L368D/K370S and the 428L/434S variants on both monomers.
  • a preferred embodiment utilizes the IL-15 D30N/E64Q/N65D variants.
  • a preferred embodiment utilizes the IL-15 D30N/E64Q/N65D variants and the skew variant pair S364K/E357Q: L368D/K370S.
  • a preferred embodiment utilizes the IL-15 D30N/E64Q/N65D variants, the skew variant pair S364K/E357Q: L368D/K370S and the 428L/434S variants on each Fc monomer.
  • a preferred embodiment utilizes the IL-15 N65D variant.
  • a preferred embodiment utilizes the IL-15 N65D variant, and the skew variant pair S364K/E357Q: L368D/K370S
  • a preferred embodiment utilizes the IL-15 N65D variant, the skew variant pair S364K/E357Q: L368D/K370S and the 428L/434S variants on each Fc monomer.
  • a preferred embodiment utilizes the IL-15 N4D/N65D variant.
  • a preferred embodiment utilizes the IL-15 N4D/N65D variant and the skew variant pair S364K/E357Q: L368D/K370S.
  • a preferred embodiment utilizes the IL-15 N4D/N65D variant, the skew variant pair S364K/E357Q: L368D/K370S and the 428L/434S variants on each Fc monomer.
  • a preferred embodiment utilizes the IL-15 N1D/N65D variant.
  • a preferred embodiment utilizes the IL-15 N1D/N65D variant and the skew variant pair S364K/E357Q: L368D/K370S.
  • a preferred embodiment utilizes the IL-15 N1D/N65D variant, the skew variant pair S364K/E357Q: L368D/K370S and the 428L/434S variants on each Fc monomer.
  • FIG. 48A (XENP22822 including chain 1 (17693) and chain 2 (15908)), FIG. 94A (XENP23504 including chain 1 and chain 2), FIG. 104AO (XENP24045 including chain 1 and chain 2), FIG. 104AQ (XENP24306 including chain 1 and chain 2), FIG. 48A (XENP22821 including chain 1 and chain 2), FIG. 94A (XENP23343 including chain 1 and chain 2), FIG. 104AJ (XENP23557 including chain 1 and chain 2), FIG. 104AP (XENP24113 including chain 1 and chain 2), FIG. 104AP (XENP24051 including chain 1 and chain 2), FIG. 104AR (XENP24341 including chain 1 and chain 2), FIG. 104AP (XENP24052 including chain 1 and chain 2), and FIG. 104AP (XENP24301 including chain 1 and chain 2).
  • the heterodimeric fusion protein comprises two monomers.
  • the first monomer comprises (from N- to C-terminus) IL-15/R ⁇ (sushi)-domain linker-IL-15-optional domain linker-CH2-CH3, where the domain linker sometimes comprises all or part of the hinge.
  • the second monomer comprises and “empty” Fc, comprising all or part of the hinge-CH2-CH3. This is referred to as “scIL-15/R ⁇ -Fc” with the “sc” standing for “single chain” (e.g. of the IL-15/sushi complex).
  • a preferred embodiment utilizes the skew variant pair S364K/E357Q: L368D/K370S.
  • a preferred embodiment utilizes the IL-15 variant Q108E.
  • a preferred embodiment utilizes the IL-15 variant Q108E and the skew variant pair S364K/E357Q: L368D/K370S.
  • a preferred embodiment utilizes the IL-15 variant Q108E and the skew variant pair S364K/E357Q: L368D/K370S and the 428L/434S variants on both monomers.
  • a preferred embodiment utilizes the IL-15 D30N/E64Q/N65D variants.
  • a preferred embodiment utilizes the IL-15 D30N/E64Q/N65D variants and the skew variant pair S364K/E357Q: L368D/K370S.
  • a preferred embodiment utilizes the IL-15 D30N/E64Q/N65D variants, the skew variant pair S364K/E357Q: L368D/K370S and the 428L/434S variants on each Fc monomer.
  • a preferred embodiment utilizes the IL-15 N65D variant.
  • a preferred embodiment utilizes the IL-15 N65D variant, and the skew variant pair S364K/E357Q: L368D/K370S
  • a preferred embodiment utilizes the IL-15 N65D variant, the skew variant pair S364K/E357Q: L368D/K370S and the 428L/434S variants on each Fc monomer.
  • a preferred embodiment utilizes the IL-15 N4D/N65D variant.
  • a preferred embodiment utilizes the IL-15 N4D/N65D variant and the skew variant pair S364K/E357Q: L368D/K370S.
  • a preferred embodiment utilizes the IL-15 N4D/N65D variant, the skew variant pair S364K/E357Q: L368D/K370S and the 428L/434S variants on each Fc monomer.
  • a preferred embodiment utilizes the IL-15 N1D/N65D variant.
  • a preferred embodiment utilizes the IL-15 N1D/N65D variant and the skew variant pair S364K/E357Q: L368D/K370S.
  • a preferred embodiment utilizes the IL-15 N1D/N65D variant, the skew variant pair S364K/E357Q: L368D/K370S and the 428L/434S variants on each Fc monomer.
  • the heterodimeric fusion protein comprises three monomers.
  • the first monomer comprises (from N- to C-terminus) IL-15/R ⁇ (sushi)-domain linker-CH2-CH3, where the domain linker sometimes comprises all or part of the hinge.
  • the second monomer comprises and “empty” Fc, comprising all or part of the hinge-CH2-CH3.
  • the third monomer is IL-15. This is referred to as “ncIL-15/R ⁇ -Fc” with the “nc” standing for “non-covalent”).
  • a preferred embodiment utilizes the skew variant pair S364K/E357Q: L368D/K370S.
  • ncIL-15/R ⁇ -Fc format a preferred embodiment utilizes the IL-15 variant Q108E.
  • a preferred embodiment utilizes the IL-15 variant Q108E and the skew variant pair S364K/E357Q: L368D/K370S.
  • a preferred embodiment utilizes the IL-15 variant Q108E and the skew variant pair S364K/E357Q: L368D/K370S and the 428L/434S variants on both monomers.
  • ncIL-15/R ⁇ -Fc format a preferred embodiment utilizes the IL-15 D30N/E64Q/N65D variants.
  • a preferred embodiment utilizes the IL-15 D30N/E64Q/N65D variants and the skew variant pair S364K/E357Q: L368D/K370S.
  • a preferred embodiment utilizes the IL-15 D30N/E64Q/N65D variants, the skew variant pair S364K/E357Q: L368D/K370S and the 428L/434S variants on each Fc monomer.
  • ncIL-15/R ⁇ -Fc format a preferred embodiment utilizes the IL-15 N65D variant.
  • a preferred embodiment utilizes the IL-15 N65D variant, and the skew variant pair S364K/E357Q: L368D/K370S
  • a preferred embodiment utilizes the IL-15 N65D variant, the skew variant pair S364K/E357Q: L368D/K370S and the 428L/434S variants on each Fc monomer.
  • ncIL-15/R ⁇ -Fc format a preferred embodiment utilizes the IL-15 N4D/N65D variant.
  • a preferred embodiment utilizes the IL-15 N4D/N65D variant and the skew variant pair S364K/E357Q: L368D/K370S.
  • a preferred embodiment utilizes the IL-15 N4D/N65D variant, the skew variant pair S364K/E357Q: L368D/K370S and the 428L/434S variants on each Fc monomer.
  • ncIL-15/R ⁇ -Fc format a preferred embodiment utilizes the IL-15 N1D/N65D variant.
  • a preferred embodiment utilizes the IL-15 N1D/N65D variant and the skew variant pair S364K/E357Q: L368D/K370S.
  • a preferred embodiment utilizes the IL-15 N1D/N65D variant, the skew variant pair S364K/E357Q: L368D/K370S and the 428L/434S variants on each Fc monomer.
  • FIG. 104AS XENP24349 including chain 1 and chain 2
  • FIG. 104AT XENP24383 including chain 1 and chain 2.
  • the heterodimeric fusion protein comprises four monomers.
  • the first and second monomers comprise (from N- to C-terminus) IL-15/R ⁇ (sushi)-domain linker-CH2-CH3, where the domain linker sometimes comprises all or part of the hinge.
  • the third and fourth monomers comprise IL-15. This is referred to as “bivalent ncIL-15/R ⁇ -Fc” with the “nc” standing for “non-covalent”).
  • a preferred embodiment utilizes the skew variant pair S364K/E357Q: L368D/K370S.
  • ncIL-15/R ⁇ -Fc format a preferred embodiment utilizes the IL-15 variant Q108E.
  • ncIL-15/R ⁇ -Fc format a preferred embodiment utilizes the IL-15 variant Q108E and the skew variant pair S364K/E357Q: L368D/K370S.
  • a preferred embodiment utilizes the IL-15 variant Q108E and the skew variant pair S364K/E357Q: L368D/K370S and the 428L/434S variants on both monomers.
  • ncIL-15/R ⁇ -Fc format a preferred embodiment utilizes the IL-15 D30N/E64Q/N65D variants.
  • ncIL-15/R ⁇ -Fc format a preferred embodiment utilizes the IL-15 D30N/E64Q/N65D variants and the skew variant pair S364K/E357Q: L368D/K370S.
  • ncIL-15/R ⁇ -Fc format a preferred embodiment utilizes the IL-15 D30N/E64Q/N65D variants, the skew variant pair S364K/E357Q: L368D/K370S and the 428L/434S variants on each Fc monomer.
  • ncIL-15/R ⁇ -Fc format a preferred embodiment utilizes the IL-15 N65D variant.
  • ncIL-15/R ⁇ -Fc format a preferred embodiment utilizes the IL-15 N65D variant, and the skew variant pair S364K/E357Q: L368D/K370S
  • ncIL-15/R ⁇ -Fc format a preferred embodiment utilizes the IL-15 N65D variant, the skew variant pair S364K/E357Q: L368D/K370S and the 428L/434S variants on each Fc monomer.
  • ncIL-15/R ⁇ -Fc format a preferred embodiment utilizes the IL-15 N4D/N65D variant.
  • ncIL-15/R ⁇ -Fc format a preferred embodiment utilizes the IL-15 N4D/N65D variant and the skew variant pair S364K/E357Q: L368D/K370S.
  • ncIL-15/R ⁇ -Fc format a preferred embodiment utilizes the IL-15 N4D/N65D variant, the skew variant pair S364K/E357Q: L368D/K370S and the 428L/434S variants on each Fc monomer.
  • ncIL-15/R ⁇ -Fc format a preferred embodiment utilizes the IL-15 N1D/N65D variant.
  • ncIL-15/R ⁇ -Fc format a preferred embodiment utilizes the IL-15 N1D/N65D variant and the skew variant pair S364K/E357Q: L368D/K370S.
  • ncIL-15/R ⁇ -Fc format a preferred embodiment utilizes the IL-15 N1D/N65D variant, the skew variant pair S364K/E357Q: L368D/K370S and the 428L/434S variants on each Fc monomer.
  • FIG. 104AR In the bivalent ncIL-15/R ⁇ -Fc format, preferred embodiments are shown in FIG. 104AR (XENP24342 including chain 1 and chain 2) and (XENP24346 including chain 1 and chain 2).
  • heterodimeric fusion proteins of the present invention can take on a wide variety of configurations, as are generally depicted in FIGS. 9A-9G and FIGS. 39A-39D .
  • the amino acid sequences of exemplary fusion proteins are provided in 8 A- 8 E, 10 , 11 , 12 A, 12 B, 13 - 15 , 40 A, 40 B, 41 A, 41 B, 42 , 43 , 48 A- 48 D, 49 A- 49 C, 50 A, 50 B, 51 , 52 , 53 , and 94 A- 94 D.
  • first fusion protein comprising an IL-15 protein domain covalently attached using a first domain linker to the N-terminus of a first Fc domain
  • second fusion protein comprising an IL-15R ⁇ protein domain covalently attached using a second domain linker to the N-terminus of a second Fc domain
  • IL-15/R ⁇ hetero Fc and “dsIL-15/R ⁇ hetero Fc”) include, but are not limited to, XENP20818, XENP20819, XENP21471, XENP21472, XENP21473, XENP21474, XENP21475, XENP21476, XENP21477, XENP22013, XENP22815, XENP22816, XENP22817, XENP22818, XENP22819, XENP22820, XENP22821, XENP22822, XENP22823, XENP22824, XENP22825, XENP22826, XENP22827, XENP22828, XENP22829, XENP22830, XENP22831, XENP22832, XENP22833,
  • a useful format of a heterodimer Fc fusion protein comprises a fusion protein comprising a first protein domain covalently attached to the N-terminus of a second protein domain via a first domain linker that is covalently attached to the N-terminus of a first Fc domain via a second domain linker, and a second Fc domain (e.g., an empty Fc domain).
  • the first protein domain is an IL-15R ⁇ protein domain
  • the second protein domain is an IL-15 protein domain.
  • An exemplary embodiment of this format (“scIL-15/R ⁇ -Fc”) includes, but is not limited to, XENP21478.
  • Yet another useful of a heterodimer Fc fusion protein outlined herein comprises a fusion protein comprising a first protein domain covalently attached to the N-terminus a first Fc domain via a domain linker, a second Fc domain (e.g., an empty Fc domain), and a second protein domain that is noncovalently attached to the first protein domain.
  • the first protein domain is an IL-15 protein domain and the second protein domain is an IL-15R ⁇ protein domain.
  • ncIL-15/R ⁇ -Fc includes, but is not limited to, XENP21479, XENP22357, XENP22354, XENP22355, XENP22356, XENP22357, XENP22358, XENP22359, XENP22360, XENP22361, XENP22362, XENP22363, XENP22364, XENP22365, XENP22366, XENP22637, XENP24348, XENP24349, and XENP24383.
  • Another useful format of a heterodimer Fc fusion protein outlined herein comprises a first fusion protein comprising a first protein domain covalently attached to the N-terminus of said first Fc domain via a first domain linker, a second fusion protein comprising a second protein domain covalently attached to the N-terminus of said second Fc domain via a second domain linker, a third protein domain noncovalently attached to said first protein domain of said first fusion protein, and a fourth protein domain noncovalently attached to said second protein domain of said second fusion protein.
  • the first and second protein domains are IL-15 R ⁇ protein domains
  • the third and fourth protein domains are IL-15 protein domains.
  • bivalent ncIL-15/R ⁇ -Fc or “bivalent dsIL-15/R ⁇ -Fc”
  • XENP21978 includes, but is not limited to, XENP21978, XENP22634, XENP24342, and XENP24346.
  • bivalent scIL-15/R ⁇ -Fc Another useful format (“bivalent scIL-15/R ⁇ -Fc”) is outlined herein in FIG. 14 .
  • Yet another useful format of a heterodimer Fc fusion protein outlined herein comprises a first fusion protein comprising a first Fc domain covalently attached to the N-terminus of a first protein domain using a domain linker, a second Fc domain (e.g., an empty Fc domain), and a second protein domain noncovalently attached to said first protein domain.
  • An exemplary embodiment of this format (“Fc-ncIL-15/R ⁇ ” or “Fc-dsIL-15/R ⁇ ”) includes, but is not limited to, XENP22637 and XENP22639, and those depicted in FIG. 16 .
  • the first protein and the second protein are attached via a linker ( FIG. 9G ).
  • the first domain linker and the second domain linker can be the same or different.
  • the first Fc domain and the second Fc domain of the heterodimeric protein can have different amino acid sequences.
  • the Fc domains of the present invention comprise IgG Fc domains, e.g., IgG1 Fc domains.
  • the first and second Fc domains comprising a set of amino acid substitutions selected from the group consisting of: L368D/K370S and S364K; L368D/K370S and S364K/E357L; L368D/K370S and S364K/E357Q; T411E/K360E/Q362E and D401K; L368E/K370S and S364K; K370S and S364K/E357Q; K370S and S364K/E357Q; S267K/L368D/K370S and S267K/S364K/E357Q, according to EU numbering.
  • the first and/or the second Fc domains of any of the heterodimeric Fc fusion formats outlined herein can have an additional set of amino acid substitutions comprising Q295E/N384D/Q418E/N421D, according to EU numbering.
  • the first and/or the second Fc domains have an additional set of amino acid substitutions consisting of G236R/L328R, E233P/L234V/L235A/G236del/S239K, E233P/L234V/L235A/G236del/S267K, E233P/L234V/L235A/G236del/S239K/A327G, E233P/L234V/L235A/G236del/S267K/A327G and E233P/L234V/L235A/G236del, according to EU numbering.
  • compositions can further comprise ablation variants, pI variants, charged variants, isotypic variants, etc.
  • the invention further provides nucleic acid compositions encoding the heterodimeric Fc fusion protein of the invention (or, in the case of a monomer Fc domain protein, nucleic acids encoding those as well).
  • nucleic acid compositions will depend on the format of the heterodimeric protein.
  • the format requires three amino acid sequences
  • three nucleic acid sequences can be incorporated into one or more expression vectors for expression.
  • some formats only two nucleic acids are needed; again, they can be put into one or two expression vectors.
  • the nucleic acids encoding the components of the invention can be incorporated into expression vectors as is known in the art, and depending on the host cells used to produce the heterodimeric Fc fusion proteins of the invention. Generally the nucleic acids are operably linked to any number of regulatory elements (promoters, origin of replication, selectable markers, ribosomal binding sites, inducers, etc.).
  • the expression vectors can be extra-chromosomal or integrating vectors.
  • nucleic acids and/or expression vectors of the invention are then transformed into any number of different types of host cells as is well known in the art, including mammalian, bacterial, yeast, insect and/or fungal cells, with mammalian cells (e.g. CHO cells), finding use in many embodiments.
  • mammalian cells e.g. CHO cells
  • nucleic acids encoding each monomer are each contained within a single expression vector, generally under different or the same promoter controls. In embodiments of particular use in the present invention, each of these two or three nucleic acids are contained on a different expression vector.
  • the heterodimeric Fc fusion protein of the invention are made by culturing host cells comprising the expression vector(s) as is well known in the art. Once produced, traditional fusion protein or antibody purification steps are done, including an ion exchange chromotography step. As discussed herein, having the pIs of the two monomers differ by at least 0.5 can allow separation by ion exchange chromatography or isoelectric focusing, or other methods sensitive to isoelectric point.
  • substitutions that alter the isoelectric point (pI) of each monomer so that such that each monomer has a different pI and the heterodimer also has a distinct pI, thus facilitating isoelectric purification of the heterodimer (e.g., anionic exchange columns, cationic exchange columns).
  • substitutions also aid in the determination and monitoring of any contaminating homodimers post-purification (e.g., IEF gels, cIEF, and analytical IEX columns).
  • the heterodimeric Fc fusion proteins of the invention are administered to patients with cancer, and efficacy is assessed, in a number of ways as described herein.
  • efficacy is assessed, in a number of ways as described herein.
  • standard assays of efficacy can be run, such as cancer load, size of tumor, evaluation of presence or extent of metastasis, etc.
  • immuno-oncology treatments can be assessed on the basis of immune status evaluations as well. This can be done in a number of ways, including both in vitro and in vivo assays. For example, evaluation of changes in immune status (e.g., presence of ICOS+CD4+ T cells following ipi treatment) along with “old fashioned” measurements such as tumor burden, size, invasiveness, LN involvement, metastasis, etc. can be done.
  • any or all of the following can be evaluated: the inhibitory effects of PVRIG on CD4+ T cell activation or proliferation, CD8+ T (CTL) cell activation or proliferation, CD8+ T cell-mediated cytotoxic activity and/or CTL mediated cell depletion, NK cell activity and NK mediated cell depletion, the potentiating effects of PVRIG on Treg cell differentiation and proliferation and Treg- or myeloid derived suppressor cell (MDSC)-mediated immunosuppression or immune tolerance, and/or the effects of PVRIG on proinflammatory cytokine production by immune cells, e.g., IL-2, IFN- ⁇ or TNF- ⁇ production by T or other immune cells.
  • CTL CD8+ T
  • CTL CD8+ T cell activation or proliferation
  • CD8+ T cell-mediated cytotoxic activity and/or CTL mediated cell depletion CD8+ T cell-mediated cytotoxic activity and/or CTL mediated cell depletion
  • NK cell activity and NK mediated cell depletion
  • assessment of treatment is done by evaluating immune cell proliferation, using for example, CFSE dilution method, Ki67 intracellular staining of immune effector cells, and 3 H-thymidine incorporation method,
  • assessment of treatment is done by evaluating the increase in gene expression or increased protein levels of activation-associated markers, including one or more of: CD25, CD69, CD137, ICOS, PD1, GITR, OX40, and cell degranulation measured by surface expression of CD107A.
  • gene expression assays are done as is known in the art.
  • assessment of treatment is done by assessing cytotoxic activity measured by target cell viability detection via estimating numerous cell parameters such as enzyme activity (including protease activity), cell membrane permeability, cell adherence, ATP production, co-enzyme production, and nucleotide uptake activity.
  • enzyme activity including protease activity
  • cell membrane permeability cell permeability
  • cell adherence cell adherence
  • ATP production co-enzyme production
  • nucleotide uptake activity include, but are not limited to, Trypan Blue or PI staining, 51 Cr or 35 S release method, LDH activity, MTT and/or WST assays, Calcein-AM assay, Luminescent based assay, and others.
  • assessment of treatment is done by assessing T cell activity measured by cytokine production, measure either intracellularly in culture supernatant using cytokines including, but not limited to, IFN ⁇ , TNF ⁇ , GM-CSF, IL2, IL6, IL4, IL5, IL10, IL13 using well known techniques.
  • cytokines including, but not limited to, IFN ⁇ , TNF ⁇ , GM-CSF, IL2, IL6, IL4, IL5, IL10, IL13 using well known techniques.
  • assessment of treatment can be done using assays that evaluate one or more of the following: (i) increases in immune response, (ii) increases in activation of and/or ⁇ T cells, (iii) increases in cytotoxic T cell activity, (iv) increases in NK and/or NKT cell activity, (v) alleviation of and/or ⁇ T-cell suppression, (vi) increases in pro-inflammatory cytokine secretion, (vii) increases in IL-2 secretion; (viii) increases in interferon- ⁇ production, (ix) increases in Th1 response, (x) decreases in Th2 response, (xi) decreases or eliminates cell number and/or activity of at least one of regulatory T cells (Tregs).
  • T cell activation is assessed using a Mixed Lymphocyte Reaction (MLR) assay as is known in the art.
  • MLR Mixed Lymphocyte Reaction
  • An increase in activity indicates immunostimulatory activity. Appropriate increases in activity are outlined below.
  • the signaling pathway assay measures increases or decreases in immune response as measured for an example by phosphorylation or de-phosphorylation of different factors, or by measuring other post translational modifications.
  • An increase in activity indicates immunostimulatory activity. Appropriate increases in activity are outlined below.
  • the signaling pathway assay measures increases or decreases in activation of and/or ⁇ T cells as measured for an example by cytokine secretion or by proliferation or by changes in expression of activation markers like for an example CD137, CD107a, PD1, etc.
  • An increase in activity indicates immunostimulatory activity. Appropriate increases in activity are outlined below.
  • the signaling pathway assay measures increases or decreases in cytotoxic T cell activity as measured for an example by direct killing of target cells like for an example cancer cells or by cytokine secretion or by proliferation or by changes in expression of activation markers like for an example CD137, CD107a, PD1, etc.
  • An increase in activity indicates immunostimulatory activity. Appropriate increases in activity are outlined below.
  • the signaling pathway assay measures increases or decreases in NK and/or NKT cell activity as measured for an example by direct killing of target cells like for an example cancer cells or by cytokine secretion or by changes in expression of activation markers like for an example CD107a, etc.
  • An increase in activity indicates immunostimulatory activity. Appropriate increases in activity are outlined below.
  • the signaling pathway assay measures increases or decreases in 1343 and/or ⁇ T-cell suppression, as measured for an example by cytokine secretion or by proliferation or by changes in expression of activation markers like for an example CD137, CD107a, PD1, etc.
  • An increase in activity indicates immunostimulatory activity. Appropriate increases in activity are outlined below.
  • the signaling pathway assay measures increases or decreases in pro-inflammatory cytokine secretion as measured for example by ELISA or by Luminex or by Multiplex bead based methods or by intracellular staining and FACS analysis or by Alispot etc.
  • An increase in activity indicates immunostimulatory activity. Appropriate increases in activity are outlined below.
  • the signaling pathway assay measures increases or decreases in IL-2 secretion as measured for example by ELISA or by Luminex or by Multiplex bead based methods or by intracellular staining and FACS analysis or by Alispot etc.
  • An increase in activity indicates immunostimulatory activity. Appropriate increases in activity are outlined below.
  • the signaling pathway assay measures increases or decreases in interferon- ⁇ production as measured for example by ELISA or by Luminex or by Multiplex bead based methods or by intracellular staining and FACS analysis or by Alispot etc.
  • An increase in activity indicates immunostimulatory activity. Appropriate increases in activity are outlined below.
  • the signaling pathway assay measures increases or decreases in Th1 response as measured for an example by cytokine secretion or by changes in expression of activation markers.
  • An increase in activity indicates immunostimulatory activity. Appropriate increases in activity are outlined below.
  • the signaling pathway assay measures increases or decreases in Th2 response as measured for an example by cytokine secretion or by changes in expression of activation markers.
  • An increase in activity indicates immunostimulatory activity. Appropriate increases in activity are outlined below.
  • the signaling pathway assay measures increases or decreases cell number and/or activity of at least one of regulatory T cells (Tregs), as measured for example by flow cytometry or by IHC.
  • Tregs regulatory T cells
  • a decrease in response indicates immunostimulatory activity. Appropriate decreases are the same as for increases, outlined below.
  • the signaling pathway assay measures increases or decreases in M2 macrophages cell numbers, as measured for example by flow cytometry or by IHC. A decrease in response indicates immunostimulatory activity. Appropriate decreases are the same as for increases, outlined below.
  • the signaling pathway assay measures increases or decreases in M2 macrophage pro-tumorigenic activity, as measured for an example by cytokine secretion or by changes in expression of activation markers. A decrease in response indicates immunostimulatory activity. Appropriate decreases are the same as for increases, outlined below.
  • the signaling pathway assay measures increases or decreases in N2 neutrophils increase, as measured for example by flow cytometry or by IHC. A decrease in response indicates immunostimulatory activity. Appropriate decreases are the same as for increases, outlined below.
  • the signaling pathway assay measures increases or decreases in N2 neutrophils pro-tumorigenic activity, as measured for an example by cytokine secretion or by changes in expression of activation markers. A decrease in response indicates immunostimulatory activity. Appropriate decreases are the same as for increases, outlined below.
  • the signaling pathway assay measures increases or decreases in inhibition of T cell activation, as measured for an example by cytokine secretion or by proliferation or by changes in expression of activation markers like for an example CD137, CD107a, PD1, etc.
  • An increase in activity indicates immunostimulatory activity. Appropriate increases in activity are outlined below.
  • the signaling pathway assay measures increases or decreases in inhibition of CTL activation as measured for an example by direct killing of target cells like for an example cancer cells or by cytokine secretion or by proliferation or by changes in expression of activation markers like for an example CD137, CD107a, PD1, etc.
  • An increase in activity indicates immunostimulatory activity. Appropriate increases in activity are outlined below.
  • the signaling pathway assay measures increases or decreases in ⁇ and/or ⁇ T cell exhaustion as measured for an example by changes in expression of activation markers.
  • a decrease in response indicates immunostimulatory activity. Appropriate decreases are the same as for increases, outlined below.
  • the signaling pathway assay measures increases or decreases ⁇ and/or ⁇ T cell response as measured for an example by cytokine secretion or by proliferation or by changes in expression of activation markers like for an example CD137, CD107a, PD1, etc.
  • An increase in activity indicates immunostimulatory activity. Appropriate increases in activity are outlined below.
  • the signaling pathway assay measures increases or decreases in stimulation of antigen-specific memory responses as measured for an example by cytokine secretion or by proliferation or by changes in expression of activation markers like for an example CD45RA, CCR7 etc.
  • An increase in activity indicates immunostimulatory activity. Appropriate increases in activity are outlined below.
  • the signaling pathway assay measures increases or decreases in apoptosis or lysis of cancer cells as measured for an example by cytotoxicity assays such as for an example MTT, Cr release, Calcine AM, or by flow cytometry based assays like for an example CFSE dilution or propidium iodide staining etc.
  • cytotoxicity assays such as for an example MTT, Cr release, Calcine AM
  • flow cytometry based assays like for an example CFSE dilution or propidium iodide staining etc.
  • An increase in activity indicates immunostimulatory activity. Appropriate increases in activity are outlined below.
  • the signaling pathway assay measures increases or decreases in stimulation of cytotoxic or cytostatic effect on cancer cells, as measured for an example by cytotoxicity assays such as for an example MTT, Cr release, Calcine AM, or by flow cytometry based assays like for an example CFSE dilution or propidium iodide staining etc.
  • cytotoxicity assays such as for an example MTT, Cr release, Calcine AM
  • flow cytometry based assays like for an example CFSE dilution or propidium iodide staining etc.
  • An increase in activity indicates immunostimulatory activity. Appropriate increases in activity are outlined below.
  • the signaling pathway assay measures increases or decreases direct killing of cancer cells as measured for an example by cytotoxicity assays such as for an example MTT, Cr release, Calcine AM, or by flow cytometry based assays like for an example CFSE dilution or propidium iodide staining etc.
  • cytotoxicity assays such as for an example MTT, Cr release, Calcine AM
  • flow cytometry based assays like for an example CFSE dilution or propidium iodide staining etc.
  • An increase in activity indicates immunostimulatory activity. Appropriate increases in activity are outlined below.
  • the signaling pathway assay measures increases or decreases Th17 activity as measured for an example by cytokine secretion or by proliferation or by changes in expression of activation markers.
  • An increase in activity indicates immunostimulatory activity. Appropriate increases in activity are outlined below.
  • the signaling pathway assay measures increases or decreases in induction of complement dependent cytotoxicity and/or antibody dependent cell-mediated cytotoxicity, as measured for an example by cytotoxicity assays such as for an example MTT, Cr release, Calcine AM, or by flow cytometry based assays like for an example CFSE dilution or propidium iodide staining etc.
  • cytotoxicity assays such as for an example MTT, Cr release, Calcine AM, or by flow cytometry based assays like for an example CFSE dilution or propidium iodide staining etc.
  • An increase in activity indicates immunostimulatory activity. Appropriate increases in activity are outlined below.
  • T cell activation is measured for an example by direct killing of target cells like for an example cancer cells or by cytokine secretion or by proliferation or by changes in expression of activation markers like for an example CD137, CD107a, PD1, etc.
  • increases in proliferation cell surface markers of activation (e.g., CD25, CD69, CD137, PD1), cytotoxicity (ability to kill target cells), and cytokine production (e.g., IL-2, IL-4, IL-6, IFN ⁇ , TNF-a, IL-10, IL-17A) would be indicative of immune modulation that would be consistent with enhanced killing of cancer cells.
  • NK cell activation is measured for example by direct killing of target cells like for an example cancer cells or by cytokine secretion or by changes in expression of activation markers like for an example CD107a, etc.
  • increases in proliferation, cytotoxicity (ability to kill target cells and increases CD107a, granzyme, and perforin expression), cytokine production (e.g., IFN ⁇ and TNF), and cell surface receptor expression (e.g. CD25) would be indicative of immune modulation that would be consistent with enhanced killing of cancer cells.
  • ⁇ T cell activation is measured for example by cytokine secretion or by proliferation or by changes in expression of activation markers.
  • Th1 cell activation is measured for example by cytokine secretion or by changes in expression of activation markers.
  • Appropriate increases in activity or response are increases of 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or 98 to 99% percent over the signal in either a reference sample or in control samples, for example test samples that do not contain an anti-PVRIG antibody of the invention.
  • increases of at least one-, two-, three-, four- or five-fold as compared to reference or control samples show efficacy.
  • compositions of the invention find use in a number of oncology applications, by treating cancer, generally by promoting T cell activation (e.g., T cells are no longer suppressed) with the binding of the heterodimeric Fc fusion proteins of the invention.
  • heterodimeric compositions of the invention find use in the treatment of these cancers.
  • Formulations of the antibodies used in accordance with the present invention are prepared for storage by mixing an antibody having the desired degree of purity with optional pharmaceutically acceptable carriers, excipients or stabilizers (as generally outlined in Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. [1980]), in the form of lyophilized formulations or aqueous solutions.
  • Acceptable carriers, buffers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, hist
  • heterodimeric proteins and chemotherapeutic agents of the invention are administered to a subject, in accord with known methods, such as intravenous administration as a bolus or by continuous infusion over a period of time.
  • therapy is used to provide a positive therapeutic response with respect to a disease or condition.
  • positive therapeutic response is intended an improvement in the disease or condition, and/or an improvement in the symptoms associated with the disease or condition.
  • a positive therapeutic response would refer to one or more of the following improvements in the disease: (1) a reduction in the number of neoplastic cells; (2) an increase in neoplastic cell death; (3) inhibition of neoplastic cell survival; (5) inhibition (i.e., slowing to some extent, preferably halting) of tumor growth; (6) an increased patient survival rate; and (7) some relief from one or more symptoms associated with the disease or condition.
  • Positive therapeutic responses in any given disease or condition can be determined by standardized response criteria specific to that disease or condition.
  • Tumor response can be assessed for changes in tumor morphology (i.e., overall tumor burden, tumor size, and the like) using screening techniques such as magnetic resonance imaging (MRI) scan, x-radiographic imaging, computed tomographic (CT) scan, bone scan imaging, endoscopy, and tumor biopsy sampling including bone marrow aspiration (BMA) and counting of tumor cells in the circulation.
  • MRI magnetic resonance imaging
  • CT computed tomographic
  • BMA bone marrow aspiration
  • the subject undergoing therapy may experience the beneficial effect of an improvement in the symptoms associated with the disease.
  • Treatment according to the present invention includes a “therapeutically effective amount” of the medicaments used.
  • a “therapeutically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve a desired therapeutic result.
  • a therapeutically effective amount may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the medicaments to elicit a desired response in the individual.
  • a therapeutically effective amount is also one in which any toxic or detrimental effects of the antibody or antibody portion are outweighed by the therapeutically beneficial effects.
  • a “therapeutically effective amount” for tumor therapy may also be measured by its ability to stabilize the progression of disease.
  • the ability of a compound to inhibit cancer may be evaluated in an animal model system predictive of efficacy in human tumors.
  • this property of a composition may be evaluated by examining the ability of the compound to inhibit cell growth or to induce apoptosis by in vitro assays known to the skilled practitioner.
  • a therapeutically effective amount of a therapeutic compound may decrease tumor size, or otherwise ameliorate symptoms in a subject.
  • One of ordinary skill in the art would be able to determine such amounts based on such factors as the subject's size, the severity of the subject's symptoms, and the particular composition or route of administration selected.
  • Dosage regimens are adjusted to provide the optimum desired response (e.g., a therapeutic response). For example, a single bolus may be administered, several divided doses may be administered over time or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation.
  • Parenteral compositions may be formulated in dosage unit form for ease of administration and uniformity of dosage.
  • Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subjects to be treated; each unit contains a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
  • the efficient dosages and the dosage regimens for the bispecific antibodies used in the present invention depend on the disease or condition to be treated and may be determined by the persons skilled in the art.
  • An exemplary, non-limiting range for a therapeutically effective amount of an bispecific antibody used in the present invention is about 0.1-100 mg/kg.
  • IL-15/IL-15R ⁇ (sushi) complex as a Fc fusion (hereon referred to as IL-15/R ⁇ -Fc fusion proteins) with the goal of facilitating production and promoting FcRn-mediated recycling of the complex and prolonging half-life.
  • Example 1A Engineering IL-15/R ⁇ -Fc Fusion Proteins
  • Plasmids coding for IL-15 or IL-15R ⁇ sushi domain were constructed by standard gene synthesis, followed by subcloning into a pTT5 expression vector containing Fc fusion partners (e.g., constant regions as depicted in FIG. 8 ).
  • Cartoon schematics of illustrative IL-15/R ⁇ -Fc fusion protein formats are depicted in FIGS. 9A-G .
  • the IL-15R ⁇ heterodimeric Fc fusion or “IL-15/R ⁇ -heteroFc” format comprises IL-15 recombinantly fused to one side of a heterodimeric Fc and IL-15R ⁇ sushi domain recombinantly fused to the other side of the heterodimeric Fc ( FIG. 9A ).
  • the IL-15 and IL-15R ⁇ may have a variable length linker (see FIG. 7 ) between their respective C-terminus and the N-terminus of the Fc region.
  • Illustrative proteins of this format include XENP20818 and XENP21475, sequences for which are depicted in FIG. 10 (see also Table 1). Sequences for additional proteins of this format are listed as XENPs 20819, 21471, 21472, 21473, 21474, 21476, and 21477 in the figures and in the sequence listing.
  • the single-chain IL-15/R ⁇ -Fc fusion or “scIL-15/R ⁇ -Fc” format comprises IL-15R ⁇ sushi domain fused to IL-15 by a variable length linker (termed a “single-chain” IL-15/IL-15R ⁇ complex or “scIL-15/R ⁇ ”) which is then fused to the N-terminus of a heterodimeric Fc-region, with the other side of the molecule being a “Fc-only” or “empty-Fc” heterodimeric Fc ( FIG. 9B ). Sequences for illustrative linkers are depicted in FIG. 7 .
  • An illustrative protein of this format is XENP21478, sequences for which are depicted in FIG. 11 (also see Table 2). Sequences for additional proteins of this format are listed as XENPs 21993, 21994, 21995, 23174, 23175, 24477, and 24480 in the figures and the sequence listing.
  • the non-covalent IL-15/R ⁇ -Fc fusion or “ncIL-15/R ⁇ -Fc” format comprises IL-15R ⁇ sushi domain fused to a heterodimeric Fc region, while IL-15 is transfected separately so that a non-covalent IL-15/IL-15R ⁇ complex is formed, with the other side of the molecule being a “Fc-only” or “empty-Fc” heterodimeric Fc ( FIG. 9C ).
  • Illustrative proteins of this format include XENP21479, XENP22366 and XENP24348, sequences for which are depicted in FIG. 12 .
  • the bivalent non-covalent IL-15/R ⁇ -Fc fusion or “bivalent ncIL-15/R ⁇ -Fc” format ( FIG. 9D ) comprises IL-15R ⁇ (sushi) fused to the N-terminus of a homodimeric Fc region, while IL-15 is transfected separately so that a non-covalent IL-15/R ⁇ complex is formed.
  • An illustrative protein of this format is XENP21978, sequences for which are depicted in FIG. 13 . Sequences for additional proteins of this format are listed as XENP21979 in the figures and in the sequence listing.
  • the bivalent single-chain IL-15/R ⁇ -Fc fusion or “bivalent scIL-15/R ⁇ -Fc” format ( FIG. 9E ) comprises IL-15 fused to IL-15R ⁇ (sushi) by a variable length linker (termed a “single-chain” IL-15/IL-15R ⁇ (sushi) complex or “scIL-15/R ⁇ ”) which is then fused to the N-terminus of a homodimeric Fc-region. Sequences for illustrative linkers are depicted in FIG. 7 . Sequences for an illustrative protein of this format are depicted in FIG. 14 .
  • the Fc-non-covalent IL-15/R ⁇ fusion or “Fc-ncIL-15/R ⁇ ” format ( FIG. 9E ) comprises IL-15R ⁇ (sushi) fused to the C-terminus of a heterodimeric Fc region, while IL-15 is transfected separately so that a non-covalent IL-15/R ⁇ complex is formed, with the other side of the molecule being “Fc-only” or “empty Fc”.
  • An illustrative protein of this format is XENP22637, sequences for which are depicted in FIG. 15 . Sequences for additional proteins of this format are listed XENP22638 in the figures and the sequence listing.
  • the Fc-single-chain IL-15/R ⁇ fusion or “Fc-scIL-15/R ⁇ ” format ( FIG. 9G ) comprises IL-15 fused to IL-15R ⁇ (sushi) by a variable length linker (“scIL-15/R ⁇ ”) which is then fused to the C-terminus of a heterodimeric Fc region, with the other side of the molecule being “Fc-only” or “empty Fc”. Sequences for illustrative linkers are depicted in FIG. 7 . Sequences for an illustrative protein of this format are depicted in FIG. 16 .
  • Proteins were produced by transient transfection in HEK293E cells and were purified by a two-step purification process comprising protein A chromatography (GE Healthcare) and anion exchange chromatography (HiTrapQ 5 mL column with a 5-40% gradient of 50 mM Tris pH 8.5 and 50 mM Tris pH 8.5 with 1 M NaCl).
  • Example 1B Engineering IL-15/R ⁇ -Fc Fusion Proteins
  • IL-15/R ⁇ -Fc fusion proteins produced in several of the formats as described above were characterized by size-exclusion chromatography (SEC) and capillary isoelectric focusing (CEF) for purity and homogeneity as generally described below.
  • SEC size-exclusion chromatography
  • CEF capillary isoelectric focusing
  • the proteins were analyzed using SEC to measure their size (i.e. hydrodynamic volume) and determine the native-like behavior of the purified samples.
  • the analysis was performed on an Agilent 1200 high-performance liquid chromatography (HPLC) system. Samples were injected onto a SuperdexTM 200 10/300 GL column (GE Healthcare Life Sciences) at 1.0 mL/min using 1 ⁇ PBS, pH 7.4 as the mobile phase at 4° C. for 25 minutes with UV detection wavelength at 280 nM. Analysis was performed using Agilent OpenLab Chromatography Data System (CDS) ChemStation Edition AIC version C.01.07.
  • CDS Agilent OpenLab Chromatography Data System
  • FIGS. 17B, 18B, and 19B Chromatograms for selected IL-15/R ⁇ -Fc fusion proteins are shown in FIGS. 17B, 18B, and 19B .
  • the proteins were analyzed electrophoretically via CEF using LabChip GXII Touch HT (PerkinElmer, Waltham, Mass.) using Protein Express Assay LabChip and Protein Express Assay Reagent Kit carried out using the manufacturer's instructions. Samples were run in duplicate, one under reducing (with dithiothreitol) and the other under non-reducing conditions. Gel images for selected IL-15/R ⁇ -Fc fusion proteins are shown in FIGS. 17C, 18C, and 19C .
  • Affinity screens of IL-15/R ⁇ -Fc fusion proteins were performed using Octet, a BioLayer Interferometry (BLI)-based method.
  • Experimental steps for Octet generally included the following: Immobilization (capture of ligand or test article onto a biosensor); Association (dipping of ligand- or test article-coated biosensors into wells containing serial dilutions of the corresponding test article or ligand); and Dissociation (returning of biosensors to well containing buffer) in order to determine the affinity of the test articles.
  • a reference well containing buffer alone was also included in the method for background correction during data processing.
  • anti-human Fc (AHC) biosensors were used to capture the test articles and then dipped into multiple concentration of IL-2R ⁇ (R&D Systems, Minneapolis, Minn.) for KD determination.
  • the affinity results and corresponding sensorgrams are depicted in FIGS. 17D, 18D, and 19D .
  • Each of the three constructs showed high affinity binding (3-8 nM) for IL-1R ⁇ .
  • Example 1D Activity of IL-15/R ⁇ -Fc Fusion Proteins in Cell Proliferation Assays
  • IL-15/R ⁇ -Fc fusion proteins in the various formats as described above were tested in a cell proliferation assay.
  • Human PBMCs were treated with the test articles at the indicated concentrations. 4 days after treatment, the PBMCs were stained with anti-CD8-FITC (RPA-T8), anti-CD4-PerCP/Cy5.5 (OKT4), anti-CD27-PE (M-T271), anti-CD56-BV421 (5.1H11), anti-CD16-BV421 (3G8), and anti-CD45RA-BV605 (Hi100) to gate for the following cell types: CD4+ T cells, CD8+ T cells, and NK cells (CD56+/CD16+).
  • Ki67 is a protein strictly associated with cell proliferation, and staining for intracellular Ki67 was performed using anti-Ki67-APC (Ki-67) and Foxp3/Transcription Factor Staining Buffer Set (Thermo Fisher Scientific, Waltham, Mass.). The percentage of Ki67 on the above cell types was measured using FACS (depicted in FIGS. 20A-20C and 21A-21C ).
  • the various IL-15/R ⁇ -Fc fusion proteins induced strong proliferation of CD8+ T cells and NK cells. Notably, differences in proliferative activity were dependent on the linker length on the IL-15-Fc side. In particular, constructs having no linker (hinge only), including XENP21471, XENP21474, and XENP21475, demonstrated weaker proliferative activity.
  • Example 1E Activity of IL-15/R ⁇ -Fc Fusion Proteins in an SEB-Stimulated PBMC Assay
  • IL-15/R ⁇ heterodimers can potently activate T cells.
  • IL-15/R ⁇ -Fc fusion proteins in the various formats as described above were tested in an SEB-stimulated PBMC assay.
  • Staphylococcal Enterotoxin B SEB is a superantigen that causes T cell activation and proliferation in a manner similar to that achieved by activation via the T cell receptor (TCR).
  • TCR T cell receptor
  • Stimulating human PBMC with SEB is a common method for assaying T cell activation and proliferation.
  • PBMCs from multiple donors were stimulated with 10 ng/mL of SEB for 72 hours in combination with 20 ⁇ g/mL of various IL-15/R ⁇ -Fc fusion proteins or controls (PBS, an isotype control, and a bivalent anti-PD-1 antibody). After treatment, supernatant was collected and assayed for IL-2, data for which is depicted in FIG. 22 .
  • the data clearly show that the IL-15/R ⁇ -Fc fusion proteins enhanced IL-2 secretion more than PBS and isotype control.
  • a number of the IL-15/R ⁇ -Fc fusion proteins have activity equivalent to or better than that of the anti-PD-1 antibody.
  • Example 1F IL-15/R ⁇ -Fc Fusion Proteins Enhance Engraftment and Disease Activity in Human PBMC-Engrafted NSG Mice
  • IL-15/R ⁇ -Fc fusion protein XENP20818 was evaluated in a Graft-versus-Host Disease (GVHD) model conducted in female NSG (NOD-SCID-gamma) immunodeficient mice.
  • GVHD Graft-versus-Host Disease
  • NOD-SCID-gamma female NSG
  • IL-15/R ⁇ -Fc fusion proteins enhances proliferation of the engrafted T cells.
  • mice 10 million human PBMCs were engrafted into NSG mice via IV-OSP on Day 0 followed by dosing of XENP20818 (1 mg/kg on Day 1 and then weekly thereafter) and recombinant IL-15 (Biolegend; 0.17 mg/kg on Day 1 and then weekly thereafter).
  • the survival curve is shown in FIG. 23 .
  • the data show that mice receiving the IL-15/R ⁇ -Fc fusion protein demonstrated rapid morbidity and mortality (all dead by Day 10) compared with mice receiving recombinant IL-15 (all alive by Day 14). This is likely due to the expected longer half-life of the IL-15/R ⁇ -Fc fusion protein.
  • mice 10 million human PBMCs were engrafted in NSG mice via IV-OSP on Day 0 followed by dosing of XENP20818 (1 mg/kg, 0.3 mg/kg, 0.1 mg/kg, or 0.03 mg/kg on Day 1 and then weekly thereafter) or PBS.
  • Control groups in which mice were not engrafted with PBMCs were included to investigate any effect of XENP20818 on wild-type NSG mice.
  • Blood was collected on Day 7 to measure IFN ⁇ , data for which is depicted in FIG. 24 , and to measure CD4+ T cell, CD8+ T cell, and CD45+ cell counts, data for which are depicted in FIG. 25 .
  • the data shows a clear dose response for XENP20818.
  • Plasmids coding for IL-15 or IL-15R ⁇ (sushi) were constructed by standard gene synthesis, followed by subcloning into a pTT5 expression vector.
  • the IL-15R ⁇ (sushi) chain included a C-terminal polyhistidine tag. Residues identified as described above were substituted with cysteines by standard mutagenesis techniques. Additionally, up to three amino acids following the sushi domain in IL-15R ⁇ were added to the C-terminus of IL-15R ⁇ (sushi) as a scaffold for engineering cysteines (illustrative sequences for which are depicted in FIG. 27 ). Sequences for illustrative IL-15 and IL-15R ⁇ (sushi) variants engineered with cysteines are respectively depicted in FIGS. 28 and 29 .
  • FIGS. 30A-C Cartoon schematics of IL-15/R ⁇ heterodimers with and without engineered disulfides are depicted in FIGS. 30A-C .
  • Sequences for an illustrative ncIL-15/R ⁇ heterodimer XENP21996 is depicted in FIG. 31 .
  • Sequences for illustrative dsIL-15/R ⁇ heterodimers XENP22004, XENP22005, XENP22006, XENP22008, and XENP22494 are depicted in FIG. 32 .
  • Sequences for an illustrative scIL-15/R ⁇ heterodimer are depicted in FIG. 33 .
  • Wild-type IL-15/R ⁇ heterodimers with additional residues at the C-terminus but without engineered cysteines, were generated as controls. Sequences for these control IL-15/R ⁇ heterodimers are listed as XENPs 22001, 22002, and 22003 in the figures and the sequence listing. Proteins were produced by transient transfection in HEK293E cells and purified by Ni-NTA chromatography.
  • Example 1B After the proteins were purified, they were characterized by capillary isoelectric focusing (CEF) for purity and homogeneity as generally described in Example 1B, gel images for which are depicted in FIGS. 34-35 . The proteins were then screened for stability using DSF as generally described in Example 1C, data for which are depicted in FIGS. 36-38 . Finally, the proteins were screened for binding to IL-2R ⁇ by Octet as generally described in Example 1C, data for which is depicted in FIG. 38 .
  • CEF capillary isoelectric focusing
  • Plasmids coding for IL-15 or IL-15R ⁇ sushi domain with the above-described mutations were subcloned into a pTT5 expression vector containing Fc fusion partners (e.g., constant regions as depicted in FIG. 8 ).
  • Cartoon schematics of IL-15/R ⁇ -Fc fusion proteins with engineered disulfide bonds are depicted in FIGS. 39A-D .
  • Disulfide-bonded IL-15/R ⁇ heterodimeric Fc fusion or “dsIL-15/R ⁇ -heteroFc” ( FIG. 39A ) is the same as “IL-15/R ⁇ -heteroFc”, but wherein IL-15R ⁇ (sushi) and IL-15 are further covalently linked as a result of engineered cysteines.
  • Illustrative proteins of this format include XENP22013, XENP22014, XENP22015, and XENP22017, sequences for which are depicted in FIG. 40 .
  • Disulfide-bonded IL-15/R ⁇ Fc fusion or “dsIL-15/R ⁇ -Fc” is the same as “ncIL-15/R ⁇ -Fc”, but wherein IL-15R ⁇ (sushi) and IL-15 are further covalently linked as a result of engineered cysteines.
  • Illustrative proteins of this format include XENP22357, XENP22358, XENP22359, XENP22684, and XENP22361, sequences for which are depicted in FIG. 41 . Sequences for additional proteins of this format are listed as XENPs 22360, 22362, 22363, 22364, 22365, and 22366 in the figures and the sequence listing.
  • Bivalent disulfide-bonded IL-15/R ⁇ -Fc or “bivalent dsIL-15/R ⁇ -Fc” is the same as “bivalent ncIL-15/R ⁇ -Fc”, but wherein IL-15R ⁇ (sushi) and IL-15 are further covalently linked as a result of engineered cysteines.
  • Illustrative proteins of this format include XENP22634, XENP22635, and XENP22636, sequences for which are depicted in FIG. 42 . Sequences for additional proteins of this format are listed as XENP22687 in the figures and the sequence listing.
  • Fc-disulfide-bonded IL-15/R ⁇ fusion or “Fc-dsIL-15/R ⁇ ” ( FIG. 39D ) is the same as “Fc-ncIL-15/R ⁇ ”, but wherein IL-15R ⁇ (sushi) and IL-15 are further covalently linked as a result of engineered cysteines.
  • Illustrative proteins of this format include XENP22639 and XENP22640, sequences for which are depicted in FIG. 43 .
  • “Wild-type” IL-15/R ⁇ -Fc fusion proteins with additional residues at the C-terminus but without engineered cysteines, were generated as controls. Sequences for these control IL-15/R ⁇ -Fc fusion proteins are listed as XENPs 21988, 21989, 21990, 21991, 21992, 22354, 22355, and 22356 in the figures and the sequence listing.
  • Proteins were produced by transient transfection in HEK293E cells and were purified by a two-step purification process comprising protein A chromatography (GE Healthcare) and anion exchange chromatography (HiTrapQ 5 mL column with a 5-40% gradient of 50 mM Tris pH 8.5 and 50 mM Tris pH 8.5 with 1 M NaCl).
  • Example 1B After the proteins were purified, they were characterized by capillary isoelectric focusing (CEF) for purity and homogeneity as generally described in Example 1B. As above, many of the disulfide bonds were correctly formed as indicated by denaturing non-reducing CEF, where the larger molecular weight of the covalent complex can be seen when compared to the controls without engineered disulfide bonds ( FIG. 44 ).
  • CEF capillary isoelectric focusing
  • IL-15/R ⁇ -Fc fusion proteins (with or without engineered disulfide bonds) or controls were incubated with PBMCs for 4 days. Following incubation, PBMCs were stained with anti-CD4-PerCP/Cy5.5 (RPA-T4), anti-CD8-FITC (RPA-T8), anti-CD45RA-BV510 (HI100), anti-CD16-BV421 (3G8), anti-CD56-BV421 (HCD56), anti-CD27-PE (0323), and anti-Ki67-APC (Ki-67) to mark various cell populations and analyzed by FACS as generally described in Example 1D.
  • FIGS. 45A-C Proliferation of NK cells, CD4+ T cells, and CD8+ T cells as indicated by Ki67 expression are depicted in FIGS. 45A-C .
  • Example 3A Engineering and Production of Variant IL-15/R ⁇ -Fc Fusion Proteins
  • FIG. 46 depicts a structural model of the IL-15:receptor complexes showing locations of the predicted residues where we engineered isosteric substitutions (in order to reduce the risk of immunogenicity). Sequences for illustrative IL-15 variants engineered for reduced potency are depicted in FIG. 47 .
  • Plasmids coding for IL-15 or IL-15R ⁇ (sushi) were constructed by standard gene synthesis, followed by subcloning into a pTT5 expression vector containing Fc fusion partners (e.g., constant regions as depicted in FIG. 8 ). Substitutions identified as described above were incorporated by standard mutagenesis techniques. Sequences for illustrative IL-15/R ⁇ -Fc fusion proteins of the “IL-15/R ⁇ -heteroFc” format engineered for reduced potency are depicted in FIG.
  • Sequences for illustrative IL-15/R ⁇ -Fc fusion proteins of the “scIL-15/R ⁇ -Fc” format engineered for lower potency are depicted in FIG. 49 , with additional sequences listed as XENPs 24013, 24014, and 24016 in the figures and the sequence listing. Sequences for illustrative IL-15/R ⁇ -Fc fusion proteins of the “ncIL-15/R ⁇ -Fc” format engineered for lower potency are depicted in FIG. 50 . Sequences for illustrative ncIL-15/R ⁇ heterodimers engineered for lower potency are depicted in FIG.
  • Sequences for an illustrative IL-15/R ⁇ -Fc fusion protein of the “bivalent ncIL-15/R ⁇ -Fc” format engineered for lower potency are depicted in FIG. 52 .
  • Sequences for illustrative IL-15/R ⁇ -Fc fusion proteins of the “dsIL-15/R ⁇ -Fc” format engineered for lower potency are depicted in FIG. 53 .
  • Proteins were produced by transient transfection in HEK293E cells and were purified by a two-step purification process comprising protein A chromatography (GE Healthcare) and anion exchange chromatography (HiTrapQ 5 mL column with a 5-40% gradient of 50 mM Tris pH 8.5 and 50 mM Tris pH 8.5 with 1 M NaCl).
  • Example 3B In Vitro Activity of Variant IL-15/R ⁇ -heteroFc and scIL-15/R ⁇ -Fc Fusion Proteins Engineered for Decreased Potency
  • the variant IL-15/R ⁇ -Fc fusion proteins were tested in a number of cell proliferation assays.
  • IL-15/R ⁇ -Fc fusion proteins (with or without engineered substitutions) or control were incubated with PBMCs for 4 days. Following incubation, PBMCs were stained with anti-CD4-Evolve605 (SK-3), anti-CD8-PerCP/Cy5.5 (RPA-T8), anti-CD45RA-APC/C ⁇ 7 (HI100), anti-CD16-eFluor450 (CB16), anti-CD56-eFluor450 (TULY56), anti-CD3-FITC (OKT3), and anti-Ki67-APC (Ki-67) to mark various cell populations and analyzed by FACS as generally described in Example 1D.
  • SK-3 anti-CD8-PerCP/Cy5.5
  • RPA-T8-PerCP/Cy5.5 anti-CD45RA-APC/C ⁇ 7
  • CB16 anti-CD16-eFluor450
  • TULY56 anti-CD3-FITC
  • Ki-67 anti-K
  • NK cells Proliferation of NK cells, CD8+ T cells, and CD4+ T cells as indicated by Ki67 expression are depicted in FIGS. 54-55 .
  • Most of the IL-15/R ⁇ -Fc fusion proteins induced proliferation of each cell population; however, activity varied depending on the particular engineered substitutions.
  • IL-15/R ⁇ -Fc fusion proteins (with or without engineered substitutions) were incubated with PBMCs for 3 days. Following incubation, PBMCs were stained with anti-CD3-FITC (OKT3), anti-CD4-Evolve604 (SK-3), anti-CD8-PerCP/Cy5.5 (RPA-T8), anti-CD16-eFluor450 (CB16), anti-CD56-eFluor450 (TULY56), anti-CD27-PE (0323), anti-CD45RA-APC/C ⁇ 7 (HI100) and anti-Ki67-APC (20Raj1) antibodies to mark various cell populations.
  • FIG. 56-57 depict selection of various cell populations following incubation with XENP22821 by FACS. Lymphocytes were first gated on the basis of side scatter (SSC) and forward scatter (FSC) ( FIG. 56A ). Lymphocytes were then gated based on CD3 expression ( FIG. 56B ). Cells negative for CD3 expression were further gated based on CD16 expression to identify NK cells (CD16+) ( FIG. 56C ). CD3+ T cells were further gated based on CD4 and CD8 expression to identify CD4+ T cells, CD8+ T cells, and ⁇ T cells (CD3+CD4 ⁇ CD8 ⁇ ) ( FIG. 57A ).
  • FIGS. 59A-D show the proliferation of the various cell populations.
  • NK and CD8+ T cells are more sensitive than CD4+ T cells to IL-15/R ⁇ -Fc fusion proteins, and as above, proliferative activity varied depending on the particular engineered substitutions.
  • FIG. 59D shows the fold change in EC50 of various IL-15/R ⁇ -Fc fusion proteins relative to control XENP20818.
  • 58A and B further depict the activation of lymphocytes following treatment with IL-15/R ⁇ -Fc fusion proteins by gating for the expression of CD69 and CD25 (T cell activation markers) before and after incubation of PBMCs with XENP22821.
  • IL-15/R ⁇ -Fc fusion proteins were incubated with human PBMCs for 3 days at 37° C. Following incubation, PBMCs were stained with anti-CD3-FITC (OKT3), anti-CD4-SB600 (SK-3), anti-CD8-PerCP/Cy5.5 (RPA-T8), anti-CD45RA-APC/C ⁇ 7 (HI100), anti-CD16-eFluor450 (CB16), anti-CD25-PE (M-A251), and anti-Ki67-APC (Ki-67) to mark various cell populations and analyzed by FACS as generally described in Example 1D. Proliferation of CD8+(CD45RA ⁇ ) T cells, CD4+(CD45RA ⁇ ) T cells, ⁇ T cells, and NK cells as indicated by Ki67 expression are depicted in FIGS. 60A-D .
  • PBMCs were incubated with the additional IL-15/R ⁇ -Fc variants at the indicated concentrations for 3 days. Following incubation, PBMCs were stained with anti-CD3-FITC (OKT3), anti-CD4 (SB600), anti-CD8-PerCP/Cy5.5 (RPA-T8), anti-CD16-eFluor450 (CB16), anti-CD25-PE (M-A251), anti-CD45RA-APC/C ⁇ 7 (HI100), and anti-Ki67-APC (Ki67) and analyzed by FACS as generally described in Example 1D. Percentage of Ki67 on CD8+ T cells, CD4+ T cells and NK cells following treatment are depicted in FIG. 61 .
  • variant IL-15/R ⁇ -Fc fusion proteins were incubated with human PBMCs for 3 days at 37° C. Following incubation, cells were stained with anti-CD3-PE (OKT3), anti-CD4-FITC (RPA-T4), anti-CD8 ⁇ -BV510 (SK1), anti-CD8 ⁇ -APC (2ST8.5H7), anti-CD16-BV421 (3G8), anti-CD25-PerCP/Cy5.5 (M-A251), anti-CD45RA-APC/C ⁇ 7 (HI100), anti-CD56-BV605 (NCAM16.2), and anti-Ki67-PE/C ⁇ 7 (Ki-67) and analyzed by FACS as generally described in Example 1D. Percentage of Ki67 on CD8+ T cells, CD4+ T cells, ⁇ T cells, and NK cells are depicted in FIGS. 62A-E .
  • variant IL-15/R ⁇ -Fc fusion proteins were incubated with human PBMCs for 3 days at 37° C. Following incubation, cells were stained with anti-CD3-PE (OKT3), anti-CD4-FITC (RPA-T4), anti-CD8 ⁇ -BV510 (SK1), anti-CD8 ⁇ -APC (SIDI8BEE), anti-CD16-BV421 (3G8), anti-CD25-PerCP/Cy5.5 (M-A251), anti-CD45RA-APC/C ⁇ 7 (HI100), anti-CD56-BV605 (NCAM16.2), and anti-Ki67-PE/C ⁇ 7 (Ki-67) and analyzed by FACS as generally described in Example 1D. Percentage of Ki67 on CD8+ T cells, CD4+ T cells, ⁇ T cells, and NK cells are depicted in FIGS. 63A-E .
  • Example 3C In Vitro Activity of Variant scIL-15/R ⁇ -Fc Fusion Proteins Engineered for Decreased Potency with Different Linker Lengths Between IL-15 and IL-15R ⁇
  • IL-15/R ⁇ -Fc fusion proteins with some of the substitutions described above, further with different lengths linkers between IL-15 and IL-15R ⁇ (as depicted in Table 3) were incubated with human PBMCs at the indicated concentrations for 3 days at 37° C.
  • PBMCs were stained with anti-CD3-PE (OKT3), anti-CD4-FITC (RPA-T4), anti-CD8-APC (RPA-T8), anti-CD16-BV605 (3G8), anti-CD25-PerCP/Cy5.5 (M-A251), anti-CD45RA-APC/Fire750 (HI100) and anti-Ki67-PE/C ⁇ 7 (Ki-67) and analyzed by FACS as generally described in Example 1D. Percentage Ki67 on CD8+ T cells, CD4+ T cells, ⁇ T cells and NK (CD16+) cells are depicted in FIGS. 64A-D .
  • ncIL-15/R ⁇ -Fc fusion protein XENP21479 is the most potent inducer of CD8+ T cell, CD4+ T cell, NK (CD16+) cell, and ⁇ T cell proliferation.
  • scIL-15/R ⁇ -Fc fusion proteins were less potent than XENP21479 in inducing proliferation, but differences were dependent on both the linker length, as well as the particular engineered substitutions.
  • Example 3D In Vitro Activity of Variant IL-15/R ⁇ -Fc Fusion Proteins Engineered for Decreased Potency in Additional Formats
  • Variant IL-15/R ⁇ -Fc fusion proteins in different formats were incubated with human PBMCs at the indicated concentrations for 3 days at 37° C. Following incubation, PBMCs were stained with anti-CD3-PE (OKT3), anti-CD4-FITC (RPA-T4), anti-CD8-APC (RPA-T8), anti-CD16-BV605 (3G8), anti-CD25-PerCP/Cy5.5 (M-A251), anti-CD45RA-APC/Fire750 (HI100) and anti-Ki67-PE/C ⁇ 7 (Ki-67) and analyzed by FACS as generally described in Example 1D.
  • ncIL-15/R ⁇ -Fc fusion protein XENP21479 is the most potent inducer of CD8+ T cell, CD4+ T cell, NK (CD16+) cell, and ⁇ T cell proliferation.
  • introduction of Q108E substitution into the ncIL-15/R ⁇ -Fc format drastically reduces its proliferative activity in comparison to wildtype (XENP21479).
  • Example 3E STATS Phosphorylation by Variant IL-15/R ⁇ -Fc Fusion Proteins
  • Transpresentation of IL-15 and IL-15R ⁇ drives phosphorylation of STATS and subsequent proliferation of NK and T cells (CD4+ and CD8+). Accordingly, CD8+ and CD4+ T cells were analyzed for STATS phosphorylation following 15 minutes incubation with the indicated IL-15/R ⁇ -Fc test articles.
  • PBMCs were stained with anti-CD4-BV421 (RPA-T4) and anti-CD8-A700 (SK1) for 30-45 minutes at room temperature. Cells were washed and incubated with pre-chilled ( ⁇ 20° C.) 90% methanol for 20-60 minutes.
  • FIGS. 66A-D depict selection of various cell populations following incubation with XENP22821. Lymphocytes were first gated on the basis of SSC and FSC ( FIG. 66A ). The lymphocytes were then gated based on CD4 and CD8 expression to identify CD4+ and CD8+ T cells ( FIG. 66B ).
  • FIGS. 67A-C shows the fold change in EC50 for STATS phosphorylation of the variant IL-15/R ⁇ -Fc fusion proteins relative to control.
  • Example 3F PK of Variant IL-15/R ⁇ -Fc Fusion Proteins Engineered for Lower Potency
  • mice per test article per cohort were dosed with 0.1 mg/kg of the indicated test articles via IV-TV on Day 0.
  • Serum was collected 60 minutes after dosing and then on Days 2, 4, and 7 for Cohort 1 and Days 1, 3, and 8 for Cohort 2.
  • Serum levels of IL-15/R ⁇ -Fc fusion proteins were determined using anti-IL-15 and anti-IL-15R ⁇ antibodies in a sandwich ELISA. The results are depicted in FIG. 68 .
  • FIG. 69 depicts the correlation between potency and half-life of the test articles.
  • variants with reduced potency demonstrated substantially longer half-life. Notably, half-life was improved up to almost 9 days (see XENP22821 and XENP22822), as compared to 0.5 days for the wild-type control XENP20818.
  • the variant IL-15/R ⁇ -Fc fusion proteins were evaluated in a GVHD models conducted in female NSG immunodeficient mice as generally described in Example 1F.
  • FIG. 77 depicts IFN ⁇ levels in mice serum on Days 4, 7, and 11.
  • FIGS. 78A-C respectively depict CD8+ T cell counts on Days 4, 7, and 11.
  • FIGS. 79A-C respectively depict CD4+ T cell counts on Days 4, 7, and 11.
  • FIGS. 80A-C respectively depict CD45+ cell counts on Days 4, 7, and 11.
  • Body weight of the mice were also measured on Days 4, 7, and 11 and depicted as percentage of initial body weight in FIG. 81 .
  • Example 3H IL-15/R ⁇ -Fc Fusion Proteins are Active in Cynomolgus Monkeys
  • Lymphocyte counts FIGS. 82, 84, 86, 88, 90, and 92
  • proliferation FIGS. 83, 85, 87, 89, 91, and 93
  • FIG. 86B ⁇ T cells
  • FIG. 86C CD8+ T cells
  • FIG. 86D CD8+ T cells
  • FIG. 86E CD8+ T cells
  • FIG. 86F CD4+ T cells
  • IL-15/R ⁇ -Fc variants engineered for decreased potency as described above were further engineered with Xtend Fc (hereon referred to as “IL-15/R ⁇ -XtendFc” fusion proteins) to further increase half-life by subcloning plasmids coding for IL-15 and/or IL-15R ⁇ (sushi) into a pTT5 expression vector containing Fc fusion partners with M428L/N434S substitutions (see FIG. 8 , Backbone 11). Sequences for illustrative IL-15/R ⁇ -XtendFc are depicted in FIGS. 94-96 (see also Table 5).
  • Example 4A In Vitro Activity of Additional IL-15/R ⁇ -Fc Variants
  • PBMCs Human PBMCs were incubated with the IL-15/R ⁇ -XtendFc variants at the indicated concentrations for 3 days. Following incubation, PBMCs were stained with anti-CD3-FITC (OKT3), anti-CD4-PE (RPA-T4), anti-CD8-eFluor450 (SK-1), anti-CD45RA ⁇ PE/C ⁇ 7 (HI100), anti-CD16-PerCP/Cy5.5 (3G8), anti-CD25-APC/Fire750 (M-A251), and anti-Ki67-APC (Ki-67) to mark various cell populations and analyzed by FACS as generally described in Example 1D. Proliferation of CD8+ T cells, CD4+ T cells and NK cells following treatment as indicated by Ki67 expression are depicted in FIG. 97 .
  • Xtend variants were selected for investigating activity in cynomolgus monkeys, their ability to proliferate cynomolgus T cells was investigated. Cyno PBMCs were incubated with selected test articles at the indicated concentrations for 3 days.
  • PBMCs were stained with anti-CD3-FITC (SP34), anti-CD4-PE/C ⁇ 7 (OKT4), anti-CD8-APC (RPA-T8), anti-CD45RA-APC/Fire750 (HI100), anti-CD16-BV605 (3G8), anti-CD25-BV421 (M-A251), and anti-Ki67-PerCP/Cy5.5 (Ki-67) to mark various cell populations and analyzed by FACS as generally described in Example 1D. Proliferation of CD8+ T cells, CD4+ T cells and NK cells following treatment as indicated by Ki67 expression are depicted in FIG. 98 .
  • Example 4B In Vivo Activity of IL-15/R ⁇ -XtendFc Variants in a GVHD Model
  • FIGS. 99A-C respectively depict CD4+ T cell counts on Days 4 and 7 in whole blood and Day 8 in spleen.
  • FIGS. 100A-C respectively depict CD8+ T cell counts on Days 4 and 7 in whole blood and Day 8 in spleen.
  • 101A-C respectively depict CD4+ T cell counts on Days 4 and 7 in whole blood and Day 8 in spleen. Body weight of the mice were also measured on Day ⁇ 8, ⁇ 2, 1, 5, 8 and 11 as depicted in FIGS. 102A-102F . Each point represents one female NSG mouse.
  • Example 4C In Vivo Activity of Variant IL-15/R ⁇ -XtendFc Fusion Proteins in Cynomolgus Monkeys
  • CD8+ T cell, CD4+ T cell and NK cell counts in blood were assessed over time as depicted respectively in FIGS. 103A-C .
  • Each point is an average of 3 cynomolgus monkeys. The data show that each of the variants were active in proliferating immune cells indicating that the IL-15/R ⁇ -Fc fusion proteins of the invention could be useful as therapeutics for cancer in humans.

Abstract

The present invention is directed to novel IL15/IL15Rα heterodimeric Fc fusion proteins.

Description

    PRIORITY CLAIM
  • This application is a continuation of U.S. patent application Ser. No. 15/785,401, filed Oct. 16, 2017 which claims priority to U.S. Ser. No. 62/408,655, filed Oct. 14, 2016, U.S. Ser. No. 62/416,087, filed Nov. 1, 2016, U.S. Ser. No. 62/443,465, filed Jan. 6, 2017, and U.S. Ser. No. 62/477,926, filed Mar. 28, 2017, which are expressly incorporated herein by reference in their entirety, with particular reference to the figures, legends and claims therein.
    • SEQUENCE LISTING
  • The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Oct. 21, 2019, is named 067461-5201-WO_SL.txt and is 2,193,974 bytes in size.
    • BACKGROUND OF THE INVENTION
  • IL-2 and IL-15 function in aiding the proliferation and differentiation of B cells, T cells, and NK cells. IL-2 is also essential for regulatory T cell (Treg) function and survival. Both cytokines exert their cell signaling function through binding to a trimeric complex consisting of two shared receptors, the common gamma chain (γc; CD132) and IL-2 receptor B-chain (IL-2Rβ; CD122), as well as an alpha chain receptor unique to each cytokine: IL-2 receptor alpha (IL-2Rα; CD25) or IL-15 receptor alpha (IL-15Rα; CD215). Both cytokines are considered as potentially valuable therapeutics in oncology and IL-2 has been approved for use in patients with metastatic renal-cell carcinoma and malignant melanoma. Currently there are no approved uses of recombinant IL-15, although several clinical trials are ongoing.
  • IL-2 presents several challenges as a therapeutic agent. First, it preferentially activates T cells that express the high affinity receptor complex, which depends on CD25 expression. Because Treg cells constitutively express CD25, they compete for IL-2 supplies with effector T cells, whose activation is preferred for oncology treatment. This imbalance has led to the concept of high dose IL-2. However, this approach creates additional problems because of IL-2-mediated toxicities such as vascular leak syndrome.
  • IL-2 is secreted primarily by activated T cells, while its receptors are located on activated T cells, Tregs, NK cells, and B cells. In contrast, IL-15 is produced on monocytes and dendritic cells and is primarily presented as a membrane-bound heterodimeric complex with IL-15Rα present on the same cells. Its effects are realized through trans-presentation of the IL-15/IL-15Rα complex to NK cells and CD8+ T cells expressing IL-2Rβ and the common gamma chain.
  • As potential drugs, both cytokines suffer from a very fast clearance, with half-lives measured in minutes. In addition, IL-15 by itself is less stable due to its preference for the IL-15Rα-associated complex. It has also been shown that recombinantly produced IL15/IL15Rα heterodimer can potently activate T cells. Nevertheless, a short half-life hinders favorable dosing. The present invention solves this problem by providing novel IL15/IL15Rα heterodimer Fc fusion proteins.
    • BRIEF SUMMARY OF THE INVENTION
  • Accordingly, in one aspect the present invention provides a heterodimeric protein comprising a) a first fusion protein comprising a first protein domain and a first Fc domain, wherein the first protein domain is covalently attached to the N-terminus of the first Fc domain using a first domain linker; b) a second fusion protein comprising a second protein domain and a second Fc domain, wherein the second protein domain is covalently attached to the N-terminus of the Fc domain using a seconddomain linker; wherein the first and the second Fc domains have a set of amino acid substitutions selected from the group consisting of S267K/L368D/K370S: S267K/LS364K/E357Q; S364K/E357Q: L368D/K370S; L368D/K370S: S364K; L368E/K370S: S364K; T411T/E360E/Q362E: D401K; L368D/K370S: S364K/E357L and K370S: S364K/E357Q, according to EU numbering and wherein the first protein domain comprises an IL15 protein and the second protein domain comprises an IL15Rα protein. In some embodiments, the first protein domain is covalently attached to the N-terminus of the first Fc domain directly and without using the first domain linker and/or the second protein domain is covalently attached to the N-terminus of the second Fc domain directly and without using the second domain linker.
  • In some embodiments, the heterodimeric protein comprises: (i) the first fusion protein having a polypeptide sequence of SEQ ID NOS 52, 412, 418, 430 and 436 (15902) and the second fusion protein having a polypeptide sequence of SEQ ID NOS 55, 76, 231, 237, 243, 249, 415, 427, 644, 732, 738, 744, 750, 756, 762, 768, 774, 780, 786, 792, 798, 804, 810, 816, 822, 828, 834, 840, 846, 884, 890, 896 and 902 (15908), (ii) the first fusion protein having a polypeptide sequence of SEQ ID NOS 52, 412, 418, 430 and 436 (15902) and the second fusion protein having a polypeptide sequence of SEQ ID NOS 421, 445 and 463 (15909), (iii) the first fusion protein having a polypeptide sequence of SEQ ID NOS 58, 424, 442 and 448 (16479) and the second fusion protein having a polypeptide sequence of SEQ ID NOS 55, 76, 231, 237, 243, 249, 415, 427, 644, 732, 738, 744, 750, 756, 762, 768, 774, 780, 786, 792, 798, 804, 810, 816, 822, 828, 834, 840, 846, 884, 890, 896 and 902 (15908), (iv) the first fusion protein having a polypeptide sequence of SEQ ID NOS 52, 412, 418, 430 and 436 (15902) and the second fusion protein having a polypeptide sequence of SEQ ID NOS 61, 71, 267, 433, 451, 473, 952 and 958 (16481), (v) the first fusion protein having a polypeptide sequence of SEQ ID NOS 52, 412, 418, 430 and 436 (15902) and the second fusion protein having a polypeptide sequence of SEQ ID NO: 439 (16483), (vi) the first fusion protein having a polypeptide sequence of SEQ ID NOS 58, 424, 442 and 448 (16479) and the second fusion protein having a polypeptide sequence of SEQ ID NOS 421, 445 and 463 (15909), (vii) the first fusion protein having a polypeptide sequence of SEQ ID NOS 58, 424, 442 and 448 (16479) and the second fusion protein having a polypeptide sequence of SEQ ID NOS 61, 71, 267, 433, 451, 473, 952 and 958 (16481), (viii) the first fusion protein having a polypeptide sequence of SEQ ID NOS 454 and 460 (16480) and the second fusion protein having a polypeptide sequence of SEQ ID NO: 457 (16482), (ix) the first fusion protein having a polypeptide sequence of SEQ ID NOS 454 and 460 (16480) and the second fusion protein h having as a polypeptide sequence of SEQ ID NOS 421, 445 and 463 (15909), (x) the first fusion protein having a polypeptide sequence of SEQ ID NO:XX (17064) and the second fusion protein having a polypeptide sequence of SEQ ID NO: 599 (17038), (xi) the first fusion protein having a polypeptide sequence of SEQ ID NO:XX (17064) and the second fusion protein having a polypeptide sequence of SEQ ID NOS 167 and 609 (17040), (xii) the first fusion protein having a polypeptide sequence of SEQ ID NO:XX (17062) and the second fusion protein having a polypeptide sequence of SEQ ID NOS 172, 614 and 619 (17044), (xiii) the first fusion protein having a polypeptide sequence of SEQ ID NO: 729 (17686) and the second fusion protein having a polypeptide sequence of SEQ ID NOS 55, 76, 231, 237, 243, 249, 415, 427, 644, 732, 738, 744, 750, 756, 762, 768, 774, 780, 786, 792, 798, 804, 810, 816, 822, 828, 834, 840, 846, 884, 890, 896 and 902 (15908), (xiv) the first fusion protein having a polypeptide sequence of SEQ ID NO: 735 (17687) and the second fusion protein having a polypeptide sequence of SEQ ID NOS 55, 76, 231, 237, 243, 249, 415, 427, 644, 732, 738, 744, 750, 756, 762, 768, 774, 780, 786, 792, 798, 804, 810, 816, 822, 828, 834, 840, 846, 884, 890, 896 and 902 (15908), (xv) the first fusion protein having a polypeptide sequence of SEQ ID NO: 741 (17688) and the second fusion protein having a polypeptide sequence of SEQ ID NOS 55, 76, 231, 237, 243, 249, 415, 427, 644, 732, 738, 744, 750, 756, 762, 768, 774, 780, 786, 792, 798, 804, 810, 816, 822, 828, 834, 840, 846, 884, 890, 896 and 902 (15908), (xvi) the first fusion protein having a polypeptide sequence of SEQ ID NO: 747 (17689) and the second fusion protein having a polypeptide sequence of SEQ ID NOS 55, 76, 231, 237, 243, 249, 415, 427, 644, 732, 738, 744, 750, 756, 762, 768, 774, 780, 786, 792, 798, 804, 810, 816, 822, 828, 834, 840, 846, 884, 890, 896 and 902 (15908), (xvii) the first fusion protein having a polypeptide sequence of SEQ ID NO: 753 (17690) and the second fusion protein having a polypeptide sequence of SEQ ID NOS 55, 76, 231, 237, 243, 249, 415, 427, 644, 732, 738, 744, 750, 756, 762, 768, 774, 780, 786, 792, 798, 804, 810, 816, 822, 828, 834, 840, 846, 884, 890, 896 and 902 (15908), (xviii) the first fusion protein having a polypeptide sequence of SEQ ID NO: 759 (17691) and the second fusion protein having a polypeptide sequence of SEQ ID NOS 55, 76, 231, 237, 243, 249, 415, 427, 644, 732, 738, 744, 750, 756, 762, 768, 774, 780, 786, 792, 798, 804, 810, 816, 822, 828, 834, 840, 846, 884, 890, 896 and 902 (15908), (xix) the first fusion protein having a polypeptide sequence of SEQ ID NOS 228 and 765 (17692) and the second fusion protein having a polypeptide sequence of SEQ ID NOS 55, 76, 231, 237, 243, 249, 415, 427, 644, 732, 738, 744, 750, 756, 762, 768, 774, 780, 786, 792, 798, 804, 810, 816, 822, 828, 834, 840, 846, 884, 890, 896 and 902 (15908), (xx) the first fusion protein having a polypeptide sequence of SEQ ID NOS 234 and 771 (17693) and the second fusion protein having a polypeptide sequence of SEQ ID NOS 55, 76, 231, 237, 243, 249, 415, 427, 644, 732, 738, 744, 750, 756, 762, 768, 774, 780, 786, 792, 798, 804, 810, 816, 822, 828, 834, 840, 846, 884, 890, 896 and 902 (15908), (xxi) the first fusion protein having a polypeptide sequence of SEQ ID NO: 777 (17694) and the second fusion protein having a polypeptide sequence of SEQ ID NOS 55, 76, 231, 237, 243, 249, 415, 427, 644, 732, 738, 744, 750, 756, 762, 768, 774, 780, 786, 792, 798, 804, 810, 816, 822, 828, 834, 840, 846, 884, 890, 896 and 902 (15908), (xxii) the first fusion protein having a polypeptide sequence of SEQ ID NO: 783 (17695) and the second fusion protein having a polypeptide sequence of SEQ ID NOS 55, 76, 231, 237, 243, 249, 415, 427, 644, 732, 738, 744, 750, 756, 762, 768, 774, 780, 786, 792, 798, 804, 810, 816, 822, 828, 834, 840, 846, 884, 890, 896 and 902 (15908), (xxiii) the first fusion protein having a polypeptide sequence of SEQ ID NO: 789 (17696) and the second fusion protein having a polypeptide sequence of SEQ ID NOS 55, 76, 231, 237, 243, 249, 415, 427, 644, 732, 738, 744, 750, 756, 762, 768, 774, 780, 786, 792, 798, 804, 810, 816, 822, 828, 834, 840, 846, 884, 890, 896 and 902 (15908), (xxiv) the first fusion protein having a polypeptide sequence of SEQ ID NO: 795 (17697) and the second fusion protein having a polypeptide sequence of SEQ ID NOS 55, 76, 231, 237, 243, 249, 415, 427, 644, 732, 738, 744, 750, 756, 762, 768, 774, 780, 786, 792, 798, 804, 810, 816, 822, 828, 834, 840, 846, 884, 890, 896 and 902 (15908), (xxv) the first fusion protein having a polypeptide sequence of SEQ ID NO: 801 (17698) and the second fusion protein having a polypeptide sequence of SEQ ID NOS 55, 76, 231, 237, 243, 249, 415, 427, 644, 732, 738, 744, 750, 756, 762, 768, 774, 780, 786, 792, 798, 804, 810, 816, 822, 828, 834, 840, 846, 884, 890, 896 and 902 (15908), (xxvi) the first fusion protein having a polypeptide sequence of SEQ ID NO: 807 (17699) and the second fusion protein having a polypeptide sequence of SEQ ID NOS 55, 76, 231, 237, 243, 249, 415, 427, 644, 732, 738, 744, 750, 756, 762, 768, 774, 780, 786, 792, 798, 804, 810, 816, 822, 828, 834, 840, 846, 884, 890, 896 and 902 (15908), (xxvii) the first fusion protein having a polypeptide sequence of SEQ ID NO: 819 (17701) and the second fusion protein having a polypeptide sequence of SEQ ID NOS 55, 76, 231, 237, 243, 249, 415, 427, 644, 732, 738, 744, 750, 756, 762, 768, 774, 780, 786, 792, 798, 804, 810, 816, 822, 828, 834, 840, 846, 884, 890, 896 and 902 (15908), (xxviii) the first fusion protein having a polypeptide sequence of SEQ ID NO: 759 (17691) and the second fusion protein having a polypeptide sequence of SEQ ID NOS 55, 76, 231, 237, 243, 249, 415, 427, 644, 732, 738, 744, 750, 756, 762, 768, 774, 780, 786, 792, 798, 804, 810, 816, 822, 828, 834, 840, 846, 884, 890, 896 and 902 (15908), (xxix) the first fusion protein having a polypeptide sequence of SEQ ID NO: 825 (17702) and the second fusion protein having a polypeptide sequence of SEQ ID NOS 55, 76, 231, 237, 243, 249, 415, 427, 644, 732, 738, 744, 750, 756, 762, 768, 774, 780, 786, 792, 798, 804, 810, 816, 822, 828, 834, 840, 846, 884, 890, 896 and 902 (15908), (xxx) the first fusion protein having a polypeptide sequence of SEQ ID NO: 831 (17703) and the second fusion protein having a polypeptide sequence of SEQ ID NOS 55, 76, 231, 237, 243, 249, 415, 427, 644, 732, 738, 744, 750, 756, 762, 768, 774, 780, 786, 792, 798, 804, 810, 816, 822, 828, 834, 840, 846, 884, 890, 896 and 902 (15908), (xxxi) the first fusion protein having a polypeptide sequence of SEQ ID NO: 837 (17704) and the second fusion protein having a polypeptide sequence of SEQ ID NOS 55, 76, 231, 237, 243, 249, 415, 427, 644, 732, 738, 744, 750, 756, 762, 768, 774, 780, 786, 792, 798, 804, 810, 816, 822, 828, 834, 840, 846, 884, 890, 896 and 902 (15908), (xxxii) the first fusion protein having a polypeptide sequence of SEQ ID NO: 843 (17705) and the second fusion protein having a polypeptide sequence of SEQ ID NOS 55, 76, 231, 237, 243, 249, 415, 427, 644, 732, 738, 744, 750, 756, 762, 768, 774, 780, 786, 792, 798, 804, 810, 816, 822, 828, 834, 840, 846, 884, 890, 896 and 902 (15908), (xxxiii) said first fusion protein having a polypeptide sequence of SEQ ID NOS 358 and 859 (18295) and said second fusion protein having a polypeptide sequence of SEQ ID NOS 361 and 862 (17761), (xxxiv) said first fusion protein having a polypeptide sequence of SEQ ID NOS 240 and 881 (18783) and said second fusion protein having a polypeptide sequence of SEQ ID NOS 55, 76, 231, 237, 243, 249, 415, 427, 644, 732, 738, 744, 750, 756, 762, 768, 774, 780, 786, 792, 798, 804, 810, 816, 822, 828, 834, 840, 846, 884, 890, 896 and 902 (15908), (xxxv) said first fusion protein having a polypeptide sequence of SEQ ID NO: 887 (18784) and said second fusion protein having a polypeptide sequence of SEQ ID NOS 55, 76, 231, 237, 243, 249, 415, 427, 644, 732, 738, 744, 750, 756, 762, 768, 774, 780, 786, 792, 798, 804, 810, 816, 822, 828, 834, 840, 846, 884, 890, 896 and 902 (15908), (xxxvi) said first fusion protein having a polypeptide sequence of SEQ ID NOS 246 and 893 (18786) and said second fusion protein having a polypeptide sequence of SEQ ID NOS 55, 76, 231, 237, 243, 249, 415, 427, 644, 732, 738, 744, 750, 756, 762, 768, 774, 780, 786, 792, 798, 804, 810, 816, 822, 828, 834, 840, 846, 884, 890, 896 and 902 (15908), (xxxvii) said first fusion protein having a polypeptide sequence of SEQ ID NO: 899 (18788) and said second fusion protein having a polypeptide sequence of SEQ ID NOS 55, 76, 231, 237, 243, 249, 415, 427, 644, 732, 738, 744, 750, 756, 762, 768, 774, 780, 786, 792, 798, 804, 810, 816, 822, 828, 834, 840, 846, 884, 890, 896 and 902 (15908), (xxxviii) said first fusion protein having a polypeptide sequence of SEQ ID NOS 264 and 949 (19242) and said second fusion protein having a polypeptide sequence of SEQ ID NOS 61, 71, 267, 433, 451, 473, 952 and 958 (16481), or (xxxix) said first fusion protein having a polypeptide sequence of SEQ ID NO: 955 (19243) and said second fusion protein having a polypeptide sequence of SEQ ID NOS 61, 71, 267, 433, 451, 473, 952 and 958 (16481).
  • In some instances, the heterodimeric protein is selected from the group consisting of XENP20818, XENP20819, XENP21471, XENP21472, XENP21473, XENP21474, XENP21475, XENP21476, XENP21477, XENP22013, XENP22815, XENP22816, XENP22817, XENP22818, XENP22819, XENP22820, XENP22821, XENP22822, XENP22823, XENP22824, XENP22825, XENP22826, XENP22827, XENP22828, XENP22829, XENP22830, XENP22831, XENP22832, XENP22833, XENP22834, XENP23343, XENP23554, XENP23555, XENP23557, XENP23559, XENP24019, and XENP24020.
  • In a further aspect, the invention provides a heterodimeric protein comprising: a) a fusion protein comprising a first protein domain, a second protein domain, and a first Fc domain, wherein the first protein domain is covalently attached to the N-terminus of the second protein domain using a first domain linker, and wherein the second protein domain is covalently attached to the N-terminus of the first Fc domain using a second domain linker; b) a second Fc domain; wherein the first and the second Fc domains have a set of amino acid substitutions selected from the group consisting of S267K/L368D/K370S: S267K/LS364K/E357Q; S364K/E357Q: L368D/K370S; L368D/K370S: S364K; L368E/K370S: S364K; T411T/E360E/Q362E: D401K; L368D/K370S: S364K/E357L and K370S: S364K/E357Q, according to EU numbering and wherein the first protein domain comprises an IL15Rα protein and the second protein domain comprises an IL15 protein.
  • In some embodiments, the first fusion protein has a polypeptide sequence of SEQ ID NOS 64 and 466 (16478) and the Fc domain has a polypeptide sequence of SEQ ID NOS 68 and 470 (8924). The heterodimeric protein can be XENP21478.
  • In another aspect, the invention provides a heterodimeric protein comprising: a) a fusion protein comprising a first protein domain and a first Fc domain, wherein the first protein domain is covalently attached to the N-terminus of the first Fc domain using a domain linker; b) a second Fc domain; and c) a second protein domain noncovalently attached to the first protein domain; wherein the first and the second Fc domains have a set of amino acid substitutions selected from the group consisting of S267K/L368D/K370S: S267K/LS364K/E357Q; S364K/E357Q: L368D/K370S; L368D/K370S: S364K; L368E/K370S: S364K; T411T/E360E/Q362E: D401K; L368D/K370S: S364K/E357L and K370S: S364K/E357Q, according to EU numbering and wherein the first protein domain comprises an IL15Rα and the second protein domain comprises an IL15 protein.
  • In some embodiments, the heterodimer protein comprises: (i) the fusion protein having a polypeptide sequence of SEQ ID NOS 61, 71, 267, 433, 451, 473, 952 and 958 (16481), the second Fc domain having a polypeptide sequence of SEQ ID NOS 70, 75, 161, 166, 171, 472, 583, 588, 593, 598, 603, 608, 613, 618, 623, 628, 633, 638 and 643 (8793), and a second protein domain having a polypeptide sequence of SEQ ID NOS 69, 74, 87, 96, 121, 471, 479, 529, 531, 533, 535, 582, 587, 592, 642 and 667 (16484); (ii) the fusion protein having a polypeptide sequence of SEQ ID NO: 584 (17034), the second Fc domain having a polypeptide sequence of SEQ ID NOS 70, 75, 161, 166, 171, 472, 583, 588, 593, 598, 603, 608, 613, 618, 623, 628, 633, 638 and 643 (8793), and a second protein domain having a polypeptide sequence of SEQ ID NOS 69, 74, 87, 96, 121, 471, 479, 529, 531, 533, 535, 582, 587, 592, 642 and 667 (16484); (iii) the fusion protein having a polypeptide sequence of SEQ ID NO: 599 (17038), the second Fc domain having a polypeptide sequence of SEQ ID NOS 70, 75, 161, 166, 171, 472, 583, 588, 593, 598, 603, 608, 613, 618, 623, 628, 633, 638 and 643 (8793), and a second protein domain having a polypeptide sequence of SEQ ID NOS 69, 74, 87, 96, 121, 471, 479, 529, 531, 533, 535, 582, 587, 592, 642 and 667 (16484); (iv) the fusion protein having a polypeptide sequence of SEQ ID NO: 594 (17036), the second Fc domain having a polypeptide sequence of SEQ ID NOS 70, 75, 161, 166, 171, 472, 583, 588, 593, 598, 603, 608, 613, 618, 623, 628, 633, 638 and 643 (8793), and a second protein domain having a polypeptide sequence of SEQ ID NOS 69, 74, 87, 96, 121, 471, 479, 529, 531, 533, 535, 582, 587, 592, 642 and 667 (16484); (v) the fusion protein having a polypeptide sequence of SEQ ID NO: 599 (17038), the second Fc domain having a polypeptide sequence of SEQ ID NOS 70, 75, 161, 166, 171, 472, 583, 588, 593, 598, 603, 608, 613, 618, 623, 628, 633, 638 and 643 (8793), and a second protein domain having a polypeptide sequence of SEQ ID NOS 123, 125, 127, 160, 165, 182, 186, 195, 537, 539, 541, 597, 602, 607, 654, 658 and 677 (17074); (vi) the fusion protein having a polypeptide sequence of SEQ ID NOS 162 and 604 (17039), the second Fc domain having a polypeptide sequence of SEQ ID NOS 70, 75, 161, 166, 171, 472, 583, 588, 593, 598, 603, 608, 613, 618, 623, 628, 633, 638 and 643 (8793), and a second protein domain having a polypeptide sequence of SEQ ID NOS 123, 125, 127, 160, 165, 182, 186, 195, 537, 539, 541, 597, 602, 607, 654, 658 and 677 (17074); (vii) the fusion protein having a polypeptide sequence of SEQ ID NOS 167 and 609 (17040), the second Fc domain having a polypeptide sequence of SEQ ID NOS 70, 75, 161, 166, 171, 472, 583, 588, 593, 598, 603, 608, 613, 618, 623, 628, 633, 638 and 643 (8793), and a second protein domain having a polypeptide sequence of SEQ ID NOS 123, 125, 127, 160, 165, 182, 186, 195, 537, 539, 541, 597, 602, 607, 654, 658 and 677 (17074); (viii) the fusion protein having a polypeptide sequence of SEQ ID NOS 172, 614 and 619 (17044), the second Fc domain having a polypeptide sequence of SEQ ID NOS 70, 75, 161, 166, 171, 472, 583, 588, 593, 598, 603, 608, 613, 618, 623, 628, 633, 638 and 643 (8793), and a second protein domain having a polypeptide sequence of SEQ ID NOS 543 and 612 (17071); (ix) the fusion protein having a polypeptide sequence of SEQ ID NOS 172, 614 and 619 (17044), the second Fc domain having a polypeptide sequence of SEQ ID NOS 70, 75, 161, 166, 171, 472, 583, 588, 593, 598, 603, 608, 613, 618, 623, 628, 633, 638 and 643 (8793), and a second protein domain having a polypeptide sequence of SEQ ID NOS 170, 190, 545, 617 and 662 (17072); (x) the fusion protein having a polypeptide sequence of SEQ ID NOS 547 and 622 (17075), the second Fc domain having a polypeptide sequence of SEQ ID NOS 70, 75, 161, 166, 171, 472, 583, 588, 593, 598, 603, 608, 613, 618, 623, 628, 633, 638 and 643 (8793), and a second protein domain having a polypeptide sequence of SEQ ID NO: 624 (17041); (xi) the fusion protein having a polypeptide sequence of SEQ ID NO: 629 (17043), the second Fc domain having a polypeptide sequence of SEQ ID NOS 70, 75, 161, 166, 171, 472, 583, 588, 593, 598, 603, 608, 613, 618, 623, 628, 633, 638 and 643 (8793), and a second protein domain having a polypeptide sequence of SEQ ID NOS 549 and 627 (17070); (xii) the fusion protein having a polypeptide sequence of SEQ ID NO: 634 (17045), the second Fc domain having a polypeptide sequence of SEQ ID NOS 70, 75, 161, 166, 171, 472, 583, 588, 593, 598, 603, 608, 613, 618, 623, 628, 633, 638 and 643 (8793), and a second protein domain having a polypeptide sequence of SEQ ID NOS 551 and 632 (17073); (xiii) the fusion protein having a polypeptide sequence of SEQ ID NO: 639 (17042), the second Fc domain having a polypeptide sequence of SEQ ID NOS 70, 75, 161, 166, 171, 472, 583, 588, 593, 598, 603, 608, 613, 618, 623, 628, 633, 638 and 643 (8793), and a second protein domain having a polypeptide sequence of SEQ ID NOS 553 and 637 (17083); or (xiv) the fusion protein having a polypeptide sequence of SEQ ID NOS 55, 76, 231, 237, 243, 249, 415, 427, 644, 732, 738, 744, 750, 756, 762, 768, 774, 780, 786, 792, 798, 804, 810, 816, 822, 828, 834, 840, 846, 884, 890, 896 and 902 (15908), the second Fc domain having a polypeptide sequence of SEQ ID NOS 70, 75, 161, 166, 171, 472, 583, 588, 593, 598, 603, 608, 613, 618, 623, 628, 633, 638 and 643 (8793), and a second protein domain having a polypeptide sequence of SEQ ID NOS 69, 74, 87, 96, 121, 471, 479, 529, 531, 533, 535, 582, 587, 592, 642 and 667 (16484). The heterodimer protein can be selected from the group consisting of XENP21479, XENP22357, XENP22354, XENP22355, XENP22356, XENP22357, XENP22358, XENP22359, XENP22360, XENP22361, XENP22362, XENP22363, XENP22364, XENP22365, XENP22366, and XENP22637.
  • In an additional aspect, the invention provides a heterodimeric protein comprising: a) a first fusion protein comprising a first protein domain and a first Fc domain, wherein the first protein domain is covalently attached to the N-terminus of said first Fc domain using a domain linker; b) a second fusion protein comprising a second heavy chain comprising a second protein domain and a first second heavy chain comprising a second Fc domain, wherein the second protein domain is covalently attached to the C-terminus of the second Fc domain using a domain linker; c) a third protein domain noncovalently attached to the first protein domain of the first fusion protein; and d) a fourth protein domain noncovalently attached to the second protein domain of the second fusion protein, wherein the first and the second Fc domains have a set of amino acid substitutions selected from the group consisting of S267K/L368D/K370S: S267K/LS364K/E357Q; S364K/E357Q: L368D/K370S; L368D/K370S: S364K; L368E/K370S: S364K; T411T/E360E/Q362E: D401K; L368D/K370S: S364K/E357L and K370S: S364K/E357Q, according to EU numbering and wherein the first protein domain and the second protein domain comprise an IL15Rα protein, and wherein the third protein domain and the fourth protein domain comprises an IL15 protein.
  • In some embodiments, the heterodimer protein comprises (i) the first fusion protein has a polypeptide sequence of SEQ ID NOS 84, 476 and 480 (17023) the second fusion protein has a polypeptide sequence of SEQ ID NOS 84, 476 and 480 (17023), the third protein domain has a polypeptide sequence of SEQ ID NOS 69, 74, 87, 96, 121, 471, 479, 529, 531, 533, 535, 582, 587, 592, 642 and 667 (16484), and the fourth protein domain has a polypeptide sequence of SEQ ID NOS 69, 74, 87, 96, 121, 471, 479, 529, 531, 533, 535, 582, 587, 592, 642 and 667 (16484) or (ii) the first fusion protein has a polypeptide sequence of SEQ ID NOS 179 and 651 (17581), the second fusion protein has a polypeptide sequence of SEQ ID NOS 179 and 651 (17581), the third protein domain has a polypeptide sequence of SEQ ID NOS 123, 125, 127, 160, 165, 182, 186, 195, 537, 539, 541, 597, 602, 607, 654, 658 and 677 (17074), and the fourth protein domain has a polypeptide sequence of SEQ ID NOS 123, 125, 127, 160, 165, 182, 186, 195, 537, 539, 541, 597, 602, 607, 654, 658 and 677 (17074). The heterodimer protein can be XENP21978 or XENP22634.
  • In an additional aspect, the invention provides a heterodimeric protein comprising: a) a first fusion protein comprising a first Fc domain and a first protein domain, wherein the first Fc domain is covalently attached to the N-terminus of the first protein domain using a domain linker; b) a second Fc domain, and c) a second protein domain noncovalently attached to the first protein domain of the first fusion protein; wherein the first and the second Fc domains have a set of amino acid substitutions selected from the group consisting of S267K/L368D/K370S: S267K/LS364K/E357Q; S364K/E357Q: L368D/K370S; L368D/K370S: S364K; L368E/K370S: S364K; T411T/E360E/Q362E: D401K; L368D/K370S: S364K/E357L and K370S: S364K/E357Q, according to EU numbering and wherein the first protein domain comprises an IL15Rα protein and the second protein domain comprises an IL15 protein.
  • In some embodiments, the heterodimer protein comprises (i) the first fusion protein having a polypeptide sequence of SEQ ID NOS 92 and 663 (17603), the second Fc domain having a polypeptide sequence of SEQ ID NOS 95, 101, 194, 666, 676 and 1113 (8927), and the second protein domain having a polypeptide sequence of SEQ ID NOS 69, 74, 87, 96, 121, 471, 479, 529, 531, 533, 535, 582, 587, 592, 642 and 667 (16484); or ii) the first fusion protein having a polypeptide sequence of SEQ ID NOS 191 and 673 (17605), the second Fc domain having a polypeptide sequence of SEQ ID NOS 95, 101, 194, 666, 676 and 1113 (8927), and the second protein domain having a polypeptide sequence of SEQ ID NOS 123, 125, 127, 160, 165, 182, 186, 195, 537, 539, 541, 597, 602, 607, 654, 658 and 677 (17074).
  • In any of the embodiments of the present invention, the first and/or the second Fc domains can have an additional set of amino acid substitutions comprising Q295E/N384D/Q418E/N421D, according to EU numbering. In some cases, the first and/or the second Fc domains have an additional set of amino acid substitutions consisting of G236R/L328R, E233P/L234V/L235A/G236del/S239K, E233P/L234V/L235A/G236del/S267K, E233P/L234V/L235A/G236del/S239K/A327G, E233P/L234V/L235A/G236del/S267K/A327G and E233P/L234V/L235A/G236del, according to EU numbering.
  • In any of the embodiments of the present invention, the IL15 protein has a polypeptide sequence selected from the group consisting of SEQ ID NO:1 (full-length human IL15) and SEQ ID NO:2 (truncated human IL15), and the IL15Rα protein has a polypeptide sequence selected from the group consisting of SEQ ID NO:3 (full-length human IL15Rα) and SEQ ID NO:4 (sushi domain of human IL15Rα). In some cases, the IL15 protein and the IL15Rα protein have a set of amino acid substitutions or additions selected from the group consisting of E87C: D96/P97/C98; E87C: D96/C97/A98; V49C: S40C; L52C: S40C; E89C: K34C; Q48C: G38C; E53C: L42C; C42S: A37C; and L45C: A37C, respectively.
  • In an additional aspect, the present invention provides a heterodimeric protein selected from the group consisting of XENP20818, XENP20819, XENP21471, XENP21472, XENP21473, XENP21474, XENP21475, XENP21476, XENP21477, XENP21478, XENP21479, XENP21978, XENP22013, XENP22015, XENP22017, XENP22354, XENP22355, XENP22356, XENP22357, XENP22358, XENP22359, XENP22360, XENP22361, XENP22362, XENP22363, XENP22364, XENP22365, XENP22366, XENP22637, and XENP22639. In some aspects, the present invention provides a heterodimeric protein selected from the group consisting of XENP20818, XENP20819, XENP21471, XENP21472, XENP21473, XENP21474, XENP21475, XENP21476, XENP21477, XENP22013, XENP22815, XENP22816, XENP22817, XENP22818, XENP22819, XENP22820, XENP22821, XENP22822, XENP22823, XENP22824, XENP22825, XENP22826, XENP22827, XENP22828, XENP22829, XENP22830, XENP22831, XENP22832, XENP22833, XENP22834, XENP23343, XENP23554, XENP23555, XENP23557, XENP23559, XENP24019, and XENP24020. Nucleic acids, expression vectors and host cells are all provided as well, in addition to methods of making these proteins and treating patients with them.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 depicts the structure of IL-15 in complex with its receptors IL-15Rα (CD215), IL-15Rβ (CD122), and the common gamma chain (CD132).
  • FIGS. 2A-2B depict the sequences for IL-15 and its receptors. FIG. 2A shows the sequences for human IL-15, human IL-15Rα and human IL-15Rβ. FIG. 2A shows the sequences for the human common gamma receptor.
  • FIGS. 3A-3E depict useful pairs of Fc heterodimerization variant sets (including skew and pI variants). On FIGS. 3D and 3E, there are variants for which there are no corresponding “monomer 2” variants; these are pI variants which can be used alone on either monomer.
  • FIG. 4 depict a list of isosteric variant antibody constant regions and their respective substitutions. pI_(−) indicates lower pI variants, while pI_(+) indicates higher pI variants. These can be optionally and independently combined with other heterodimerization variants of the inventions (and other variant types as well, as outlined herein).
  • FIG. 5 depict useful ablation variants that ablate FcγR binding (sometimes referred to as “knock outs” or “KO” variants). Generally, ablation variants are found on both monomers, although in some cases they may be on only one monomer.
  • FIGS. 6A-6E show a particularly useful embodiments of “non-cytokine” components of the invention.
  • FIG. 7 depicts a number of exemplary variable length linkers. In some embodiments, these linkers find use linking the C-terminus of IL-15 and/or IL-15Rα(sushi) to the N-terminus of the Fc region. In some embodiments, these linkers find use fusing IL-15 to the IL-15Rα(sushi).
  • FIGS. 8A-8E show the sequences of several useful IL-15/Rα-Fc format backbones based on human IgG1, without the cytokine sequences (e.g., the Il-15 and/or IL-15Rα(sushi)). Backbone 1 is based on human IgG1 (356E/358M allotype), and includes C220S on both chain, the S364K/E357Q: L368D/K370S skew variants, the Q295E/N384D/Q418E/N421D pI variants on the chain with L368D/K370S skew variants and the E233P/L234V/L235A/G236del/S267K ablation variants on both chains. Backbone 2 is based on human IgG1 (356E/358M allotype), and includes C220S on both chain, the S364K: L368D/K370S skew variants, the Q295E/N384D/Q418E/N421D pI variants on the chain with L368D/K370S skew variants and the E233P/L234V/L235A/G236del/S267K ablation variants on both chains. Backbone 3 is based on human IgG1 (356E/358M allotype), and includes C220S on both chain, the S364K: L368E/K370S skew variants, the Q295E/N384D/Q418E/N421D pI variants on the chain with L368E/K370S skew variants and the E233P/L234V/L235A/G236del/S267K ablation variants on both chains. Backbone 4 is based on human IgG1 (356E/358M allotype), and includes C220S on both chain, the D401K: K360E/Q362E/T411E skew variants, the Q295E/N384D/Q418E/N421D pI variants on the chain with K360E/Q362E/T411E skew variants and the E233P/L234V/L235A/G236del/S267K ablation variants on both chains. Backbone 5 is based on human IgG1 (356D/358L allotype), and includes C220S on both chain, the S364K/E357Q: L368D/K370S skew variants, the Q295E/N384D/Q418E/N421D pI variants on the chain with L368D/K370S skew variants and the E233P/L234V/L235A/G236del/S267K ablation variants on both chains. Backbone 6 is based on human IgG1 (356E/358M allotype), and includes C220S on both chain, the S364K/E357Q: L368D/K370S skew variants, Q295E/N384D/Q418E/N421D pI variants on the chain with L368D/K370S skew variants and the E233P/L234V/L235A/G236del/S267K ablation variants on both chains, as well as an N297A variant on both chains. Backbone 7 is identical to 6 except the mutation is N297S. Alternative formats for backbones 6 and 7 can exclude the ablation variants E233P/L234V/L235A/G236del/S267K in both chains. Backbone 8 is based on human IgG4, and includes the S364K/E357Q: L368D/K370S skew variants, the Q295E/N384D/Q418E/N421D pI variants on the chain with L368D/K370S skew variants, as well as a S228P (EU numbering, this is S241P in Kabat) variant on both chains that ablates Fab arm exchange as is known in the art. Backbone 9 is based on human IgG2, and includes the S364K/E357Q: L368D/K370S skew variants, the Q295E/N384D/Q418E/N421D pI variants on the chain with L368D/K370S skew variants. Backbone 10 is based on human IgG2, and includes the S364K/E357Q: L368D/K370S skew variants, the Q295E/N384D/Q418E/N421D pI variants on the chain with L368D/K370S skew variants as well as a S267K variant on both chains. Backbone 11 is identical to backbone 1, except it includes M428L/N434S Xtend mutations. Backbone 12 is based on human IgG1 (356E/358M allotype), and includes C220S on both identical chain, the the E233P/L234V/L235A/G236del/S267K ablation variants on both identical chains. Backbone 13 is based on human IgG1 (356E/358M allotype), and includes C220S on both chain, the S364K/E357Q: L368D/K370S skew variants, the P217R/P229R/N276K pI variants on the chain with S364K/E357Q skew variants and the E233P/L234V/L235A/G236del/S267K ablation variants on both chains.
  • As will be appreciated by those in the art and outlined below, these sequences can be used with any IL-15 and IL-15Rα(sushi) pairs outlined herein, including but not limited to IL-15/Rα-heteroFc, ncIL-15/Rα, scIL-15/Rα, and dsIL-15/Rα as schematically depicted in FIGS. 9A-9G, and FIGS. 39A-39D. Additionally, any IL-15 and/or IL-15Rα(sushi) variants can be incorporated into these FIGS. 8A-8E backbones in any combination.
  • Included within each of these backbones are sequences that are 90%, 95%, 98% and 99% identical (as defined herein) to the recited sequences, and/or contain from 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional amino acid substitutions (as compared to the “parent” of the Figure, which, as will be appreciated by those in the art, already contain a number of amino acid modifications as compared to the parental human IgG1 (or IgG2 or IgG4, depending on the backbone). That is, the recited backbones may contain additional amino acid modifications (generally amino acid substitutions) in addition to the skew, pI and ablation variants contained within the backbones of this figure (FIG. 8).
  • FIGS. 9A-9G depict several formats for the IL-15/Rα-Fc fusion proteins of the present invention. IL-15Rα Heterodimeric Fc fusion or “IL-15/Rα-heteroFc” (FIG. 9A) comprises IL-15 recombinantly fused to one side of a heterodimeric Fc and IL-15Rα(sushi) recombinantly fused to the other side of a heterodimeric Fc. The IL-15 and IL-15Rα(sushi) may have a variable length Gly-Ser linker between the C-terminus and the N-terminus of the Fc region. Single-chain IL-15/Rα-Fc fusion or “scIL-15/Rα-Fc” (FIG. 9B) comprises IL-15Rα(sushi) fused to IL-15 by a variable length linker (termed a “single-chain” IL-15/IL-15Rα(sushi) complex or “scIL-15/Rα”) which is then fused to the N-terminus of a heterodimeric Fc-region, with the other side of the molecule being “Fc-only” or “empty Fc”. Non-covalent IL-15/Rα-Fc or “ncIL-15/Rα-Fc” (FIG. 9C) comprises IL-15Rα(sushi) fused to a heterodimeric Fc region, while IL-15 is transfected separatedly so that a non-covalent IL-15/Rα complex is formed, with the other side of the molecule being “Fc-only” or “empty Fc”. Bivalent non-covalent IL-15/Rα-Fc fusion or “bivalent ncIL-15/Rα-Fc” (FIG. 9D) comprises IL-15Rα(sushi) fused to the N-terminus of a homodimeric Fc region, while IL-15 is transfected separately so that a non-covalent IL-15/Rα complex is formed. Bivalent single-chain IL-15/Rα-Fc fusion or “bivalent scIL-15/Rα-Fc” (FIG. 9E) comprises IL-15 fused to IL-15Rα(sushi) by a variable length linker (termed a “single-chain” IL-15/IL-15Rα(sushi) complex or “scIL-15/Rα”) which is then fused to the N-terminus of a homodimeric Fc-region. Fc-non-covalent IL-15/Rα fusion or “Fc-ncIL-15/Rα” (FIG. 9F) comprises IL-15Rα(sushi) fused to the C-terminus of a heterodimeric Fc region, while IL-15 is transfected separately so that a non-covalent IL-15/Rα complex is formed, with the other side of the molecule being “Fc-only” or “empty Fc”. Fc-single-chain IL-15/Rα fusion or “Fc-scIL-15/Rα” (FIG. 9G) comprises IL-15 fused to IL-15Rα(sushi) by a variable length linker (termed a “single-chain” IL-15/IL-15Rα(sushi) complex or “scIL-15/Rα”) which is then fused to the C-terminus of a heterodimeric Fc region, with the other side of the molecule being “Fc-only” or “empty Fc”.
  • FIG. 10 depicts sequences of XENP20818 and XENP21475, illustrative IL-15/Rα-Fc fusion proteins of the “IL-15/Rα-heteroFc” format, with additional sequences being listed as XENPs 20819, 21471, 21472, 21473, 21474, 21476, and 21477 in the sequence listing. IL-15 and IL-15Rα(sushi) are underlined, linkers are double underlined (although as will be appreciated by those in the art, the linkers can be replaced by other linkers, some of which are depicted in FIG. 7), and slashes (/) indicate the border(s) between IL-15, IL-15Rα, linkers, and Fc regions.
  • FIG. 11 depicts sequences of XENP21478, an illustrative IL-15/Rα-Fc fusion protein of the “scIL-15/Rα-Fc” format, with additional sequences being listed as XENPs 21993, 21994, 21995, 23174, 23175, 24477, and 24480 in the sequence listing. IL-15 and IL-15Rα(sushi) are underlined, linkers are double underlined (although as will be appreciated by those in the art, the linkers can be replaced by other linkers, some of which are depicted in FIG. 7), and slashes (/) indicate the border(s) between IL-15, IL-15Rα, linkers, and Fc regions.
  • FIGS. 12A-12B depict sequences of XENP21479, XENP22366 and XENP24348, illustrative IL-15/Rα-Fc fusion proteins of the “ncIL-15/Rα-Fc” format. IL-15 and IL-15Rα(sushi) are underlined, linkers are double underlined (although as will be appreciated by those in the art, the linkers can be replaced by other linkers, some of which are depicted in FIG. 7), and slashes (/) indicate the border(s) between IL-15, IL-15Rα, linkers, and Fc regions.
  • FIG. 13 depicts sequences of XENP21978, an illustrative IL-15/Rα-Fc fusion protein of the “bivalent ncIL-15/Rα-Fc” format, with additional sequences being listed as XENP21979 in the sequence listing. IL-15 and IL-15Rα(sushi) are underlined, linkers are double underlined (although as will be appreciated by those in the art, the linkers can be replaced by other linkers, some of which are depicted in FIG. 7), and slashes (/) indicate the border(s) between IL-15, IL-15Rα, linkers, and Fc regions.
  • FIG. 14 depicts sequences of an illustrative IL-15/Rα-Fc fusion protein of the “bivalent scIL-15/Rα-Fc” format. IL-15 and IL-15Rα(sushi) are underlined, linkers are double underlined (although as will be appreciated by those in the art, the linkers can be replaced by other linkers, some of which are depicted in FIG. 7), and slashes (/) indicate the border(s) between IL-15, IL-15Rα, linkers, and Fc regions.
  • FIG. 15 depicts sequences of XENP22637, an illustrative IL-15/Rα-Fc fusion protein of the “Fc-ncIL-15/Rα” format, with additional sequences being listed as XENP22638 in the sequence listing. IL-15 and IL-15Rα(sushi) are underlined, linkers are double underlined (although as will be appreciated by those in the art, the linkers can be replaced by other linkers, some of which are depicted in FIG. 7), and slashes (/) indicate the border(s) between IL-15, IL-15Rα, linkers, and Fc regions.
  • FIG. 16 depicts sequences of an illustrative IL-15/Rα-Fc fusion protein of the “Fc-scIL-15/Rα” format. IL-15 and IL-15Rα(sushi) are underlined, linkers are double underlined (although as will be appreciated by those in the art, the linkers can be replaced by other linkers, some of which are depicted in FIG. 7), and slashes (/) indicate the border(s) between IL-15, IL-15Rα, linkers, and Fc regions.
  • FIGS. 17A-17E depict A) the IL-15/Rα-Fc fusion protein format for XENP20818, the purity and homogeneity of XENP20818 as determined by B) SEC and C) CEF, D) the affinity of XENP20818 for IL-2Rβ as determined by Octet, and E) the stability of XENP20818 as determined by DSF
  • FIGS. 18A-18E depict A) the IL-15/Rα-Fc fusion protein format for XENP21478, the purity and homogeneity of XENP21478 as determined by B) SEC and C) CEF, D) the affinity of XENP21478 for IL-2Rβ as determined by Octet, and E) the stability of XENP21478 as determined by DSF.
  • FIGS. 19A-19E depicts A) the IL-15/Rα-Fc fusion protein format for XENP21479, the purity and homogeneity of XENP21479 as determined by B) SEC and C) CEF, D) the affinity of XENP21479 for IL-2Rβ as determined by Octet, and E) the stability of XENP21479 as determined by DSF.
  • FIGS. 20A-20C depict the induction of A) NK (CD56+/CD16+) cells, B) CD4+ T cells, and C) CD8+ T cells proliferation by illustrative IL-15/Rα-Fc fusion proteins of the IL-15/Rα-heteroFc format with different linker lengths based on Ki67 expression as measured by FACS.
  • FIGS. 21A-21C depict the induction of A) NK (CD56+/CD16+) cells, B) CD4+ T cells, and C) CD8+ T cells proliferation by illustrative IL-15/Rα-Fc fusion proteins of the scIL-15/Rα-Fc format (XENP21478) and the ncIL-15/Rα-Fc format (XENP21479) based on Ki67 expression as measured by FACS.
  • FIG. 22 depicts enhancement of IL-2 secretion by illustrative IL-15/Rα-Fc fusion proteins, an isotype control, and a bivalent anti-PD-1 antibody over PBS control in an SEB-stimulated PBMC assay.
  • FIG. 23 depicts the survival curve for PBMC-engrafted NSG mice following treatment with XENP20818 and recombinant IL-15.
  • FIG. 24 depicts the concentration of IFNγ in serum of NSG mice on Day 7 after engraftment with human PBMCs and treatment with XENP20818 at the indicated concentrations.
  • FIGS. 25A-25C depict A) CD4+ T cell, B) CD8+ T cell, and C) CD45+ cell counts in whole blood of human PBMC-engrafted NSG mice 7 days after treatment with XENP20818 at the indicated concentrations.
  • FIG. 26 depicts a structural model of the IL-15/Rα heterodimer showing locations of engineered disulfide bond pairs.
  • FIG. 27 depicts sequences for illustrative IL-15Rα(sushi) variants engineered with additional residues at the C-terminus to serve as a scaffold for engineering cysteine residues.
  • FIG. 28 depicts sequences for illustrative IL-15 variants engineered with cysteines in order to form covalent disulfide bonds with IL-15Rα(sushi) variants engineered with cysteines.
  • FIG. 29 depicts sequences for illustrative IL-15Rα(sushi) variants engineered with cysteines in order to form covalent disulfide bonds with IL-15 variants engineered with cysteines.
  • FIGS. 30A-30C depict IL-15/Rα heterodimers with and without engineered disulfide bonds between IL-15 and IL-15Rα(sushi). Non-covalent IL-15/Rα heterodimer or “ncIL-15/Rα heterodimer” (FIG. 30A) comprises IL-15Rα(sushi) and IL-15 transfected separately and non-covalently linked. Disulfide-bonded IL-15/Rα heterodimer or “dsIL-15/Rα heterodimer” (FIG. 30B) comprises IL-15Rα(sushi) and IL-15 transfected separately and covalently linked as a result of engineered cysteines. Single-chain IL-15/Rα heterodimer or “scIL-15/Rα Heterodimer” (FIG. 30C) comprises IL-15Rα(sushi) fused to IL-15 by a variable length Gly-Ser linker.
  • FIG. 31 depicts sequences of XENP21996, an illustrative ncIL-15/Rα heterodimer. It is important to note that these sequences were generated using polyhistidine (Hisx6 or HHHHHH (SEQ ID NO: 1198)) C-terminal tags at the C-terminus of IL-15Rα(sushi).
  • FIG. 32 depicts sequences of XENP22004, XENP22005, XENP22006, XENP22008, and XENP22494, illustrative dsIL-15/Rα heterodimers, with additional sequences depicted as XENPs 22007, 22009, 22010, 22011, 22012, and 22493 in the sequence listing. It is important to note that these sequences were generated using polyhistidine (Hisx6 or HHHHHH (SEQ ID NO: 1198)) C-terminal tags at the C-terminus of IL-15Rα(sushi).
  • FIG. 33 depicts the sequence for XENP22049, an illustrative scIL-15/Rα Heterodimer. It is important to note that these sequences were generated using polyhistidine (Hisx6 or HHHHHH (SEQ ID NO: 1198)) C-terminal tags at the C-terminus of IL-15. IL-15 and IL-15Rα(sushi) are underlined, linkers are double underlined (although as will be appreciated by those in the art, the linkers can be replaced by other linkers, some of which are depicted in FIG. 7), and slashes (/) indicate the border(s) between IL-15, IL-15Rα, and linker
  • FIG. 34 depicts the purity and homogeneity of illustrative IL-15/Rα heterodimers with and without engineered disulfide bonds as determined by CEF.
  • FIG. 35 depicts the purity and homogeneity of illustrative IL-15/Rα heterodimers with and without engineered disulfide bonds as determined by CEF.
  • FIG. 36 depicts the stability and melting temperatures of illustrative IL-15/Rα heterodimers with and without engineered disulfide bonds as indicated by melting curves from DSF.
  • FIG. 37 depicts the stability and melting temperatures of illustrative IL-15/Rα heterodimers with and without engineered disulfide bonds as indicated by melting curves from DSF.
  • FIG. 38 depicts the expression yield, molecular weight, predicted change in affinity between IL-15 and IL-15Rα(sushi) as calculated by MOE software, melting temperature, and affinity for IL-2RB for IL-15/Rα heterodimers with and without engineered disulfide bonds. Mutations are indicated in parentheses after the relevant monomer.
  • FIGS. 39A-39D depict additional formats for the IL-15/Rα-Fc fusion proteins of the present invention with engineered disulfide bonds. Disulfide-bonded IL-15/Rα heterodimeric Fc fusion or “dsIL-15/Rα-heteroFc” (FIG. 39A) is the same as “IL-15/Rα-heteroFc”, but wherein IL-15Rα(sushi) and IL-15 are further covalently linked as a result of engineered cysteines. Disulfide-bonded IL-15/Rα Fc fusion or “dsIL-15/Rα-Fc” (FIG. 39B) is the same as “ncIL-15/Rα-Fc”, but wherein IL-15Rα(sushi) and IL-15 are further covalently linked as a result of engineered cysteines. Bivalent disulfide-bonded IL-15/Rα-Fc or “bivalent dsIL-15/Rα-Fc” (FIG. 39C) is the same as “bivalent ncIL-15/Rα-Fc”, but wherein IL-15Rα(sushi) and IL-15 are further covalently linked as a result of engineered cysteines. Fc-disulfide-bonded IL-15/Rα fusion or “Fc-dsIL-15/Rα” (FIG. 39D) is the same as “Fc-ncIL-15/Rα”, but wherein IL-15Rα(sushi) and IL-15 are further covalently linked as a result of engineered cysteines.
  • FIGS. 40A-40B depicts sequences of XENP22013, XENP22014, XENP22015, and XENP22017, illustrative IL-15/Rα-Fc fusion protein of the “dsIL-15/Rα-heteroFc” format. IL-15 and IL-15Rα(sushi) are underlined, linkers are double underlined (although as will be appreciated by those in the art, the linkers can be replaced by other linkers, some of which are depicted in FIG. 7), and slashes (/) indicate the border(s) between IL-15, IL-15Rα, linkers, and Fc regions.
  • FIGS. 41A-41B depict sequences of XENP22357, XENP22358, XENP22359, XENP22684, and XENP22361, illustrative IL-15/Rα-Fc fusion proteins of the “dsIL-15/Rα-Fc” format. Additional sequences are depicted as XENPs 22360, 22362, 22363, 22364, 22365, and 22366 in the sequence listing. IL-15 and IL-15Rα(sushi) are underlined, linkers are double underlined (although as will be appreciated by those in the art, the linkers can be replaced by other linkers, some of which are depicted in FIG. 7), and slashes (/) indicate the border(s) between IL-15, IL-15Rα, linkers, and Fc regions.
  • FIG. 42 depicts sequences of XENP22634, XENP22635, and XENP22636, illustrative IL-15/Rα-Fc fusion proteins of the “bivalent dsIL-15/Rα-Fc” format. Additional sequences are depicted as XENP22687 in the sequence listing. IL-15 and IL-15Rα(sushi) are underlined, linkers are double underlined (although as will be appreciated by those in the art, the linkers can be replaced by other linkers, some of which are depicted in FIG. 7), and slashes (/) indicate the border(s) between IL-15, IL-15Rα, linkers, and Fc regions.
  • FIG. 43 depicts sequences of XENP22639 and XENP22640, illustrative IL-15/Rα-Fc fusion proteins of the “Fc-dsIL-15/Rα” format. IL-15 and IL-15Rα(sushi) are underlined, linkers are double underlined (although as will be appreciated by those in the art, the linkers can be replaced by other linkers, some of which are depicted in FIG. 7), and slashes (/) indicate the border(s) between IL-15, IL-15Rα, linkers, and Fc regions.
  • FIG. 44 depicts the purity and homogeneity of illustrative IL-15/Rα-Fc fusion proteins with and without engineered disulfide bonds as determined by CEF.
  • FIGS. 45A-45C depict the induction of A) NK (CD56+/CD16+) cell, B) CD8+ T cell, and C) CD4+ T cell proliferation by illustrative IL-15/Rα-Fc fusion proteins with and without engineered disulfide bonds based on Ki67 expression as measured by FACS.
  • FIG. 46 depicts the structure of IL-15 complexed with IL-15Rα, IL-2RB, and common gamma chain. Locations of substitutions designed to reduce potency are shown.
  • FIGS. 47A-47C depict sequences for illustrative IL-15 variants engineered for reduced potency. Included within each of these variant IL-15 sequences are sequences that are 90%, 95%, 98%, and 99% identical (as defined herein) to the recited sequences, and/or contain from 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional amino acid substitutions. In a non-limiting example, the recited sequences may contain additional amino acid modifications such as those contributing to formation of covalent disulfide bonds as described in Example 2.
  • FIGS. 48A-48D depict sequences of XENP22821, XENP22822, XENP23554, XENP23557, XENP23561, XENP24018, XENP24019, XENP24045, XENP24051, and XENP24052, illustrative IL-15/Rα-Fc fusion proteins of the “IL-15/Rα-heteroFc” format engineered for lower potency. Additional sequences are depicted as XENPs 22815, 22816, 22817, 22818, 22819, 22820, 22823, 22824, 22825, 22826, 22827, 22828, 22829, 22830, 22831, 22832, 22833, 22834, 23555, 23559, 23560, 24017, 24020, 24043, and 24048 in the sequence listing. IL-15 and IL-15Rα(sushi) are underlined, linkers are double underlined (although as will be appreciated by those in the art, the linkers can be replaced by other linkers, some of which are depicted in FIG. 7), and slashes (/) indicate the border(s) between IL-15, IL-15Rα, linkers, and Fc regions.
  • FIGS. 49A-49C depict sequences of XENP24015, XENP24050, XENP24475, XENP24476, XENP24478, XENP24479, and XENP24481, illustrative IL-15/Rα-Fc fusion proteins of the “scIL-15/Rα-Fc” format engineered for lower potency. Additional sequences are depicted as XENPs 24013, 24014, and 24016 in the sequence listing. IL-15 and IL-15Rα(sushi) are underlined, linkers are double underlined (although as will be appreciated by those in the art, the linkers can be replaced by other linkers, some of which are depicted in FIG. 7), and slashes (/) indicate the border(s) between IL-15, IL-15Rα, linkers, and Fc regions.
  • FIGS. 50A-50B depict sequences of XENP24349, XENP24890, and XENP25138, illustrative IL-15/Rα-Fc fusion proteins of the “ncIL-15/Rα-Fc” format engineered for lower potency. IL-15 and IL-15Rα(sushi) are underlined, linkers are double underlined (although as will be appreciated by those in the art, the linkers can be replaced by other linkers, some of which are depicted in FIG. 7), and slashes (/) indicate the border(s) between IL-15, IL-15Rα, linkers, and Fc regions.
  • FIG. 51 depicts sequences of XENP22801 and XENP22802, illustrative ncIL-15/Rα heterodimers engineered for lower potency. Additional sequences are depicted as XENPs 22791, 22792, 22793, 22794, 22795, 22796, 22803, 22804, 22805, 22806, 22807, 22808, 22809, 22810, 22811, 22812, 22813, and 22814 in the sequence listing. It is important to note that these sequences were generated using polyhistidine (Hisx6 or HHHHHH (SEQ ID NO: 1198)) C-terminal tags at the C-terminus of IL-15Rα(sushi).
  • FIG. 52 depicts sequences of XENP24342, an illustrative IL-15/Rα-Fc fusion protein of the “bivalent ncIL-15/Rα-Fc” format engineered for lower potency. IL-15 and IL-15Rα(sushi) are underlined, linkers are double underlined (although as will be appreciated by those in the art, the linkers can be replaced by other linkers, some of which are depicted in FIG. 7), and slashes (/) indicate the border(s) between IL-15, IL-15Rα, linkers, and Fc regions.
  • FIG. 53 depicts sequences of XENP23472 and XENP23473, illustrative IL-15/Rα-Fc fusion proteins of the “dsIL-15/Rα-Fc” format engineered for lower potency. IL-15 and IL-15Rα(sushi) are underlined, linkers are double underlined (although as will be appreciated by those in the art, the linkers can be replaced by other linkers, some of which are depicted in FIG. 7), and slashes (/) indicate the border(s) between IL-15, IL-15Rα, linkers, and Fc regions.
  • FIGS. 54A-54C depict the induction of (A) NK cell, (B) CD8+(CD45RA−) T cell, and (C) CD4+(CD45RA−) T cell proliferation by variant IL-15/Rα-Fc fusion proteins based on Ki67 expression as measured by FACS.
  • FIG. 55 depicts EC50 for induction of NK and CD8+ T cells proliferation by variant IL-15/Rα-Fc fusion proteins, and fold reduction in EC50 relative to XENP20818.
  • FIGS. 56A-56C depict the gating of lymphocytes and subpopulations for the experiments depicted in FIGS. 59A-59D. FIG. 56A shows the gated lymphocyte population. FIG. 56B shows the CD3-negative and CD3-positive subpopulations. FIG. 56C shows the CD16=negative and CD16-positive subpopulations of the CD3-negative cells.
  • FIGS. 57A-57C depict the gating of CD3+ lymphocyte subpopulations for the experiments depicted in FIGS. 59A-59D. FIG. 57A shows the CD4+, CD8+ and γδ T cell subpopulations of the CD3+ T cells. FIG. 57B shows the CD45RA(−) and CD45RA(+) subpopulations of the CD4+ T cells. FIG. 57C shows the CD45RA(−) and CD45RA(+) subpopulation s of the CD8+ T cells.
  • FIGS. 58A-58B depict CD69 and CD25 expression before (FIG. 58A) and after (FIG. 58B) incubation of human PBMCs with XENP22821.
  • FIGS. 59A-59D depict cell proliferation in human PBMCs incubated for four days with the indicated variant IL-15/Rα-Fc fusion proteins. FIGS. 59A-C show the percentage of proliferating NK cells (CD3−CD16+) (FIG. 59A), CD8+ T cells (CD3+CD8+CD45RA−) (FIG. 59B) and CD4+ T cells (CD3+CD4+CD45RA−) (FIG. 59C). FIG. 59D shows the fold change in EC50 of various IL15/IL15Rα Fc heterodimers relative to control (XENP20818).
  • FIGS. 60A-60D depict cell proliferation in human PBMCs incubated for three days with the indicated variant IL-15/Rα-Fc fusion proteins. FIGS. 60A-C show the percentage of proliferating CD8+(CD45RA−) T cells (Figure A), CD4+(CD45RA−) T cells (FIG. 60B), γδ T cells (FIG. 60C), and NK cells (FIG. 60D).
  • FIGS. 61A-61C depict the percentage of Ki67 expression on (A) CD8+ T cells, (B) CD4+ T cells, and (C) NK cells following treatment with additional IL-15/Rα variants.
  • FIGS. 62A-62E depict the percentage of Ki67 expression on (A) CD8+(CD45RA−) T cells, (B) CD4+(CD45RA−) T cells, (C) γδ T cells, (D) NK (CD16+CD8α−) cells, and (E) NK (CD56+CD8α−) cells following treatment with IL-15/Rα variants.
  • FIGS. 63A-63E depict the percentage of Ki67 expression on (A) CD8+(CD45RA−) T cells, (B) CD4+(CD45RA−) T cells, (C) γδ T cells, (D) NK (CD16+CD8α−) cells, and (E) NK (CD56+CD8α−) cells following treatment with IL-15/Rα variants.
  • FIGS. 64A-64D depict the percentage of Ki67 expression on (A) CD8+ T cells, (B) CD4+ T cells, (C) γδ T cells and (D) NK (CD16+) cells following treatment with additional IL-15/Rα variants engineered for decreased potency with different linker lengths.
  • FIGS. 65A-65D depict the percentage of Ki67 expression on (A) CD8+ T cells, (B) CD4+ T cells, (C) γδ T cells and (D) NK (CD16+) cells following treatment with additional IL-15/Rα variants.
  • FIGS. 66A-66D depict gating of lymphocytes and subpopulations thereof for the experiments depicted in FIG. 67. FIG. 66A shows gating of the lymphocyte population. FIG. 66B shows CD4+ and CD8+ T cells. FIG. 66C shows the CD45RA and CD27 expressing subpopulations of CD4+ T cells. FIG. 66D shows the CD45RA and CD27 expressing subpopulations of CD8+ T cells.
  • FIGS. 67A-67C depict STATS phosphorylation on A) CD8+ T cells (CD45RA−CD27−) and B) CD4+ T cells (CD45RA−CD27−) following incubation of PBMCs for 4 days with the indicated variant IL15/IL15Rα-Fc fusion proteins at the indicated concentrations.
  • FIG. 67C shows the fold change in EC50 of various IL15/IL15Rα Fc heterodimers relative to control (XENP20818).
  • FIG. 68 depicts IV-TV Dose PK of various IL-15/Rα-Fc fusion proteins or controls in C57BL/6 mice at 0.1 mg/kg single dose.
  • FIG. 69 depicts the correlation of half-life vs NK cell potency.
  • FIG. 70 shows that CD45+ cell levels are predictive of disease.
  • FIGS. 71A-71B depict the enhancement of engraftment by variant IL-15/Rα-Fc fusion proteins as indicated by CD45+ cell counts on Days A) 4 and B) 8.
  • FIGS. 72A-72C depict IFNγ levels on Days (A) 4, (B) 7 and (C) 11 after treatment of NSG mice engrafted with human PBMCs with the indicated variant IL15/Rα-Fc fusion proteins or control.
  • FIGS. 73A-73C depict CD45+ lymphocyte cell counts on Days (A) 4, (B) 7, and (C) 11 after treatment of NSG mice engrafted with human PBMCs with the indicated variant IL15/Rα-Fc fusion proteins or control.
  • FIGS. 74A-74C depict NK cell (CD16+CD56+CD45RA+) counts on Days A) 4, B) 7 and C) 11 after treatment of NSG mice engrafted with human PBMCs with the indicated IL15/Rα-Fc fusion proteins or control.
  • FIGS. 75A-75B depict CD8+ T cell (CD8+CD45RA+) counts on Days (A) 7 and (B) 11 after treatment of NSG mice engrafted with human PBMCs with the indicated IL15/Rα-Fc fusion proteins or control.
  • FIGS. 76A-76B depict CD4+ T cell (CD4+CD45RA+) counts on Days A) 7 and B) 11 after treatment of NSG mice engrafted with human PBMCs with the indicated IL15/Rα-Fc fusion proteins or control.
  • FIG. 77 depicts IFNγ level on Days 4, 7, and 11 in serum of huPBMC engrafted mice following treatment with additional variant IL-15/Rα-Fc fusion proteins.
  • FIGS. 78A-78C depict CD8+ T cell count on Days (A) 4, (B) 7, and (C) 11 in whole blood of huPBMC engrafted mice following treatment with additional variant IL-15/Rα-Fc fusion proteins.
  • FIGS. 79A-79C depict CD4+ T cell count on Days (A) 4, (B) 7, and (C) 11 in whole blood of huPBMC engrafted mice following treatment with additional variant IL-15/Rα-Fc fusion proteins.
  • FIGS. 80A-80C depict CD45+ cell count on Days (A) 4, (B) 7, and (C) 11 in whole blood of huPBMC engrafted mice following treatment with additional variant IL-15/Rα-Fc fusion proteins.
  • FIGS. 81A-81C depict the body weight as a percentage of initial body weight of huPBMC engrafted mice on Days (A) 4, (B) 7, and (C) 11 following treatment with additional IL-15/Rα variants. Each point represents a single NSG mouse. Mice whose body weights dropped below 70% initial body weight were euthanized. Dead mice are represented as 70%.
  • FIGS. 82A-82E depict lymphocyte counts after dosing cynomolgus monkeys with XENP20818. FIGS. 82A-E respectively show the fold change in absolute count of CD56+ NK cells (FIG. 82A), CD16+ NK cells (FIG. 82B), γδ T cells (CD45RA+CD3+CD4−CD8−) (FIG. 82C), CD8+ T cells (FIG. 82D), and CD4+ T cells (FIG. 82E).
  • FIGS. 83A-83E depict proliferation of CD56+ NK cells (FIG. 83A), CD16+NK cells (FIG. 83B), CD8+ T cells (CD45RA+) (FIG. 83C), CD8+ T cells (CD45RA−) (FIG. 83D), and CD4+ T cells (CD45RA−) (FIG. 83E) after dosing cynomolgus monkeys with XENP20818.
  • FIGS. 84A-84E depict lymphocyte counts after dosing cynomolgus monkeys with XENP22819. FIGS. 84A-E respectively show the fold change in absolute count of CD56+ NK cells (FIG. 84A), CD16+ NK cells (FIG. 84B), γδ T cells (CD45RA+CD3+CD4−CD8−) (FIG. 84C), CD8+ T cells (FIG. 84D), and CD4+ T cells (FIG. 84E).
  • FIGS. 85A-85E depict proliferation of CD56+ NK cells (FIG. 85A), CD16+NK cells (FIG. 85B), CD8+ T cells (CD45RA+) (FIG. 85C), CD8+ T cells (CD45RA−) (FIG. 85D), and CD4+ T cells (CD45RA−) (FIG. 85E) after dosing cynomolgus monkeys with XENP22819.
  • FIGS. 86A-86E depict lymphocyte counts after dosing cynomolgus monkeys with XENP22821. FIGS. 86A-E respectively show the fold change in absolute count of CD56+ NK cells (FIG. 86A), CD16+ NK cells (FIG. 86B), γδ T cells (CD45RA+CD3+CD4−CD8−) (FIG. 86C), CD8+ T cells (FIG. 86D), and CD4+ T cells (FIG. 86E).
  • FIGS. 87A-87E depict proliferation of CD56+ NK cells (FIG. 87A), CD16+NK cells (FIG. 87B), CD8+ T cells (CD45RA+) (FIG. 87C), CD8+ T cells (CD45RA−) (FIG. 87D), and CD4+ T cells (CD45RA−) (FIG. 87E) after dosing cynomolgus monkeys with XENP22821.
  • FIGS. 88A-88E depict lymphocyte counts after dosing cynomolgus monkeys with XENP22822. FIGS. 88A-E respectively show the fold change in absolute count of CD56+ NK cells (FIG. 88A), CD16+ NK cells (FIG. 88B), γδ T cells (CD45RA+CD3+CD4−CD8−) (FIG. 88C), CD8+ T cells (FIG. 88D), and CD4+ T cells (FIG. 88E).
  • FIGS. 89A-89E depict proliferation of CD56+ NK cells (FIG. 89A), CD16+NK cells (FIG. 89B), CD8+ T cells (CD45RA+) (FIG. 89C), CD8+ T cells (CD45RA−) (FIG. 89D), and CD4+ T cells (CD45RA−) (FIG. 89E) after dosing cynomolgus monkeys with XENP22822.
  • FIGS. 90A-90E depict lymphocyte counts after dosing cynomolgus monkeys with XENP22834. FIGS. 90A-E respectively show the fold change in absolute count of CD56+ NK cells (FIG. 90A), CD16+ NK cells (FIG. 90B), γδ T cells (CD45RA+CD3+CD4−CD8−) (FIG. 90C), CD8+ T cells (FIG. 90D), and CD4+ T cells (FIG. 90E).
  • FIGS. 91A-91E depict proliferation of CD56+ NK cells (FIG. 91A), CD16+NK cells (FIG. 91B), CD8+ T cells (CD45RA+) (FIG. 91C), CD8+ T cells (CD45RA−) (FIG. 91D), and CD4+ T cells (CD45RA−) (FIG. 91E) after dosing cynomolgus monkeys with XENP22834.
  • FIGS. 92A-92E depict lymphocyte counts after dosing cynomolgus monkeys with XENP23343. FIGS. 92A-E respectively show the fold change in absolute count of CD56+ NK cells (FIG. 92A), CD16+ NK cells (FIG. 92B), γδ T cells (CD45RA+CD3+CD4−CD8−) (FIG. 92C), CD8+ T cells (FIG. 92D), and CD4+ T cells (FIG. 92E).
  • FIGS. 93A-93E depict proliferation of CD56+ NK cells (FIG. 93A), CD16+NK cells (FIG. 93B), CD8+ T cells (CD45RA+) (FIG. 93C), CD8+ T cells (CD45RA−) (FIG. 93D), and CD4+ T cells (CD45RA−) (FIG. 93E) after dosing cynomolgus monkeys with XENP23343.
  • FIGS. 94A-94D depict sequences of XENP23343, XENP23504, XENP24113, XENP24301, XENP24306, and XENP24341, illustrative IL-15/Rα-Fc fusion proteins of the “IL-15/Rα-heteroFc” format with M428L/N434S substitutions. IL-15 and IL-15Rα(sushi) are underlined, linkers are double underlined (although as will be appreciated by those in the art, the linkers can be replaced by other linkers, some of which are depicted in FIG. 7), and slashes (/) indicate the border(s) between IL-15, IL-15Rα, linkers, and Fc regions. FIG. 94D depicts sequences of XENP25938, an illustrative IL-15/Rα-Fc fusion protein of the “scIL-15/Rα-Fc” format with M428L/N434S substitutions.
  • FIG. 95 depicts sequences of XENP24383, an illustrative IL-15/Rα-Fc fusion protein of the “ncIL-15/Rα-Fc” format with M428L/N434S substitutions. IL-15 and IL-15Rα(sushi) are underlined, linkers are double underlined (although as will be appreciated by those in the art, the linkers can be replaced by other linkers, some of which are depicted in FIG. 7), and slashes (/) indicate the border(s) between IL-15, IL-15Rα, linkers, and Fc regions.
  • FIG. 96 depicts sequences of XENP24346 and XENP24351, illustrative IL-15/Rα-Fc fusion proteins of the “bivalent ncIL-15/Rα-Fc” format with M428L/N434S substitutions. IL-15 and IL-15Rα(sushi) are underlined, linkers are double underlined (although as will be appreciated by those in the art, the linkers can be replaced by other linkers, some of which are depicted in FIG. 7), and slashes (/) indicate the border(s) between IL-15, IL-15Rα, linkers, and Fc regions.
  • FIGS. 97A-97C depict the percentage of Ki67 expression on (A) human CD8+ T cells, (B) human CD4+ T cells and (C) human NK cells following treatment with IL-15/Rα variants with M428L/N434S Fc mutations.
  • FIGS. 98A-98C depict the percentage of Ki67 expression on (A) cyno CD8+ T cells, (B) cyno CD4+ T cells and (C) cyno NK cells following treatment with IL-15/Rα variants with M428L/N434S Fc mutations.
  • FIGS. 99A-99C depict CD4+ T cell count on (A) Day 4 and (B) Day 7 in whole blood and (C) Day 8 in spleen of huPBMC engrafted mice following treatment with additional variant IL-15/Rα-Fc fusion proteins.
  • FIGS. 100A-100C depict CD8+ T cell count on (A) Day 4 and (B) Day 7 in whole blood and (C) Day 8 in spleen of huPBMC engrafted mice following treatment with additional variant IL-15/Rα-Fc fusion proteins.
  • FIGS. 101A-101C depicts CD8+ T cell count on (A) Day 4 and (B) Day 7 in whole blood and (C) Day 8 in spleen of huPBMC engrafted mice following treatment with additional variant IL-15/Rα-Fc fusion proteins.
  • FIGS. 102A-102F depict the body weight as a percentage of initial body weight of huPBMC engrafted mice on Days (A) −2, (B) 1, (C) 5, (D) 8, and (E) 11 following treatment with additional IL-15/Rα variants. Each point represents a single NSG mouse.
  • FIG. 102F depicts a time-course of body weight in huPBMC engrafted mice following treatment with the IL-15/Rα variants.
  • FIGS. 103A-103C depict (A) CD8+ T cell, (B) CD4+ T cell, and (C) NK cell counts in cynomolgus monkeys after treatment with IL-15/Rα variants on Day 1.
  • FIGS. 104A-104Z, 104AA-104AZ, and 104BA-104BL depicts sequences of the invention. The CDRs are in bold, IL-15 and IL15-Rα(sushi) are underlined, linkers are double underlined, and slashes (/) are between IL-15, IL15-Rα(sushi), linkers, and Fc domains.
  • FIG. 105 depicts some preferred embodiments of the invention. “Xtend” versions contain the 428L/434S variants in the Fc domains of each monomer.
  • FIG. 106 depicts a list of engineered heterodimer-skewing (e.g. “steric heterodimerization”) Fc variants with heterodimer yields (determined by HPLC-CIEX) and thermal stabilities (determined by DSC). Not determined thermal stability is denoted by “n.d.”.
    •  DETAILED DESCRIPTION OF THE INVENTION I. Definitions
  • In order that the application may be more completely understood, several definitions are set forth below. Such definitions are meant to encompass grammatical equivalents.
  • By “ablation” herein is meant a decrease or removal of activity. Thus for example, “ablating FcγR binding” means the Fc region amino acid variant has less than 50% starting binding as compared to an Fc region not containing the specific variant, with less than 70-80-90-95-98% loss of activity being preferred, and in general, with the activity being below the level of detectable binding in a Biacore assay. Of particular use in the ablation of FcγR binding are those shown in FIG. 86. However, unless otherwise noted, the Fc monomers of the invention retain binding to the FcRn receptor.
  • By “ADCC” or “antibody dependent cell-mediated cytotoxicity” as used herein is meant the cell-mediated reaction wherein nonspecific cytotoxic cells that express FcγRs recognize bound antibody on a target cell and subsequently cause lysis of the target cell. ADCC is correlated with binding to FcγRIIIa; increased binding to FcγRIIIa leads to an increase in ADCC activity. As is discussed herein, many embodiments of the invention ablate ADCC activity entirely.
  • By “ADCP” or antibody dependent cell-mediated phagocytosis as used herein is meant the cell-mediated reaction wherein nonspecific cytotoxic cells that express FcγRs recognize bound antibody on a target cell and subsequently cause phagocytosis of the target cell.
  • By “modification” herein is meant an amino acid substitution, insertion, and/or deletion in a polypeptide sequence or an alteration to a moiety chemically linked to a protein. For example, a modification may be an altered carbohydrate or PEG structure attached to a protein. By “amino acid modification” herein is meant an amino acid substitution, insertion, and/or deletion in a polypeptide sequence. For clarity, unless otherwise noted, the amino acid modification is always to an amino acid coded for by DNA, e.g., the 20 amino acids that have codons in DNA and RNA.
  • By “amino acid substitution” or “substitution” herein is meant the replacement of an amino acid at a particular position in a parent polypeptide sequence with a different amino acid. In particular, in some embodiments, the substitution is to an amino acid that is not naturally occurring at the particular position, either not naturally occurring within the organism or in any organism. For example, the substitution E272Y refers to a variant polypeptide, in this case an Fc variant, in which the glutamic acid at position 272 is replaced with tyrosine. For clarity, a protein which has been engineered to change the nucleic acid coding sequence but not change the starting amino acid (for example exchanging CGG (encoding arginine) to CGA (still encoding arginine) to increase host organism expression levels) is not an “amino acid substitution”; that is, despite the creation of a new gene encoding the same protein, if the protein has the same amino acid at the particular position that it started with, it is not an amino acid substitution.
  • By “amino acid insertion” or “insertion” as used herein is meant the addition of an amino acid sequence at a particular position in a parent polypeptide sequence. For example, −233E or 233E designates an insertion of glutamic acid after position 233 and before position 234. Additionally, −233ADE or A233ADE designates an insertion of AlaAspGlu after position 233 and before position 234.
  • By “amino acid deletion” or “deletion” as used herein is meant the removal of an amino acid sequence at a particular position in a parent polypeptide sequence. For example, E233− or E233#, E233( ) or E233del designates a deletion of glutamic acid at position 233. Additionally, EDA233− or EDA233# designates a deletion of the sequence GluAspAla that begins at position 233.
  • By “variant protein” or “protein variant”, or “variant” as used herein is meant a protein that differs from that of a parent protein by virtue of at least one amino acid modification. Protein variant may refer to the protein itself, a composition comprising the protein, or the amino sequence that encodes it. Preferably, the protein variant has at least one amino acid modification compared to the parent protein, e.g. from about one to about seventy amino acid modifications, and preferably from about one to about five amino acid modifications compared to the parent. As described below, in some embodiments the parent polypeptide, for example an Fc parent polypeptide, is a human wild type sequence, such as the Fc region from IgG1, IgG2, IgG3 or IgG4, although human sequences with variants can also serve as “parent polypeptides”, for example the IgG1/2 hybrid can be included. The protein variant sequence herein will preferably possess at least about 80% identity with a parent protein sequence, and most preferably at least about 90% identity, more preferably at least about 95-98-99% identity. Variant protein can refer to the variant protein itself, compositions comprising the protein variant, or the DNA sequence that encodes it.
  • Accordingly, by “antibody variant” or “variant antibody” as used herein is meant an antibody that differs from a parent antibody by virtue of at least one amino acid modification, “IgG variant” or “variant IgG” as used herein is meant an antibody that differs from a parent IgG (again, in many cases, from a human IgG sequence) by virtue of at least one amino acid modification, and “immunoglobulin variant” or “variant immunoglobulin” as used herein is meant an immunoglobulin sequence that differs from that of a parent immunoglobulin sequence by virtue of at least one amino acid modification. “Fc variant” or “variant Fc” as used herein is meant a protein comprising an amino acid modification in an Fc domain. The Fc variants of the present invention are defined according to the amino acid modifications that compose them. Thus, for example, N434S or 434S is an Fc variant with the substitution serine at position 434 relative to the parent Fc polypeptide, wherein the numbering is according to the EU index. Likewise, M428L/N434S defines an Fc variant with the substitutions M428L and N434S relative to the parent Fc polypeptide. The identity of the WT amino acid may be unspecified, in which case the aforementioned variant is referred to as 428L/434S. It is noted that the order in which substitutions are provided is arbitrary, that is to say that, for example, 428L/434S is the same Fc variant as M428L/N434S, and so on. For all positions discussed in the present invention that relate to antibodies, unless otherwise noted, amino acid position numbering is according to the EU index. The EU index or EU index as in Kabat or EU numbering scheme refers to the numbering of the EU antibody (Edelman et al., 1969, Proc Natl Acad Sci USA 63:78-85, hereby entirely incorporated by reference). The modification can be an addition, deletion, or substitution. Substitutions can include naturally occurring amino acids and, in some cases, synthetic amino acids. Examples include U.S. Pat. No. 6,586,207; WO 98/48032; WO 03/073238; US2004-0214988A1; WO 05/35727A2; WO 05/74524A2; J. W. Chin et al., (2002), Journal of the American Chemical Society 124:9026-9027; J. W. Chin, & P. G. Schultz, (2002), ChemBioChem 11:1135-1137; J. W. Chin, et al., (2002), PICAS United States of America 99:11020-11024; and, L. Wang, & P. G. Schultz, (2002), Chem. 1-10, all entirely incorporated by reference.
  • As used herein, “protein” herein is meant at least two covalently attached amino acids, which includes proteins, polypeptides, oligopeptides and peptides. The peptidyl group may comprise naturally occurring amino acids and peptide bonds, or synthetic peptidomimetic structures, i.e. “analogs”, such as peptoids (see Simon et al., PNAS USA 89(20):9367 (1992), entirely incorporated by reference). The amino acids may either be naturally occurring or synthetic (e.g. not an amino acid that is coded for by DNA); as will be appreciated by those in the art. For example, homo-phenylalanine, citrulline, ornithine and noreleucine are considered synthetic amino acids for the purposes of the invention, and both D- and L-(R or S) configured amino acids may be utilized. The variants of the present invention may comprise modifications that include the use of synthetic amino acids incorporated using, for example, the technologies developed by Schultz and colleagues, including but not limited to methods described by Cropp & Shultz, 2004, Trends Genet. 20(12):625-30, Anderson et al., 2004, Proc Natl Acad Sci USA 101 (2):7566-71, Zhang et al., 2003, 303(5656):371-3, and Chin et al., 2003, Science 301(5635):964-7, all entirely incorporated by reference. In addition, polypeptides may include synthetic derivatization of one or more side chains or termini, glycosylation, PEGylation, circular permutation, cyclization, linkers to other molecules, fusion to proteins or protein domains, and addition of peptide tags or labels.
  • By “residue” as used herein is meant a position in a protein and its associated amino acid identity. For example, Asparagine 297 (also referred to as Asn297 or N297) is a residue at position 297 in the human antibody IgG1.
  • By “IgG subclass modification” or “isotype modification” as used herein is meant an amino acid modification that converts one amino acid of one IgG isotype to the corresponding amino acid in a different, aligned IgG isotype. For example, because IgG1 comprises a tyrosine and IgG2 a phenylalanine at EU position 296, a F296Y substitution in IgG2 is considered an IgG subclass modification.
  • By “non-naturally occurring modification” as used herein is meant an amino acid modification that is not isotypic. For example, because none of the IgGs comprise a serine at position 434, the substitution 434S in IgG1, IgG2, IgG3, or IgG4 (or hybrids thereof) is considered a non-naturally occurring modification.
  • By “amino acid” and “amino acid identity” as used herein is meant one of the 20 naturally occurring amino acids that are coded for by DNA and RNA.
  • By “effector function” as used herein is meant a biochemical event that results from the interaction of an antibody Fc region with an Fc receptor or ligand. Effector functions include but are not limited to ADCC, ADCP, and CDC.
  • By “IgG Fc ligand” as used herein is meant a molecule, preferably a polypeptide, from any organism that binds to the Fc region of an IgG antibody to form an Fc/Fc ligand complex. Fc ligands include but are not limited to FcγRIs, FcγRIIs, FcγRIIIs, FcRn, Clq, C3, mannan binding lectin, mannose receptor, staphylococcal protein A, streptococcal protein G, and viral FcγR. Fc ligands also include Fc receptor homologs (FcRH), which are a family of Fc receptors that are homologous to the FcγRs (Davis et al., 2002, Immunological Reviews 190:123-136, entirely incorporated by reference). Fc ligands may include undiscovered molecules that bind Fc. Particular IgG Fc ligands are FcRn and Fc gamma receptors. By “Fc ligand” as used herein is meant a molecule, preferably a polypeptide, from any organism that binds to the Fc region of an antibody to form an Fc/Fc ligand complex.
  • By “Fc gamma receptor”, “FcγR” or “FcgammaR” as used herein is meant any member of the family of proteins that bind the IgG antibody Fc region and is encoded by an FcγR gene. In humans this family includes but is not limited to FcγRI (CD64), including isoforms FcγRIa, FcγRIb, and FcγRIc; FcγRII (CD32), including isoforms FcγRIIa (including allotypes H131 and R131), FcγRIIb (including FcγRIIb-1 and FcγRIIb-2), and FcγRIIc; and FcγRIII (CD16), including isoforms FcγRIIIa (including allotypes V158 and F158) and FcγRIIIb (including allotypes FcγRIIb-NA1 and FcγRIIb-NA2) (Jefferis et al., 2002, Immunol Lett 82:57-65, entirely incorporated by reference), as well as any undiscovered human FcγRs or FcγR isoforms or allotypes. An FcγR may be from any organism, including but not limited to humans, mice, rats, rabbits, and monkeys. Mouse FcγRs include but are not limited to FcγRI (CD64), FcγRII (CD32), FcγRIII (CD16), and FcγRIII-2 (CD16-2), as well as any undiscovered mouse FcγRs or FcγR isoforms or allotypes.
  • By “FcRn” or “neonatal Fc Receptor” as used herein is meant a protein that binds the IgG antibody Fc region and is encoded at least in part by an FcRn gene. The FcRn may be from any organism, including but not limited to humans, mice, rats, rabbits, and monkeys. As is known in the art, the functional FcRn protein comprises two polypeptides, often referred to as the heavy chain and light chain. The light chain is beta-2-microglobulin and the heavy chain is encoded by the FcRn gene. Unless otherwise noted herein, FcRn or an FcRn protein refers to the complex of FcRn heavy chain with beta-2-microglobulin. A variety of FcRn variants can be used to increase binding to the FcRn receptor, and in some cases, to increase serum half-life. In general, unless otherwise noted, the Fc monomers of the invention retain binding to the FcRn receptor (and, as noted below, can include amino acid variants to increase binding to the FcRn receptor).
  • By “parent polypeptide” as used herein is meant a starting polypeptide that is subsequently modified to generate a variant. The parent polypeptide may be a naturally occurring polypeptide, or a variant or engineered version of a naturally occurring polypeptide. Parent polypeptide may refer to the polypeptide itself, compositions that comprise the parent polypeptide, or the amino acid sequence that encodes it. Accordingly, by “parent immunoglobulin” as used herein is meant an unmodified immunoglobulin polypeptide that is modified to generate a variant, and by “parent antibody” as used herein is meant an unmodified antibody that is modified to generate a variant antibody. It should be noted that “parent antibody” includes known commercial, recombinantly produced antibodies as outlined below.
  • By “Fc” or “Fc region” or “Fc domain” as used herein is meant the polypeptide comprising the constant region of an antibody excluding, in some instances, the first constant region immunoglobulin domain (e.g., CH1) or a portion thereof, and in some cases, part of the hinge. Thus, an Fc can refer to the last two constant region immunoglobulin domains (e.g., CH2 and CH3) of IgA, IgD, and IgG, the last three constant region immunoglobulin domains of IgE and IgM, and the flexible hinge N-terminal to these domains. For IgA and IgM, Fc may include the J chain. For IgG, the Fc domain comprises immunoglobulin domains Cγ2 and Cγ3 (Cγ2 and Cγ3) and the lower hinge region between Cγ1 (Cγ1) and Cγ2 (Cγ2). In some embodiments, an Fc refers to a truncated CH1 domain, and CH2 and CH3 of an immunoglobulin. Although the boundaries of the Fc region may vary, the human IgG heavy chain Fc region is usually defined to include residues E216 or C226 or P230 to its carboxyl-terminus, wherein the numbering is according to the EU index as in Kabat. In some embodiments, as is more fully described below, amino acid modifications are made to the Fc region, for example to alter binding to one or more FcγR receptors or to the FcRn receptor.
  • By “Fc fusion protein” or “immunoadhesin” herein is meant a protein comprising an Fc region, generally linked (optionally through a linker moiety, as described herein) to a different protein, such as to IL-15 and/or IL-15R, as described herein. In some instances, two Fc fusion proteins can form a homodimeric Fc fusion protein or a heterodimeric Fc fusion protein with the latter being preferred. In some cases, one monomer of the heterodimeric Fc fusion protein comprises an Fc domain alone (e.g., an empty Fc domain) and the other monomer is an Fc fusion, comprising a variant Fc domain and a protein domain, such as a receptor, ligand or other binding partner.
  • By “position” as used herein is meant a location in the sequence of a protein. Positions may be numbered sequentially, or according to an established format, for example the EU index for antibody numbering.
  • By “strandedness” in the context of the monomers of the heterodimeric antibodies of the invention herein is meant that, similar to the two strands of DNA that “match”, heterodimerization variants are incorporated into each monomer so as to preserve the ability to “match” to form heterodimers. For example, if some pI variants are engineered into monomer A (e.g. making the pI higher) then steric variants that are “charge pairs” that can be utilized as well do not interfere with the pI variants, e.g. the charge variants that make a pI higher are put on the same “strand” or “monomer” to preserve both functionalities. Similarly, for “skew” variants that come in pairs of a set as more fully outlined below, the skilled artisan will consider pI in deciding into which strand or monomer that incorporates one set of the pair will go, such that pI separation is maximized using the pI of the skews as well.
  • By “wild type or WT” herein is meant an amino acid sequence or a nucleotide sequence that is found in nature, including allelic variations. A WT protein has an amino acid sequence or a nucleotide sequence that has not been intentionally modified.
  • The heterodimeric proteins of the present invention are generally isolated or recombinant. “Isolated,” when used to describe the various polypeptides disclosed herein, means a polypeptide that has been identified and separated and/or recovered from a cell or cell culture from which it was expressed. Ordinarily, an isolated polypeptide will be prepared by at least one purification step. An “isolated protein,” refers to aa protein which is substantially free of other antibodies having different antigenic specificities. “Recombinant” means the proteins are generated using recombinant nucleic acid techniques in exogeneous host cells.
  • “Percent (%) amino acid sequence identity” with respect to a protein sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the specific (parental) sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. One particular program is the ALIGN-2 program outlined at paragraphs [0279] to [0280] of US Pub. No. 20160244525, hereby incorporated by reference.
  • The degree of identity between an amino acid sequence of the present invention (“invention sequence”) and the parental amino acid sequence is calculated as the number of exact matches in an alignment of the two sequences, divided by the length of the “invention sequence,” or the length of the parental sequence, whichever is the shortest. The result is expressed in percent identity.
  • In some embodiments, two or more amino acid sequences are at least 50%, 60%, 70%, 80%, or 90% identical. In some embodiments, two or more amino acid sequences are at least 95%, 97%, 98%, 99%, or even 100% identical.
  • “Specific binding” or “specifically binds to” or is “specific for” a particular antigen or an epitope means binding that is measurably different from a non-specific interaction. Specific binding can be measured, for example, by determining binding of a molecule compared to binding of a control molecule, which generally is a molecule of similar structure that does not have binding activity. For example, specific binding can be determined by competition with a control molecule that is similar to the target.
  • Before the invention is further described, it is to be understood that this invention is not limited to particular embodiments described, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims.
    • II. Heterodimeric Fc Fusion Proteins
  • The present invention relates to heterodimeric Fc fusion proteins that include IL-15 and IL-15 receptor alpha (IL-15Rα) protein domains in different orientations. The Fc domains can be derived from IgG Fc domains, e.g., IgG1, IgG2, IgG3 or IgG4 Fc domains, with IgG1 Fc domains finding particular use in the invention.
  • The carboxy-terminal portion of each chain defines a constant region primarily responsible for effector function. Kabat et al. collected numerous primary sequences of the variable regions of heavy chains and light chains. Based on the degree of conservation of the sequences, they classified individual primary sequences into the CDR and the framework and made a list thereof (see SEQUENCES OF IMMUNOLOGICAL INTEREST, 5th edition, NIH publication, No. 91-3242, E. A. Kabat et al., entirely incorporated by reference). Throughout the present specification, the Kabat numbering system is generally used when referring to a residue in the variable domain (approximately, residues 1-107 of the light chain variable region and residues 1-113 of the heavy chain variable region) and the EU numbering system for Fc regions (e.g., Kabat et al., supra (1991)).
  • In the IgG subclass of immunoglobulins, there are several immunoglobulin domains in the heavy chain. By “immunoglobulin (Ig) domain” herein is meant a region of an immunoglobulin having a distinct tertiary structure. Of interest in the present invention are the heavy chain domains, including, the constant heavy (CH) domains and the hinge domains. In the context of IgG antibodies, the IgG isotypes each have three CH regions. Accordingly, “CH” domains in the context of IgG are as follows: “CH1” refers to positions 118-220 according to the EU index as in Kabat. “CH2” refers to positions 237-340 according to the EU index as in Kabat, and “CH3” refers to positions 341-447 according to the EU index as in Kabat. As shown herein and described below, the pI variants can be in one or more of the CH regions, as well as the hinge region, discussed below.
  • Another type of Ig domain of the heavy chain is the hinge region. By “hinge” or “hinge region” or “antibody hinge region” or “immunoglobulin hinge region” herein is meant the flexible polypeptide comprising the amino acids between the first and second constant domains of an antibody. Structurally, the IgG CH1 domain ends at EU position 220, and the IgG CH2 domain begins at residue EU position 237. Thus for IgG the antibody hinge is herein defined to include positions 221 (D221 in IgG1) to 236 (G236 in IgG1), wherein the numbering is according to the EU index as in Kabat. In some embodiments, for example in the context of an Fc region, the lower hinge is included, with the “lower hinge” generally referring to positions 226 or 230. As noted herein, pI variants can be made in the hinge region as well.
  • Thus, the present invention provides different antibody domains. As described herein and known in the art, the heterodimeric proteins of the invention comprise different domains, which can be overlapping as well. These domains include, but are not limited to, the Fc domain, the CH1 domain, the CH2 domain, the CH3 domain, the hinge domain, and the heavy constant domain (CH1-hinge-Fc domain or CH1-hinge-CH2-CH3).
  • Thus, the “Fc domain” includes the -CH2-CH3 domain, and optionally a hinge domain. In some embodiments, the Fc domain also includes a truncated CH1 domain. In the embodiments herein, when a protein fragment, e.g., IL-15 or IL-15Rα is attached to an Fc domain, it is the C-terminus of the IL-15 or IL-15Rα construct that is attached to all or part of the hinge of the Fc domain; for example, it is generally attached to the sequence EPKSS (SEQ ID NO: 1204) which is the beginning of the hinge. In other embodiments, when a protein fragment, e.g., IL-15 or IL-15Rα, is attached to an Fc domain, it is the C-terminus of the IL-15 or IL15Rα construct that is attached to the CH1 domain of the Fc domain.
  • In some of the constructs and sequences outlined herein of an Fc domain protein, the C-terminus of the IL-15 or IL-15Rα protein fragment is attached to the N-terminus of a domain linker, the C-terminus of which is attached to the N-terminus of a constant Fc domain (N-IL-15 or IL-15Rα protein fragment-linker-Fc domain-C) although that can be switched (N-Fc domain-linker-IL-15 or IL-15Rα protein fragment-C). In other constructs and sequence outlined herein, C-terminus of a first protein fragment is attached to the N-terminus of a second protein fragment, optionally via a domain linker, the C-terminus of the second protein fragment is attached to the N-terminus of a constant Fc domain, optionally via a domain linker. In yet other constructs and sequences outlined herein, a constant Fc domain that is not attached to a first protein fragment or a second protein fragment is provided. A heterodimer Fc fusion protein can contain two or more of the exemplary monomeric Fc domain proteins described herein.
  • In some embodiments, the linker is a “domain linker”, used to link any two domains as outlined herein together, some of which are depicted in FIG. 87. While any suitable linker can be used, many embodiments utilize a glycine-serine polymer, including for example (GS)n (SEQ ID NO: 1199), (GSGGS)n (SEQ ID NO: 1200), (GGGGS)n (SEQ ID NO: 1203), and (GGGS)n (SEQ ID NO: 1201), where n is an integer of at least one (and generally from 0 to 1 to 2 to 3 to 4 to 5) as well as any peptide sequence that allows for recombinant attachment of the two domains with sufficient length and flexibility to allow each domain to retain its biological function. In some cases, and with attention being paid to “strandedness”, as outlined below, charged domain linkers.
  • In one embodiment, heterodimeric Fc fusion proteins contain at least two constant domains which can be engineered to produce heterodimers, such as pI engineering. Other Fc domains that can be used include fragments that contain one or more of the CHL CH2, CH3, and hinge domains of the invention that have been pI engineered. In particular, the formats depicted in FIGS. 9A-9G, and 39A-39D are heterodimeric Fc fusion proteins, meaning that the protein has two associated Fc sequences self-assembled into a heterodimeric Fc domain and at least one protein fragment (e.g., 1, 2 or more protein fragments). In some cases, a first protein fragment is linked to a first Fc sequence and a second protein fragment is linked to a second Fc sequence. In other cases, a first protein fragment is linked to a first Fc sequence, and the first protein fragment is non-covalently attached to a second protein fragment that is not linked to an Fc sequence. In some cases, the heterodimeric Fc fusion protein contains a first protein fragment linked to a second protein fragment which is linked a first Fc sequence, and a second Fc sequence that is not linked to either the first or second protein fragments.
  • Accordingly, in some embodiments the present invention provides heterodimeric Fc fusion proteins that rely on the use of two different heavy chain variant Fc sequences, that will self-assemble to form a heterodimeric Fc domain fusion polypeptide.
  • The present invention is directed to novel constructs to provide heterodimeric Fc fusion proteins that allow binding to one or more binding partners, ligands or receptors. The heterodimeric Fc fusion constructs are based on the self-assembling nature of the two Fc domains of the heavy chains of antibodies, e.g., two “monomers” that assemble into a “dimer”. Heterodimeric Fc fusions are made by altering the amino acid sequence of each monomer as more fully discussed below. Thus, the present invention is generally directed to the creation of heterodimeric Fc fusion proteins which can co-engage binding partner(s) or ligand(s) or receptor(s) in several ways, relying on amino acid variants in the constant regions that are different on each chain to promote heterodimeric formation and/or allow for ease of purification of heterodimers over the homodimers.
  • There are a number of mechanisms that can be used to generate the heterodimers of the present invention. In addition, as will be appreciated by those in the art, these mechanisms can be combined to ensure high heterodimerization. Thus, amino acid variants that lead to the production of heterodimers are referred to as “heterodimerization variants”. As discussed below, heterodimerization variants can include steric variants (e.g. the “knobs and holes” or “skew” variants described below and the “charge pairs” variants described below) as well as “pI variants”, which allows purification of homodimers away from heterodimers. As is generally described in WO2014/145806, hereby incorporated by reference in its entirety and specifically as below for the discussion of “heterodimerization variants”, useful mechanisms for heterodimerization include “knobs and holes” (“KIH”; sometimes herein as “skew” variants (see discussion in WO2014/145806), “electrostatic steering” or “charge pairs” as described in WO2014/145806, pI variants as described in WO2014/145806, and general additional Fc variants as outlined in WO2014/145806 and below.
  • In the present invention, there are several basic mechanisms that can lead to ease of purifying heterodimeric antibodies; one relies on the use of pI variants, such that each monomer has a different pI, thus allowing the isoelectric purification of A-A, A-B and B-B dimeric proteins. Alternatively, some formats also allow separation on the basis of size. As is further outlined below, it is also possible to “skew” the formation of heterodimers over homodimers. Thus, a combination of steric heterodimerization variants and pI or charge pair variants find particular use in the invention.
  • In general, embodiments of particular use in the present invention rely on sets of variants that include skew variants, that encourage heterodimerization formation over homodimerization formation, coupled with pI variants, which increase the pI difference between the two monomers.
  • Additionally, as more fully outlined below, depending on the format of the heterodimer Fc fusion protein, pI variants can be either contained within the constant and/or Fc domains of a monomer, or domain linkers can be used. That is, the invention provides pI variants that are on one or both of the monomers, and/or charged domain linkers as well. In addition, additional amino acid engineering for alternative functionalities may also confer pI changes, such as Fc, FcRn and KO variants.
  • In the present invention that utilizes pI as a separation mechanism to allow the purification of heterodimeric proteins, amino acid variants can be introduced into one or both of the monomer polypeptides; that is, the pI of one of the monomers (referred to herein for simplicity as “monomer A”) can be engineered away from monomer B, or both monomer A and B change be changed, with the pI of monomer A increasing and the pI of monomer B decreasing. As discussed, the pI changes of either or both monomers can be done by removing or adding a charged residue (e.g., a neutral amino acid is replaced by a positively or negatively charged amino acid residue, e.g., glycine to glutamic acid), changing a charged residue from positive or negative to the opposite charge (e.g. aspartic acid to lysine) or changing a charged residue to a neutral residue (e.g., loss of a charge; lysine to serine.). A number of these variants are shown in the Figures.
  • Accordingly, this embodiment of the present invention provides for creating a sufficient change in pI in at least one of the monomers such that heterodimers can be separated from homodimers. As will be appreciated by those in the art, and as discussed further below, this can be done by using a “wild type” heavy chain constant region and a variant region that has been engineered to either increase or decrease its pI (wt A−+B or wt A−−B), or by increasing one region and decreasing the other region (A+−B− or A−B+).
  • Thus, in general, a component of some embodiments of the present invention are amino acid variants in the constant regions that are directed to altering the isoelectric point (pI) of at least one, if not both, of the monomers of a dimeric protein by incorporating amino acid substitutions (“pI variants” or “pI substitutions”) into one or both of the monomers. As shown herein, the separation of the heterodimers from the two homodimers can be accomplished if the pIs of the two monomers differ by as little as 0.1 pH unit, with 0.2, 0.3, 0.4 and 0.5 or greater all finding use in the present invention.
  • As will be appreciated by those in the art, the number of pI variants to be included on each or both monomer(s) to get good separation will depend in part on the starting pI of the components. As is known in the art, different Fcs will have different starting pIs which are exploited in the present invention. In general, as outlined herein, the pIs are engineered to result in a total pI difference of each monomer of at least about 0.1 logs, with 0.2 to 0.5 being preferred as outlined herein.
  • As will be appreciated by those in the art, the number of pI variants to be included on each or both monomer(s) to get good separation will depend in part on the starting pI of the components. That is, to determine which monomer to engineer or in which “direction” (e.g., more positive or more negative), the sequences of the Fc domains, and in some cases, the protein domain(s) linked to the Fc domain are calculated and a decision is made from there. As is known in the art, different Fc domains and/or protein domains will have different starting pIs which are exploited in the present invention. In general, as outlined herein, the pIs are engineered to result in a total pI difference of each monomer of at least about 0.1 logs, with 0.2 to 0.5 being preferred as outlined herein.
  • Furthermore, as will be appreciated by those in the art and outlined herein, in some embodiments, heterodimers can be separated from homodimers on the basis of size. As shown in the Figures, for example, several of the formats allow separation of heterodimers and homodimers on the basis of size.
  • In the case where pI variants are used to achieve heterodimerization, by using the constant region(s) of Fc domains(s), a more modular approach to designing and purifying heterodimeric Fc fusion proteins is provided. Thus, in some embodiments, heterodimerization variants (including skew and purification heterodimerization variants) must be engineered. In addition, in some embodiments, the possibility of immunogenicity resulting from the pI variants is significantly reduced by importing pI variants from different IgG isotypes such that pI is changed without introducing significant immunogenicity. Thus, an additional problem to be solved is the elucidation of low pI constant domains with high human sequence content, e.g. the minimization or avoidance of non-human residues at any particular position.
  • A side benefit that can occur with this pI engineering is also the extension of serum half-life and increased FcRn binding. That is, as described in U.S. Ser. No. 13/194,904 (incorporated by reference in its entirety), lowering the pI of antibody constant domains (including those found in antibodies and Fc fusions) can lead to longer serum retention in vivo. These pI variants for increased serum half life also facilitate pI changes for purification.
  • In addition, it should be noted that the pI variants of the heterodimerization variants give an additional benefit for the analytics and quality control process of Fc fusion proteins, as the ability to either eliminate, minimize and distinguish when homodimers are present is significant. Similarly, the ability to reliably test the reproducibility of the heterodimeric Fc fusion protein production is important.
  • A. Heterodimerization Variants
  • The present invention provides heterodimeric proteins, including heterodimeric Fc fusion proteins in a variety of formats, which utilize heterodimeric variants to allow for heterodimeric formation and/or purification away from homodimers. The heterodimeric fusion constructs are based on the self-assembling nature of the two Fc domains, e.g., two “monomers” that assemble into a “dimer”.
  • There are a number of suitable pairs of sets of heterodimerization skew variants. These variants come in “pairs” of “sets”. That is, one set of the pair is incorporated into the first monomer and the other set of the pair is incorporated into the second monomer. It should be noted that these sets do not necessarily behave as “knobs in holes” variants, with a one-to-one correspondence between a residue on one monomer and a residue on the other; that is, these pairs of sets form an interface between the two monomers that encourages heterodimer formation and discourages homodimer formation, allowing the percentage of heterodimers that spontaneously form under biological conditions to be over 90%, rather than the expected 50% (25% homodimer A/A:50% heterodimer A/B:25% homodimer B/B).
  • B. Steric Variants
  • In some embodiments, the formation of heterodimers can be facilitated by the addition of steric variants. That is, by changing amino acids in each heavy chain, different heavy chains are more likely to associate to form the heterodimeric structure than to form homodimers with the same Fc amino acid sequences. Suitable steric variants are included in in the FIG. 29 of U.S. Ser. No. 15/141,350, all of which is hereby incorporated by reference in its entirety, as well as in FIG. 84.
  • One mechanism is generally referred to in the art as “knobs and holes”, referring to amino acid engineering that creates steric influences to favor heterodimeric formation and disfavor homodimeric formation can also optionally be used; this is sometimes referred to as “knobs and holes”, as described in U.S. Ser. No. 61/596,846, Ridgway et al., Protein Engineering 9(7):617 (1996); Atwell et al., J. Mol. Biol. 1997 270:26; U.S. Pat. No. 8,216,805, all of which are hereby incorporated by reference in their entirety. The Figures identify a number of “monomer A-monomer B” pairs that rely on “knobs and holes”. In addition, as described in Merchant et al., Nature Biotech. 16:677 (1998), these “knobs and hole” mutations can be combined with disulfide bonds to skew formation to heterodimerization.
  • An additional mechanism that finds use in the generation of heterodimers is sometimes referred to as “electrostatic steering” as described in Gunasekaran et al., J. Biol. Chem. 285(25):19637 (2010), hereby incorporated by reference in its entirety. This is sometimes referred to herein as “charge pairs”. In this embodiment, electrostatics are used to skew the formation towards heterodimerization. As those in the art will appreciate, these may also have an effect on pI, and thus on purification, and thus could in some cases also be considered pI variants. However, as these were generated to force heterodimerization and were not used as purification tools, they are classified as “steric variants”. These include, but are not limited to, D221E/P228E/L368E paired with D221R/P228R/K409R (e.g., these are “monomer corresponding sets) and C220E/P228E/368E paired with C220R/E224R/P228R/K409R.
  • Additional monomer A and monomer B variants that can be combined with other variants, optionally and independently in any amount, such as pI variants outlined herein or other steric variants that are shown in FIG. 37 of US 2012/0149876, all of which are incorporated expressly by reference herein.
  • In some embodiments, the steric variants outlined herein can be optionally and independently incorporated with any pI variant (or other variants such as Fc variants, FcRn variants, etc.) into one or both monomers, and can be independently and optionally included or excluded from the proteins of the invention.
  • A list of suitable skew variants is found in FIG. 84. Of particular use in many embodiments are the pairs of sets including, but not limited to, S364K/E357Q: L368D/K370S; L368D/K370S: S364K; L368E/K370S: S364K; T411T/E360E/Q362E: D401K; L368D/K370S: S364K/E357L, K370S: S364K/E357Q and T366S/L368A/Y407V: T366W (optionally including a bridging disulfide, T366S/L368A/Y407V/Y349C: T366W/S354C). In terms of nomenclature, the pair “S364K/E357Q: L368D/K370S” means that one of the monomers has the double variant set S364K/E357Q and the other has the double variant set L368D/K370S; as above, the “strandedness” of these pairs depends on the starting pI.
  • C. pI (Isoelectric Point) Variants for Heterodimers
  • In general, as will be appreciated by those in the art, there are two general categories of pI variants: those that increase the pI of the protein (basic changes) and those that decrease the pI of the protein (acidic changes). As described herein, all combinations of these variants can be done: one monomer may be wild type, or a variant that does not display a significantly different pI from wild-type, and the other can be either more basic or more acidic. Alternatively, each monomer is changed, one to more basic and one to more acidic.
  • Preferred combinations of pI variants are shown in FIG. 30 of U.S. Ser. No. 15/141,350, all of which are herein incorporated by reference in its entirety. As outlined herein and shown in the figures, these changes are shown relative to IgG1, but all isotypes can be altered this way, as well as isotype hybrids. In the case where the heavy chain constant domain is from IgG2-4, R133E and R133Q can also be used.
  • In one embodiment, a preferred combination of pI variants has one monomer comprising 208D/295E/384D/418E/421D variants (N208D/Q295E/N384D/Q418E/N421D when relative to human IgG1) if one of the Fc monomers includes a CH1 domain. In some instances, the second monomer comprising a positively charged domain linker, including (GKPGS)4 (SEQ ID NO: 1202). In some cases, the first monomer includes a CH1 domain, including position 208. Accordingly, in constructs that do not include a CH1 domain (for example for heterodimeric Fc fusion proteins that do not utilize a CH1 domain on one of the domains), a preferred negative pI variant Fc set includes 295E/384D/418E/421D variants (Q295E/N384D/Q418E/N421D when relative to human IgG1).
  • In some embodiments, mutations are made in the hinge domain of the Fc domain, including positions 221, 222, 223, 224, 225, 233, 234, 235 and 236. It should be noted that changes in 233-236 can be made to increase effector function (along with 327A) in the IgG2 backbone. Thus, pI mutations and particularly substitutions can be made in one or more of positions 221-225, with 1, 2, 3, 4 or 5 mutations finding use in the present invention. Again, all possible combinations are contemplated, alone or with other pI variants in other domains.
  • Specific substitutions that find use in lowering the pI of hinge domains include, but are not limited to, a deletion at position 221, a non-native valine or threonine at position 222, a deletion at position 223, a non-native glutamic acid at position 224, a deletion at position 225, a deletion at position 235 and a deletion or a non-native alanine at position 236. In some cases, only pI substitutions are done in the hinge domain, and in others, these substitution(s) are added to other pI variants in other domains in any combination.
  • In some embodiments, mutations can be made in the CH2 region, including positions 274, 296, 300, 309, 320, 322, 326, 327, 334 and 339. Again, all possible combinations of these 10 positions can be made; e.g., a pI antibody may have 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 CH2 pI substitutions.
  • Specific substitutions that find use in lowering the pI of CH2 domains include, but are not limited to, a non-native glutamine or glutamic acid at position 274, a non-native phenylalanine at position 296, a non native phenylalanine at position 300, a non-native valine at position 309, a non-native glutamic acid at position 320, a non-native glutamic acid at position 322, a non-native glutamic acid at position 326, a non-native glycine at position 327, a non-native glutamic acid at position 334, a non native threonine at position 339, and all possible combinations within CH2 and with other domains.
  • In this embodiment, the mutations can be independently and optionally selected from position 355, 359, 362, 384, 389,392, 397, 418, 419, 444 and 447. Specific substitutions that find use in lowering the pI of CH3 domains include, but are not limited to, a non native glutamine or glutamic acid at position 355, a non-native serine at position 384, a non-native asparagine or glutamic acid at position 392, a non-native methionine at position 397, a non native glutamic acid at position 419, a non native glutamic acid at position 359, a non native glutamic acid at position 362, a non native glutamic acid at position 389, a non native glutamic acid at position 418, a non native glutamic acid at position 444, and a deletion or non-native aspartic acid at position 447.
  • D. Isotypic Variants
  • In addition, many embodiments of the invention rely on the “importation” of pI amino acids at particular positions from one IgG isotype into another, thus reducing or eliminating the possibility of unwanted immunogenicity being introduced into the variants. A number of these are shown in FIG. 21 of US Publ. App. No. 2014/0370013, hereby incorporated by reference. That is, IgG1 is a common isotype for therapeutic antibodies for a variety of reasons, including high effector function. However, the heavy constant region of IgG1 has a higher pI than that of IgG2 (8.10 versus 7.31). By introducing IgG2 residues at particular positions into the IgG1 backbone, the pI of the resulting monomer is lowered (or increased) and additionally exhibits longer serum half-life. For example, IgG1 has a glycine (pI 5.97) at position 137, and IgG2 has a glutamic acid (pI 3.22); importing the glutamic acid will affect the pI of the resulting protein. As is described below, a number of amino acid substitutions are generally required to significant affect the pI of the variant Fc fusion protein. However, it should be noted as discussed below that even changes in IgG2 molecules allow for increased serum half-life.
  • In other embodiments, non-isotypic amino acid changes are made, either to reduce the overall charge state of the resulting protein (e.g., by changing a higher pI amino acid to a lower pI amino acid), or to allow accommodations in structure for stability, etc. as is more further described below.
  • In addition, by pI engineering both the heavy and light constant domains, significant changes in each monomer of the heterodimer can be seen. As discussed herein, having the pIs of the two monomers differ by at least 0.5 can allow separation by ion exchange chromatography or isoelectric focusing, or other methods sensitive to isoelectric point.
  • E. Calculating pI
  • The pI of each monomer can depend on the pI of the variant heavy chain constant domain and the pI of the total monomer, including the variant heavy chain constant domain and the fusion partner. Thus, in some embodiments, the change in pI is calculated on the basis of the variant heavy chain constant domain, using the chart in the FIG. 19 of US Publ. App. No. 2014/0370013. As discussed herein, which monomer to engineer is generally decided by the inherent pI of each monomer.
  • F. pI Variants that also confer better FcRn in vivo binding
  • In the case where the pI variant decreases the pI of the monomer, they can have the added benefit of improving serum retention in vivo.
  • Although still under examination, Fc regions are believed to have longer half-lives in vivo, because binding to FcRn at pH 6 in an endosome sequesters the Fc (Ghetie and Ward, 1997 Immunol Today. 18(12): 592-598, entirely incorporated by reference). The endosomal compartment then recycles the Fc to the cell surface. Once the compartment opens to the extracellular space, the higher pH, ˜7.4, induces the release of Fc back into the blood. In mice, Dall'Acqua et al. showed that Fc mutants with increased FcRn binding at pH 6 and pH 7.4 actually had reduced serum concentrations and the same half-life as wild-type Fc (Dall' Acqua et al. 2002, J. Immunol. 169:5171-5180, entirely incorporated by reference). The increased affinity of Fc for FcRn at pH 7.4 is thought to forbid the release of the Fc back into the blood. Therefore, the Fc mutations that will increase Fc's half-life in vivo will ideally increase FcRn binding at the lower pH while still allowing release of Fc at higher pH. The amino acid histidine changes its charge state in the pH range of 6.0 to 7.4. Therefore, it is not surprising to find His residues at important positions in the Fc/FcRn complex.
  • G. Additional Fc Variants for Additional Functionality
  • In addition to pI amino acid variants, there are a number of useful Fc amino acid modification that can be made for a variety of reasons, including, but not limited to, altering binding to one or more FcγR receptors, altered binding to FcRn receptors, etc.
  • Accordingly, the proteins of the invention can include amino acid modifications, including the heterodimerization variants outlined herein, which includes the pI variants and steric variants. Each set of variants can be independently and optionally included or excluded from any particular heterodimeric protein.
  • H. FcγR Variants
  • Accordingly, there are a number of useful Fc substitutions that can be made to alter binding to one or more of the FcγR receptors. Substitutions that result in increased binding as well as decreased binding can be useful. For example, it is known that increased binding to FcγRIIIa results in increased ADCC (antibody dependent cell-mediated cytotoxicity; the cell-mediated reaction wherein nonspecific cytotoxic cells that express FcγRs recognize bound antibody on a target cell and subsequently cause lysis of the target cell). Similarly, decreased binding to FcγRIIb (an inhibitory receptor) can be beneficial as well in some circumstances. Amino acid substitutions that find use in the present invention include those listed in U.S. Ser. Nos. 11/124,620 (particularly FIG. 41), 11/174,287, 11/396,495, 11/538,406, all of which are expressly incorporated herein by reference in their entirety and specifically for the variants disclosed therein. Particular variants that find use include, but are not limited to, 236A, 239D, 239E, 332E, 332D, 239D/332E, 267D, 267E, 328F, 267E/328F, 236A/332E, 239D/332E/330Y, 239D, 332E/330L, 243A, 243L, 264A, 264V and 299T.
  • In addition, amino acid substitutions that increase affinity for FcγRIIc can also be included in the Fc domain variants outlined herein. The substitutions described in, for example, U.S. Ser. Nos. 11/124,620 and 14/578,305 are useful.
  • In addition, there are additional Fc substitutions that find use in increased binding to the FcRn receptor and increased serum half-life, as specifically disclosed in U.S. Ser. No. 12/341,769, hereby incorporated by reference in its entirety, including, but not limited to, 434S, 434A, 428L, 308F, 259I, 428L/434S, 259I/308F, 436I/428L, 436I or V/434S, 436V/428L and 259I/308F/428L.
  • I. Ablation Variants
  • Similarly, another category of functional variants are “FcγR ablation variants” or “Fc knock out (FcKO or KO)” variants. In these embodiments, for some therapeutic applications, it is desirable to reduce or remove the normal binding of the Fc domain to one or more or all of the Fcγ receptors (e.g., FcγR1, FcγRIIa, FcγRIIb, FcγRIIIa, etc.) to avoid additional mechanisms of action. That is, for example, in many embodiments, particularly in the use of bispecific immunomodulatory antibodies desirable to ablate FcγRIIIa binding to eliminate or significantly reduce ADCC activity such that one of the Fc domains comprises one or more Fcγ receptor ablation variants. These ablation variants are depicted in FIG. 31 of U.S. Ser. No. 15/141,350, all of which are herein incorporated by reference in its entirety, and each can be independently and optionally included or excluded, with preferred aspects utilizing ablation variants selected from the group consisting of G236R/L328R, E233P/L234V/L235A/G236del/S239K, E233P/L234V/L235A/G236del/S267K, E233P/L234V/L235A/G236del/S239K/A327G, E233P/L234V/L235A/G236del/S267K/A327G and E233P/L234V/L235A/G236del, according to the EU index. It should be noted that the ablation variants referenced herein ablate FcγR binding but generally not FcRn binding.
  • J. Combination of Heterodimeric and Fc Variants
  • As will be appreciated by those in the art, all of the recited heterodimerization variants (including skew and/or pI variants) can be optionally and independently combined in any way, as long as they retain their “strandedness” or “monomer partition”. In addition, all of these variants can be combined into any of the heterodimerization formats.
  • In the case of pI variants, while embodiments finding particular use are shown in the Figures, other combinations can be generated, following the basic rule of altering the pI difference between two monomers to facilitate purification.
  • In addition, any of the heterodimerization variants, skew and pI, are also independently and optionally combined with Fc ablation variants, Fc variants, FcRn variants, as generally outlined herein.
  • In addition, a monomeric Fc domain can comprise a set of amino acid substitutions that includes C220S/S267K/L368D/K370S or C220S/S267K/S364K/E357Q.
  • In addition, the heterodimeric Fc fusion proteins can comprise skew variants (e.g., a set of amino acid substitutions as shown in FIGS. 1A-1C of U.S. Ser. No. 15/141,350, all of which are herein incorporated by reference in its entirety), with particularly useful skew variants being selected from the group consisting of S364K/E357Q: L368D/K370S; L368D/K370S: S364K; L368E/K370S: S364K; T411T/E360E/Q362E: D401K; L368D/K370S: S364K/E357L, K370S: S364K/E357Q, T366S/L368A/Y407V: T366W and T366S/L368A/Y407V/Y349C: T366W/S354C, optionally ablation variants, optionally charged domain linkers and the heavy chain comprises pI variants.
  • In some embodiments, the Fc domain comprising an amino acid substitution selected from the group consisting of: 236R, 239D, 239E, 243L, M252Y, V259I, 267D, 267E, 298A, V308F, 328F, 328R, 330L, 332D, 332E, M428L, N434A, N434S, 236R/328R, 239D/332E, M428L, 236R/328F, V259I/V308F, 267E/328F, M428L/N434S, Y436I/M428L, Y436V/M428L, Y436I/N434S, Y436V/N434S, 239D/332E/330L, M252Y/S254T/T256E, V259IN308F/M428L, E233P/L234V/L235A/G236del/S267K, G236R/L328R and PVA/S267K. In some cases, the Fc domain comprises the amino acid substitution 239D/332E. In other cases, the Fc domain comprises the amino acid substitution G236R/L328R or PVA/S267K.
  • In one embodiment, a particular combination of skew and pI variants that finds use in the present invention is T366S/L368A/Y407V: T366W (optionally including a bridging disulfide, T366S/L368A/Y407V/Y349C: T366W/S354C) with one monomer comprises Q295E/N384D/Q418E/N481D and the other a positively charged domain linker. As will be appreciated in the art, the “knobs in holes” variants do not change pI, and thus can be used on either monomer.
    • III. IL-15 and IL15Rα Protein Domains
  • The present invention provides heterodimeric Fc fusion proteins containing IL-15 and IL-15Rα proteins. As shown in the figures, the IL-15 complex can take several forms. As stated above, the IL-15 protein on its own is less stable than when complexed with the IL-15Rα protein. As is known in the art, the IL-15Rα protein contains a “sushi domain”, which is the shortest region of the receptor that retains IL-15 binding activity. Thus, while heterodimeric fusion proteins comprising the entire IL-15Rα protein can be made, preferred embodiments herein include complexes that just use the sushi domain, the sequence of which is shown in the figures.
  • Accordingly, the IL-15 complexes generally comprises the IL-15 protein and the sushi domain of IL IL-15Rα (unless otherwise noted that the full length sequence is used, “IL-15Rα”, “IL-15Rα(sushi)” and “sushi” are used interchangeably throughout). This complex can be used in three different formats. As shown in FIG. 9A, the IL-15 protein and the IL-15Rα(sushi) are not covalently attached, but rather are self-assembled through regular ligand-ligand interactions. As is more fully described herein, it can be either the IL-15 domain or the sushi domain that is covalently linked to the Fc domain (generally using an optional domain linker). Alternatively, they can be covalently attached using a domain linker as generally shown in FIGS. 9B, 9E, 9G FIG. 9B depicts the sushi domain as the N-terminal domain, although this can be reversed. Finally, each of the IL-15 and sushi domains can be engineered to contain a cysteine amino acid, that forms a disulfide bond to form the complex as is generally shown in FIGS. 39A-39D, again, with either the IL-15 domain or the sushi domain being covalently attached (using an optional domain linker) to the Fc domain.
  • In some embodiments, the human IL-15 protein has the amino acid sequence set forth in NCBI Ref. Seq. No. NP 000576.1 or SEQ ID NO:1. In some cases, the coding sequence of human IL-15 is set forth in NCBI Ref. Seq. No. NM_000585. An exemplary IL-15 protein of the Fc fusion heterodimeric protein outlined herein can have the amino acid sequence of SEQ ID NO:2 or amino acids 49-162 of SEQ ID NO:1. In some embodiments, the IL-15 protein has at least 90%, e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO:2. In some embodiments, the IL-15 protein has the amino acid sequence set forth in SEQ ID NO:2 and the amino acid substitution N72D. In other embodiments, the IL-15 protein has the amino acid sequence of SEQ ID NO:2 and one or more amino acid substitutions selected from the group consisting of C42S, L45C, Q48C, V49C, L52C, E53C, E87C, and E89C. Optionally, the IL-15 protein also has an N72D substitution. The IL-15 protein of the Fc fusion protein can have 1, 2, 3, 4, 5, 6, 7, 8 or 9 amino acid substitutions.
  • The amino acid substitution(s) may be isosteric substitutions at the IL-15:IL-2β and IL-15:common gamma chain interface. In some embodiments, the human IL-15 protein has one or more amino acid substitutions selected from the group consisting of N1D, N4D, D8N, D30N, D61N, E64Q, N65D, Q108E, and any combination thereof. In some embodiments, the IL-15 protein has the amino acid substitution Q108E. In some cases, the IL-15 protein has 1, 2, 3, 4, 5, 6, 7, 8, or more amino acid substitutions. The IL-15 protein can have a N1D, N4D, D8N, D30N, D61N, E64Q, N65D, or Q108E substitution. In some embodiments, the amino acid substitution can include N1D/D61N, N1D/E64Q, N4D/D61N, N4D/E64Q, D8N/D61N, D8N/E64Q, D61N/E64Q, E64Q/Q108E, N1D/N4D/D8N, D61N/E64Q/N65D, N1D/D61N/E64Q, N1D/D61N/E64Q/Q108E, or N4D/D61N/E64Q/Q108E. In some embodiments, the IL-15 protein has the amino acid substitutions D30N/E64Q/N65D.
  • In some embodiments, the human IL-15 receptor alpha (IL-15Rα) protein has the amino acid sequence set forth in NCBI Ref. Seq. No. NP_002180.1 or SEQ ID NO:3. In some cases, the coding sequence of human IL-15Rα is set forth in NCBI Ref. Seq. No. NM_002189.3. An exemplary the IL-15Rα protein of the Fc fusion heterodimeric protein outlined herein can comprise or consist of the sushi domain of SEQ ID NO:3 (e.g., amino acids 31-95 of SEQ ID NO:3), or in other words, the amino acid sequence of SEQ ID NO:4. In some embodiments, the IL-15Rα protein has the amino acid sequence of SEQ ID NO:4 and an amino acid insertion selected from the group consisting of D96, P97, A98, D96/P97, D96/C97, D96/P97/A98, D96/P97/C98, and D96/C97/A98, wherein the amino acid position is relative to full-length human IL-15Rα protein or SEQ ID NO:3. For instance, amino acid(s) such as D (e.g., Asp), P (e.g., Pro), A (e.g., Ala), DP (e.g., Asp-Pro), DC (e.g., Asp-Cys), DPA (e.g., Asp-Pro-Ala), DPC (e.g., Asp-Pro-Cys), or DCA (e.g., Asp-Cys-Ala) can be added to the C-terminus of the IL-15Rα protein of SEQ ID NO:4. In some embodiments, the IL-15Rα protein has the amino acid sequence of SEQ ID NO:4 and one or more amino acid substitutions selected from the group consisting of K34C, A37C, G38C, 540C, and L42C, wherein the amino acid position is relative to SEQ ID NO:4. The IL-15Rα protein can have 1, 2, 3, 4, 5, 6, 7, 8 or more amino acid mutations (e.g., substitutions, insertions and/or deletions).
    • IV. Domain Linkers
  • In some embodiments, the IL-15 protein and IL-15Rα protein are attached together via a linker. Optionally, the proteins are not attached via a linker. In other embodiments, the IL-15 protein and IL-15Rα protein are noncovalently attached. In some embodiments, the IL-15 protein is attached to an Fc domain via a linker. In certain embodiments, the IL-15 protein is attached to an Fc domain directly, such as without a linker. In other embodiments, the IL-15Rα protein is attached to an Fc domain via a linker. In other embodiments, the IL-15Rα protein is attached to an Fc domain directly. In some cases, a linker is not used to attach the IL-15 protein or IL-15Rα protein to an Fc domain.
  • In some embodiments, the linker is a “domain linker”, used to link any two domains as outlined herein together. While any suitable linker can be used, many embodiments utilize a glycine-serine polymer, including for example (GS)n (SEQ ID NO: 1199), (GSGGS)n (SEQ ID NO: 1200), (GGGGS)n (SEQ ID NO: 1203), and (GGGS)n (SEQ ID NO: 1201), where n is an integer of at least 0 (and generally from 0 to 1 to 2 to 3 to 4 to 5) as well as any peptide sequence that allows for recombinant attachment of the two domains with sufficient length and flexibility to allow each domain to retain its biological function. In certain cases, useful linkers include (GGGGS)0 or (GGGGS)1 (SEQ ID NO: 14) or (GGGGS)2 (SEQ ID NO: 15). In some cases, and with attention being paid to “strandedness”, as outlined below, charged domain linkers can be used as discussed herein and shown in FIG. 7.
    • V. Useful formats of the Invention
  • As shown in FIGS. 9A-9G and 39A-39D there are a number of useful formats of the bispecific heterodimeric fusion proteins of the invention. In general, the heterodimeric fusion proteins of the invention have two functional components: an IL-15/IL-15Rα(sushi) component and an Fc component, both of which can take different forms as outlined herein and both of which can be combined with the other component in any configuration.
  • The first and the second Fc domains can have a set of amino acid substitutions selected from the group consisting of a) S267K/L368D/K370S: S267K/LS364K/E357Q; b) S364K/E357Q: L368D/K370S; c) L368D/K370S: S364K; d) L368E/K370S: S364K; e) T411T/E360E/Q362E: D401K; f) L368D/K370S: S364K/E357L and g) K370S: S364K/E357Q, according to EU numbering.
  • In some embodiments, the first and/or the second Fc domains have an additional set of amino acid substitutions comprising Q295E/N384D/Q418E/N421D, according to EU numbering.
  • Optionally, the first and/or the second Fc domains have an additional set of amino acid substitutions consisting of G236R/L328R, E233P/L234V/L235A/G236del/S239K, E233P/L234V/L235A/G236del/S267K, E233P/L234V/L235A/G236del/S239K/A327G, E233P/L234V/L235A/G236del/S267K/A327G and E233P/L234V/L235A/G236del, according to EU numbering.
  • Optionally, the first and/or second Fc domains have 428L/434S variants for half life extension.
  • A. IL-15/Rα-heteroFc Format
  • In this embodiment, as shown in FIG. 9A, the heterodimeric fusion protein comprises two monomers. The first monomer comprises (from N- to C-terminus) IL-15-optional domain linker-CH2-CH3, where the domain linker sometimes comprises all or part of the hinge. The second monomer comprises the IL-15/Rα(sushi) domain-optional domain linker-CH2-CH3, where the domain linker sometimes comprises all or part of the hinge.
  • In the IL-15/Rα-heteroFc format, a preferred embodiment utilizes the skew variant pair S364K/E357Q: L368D/K370S.
  • In the IL-15/Rα-heteroFc format, a preferred embodiment utilizes the IL-15 variant Q108E.
  • In the IL-15/Rα-heteroFc format, a preferred embodiment utilizes the IL-15 variant Q108E and the skew variant pair S364K/E357Q: L368D/K370S.
  • In the IL-15/Rα-heteroFc format, a preferred embodiment utilizes the IL-15 variant Q108E and the skew variant pair S364K/E357Q: L368D/K370S and the 428L/434S variants on both monomers.
  • In the IL-15/Rα-heteroFc format, a preferred embodiment utilizes the IL-15 D30N/E64Q/N65D variants.
  • In the IL-15/Rα-heteroFc format, a preferred embodiment utilizes the IL-15 D30N/E64Q/N65D variants and the skew variant pair S364K/E357Q: L368D/K370S.
  • In the IL-15/Rα-heteroFc format, a preferred embodiment utilizes the IL-15 D30N/E64Q/N65D variants, the skew variant pair S364K/E357Q: L368D/K370S and the 428L/434S variants on each Fc monomer.
  • In the IL-15/Rα-heteroFc format, a preferred embodiment utilizes the IL-15 N65D variant.
  • In the IL-15/Rα-heteroFc format, a preferred embodiment utilizes the IL-15 N65D variant, and the skew variant pair S364K/E357Q: L368D/K370S
  • In the IL-15/Rα-heteroFc format, a preferred embodiment utilizes the IL-15 N65D variant, the skew variant pair S364K/E357Q: L368D/K370S and the 428L/434S variants on each Fc monomer.
  • In the IL-15/Rα-heteroFc format, a preferred embodiment utilizes the IL-15 N4D/N65D variant.
  • In the IL-15/Rα-heteroFc format, a preferred embodiment utilizes the IL-15 N4D/N65D variant and the skew variant pair S364K/E357Q: L368D/K370S.
  • In the IL-15/Rα-heteroFc format, a preferred embodiment utilizes the IL-15 N4D/N65D variant, the skew variant pair S364K/E357Q: L368D/K370S and the 428L/434S variants on each Fc monomer.
  • In the IL-15/Rα-heteroFc format, a preferred embodiment utilizes the IL-15 N1D/N65D variant.
  • In the IL-15/Rα-heteroFc format, a preferred embodiment utilizes the IL-15 N1D/N65D variant and the skew variant pair S364K/E357Q: L368D/K370S.
  • In the IL-15/Rα-heteroFc format, a preferred embodiment utilizes the IL-15 N1D/N65D variant, the skew variant pair S364K/E357Q: L368D/K370S and the 428L/434S variants on each Fc monomer.
  • In the IL-15/Rα-heteroFc format, preferred embodiments are shown in FIG. 48A (XENP22822 including chain 1 (17693) and chain 2 (15908)), FIG. 94A (XENP23504 including chain 1 and chain 2), FIG. 104AO (XENP24045 including chain 1 and chain 2), FIG. 104AQ (XENP24306 including chain 1 and chain 2), FIG. 48A (XENP22821 including chain 1 and chain 2), FIG. 94A (XENP23343 including chain 1 and chain 2), FIG. 104AJ (XENP23557 including chain 1 and chain 2), FIG. 104AP (XENP24113 including chain 1 and chain 2), FIG. 104AP (XENP24051 including chain 1 and chain 2), FIG. 104AR (XENP24341 including chain 1 and chain 2), FIG. 104AP (XENP24052 including chain 1 and chain 2), and FIG. 104AP (XENP24301 including chain 1 and chain 2).
  • B. scIL-15-Rα-Fc
  • In this embodiment, as shown in FIG. 9B, the heterodimeric fusion protein comprises two monomers. The first monomer comprises (from N- to C-terminus) IL-15/Rα(sushi)-domain linker-IL-15-optional domain linker-CH2-CH3, where the domain linker sometimes comprises all or part of the hinge. The second monomer comprises and “empty” Fc, comprising all or part of the hinge-CH2-CH3. This is referred to as “scIL-15/Rα-Fc” with the “sc” standing for “single chain” (e.g. of the IL-15/sushi complex).
  • In the scIL-15/Rα-Fc format, a preferred embodiment utilizes the skew variant pair S364K/E357Q: L368D/K370S.
  • In the scIL-15/Rα-Fc format, a preferred embodiment utilizes the IL-15 variant Q108E.
  • In the scIL-15/Rα-Fc format, a preferred embodiment utilizes the IL-15 variant Q108E and the skew variant pair S364K/E357Q: L368D/K370S.
  • In the scIL-15/Rα-Fc format, a preferred embodiment utilizes the IL-15 variant Q108E and the skew variant pair S364K/E357Q: L368D/K370S and the 428L/434S variants on both monomers.
  • In the scIL-15/Rα-Fc format, a preferred embodiment utilizes the IL-15 D30N/E64Q/N65D variants.
  • In the scIL-15/Rα-Fc format, a preferred embodiment utilizes the IL-15 D30N/E64Q/N65D variants and the skew variant pair S364K/E357Q: L368D/K370S.
  • In the scIL-15/Rα-Fc format, a preferred embodiment utilizes the IL-15 D30N/E64Q/N65D variants, the skew variant pair S364K/E357Q: L368D/K370S and the 428L/434S variants on each Fc monomer.
  • In the scIL-15/Rα-Fc format, a preferred embodiment utilizes the IL-15 N65D variant.
  • In the scIL-15/Rα-Fc format, a preferred embodiment utilizes the IL-15 N65D variant, and the skew variant pair S364K/E357Q: L368D/K370S
  • In the scIL-15/Rα-Fc format, a preferred embodiment utilizes the IL-15 N65D variant, the skew variant pair S364K/E357Q: L368D/K370S and the 428L/434S variants on each Fc monomer.
  • In the scIL-15/Rα-Fc format, a preferred embodiment utilizes the IL-15 N4D/N65D variant.
  • In the scIL-15/Rα-Fc format, a preferred embodiment utilizes the IL-15 N4D/N65D variant and the skew variant pair S364K/E357Q: L368D/K370S.
  • In the scIL-15/Rα-Fc format, a preferred embodiment utilizes the IL-15 N4D/N65D variant, the skew variant pair S364K/E357Q: L368D/K370S and the 428L/434S variants on each Fc monomer.
  • In the scIL-15/Rα-Fc format, a preferred embodiment utilizes the IL-15 N1D/N65D variant.
  • In the scIL-15/Rα-Fc format, a preferred embodiment utilizes the IL-15 N1D/N65D variant and the skew variant pair S364K/E357Q: L368D/K370S.
  • In the IL-15/Rα-heteroFc format, a preferred embodiment utilizes the IL-15 N1D/N65D variant, the skew variant pair S364K/E357Q: L368D/K370S and the 428L/434S variants on each Fc monomer.
  • C. ncIL-15/Rα-Fc
  • In this embodiment, as shown in FIG. 9C, the heterodimeric fusion protein comprises three monomers. The first monomer comprises (from N- to C-terminus) IL-15/Rα(sushi)-domain linker-CH2-CH3, where the domain linker sometimes comprises all or part of the hinge. The second monomer comprises and “empty” Fc, comprising all or part of the hinge-CH2-CH3. The third monomer is IL-15. This is referred to as “ncIL-15/Rα-Fc” with the “nc” standing for “non-covalent”).
  • In the ncIL-15/Rα-Fc format, a preferred embodiment utilizes the skew variant pair S364K/E357Q: L368D/K370S.
  • In the ncIL-15/Rα-Fc format, a preferred embodiment utilizes the IL-15 variant Q108E.
  • In the ncIL-15/Rα-Fc format, a preferred embodiment utilizes the IL-15 variant Q108E and the skew variant pair S364K/E357Q: L368D/K370S.
  • In the ncIL-15/Rα-Fc format, a preferred embodiment utilizes the IL-15 variant Q108E and the skew variant pair S364K/E357Q: L368D/K370S and the 428L/434S variants on both monomers.
  • In the ncIL-15/Rα-Fc format, a preferred embodiment utilizes the IL-15 D30N/E64Q/N65D variants.
  • In the ncIL-15/Rα-Fc format, a preferred embodiment utilizes the IL-15 D30N/E64Q/N65D variants and the skew variant pair S364K/E357Q: L368D/K370S.
  • In the ncIL-15/Rα-Fc format, a preferred embodiment utilizes the IL-15 D30N/E64Q/N65D variants, the skew variant pair S364K/E357Q: L368D/K370S and the 428L/434S variants on each Fc monomer.
  • In the ncIL-15/Rα-Fc format, a preferred embodiment utilizes the IL-15 N65D variant.
  • In the ncIL-15/Rα-Fc format, a preferred embodiment utilizes the IL-15 N65D variant, and the skew variant pair S364K/E357Q: L368D/K370S
  • In the ncIL-15/Rα-Fc format, a preferred embodiment utilizes the IL-15 N65D variant, the skew variant pair S364K/E357Q: L368D/K370S and the 428L/434S variants on each Fc monomer.
  • In the ncIL-15/Rα-Fc format, a preferred embodiment utilizes the IL-15 N4D/N65D variant.
  • In the ncIL-15/Rα-Fc format, a preferred embodiment utilizes the IL-15 N4D/N65D variant and the skew variant pair S364K/E357Q: L368D/K370S.
  • In the ncIL-15/Rα-Fc format, a preferred embodiment utilizes the IL-15 N4D/N65D variant, the skew variant pair S364K/E357Q: L368D/K370S and the 428L/434S variants on each Fc monomer.
  • In the ncIL-15/Rα-Fc format, a preferred embodiment utilizes the IL-15 N1D/N65D variant.
  • In the ncIL-15/Rα-Fc format, a preferred embodiment utilizes the IL-15 N1D/N65D variant and the skew variant pair S364K/E357Q: L368D/K370S.
  • In the ncIL-15/Rα-heteroFc format, a preferred embodiment utilizes the IL-15 N1D/N65D variant, the skew variant pair S364K/E357Q: L368D/K370S and the 428L/434S variants on each Fc monomer.
  • In the ncIL-15/Rα-heteroFc format, preferred embodiments are shown in FIG. 104AS (XENP24349 including chain 1 and chain 2) and FIG. 104AT (XENP24383 including chain 1 and chain 2).
  • D. Bivalent ncIL-15/Rα-Fc
  • In this embodiment, as shown in FIG. 9D, the heterodimeric fusion protein comprises four monomers. The first and second monomers comprise (from N- to C-terminus) IL-15/Rα(sushi)-domain linker-CH2-CH3, where the domain linker sometimes comprises all or part of the hinge. The third and fourth monomers comprise IL-15. This is referred to as “bivalent ncIL-15/Rα-Fc” with the “nc” standing for “non-covalent”).
  • In the bivalent ncIL-15/Rα-Fc format, a preferred embodiment utilizes the skew variant pair S364K/E357Q: L368D/K370S.
  • In the bivalent ncIL-15/Rα-Fc format, a preferred embodiment utilizes the IL-15 variant Q108E.
  • In the bivalent ncIL-15/Rα-Fc format, a preferred embodiment utilizes the IL-15 variant Q108E and the skew variant pair S364K/E357Q: L368D/K370S.
  • In the bivalent ncIL-15/Rα-Fc format, a preferred embodiment utilizes the IL-15 variant Q108E and the skew variant pair S364K/E357Q: L368D/K370S and the 428L/434S variants on both monomers.
  • In the bivalent ncIL-15/Rα-Fc format, a preferred embodiment utilizes the IL-15 D30N/E64Q/N65D variants.
  • In the bivalent ncIL-15/Rα-Fc format, a preferred embodiment utilizes the IL-15 D30N/E64Q/N65D variants and the skew variant pair S364K/E357Q: L368D/K370S.
  • In the bivalent ncIL-15/Rα-Fc format, a preferred embodiment utilizes the IL-15 D30N/E64Q/N65D variants, the skew variant pair S364K/E357Q: L368D/K370S and the 428L/434S variants on each Fc monomer.
  • In the bivalent ncIL-15/Rα-Fc format, a preferred embodiment utilizes the IL-15 N65D variant.
  • In the bivalent ncIL-15/Rα-Fc format, a preferred embodiment utilizes the IL-15 N65D variant, and the skew variant pair S364K/E357Q: L368D/K370S
  • In the bivalent ncIL-15/Rα-Fc format, a preferred embodiment utilizes the IL-15 N65D variant, the skew variant pair S364K/E357Q: L368D/K370S and the 428L/434S variants on each Fc monomer.
  • In the bivalent ncIL-15/Rα-Fc format, a preferred embodiment utilizes the IL-15 N4D/N65D variant.
  • In the bivalent ncIL-15/Rα-Fc format, a preferred embodiment utilizes the IL-15 N4D/N65D variant and the skew variant pair S364K/E357Q: L368D/K370S.
  • In the bivalent ncIL-15/Rα-Fc format, a preferred embodiment utilizes the IL-15 N4D/N65D variant, the skew variant pair S364K/E357Q: L368D/K370S and the 428L/434S variants on each Fc monomer.
  • In the bivalent ncIL-15/Rα-Fc format, a preferred embodiment utilizes the IL-15 N1D/N65D variant.
  • In the bivalent ncIL-15/Rα-Fc format, a preferred embodiment utilizes the IL-15 N1D/N65D variant and the skew variant pair S364K/E357Q: L368D/K370S.
  • In the bivalent ncIL-15/Rα-Fc format, a preferred embodiment utilizes the IL-15 N1D/N65D variant, the skew variant pair S364K/E357Q: L368D/K370S and the 428L/434S variants on each Fc monomer.
  • In the bivalent ncIL-15/Rα-Fc format, preferred embodiments are shown in FIG. 104AR (XENP24342 including chain 1 and chain 2) and (XENP24346 including chain 1 and chain 2).
    • VI. Useful Embodiments of the Invention
  • As will be appreciated by those in the art and discussed more fully below, the heterodimeric fusion proteins of the present invention can take on a wide variety of configurations, as are generally depicted in FIGS. 9A-9G and FIGS. 39A-39D. The amino acid sequences of exemplary fusion proteins are provided in 8A-8E, 10, 11, 12A, 12B, 13-15, 40A, 40B, 41A, 41B, 42, 43, 48A-48D, 49A-49C, 50A, 50B, 51, 52, 53, and 94A-94D.
  • Many of the embodiments outlined herein rely in general on the format comprising a first monomer (first fusion protein) comprising an IL-15 protein domain covalently attached using a first domain linker to the N-terminus of a first Fc domain, and a second monomer (second fusion protein) comprising an IL-15Rα protein domain covalently attached using a second domain linker to the N-terminus of a second Fc domain. Exemplary embodiments of this format (“IL-15/Rα hetero Fc” and “dsIL-15/Rα hetero Fc”) include, but are not limited to, XENP20818, XENP20819, XENP21471, XENP21472, XENP21473, XENP21474, XENP21475, XENP21476, XENP21477, XENP22013, XENP22815, XENP22816, XENP22817, XENP22818, XENP22819, XENP22820, XENP22821, XENP22822, XENP22823, XENP22824, XENP22825, XENP22826, XENP22827, XENP22828, XENP22829, XENP22830, XENP22831, XENP22832, XENP22833, XENP22834, XENP22815, XENP22816, XENP22817, XENP22818, XENP22819, XENP22820, XENP22821, XENP23343, XENP23554, XENP23555, XENP23557, XENP23559, XENP23561, XENP24018, XENP24019, XENP24020, XENP24051, XENP24052, XENP23504, XENP24306, XENP24306, XENP23343, XENO24113, XENP24341, and XENP24301.
  • A useful format of a heterodimer Fc fusion protein comprises a fusion protein comprising a first protein domain covalently attached to the N-terminus of a second protein domain via a first domain linker that is covalently attached to the N-terminus of a first Fc domain via a second domain linker, and a second Fc domain (e.g., an empty Fc domain). In some cases, the first protein domain is an IL-15Rα protein domain and the second protein domain is an IL-15 protein domain. An exemplary embodiment of this format (“scIL-15/Rα-Fc”) includes, but is not limited to, XENP21478.
  • Yet another useful of a heterodimer Fc fusion protein outlined herein comprises a fusion protein comprising a first protein domain covalently attached to the N-terminus a first Fc domain via a domain linker, a second Fc domain (e.g., an empty Fc domain), and a second protein domain that is noncovalently attached to the first protein domain. In some cases, the first protein domain is an IL-15 protein domain and the second protein domain is an IL-15Rα protein domain. An exemplary embodiment of this format (“ncIL-15/Rα-Fc” or “dsIL-15/Rα-Fc”) includes, but is not limited to, XENP21479, XENP22357, XENP22354, XENP22355, XENP22356, XENP22357, XENP22358, XENP22359, XENP22360, XENP22361, XENP22362, XENP22363, XENP22364, XENP22365, XENP22366, XENP22637, XENP24348, XENP24349, and XENP24383.
  • Another useful format of a heterodimer Fc fusion protein outlined herein comprises a first fusion protein comprising a first protein domain covalently attached to the N-terminus of said first Fc domain via a first domain linker, a second fusion protein comprising a second protein domain covalently attached to the N-terminus of said second Fc domain via a second domain linker, a third protein domain noncovalently attached to said first protein domain of said first fusion protein, and a fourth protein domain noncovalently attached to said second protein domain of said second fusion protein. In some cases, the first and second protein domains are IL-15 Rα protein domains, and the third and fourth protein domains are IL-15 protein domains. An exemplary embodiment of this format (“bivalent ncIL-15/Rα-Fc” or “bivalent dsIL-15/Rα-Fc”) includes, but is not limited to, XENP21978, XENP22634, XENP24342, and XENP24346.
  • Another useful format (“bivalent scIL-15/Rα-Fc”) is outlined herein in FIG. 14.
  • Yet another useful format of a heterodimer Fc fusion protein outlined herein comprises a first fusion protein comprising a first Fc domain covalently attached to the N-terminus of a first protein domain using a domain linker, a second Fc domain (e.g., an empty Fc domain), and a second protein domain noncovalently attached to said first protein domain. An exemplary embodiment of this format (“Fc-ncIL-15/Rα” or “Fc-dsIL-15/Rα”) includes, but is not limited to, XENP22637 and XENP22639, and those depicted in FIG. 16. In some embodiments, the first protein and the second protein are attached via a linker (FIG. 9G).
  • For any of the heterodimer Fc fusion proteins outlined herein, the first domain linker and the second domain linker can be the same or different. In addition, the first Fc domain and the second Fc domain of the heterodimeric protein can have different amino acid sequences.
  • The Fc domains of the present invention comprise IgG Fc domains, e.g., IgG1 Fc domains. In some embodiments, the first and second Fc domains comprising a set of amino acid substitutions selected from the group consisting of: L368D/K370S and S364K; L368D/K370S and S364K/E357L; L368D/K370S and S364K/E357Q; T411E/K360E/Q362E and D401K; L368E/K370S and S364K; K370S and S364K/E357Q; K370S and S364K/E357Q; S267K/L368D/K370S and S267K/S364K/E357Q, according to EU numbering. In some instances, the first and/or the second Fc domains of any of the heterodimeric Fc fusion formats outlined herein can have an additional set of amino acid substitutions comprising Q295E/N384D/Q418E/N421D, according to EU numbering. In some embodiments, the first and/or the second Fc domains have an additional set of amino acid substitutions consisting of G236R/L328R, E233P/L234V/L235A/G236del/S239K, E233P/L234V/L235A/G236del/S267K, E233P/L234V/L235A/G236del/S239K/A327G, E233P/L234V/L235A/G236del/S267K/A327G and E233P/L234V/L235A/G236del, according to EU numbering.
  • Additional heterodimerization variants can be independently and optionally included and selected from variants outlined in the figures. These compositions can further comprise ablation variants, pI variants, charged variants, isotypic variants, etc.
    • VII. Nucleic Acids of the Invention
  • The invention further provides nucleic acid compositions encoding the heterodimeric Fc fusion protein of the invention (or, in the case of a monomer Fc domain protein, nucleic acids encoding those as well).
  • As will be appreciated by those in the art, the nucleic acid compositions will depend on the format of the heterodimeric protein. Thus, for example, when the format requires three amino acid sequences, three nucleic acid sequences can be incorporated into one or more expression vectors for expression. Similarly, some formats only two nucleic acids are needed; again, they can be put into one or two expression vectors.
  • As is known in the art, the nucleic acids encoding the components of the invention can be incorporated into expression vectors as is known in the art, and depending on the host cells used to produce the heterodimeric Fc fusion proteins of the invention. Generally the nucleic acids are operably linked to any number of regulatory elements (promoters, origin of replication, selectable markers, ribosomal binding sites, inducers, etc.). The expression vectors can be extra-chromosomal or integrating vectors.
  • The nucleic acids and/or expression vectors of the invention are then transformed into any number of different types of host cells as is well known in the art, including mammalian, bacterial, yeast, insect and/or fungal cells, with mammalian cells (e.g. CHO cells), finding use in many embodiments.
  • In some embodiments, nucleic acids encoding each monomer, as applicable depending on the format, are each contained within a single expression vector, generally under different or the same promoter controls. In embodiments of particular use in the present invention, each of these two or three nucleic acids are contained on a different expression vector.
  • The heterodimeric Fc fusion protein of the invention are made by culturing host cells comprising the expression vector(s) as is well known in the art. Once produced, traditional fusion protein or antibody purification steps are done, including an ion exchange chromotography step. As discussed herein, having the pIs of the two monomers differ by at least 0.5 can allow separation by ion exchange chromatography or isoelectric focusing, or other methods sensitive to isoelectric point. That is, the inclusion of pI substitutions that alter the isoelectric point (pI) of each monomer so that such that each monomer has a different pI and the heterodimer also has a distinct pI, thus facilitating isoelectric purification of the heterodimer (e.g., anionic exchange columns, cationic exchange columns). These substitutions also aid in the determination and monitoring of any contaminating homodimers post-purification (e.g., IEF gels, cIEF, and analytical IEX columns).
    • VIII. Biological and Biochemical Functionality of IL-15/IL15Rα Heterodimeric Immunomodulatory Fc Fusion Proteins
  • Generally the heterodimeric Fc fusion proteins of the invention are administered to patients with cancer, and efficacy is assessed, in a number of ways as described herein. Thus, while standard assays of efficacy can be run, such as cancer load, size of tumor, evaluation of presence or extent of metastasis, etc., immuno-oncology treatments can be assessed on the basis of immune status evaluations as well. This can be done in a number of ways, including both in vitro and in vivo assays. For example, evaluation of changes in immune status (e.g., presence of ICOS+CD4+ T cells following ipi treatment) along with “old fashioned” measurements such as tumor burden, size, invasiveness, LN involvement, metastasis, etc. can be done. Thus, any or all of the following can be evaluated: the inhibitory effects of PVRIG on CD4+ T cell activation or proliferation, CD8+ T (CTL) cell activation or proliferation, CD8+ T cell-mediated cytotoxic activity and/or CTL mediated cell depletion, NK cell activity and NK mediated cell depletion, the potentiating effects of PVRIG on Treg cell differentiation and proliferation and Treg- or myeloid derived suppressor cell (MDSC)-mediated immunosuppression or immune tolerance, and/or the effects of PVRIG on proinflammatory cytokine production by immune cells, e.g., IL-2, IFN-γ or TNF-α production by T or other immune cells.
  • In some embodiments, assessment of treatment is done by evaluating immune cell proliferation, using for example, CFSE dilution method, Ki67 intracellular staining of immune effector cells, and 3H-thymidine incorporation method,
  • In some embodiments, assessment of treatment is done by evaluating the increase in gene expression or increased protein levels of activation-associated markers, including one or more of: CD25, CD69, CD137, ICOS, PD1, GITR, OX40, and cell degranulation measured by surface expression of CD107A.
  • In general, gene expression assays are done as is known in the art.
  • In general, protein expression measurements are also similarly done as is known in the art.
  • In some embodiments, assessment of treatment is done by assessing cytotoxic activity measured by target cell viability detection via estimating numerous cell parameters such as enzyme activity (including protease activity), cell membrane permeability, cell adherence, ATP production, co-enzyme production, and nucleotide uptake activity. Specific examples of these assays include, but are not limited to, Trypan Blue or PI staining, 51Cr or 35S release method, LDH activity, MTT and/or WST assays, Calcein-AM assay, Luminescent based assay, and others.
  • In some embodiments, assessment of treatment is done by assessing T cell activity measured by cytokine production, measure either intracellularly in culture supernatant using cytokines including, but not limited to, IFNγ, TNFα, GM-CSF, IL2, IL6, IL4, IL5, IL10, IL13 using well known techniques.
  • Accordingly, assessment of treatment can be done using assays that evaluate one or more of the following: (i) increases in immune response, (ii) increases in activation of and/or γδ T cells, (iii) increases in cytotoxic T cell activity, (iv) increases in NK and/or NKT cell activity, (v) alleviation of and/or γδ T-cell suppression, (vi) increases in pro-inflammatory cytokine secretion, (vii) increases in IL-2 secretion; (viii) increases in interferon-γ production, (ix) increases in Th1 response, (x) decreases in Th2 response, (xi) decreases or eliminates cell number and/or activity of at least one of regulatory T cells (Tregs).
  • A. Assays to Measure Efficacy
  • In some embodiments, T cell activation is assessed using a Mixed Lymphocyte Reaction (MLR) assay as is known in the art. An increase in activity indicates immunostimulatory activity. Appropriate increases in activity are outlined below.
  • In one embodiment, the signaling pathway assay measures increases or decreases in immune response as measured for an example by phosphorylation or de-phosphorylation of different factors, or by measuring other post translational modifications. An increase in activity indicates immunostimulatory activity. Appropriate increases in activity are outlined below.
  • In one embodiment, the signaling pathway assay measures increases or decreases in activation of and/or γδ T cells as measured for an example by cytokine secretion or by proliferation or by changes in expression of activation markers like for an example CD137, CD107a, PD1, etc. An increase in activity indicates immunostimulatory activity. Appropriate increases in activity are outlined below.
  • In one embodiment, the signaling pathway assay measures increases or decreases in cytotoxic T cell activity as measured for an example by direct killing of target cells like for an example cancer cells or by cytokine secretion or by proliferation or by changes in expression of activation markers like for an example CD137, CD107a, PD1, etc. An increase in activity indicates immunostimulatory activity. Appropriate increases in activity are outlined below.
  • In one embodiment, the signaling pathway assay measures increases or decreases in NK and/or NKT cell activity as measured for an example by direct killing of target cells like for an example cancer cells or by cytokine secretion or by changes in expression of activation markers like for an example CD107a, etc. An increase in activity indicates immunostimulatory activity. Appropriate increases in activity are outlined below.
  • In one embodiment, the signaling pathway assay measures increases or decreases in 1343 and/or γδ T-cell suppression, as measured for an example by cytokine secretion or by proliferation or by changes in expression of activation markers like for an example CD137, CD107a, PD1, etc. An increase in activity indicates immunostimulatory activity. Appropriate increases in activity are outlined below.
  • In one embodiment, the signaling pathway assay measures increases or decreases in pro-inflammatory cytokine secretion as measured for example by ELISA or by Luminex or by Multiplex bead based methods or by intracellular staining and FACS analysis or by Alispot etc. An increase in activity indicates immunostimulatory activity. Appropriate increases in activity are outlined below.
  • In one embodiment, the signaling pathway assay measures increases or decreases in IL-2 secretion as measured for example by ELISA or by Luminex or by Multiplex bead based methods or by intracellular staining and FACS analysis or by Alispot etc. An increase in activity indicates immunostimulatory activity. Appropriate increases in activity are outlined below.
  • In one embodiment, the signaling pathway assay measures increases or decreases in interferon-γ production as measured for example by ELISA or by Luminex or by Multiplex bead based methods or by intracellular staining and FACS analysis or by Alispot etc. An increase in activity indicates immunostimulatory activity. Appropriate increases in activity are outlined below.
  • In one embodiment, the signaling pathway assay measures increases or decreases in Th1 response as measured for an example by cytokine secretion or by changes in expression of activation markers. An increase in activity indicates immunostimulatory activity. Appropriate increases in activity are outlined below.
  • In one embodiment, the signaling pathway assay measures increases or decreases in Th2 response as measured for an example by cytokine secretion or by changes in expression of activation markers. An increase in activity indicates immunostimulatory activity. Appropriate increases in activity are outlined below.
  • In one embodiment, the signaling pathway assay measures increases or decreases cell number and/or activity of at least one of regulatory T cells (Tregs), as measured for example by flow cytometry or by IHC. A decrease in response indicates immunostimulatory activity. Appropriate decreases are the same as for increases, outlined below.
  • In one embodiment, the signaling pathway assay measures increases or decreases in M2 macrophages cell numbers, as measured for example by flow cytometry or by IHC. A decrease in response indicates immunostimulatory activity. Appropriate decreases are the same as for increases, outlined below.
  • In one embodiment, the signaling pathway assay measures increases or decreases in M2 macrophage pro-tumorigenic activity, as measured for an example by cytokine secretion or by changes in expression of activation markers. A decrease in response indicates immunostimulatory activity. Appropriate decreases are the same as for increases, outlined below.
  • In one embodiment, the signaling pathway assay measures increases or decreases in N2 neutrophils increase, as measured for example by flow cytometry or by IHC. A decrease in response indicates immunostimulatory activity. Appropriate decreases are the same as for increases, outlined below.
  • In one embodiment, the signaling pathway assay measures increases or decreases in N2 neutrophils pro-tumorigenic activity, as measured for an example by cytokine secretion or by changes in expression of activation markers. A decrease in response indicates immunostimulatory activity. Appropriate decreases are the same as for increases, outlined below.
  • In one embodiment, the signaling pathway assay measures increases or decreases in inhibition of T cell activation, as measured for an example by cytokine secretion or by proliferation or by changes in expression of activation markers like for an example CD137, CD107a, PD1, etc. An increase in activity indicates immunostimulatory activity. Appropriate increases in activity are outlined below.
  • In one embodiment, the signaling pathway assay measures increases or decreases in inhibition of CTL activation as measured for an example by direct killing of target cells like for an example cancer cells or by cytokine secretion or by proliferation or by changes in expression of activation markers like for an example CD137, CD107a, PD1, etc. An increase in activity indicates immunostimulatory activity. Appropriate increases in activity are outlined below.
  • In one embodiment, the signaling pathway assay measures increases or decreases in αβ and/or γδ T cell exhaustion as measured for an example by changes in expression of activation markers. A decrease in response indicates immunostimulatory activity. Appropriate decreases are the same as for increases, outlined below.
  • In one embodiment, the signaling pathway assay measures increases or decreases αβ and/or γδ T cell response as measured for an example by cytokine secretion or by proliferation or by changes in expression of activation markers like for an example CD137, CD107a, PD1, etc. An increase in activity indicates immunostimulatory activity. Appropriate increases in activity are outlined below.
  • In one embodiment, the signaling pathway assay measures increases or decreases in stimulation of antigen-specific memory responses as measured for an example by cytokine secretion or by proliferation or by changes in expression of activation markers like for an example CD45RA, CCR7 etc. An increase in activity indicates immunostimulatory activity. Appropriate increases in activity are outlined below.
  • In one embodiment, the signaling pathway assay measures increases or decreases in apoptosis or lysis of cancer cells as measured for an example by cytotoxicity assays such as for an example MTT, Cr release, Calcine AM, or by flow cytometry based assays like for an example CFSE dilution or propidium iodide staining etc. An increase in activity indicates immunostimulatory activity. Appropriate increases in activity are outlined below.
  • In one embodiment, the signaling pathway assay measures increases or decreases in stimulation of cytotoxic or cytostatic effect on cancer cells, as measured for an example by cytotoxicity assays such as for an example MTT, Cr release, Calcine AM, or by flow cytometry based assays like for an example CFSE dilution or propidium iodide staining etc. An increase in activity indicates immunostimulatory activity. Appropriate increases in activity are outlined below.
  • In one embodiment, the signaling pathway assay measures increases or decreases direct killing of cancer cells as measured for an example by cytotoxicity assays such as for an example MTT, Cr release, Calcine AM, or by flow cytometry based assays like for an example CFSE dilution or propidium iodide staining etc. An increase in activity indicates immunostimulatory activity. Appropriate increases in activity are outlined below.
  • In one embodiment, the signaling pathway assay measures increases or decreases Th17 activity as measured for an example by cytokine secretion or by proliferation or by changes in expression of activation markers. An increase in activity indicates immunostimulatory activity. Appropriate increases in activity are outlined below.
  • In one embodiment, the signaling pathway assay measures increases or decreases in induction of complement dependent cytotoxicity and/or antibody dependent cell-mediated cytotoxicity, as measured for an example by cytotoxicity assays such as for an example MTT, Cr release, Calcine AM, or by flow cytometry based assays like for an example CFSE dilution or propidium iodide staining etc. An increase in activity indicates immunostimulatory activity. Appropriate increases in activity are outlined below.
  • In one embodiment, T cell activation is measured for an example by direct killing of target cells like for an example cancer cells or by cytokine secretion or by proliferation or by changes in expression of activation markers like for an example CD137, CD107a, PD1, etc. For T-cells, increases in proliferation, cell surface markers of activation (e.g., CD25, CD69, CD137, PD1), cytotoxicity (ability to kill target cells), and cytokine production (e.g., IL-2, IL-4, IL-6, IFNγ, TNF-a, IL-10, IL-17A) would be indicative of immune modulation that would be consistent with enhanced killing of cancer cells.
  • In one embodiment, NK cell activation is measured for example by direct killing of target cells like for an example cancer cells or by cytokine secretion or by changes in expression of activation markers like for an example CD107a, etc. For NK cells, increases in proliferation, cytotoxicity (ability to kill target cells and increases CD107a, granzyme, and perforin expression), cytokine production (e.g., IFNγ and TNF), and cell surface receptor expression (e.g. CD25) would be indicative of immune modulation that would be consistent with enhanced killing of cancer cells.
  • In one embodiment, γδ T cell activation is measured for example by cytokine secretion or by proliferation or by changes in expression of activation markers.
  • In one embodiment, Th1 cell activation is measured for example by cytokine secretion or by changes in expression of activation markers.
  • Appropriate increases in activity or response (or decreases, as appropriate as outlined above), are increases of 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or 98 to 99% percent over the signal in either a reference sample or in control samples, for example test samples that do not contain an anti-PVRIG antibody of the invention. Similarly, increases of at least one-, two-, three-, four- or five-fold as compared to reference or control samples show efficacy.
    • IX. Treatments
  • Once made, the compositions of the invention find use in a number of oncology applications, by treating cancer, generally by promoting T cell activation (e.g., T cells are no longer suppressed) with the binding of the heterodimeric Fc fusion proteins of the invention.
  • Accordingly, the heterodimeric compositions of the invention find use in the treatment of these cancers.
  • A. Heterodimeric Protein Compositions for In Vivo Administration
  • Formulations of the antibodies used in accordance with the present invention are prepared for storage by mixing an antibody having the desired degree of purity with optional pharmaceutically acceptable carriers, excipients or stabilizers (as generally outlined in Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. [1980]), in the form of lyophilized formulations or aqueous solutions. Acceptable carriers, buffers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counter-ions such as sodium; metal complexes (e.g. Zn-protein complexes); and/or non-ionic surfactants such as TWEEN™, PLURONICS™ or polyethylene glycol (PEG).
  • B. Administrative Modalities
  • The heterodimeric proteins and chemotherapeutic agents of the invention are administered to a subject, in accord with known methods, such as intravenous administration as a bolus or by continuous infusion over a period of time.
  • C. Treatment Modalities
  • In the methods of the invention, therapy is used to provide a positive therapeutic response with respect to a disease or condition. By “positive therapeutic response” is intended an improvement in the disease or condition, and/or an improvement in the symptoms associated with the disease or condition. For example, a positive therapeutic response would refer to one or more of the following improvements in the disease: (1) a reduction in the number of neoplastic cells; (2) an increase in neoplastic cell death; (3) inhibition of neoplastic cell survival; (5) inhibition (i.e., slowing to some extent, preferably halting) of tumor growth; (6) an increased patient survival rate; and (7) some relief from one or more symptoms associated with the disease or condition.
  • Positive therapeutic responses in any given disease or condition can be determined by standardized response criteria specific to that disease or condition. Tumor response can be assessed for changes in tumor morphology (i.e., overall tumor burden, tumor size, and the like) using screening techniques such as magnetic resonance imaging (MRI) scan, x-radiographic imaging, computed tomographic (CT) scan, bone scan imaging, endoscopy, and tumor biopsy sampling including bone marrow aspiration (BMA) and counting of tumor cells in the circulation.
  • In addition to these positive therapeutic responses, the subject undergoing therapy may experience the beneficial effect of an improvement in the symptoms associated with the disease.
  • Treatment according to the present invention includes a “therapeutically effective amount” of the medicaments used. A “therapeutically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve a desired therapeutic result.
  • A therapeutically effective amount may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the medicaments to elicit a desired response in the individual. A therapeutically effective amount is also one in which any toxic or detrimental effects of the antibody or antibody portion are outweighed by the therapeutically beneficial effects.
  • A “therapeutically effective amount” for tumor therapy may also be measured by its ability to stabilize the progression of disease. The ability of a compound to inhibit cancer may be evaluated in an animal model system predictive of efficacy in human tumors.
  • Alternatively, this property of a composition may be evaluated by examining the ability of the compound to inhibit cell growth or to induce apoptosis by in vitro assays known to the skilled practitioner. A therapeutically effective amount of a therapeutic compound may decrease tumor size, or otherwise ameliorate symptoms in a subject. One of ordinary skill in the art would be able to determine such amounts based on such factors as the subject's size, the severity of the subject's symptoms, and the particular composition or route of administration selected.
  • Dosage regimens are adjusted to provide the optimum desired response (e.g., a therapeutic response). For example, a single bolus may be administered, several divided doses may be administered over time or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. Parenteral compositions may be formulated in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subjects to be treated; each unit contains a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
  • The specification for the dosage unit forms of the present invention are dictated by and directly dependent on (a) the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active compound for the treatment of sensitivity in individuals.
  • The efficient dosages and the dosage regimens for the bispecific antibodies used in the present invention depend on the disease or condition to be treated and may be determined by the persons skilled in the art.
  • An exemplary, non-limiting range for a therapeutically effective amount of an bispecific antibody used in the present invention is about 0.1-100 mg/kg.
  • All cited references are herein expressly incorporated by reference in their entirety.
  • Whereas particular embodiments of the invention have been described above for purposes of illustration, it will be appreciated by those skilled in the art that numerous variations of the details may be made without departing from the invention as described in the appended claims.
    • EXAMPLES
  • Examples are provided below to illustrate the present invention. These examples are not meant to constrain the present invention to any particular application or theory of operation. For all constant region positions discussed in the present invention, numbering is according to the EU index as in Kabat (Kabat et al., 1991, Sequences of Proteins of Immunological Interest, 5th Ed., United States Public Health Service, National Institutes of Health, Bethesda, entirely incorporated by reference). Those skilled in the art of antibodies will appreciate that this convention consists of nonsequential numbering in specific regions of an immunoglobulin sequence, enabling a normalized reference to conserved positions in immunoglobulin families. Accordingly, the positions of any given immunoglobulin as defined by the EU index will not necessarily correspond to its sequential sequence.
  • General and specific scientific techniques are outlined in US Publications 2015/0307629, 2014/0288275 and WO2014/145806, all of which are expressly incorporated by reference in their entirety and particularly for the techniques outlined therein.
    • X. Example 1: IL-15/IL-15Rα(sushi) Fe Fusion Proteins
  • In order to address the short half-life of IL-15/IL-15Rα heterodimers, we generated the IL-15/IL-15Rα(sushi) complex as a Fc fusion (hereon referred to as IL-15/Rα-Fc fusion proteins) with the goal of facilitating production and promoting FcRn-mediated recycling of the complex and prolonging half-life.
    • A. Example 1A: Engineering IL-15/Rα-Fc Fusion Proteins
  • Plasmids coding for IL-15 or IL-15Rα sushi domain were constructed by standard gene synthesis, followed by subcloning into a pTT5 expression vector containing Fc fusion partners (e.g., constant regions as depicted in FIG. 8). Cartoon schematics of illustrative IL-15/Rα-Fc fusion protein formats are depicted in FIGS. 9A-G.
  • The IL-15Rα heterodimeric Fc fusion or “IL-15/Rα-heteroFc” format comprises IL-15 recombinantly fused to one side of a heterodimeric Fc and IL-15Rα sushi domain recombinantly fused to the other side of the heterodimeric Fc (FIG. 9A). The IL-15 and IL-15Rα may have a variable length linker (see FIG. 7) between their respective C-terminus and the N-terminus of the Fc region. Illustrative proteins of this format include XENP20818 and XENP21475, sequences for which are depicted in FIG. 10 (see also Table 1). Sequences for additional proteins of this format are listed as XENPs 20819, 21471, 21472, 21473, 21474, 21476, and 21477 in the figures and in the sequence listing.
  • TABLE 1
    XENP IL-15-FC Linker IL-15Rα(sushi)-Fc Linker
    20818 (GGGGS)1  (GGGGS)1
    (SEQ ID NO: 14) (SEQ ID NO: 14)
    20819 (GGGGS)1  (GGGGS)4
    (SEQ ID NO: 14) (SEQ ID NO: 17)
    21471 NONE (GGGGS)1
    (SEQ ID NO: 14)
    21472 (GGGGS)1  NONE
    (SEQ ID NO: 14)
    21473 (GGGGS)1  (GGGGS)3
    (SEQ ID NO: 14) (SEQ ID NO: 16)
    21474 NONE (GGGGS)4
    (SEQ ID NO: 17)
    21475 NONE NONE
    21476 (GGGGS)2 (GGGGS)2
    (SEQ ID NO: 15) (SEQ ID NO: 15)
    21477 (GGGGS)2  (GGGGS)4
    (SEQ ID NO: 15) (SEQ ID NO: 17)
  • The single-chain IL-15/Rα-Fc fusion or “scIL-15/Rα-Fc” format comprises IL-15Rα sushi domain fused to IL-15 by a variable length linker (termed a “single-chain” IL-15/IL-15Rα complex or “scIL-15/Rα”) which is then fused to the N-terminus of a heterodimeric Fc-region, with the other side of the molecule being a “Fc-only” or “empty-Fc” heterodimeric Fc (FIG. 9B). Sequences for illustrative linkers are depicted in FIG. 7. An illustrative protein of this format is XENP21478, sequences for which are depicted in FIG. 11 (also see Table 2). Sequences for additional proteins of this format are listed as XENPs 21993, 21994, 21995, 23174, 23175, 24477, and 24480 in the figures and the sequence listing.
  • TABLE 2
    Linker between IL-15
    XENP and IL-15Ra
    21478 (GGGGS)6
    (SEQ ID NO: 19)
    21993 (GGGGS)5
    (SEQ ID NO: 18)
    21994 (GGGGS)4
    (SEQ ID NO: 17)
    21995 (GGGGS)3
    (SEQ ID NO: 16)
    23174 (GKPGS)6
    (SEQ ID NO: 24)
    23175 (GKPGS)5
    (SEQ ID NO: 23)
    24477 (GGGGS)7
    (SEQ ID NO: 20)
    24480 30AA-linker
  • The non-covalent IL-15/Rα-Fc fusion or “ncIL-15/Rα-Fc” format comprises IL-15Rα sushi domain fused to a heterodimeric Fc region, while IL-15 is transfected separately so that a non-covalent IL-15/IL-15Rα complex is formed, with the other side of the molecule being a “Fc-only” or “empty-Fc” heterodimeric Fc (FIG. 9C). Illustrative proteins of this format include XENP21479, XENP22366 and XENP24348, sequences for which are depicted in FIG. 12.
  • The bivalent non-covalent IL-15/Rα-Fc fusion or “bivalent ncIL-15/Rα-Fc” format (FIG. 9D) comprises IL-15Rα(sushi) fused to the N-terminus of a homodimeric Fc region, while IL-15 is transfected separately so that a non-covalent IL-15/Rα complex is formed. An illustrative protein of this format is XENP21978, sequences for which are depicted in FIG. 13. Sequences for additional proteins of this format are listed as XENP21979 in the figures and in the sequence listing.
  • The bivalent single-chain IL-15/Rα-Fc fusion or “bivalent scIL-15/Rα-Fc” format (FIG. 9E) comprises IL-15 fused to IL-15Rα(sushi) by a variable length linker (termed a “single-chain” IL-15/IL-15Rα(sushi) complex or “scIL-15/Rα”) which is then fused to the N-terminus of a homodimeric Fc-region. Sequences for illustrative linkers are depicted in FIG. 7. Sequences for an illustrative protein of this format are depicted in FIG. 14.
  • The Fc-non-covalent IL-15/Rα fusion or “Fc-ncIL-15/Rα” format (FIG. 9E) comprises IL-15Rα(sushi) fused to the C-terminus of a heterodimeric Fc region, while IL-15 is transfected separately so that a non-covalent IL-15/Rα complex is formed, with the other side of the molecule being “Fc-only” or “empty Fc”. An illustrative protein of this format is XENP22637, sequences for which are depicted in FIG. 15. Sequences for additional proteins of this format are listed XENP22638 in the figures and the sequence listing.
  • The Fc-single-chain IL-15/Rα fusion or “Fc-scIL-15/Rα” format (FIG. 9G) comprises IL-15 fused to IL-15Rα(sushi) by a variable length linker (“scIL-15/Rα”) which is then fused to the C-terminus of a heterodimeric Fc region, with the other side of the molecule being “Fc-only” or “empty Fc”. Sequences for illustrative linkers are depicted in FIG. 7. Sequences for an illustrative protein of this format are depicted in FIG. 16.
  • Proteins were produced by transient transfection in HEK293E cells and were purified by a two-step purification process comprising protein A chromatography (GE Healthcare) and anion exchange chromatography (HiTrapQ 5 mL column with a 5-40% gradient of 50 mM Tris pH 8.5 and 50 mM Tris pH 8.5 with 1 M NaCl).
    • B. Example 1B: Engineering IL-15/Rα-Fc Fusion Proteins
  • IL-15/Rα-Fc fusion proteins produced in several of the formats as described above were characterized by size-exclusion chromatography (SEC) and capillary isoelectric focusing (CEF) for purity and homogeneity as generally described below.
  • The proteins were analyzed using SEC to measure their size (i.e. hydrodynamic volume) and determine the native-like behavior of the purified samples. The analysis was performed on an Agilent 1200 high-performance liquid chromatography (HPLC) system. Samples were injected onto a Superdex™ 200 10/300 GL column (GE Healthcare Life Sciences) at 1.0 mL/min using 1×PBS, pH 7.4 as the mobile phase at 4° C. for 25 minutes with UV detection wavelength at 280 nM. Analysis was performed using Agilent OpenLab Chromatography Data System (CDS) ChemStation Edition AIC version C.01.07.
  • Chromatograms for selected IL-15/Rα-Fc fusion proteins are shown in FIGS. 17B, 18B, and 19B.
  • The proteins were analyzed electrophoretically via CEF using LabChip GXII Touch HT (PerkinElmer, Waltham, Mass.) using Protein Express Assay LabChip and Protein Express Assay Reagent Kit carried out using the manufacturer's instructions. Samples were run in duplicate, one under reducing (with dithiothreitol) and the other under non-reducing conditions. Gel images for selected IL-15/Rα-Fc fusion proteins are shown in FIGS. 17C, 18C, and 19C.
  • The symmetry of the peaks and the relatively low populations of other species for each of the fusion proteins indicate that the various formats were robust.
    • C. Example 1C: Characterization of IL-15/Rα-Fc Fusion Proteins for Affinity and Stability
  • Affinity screens of IL-15/Rα-Fc fusion proteins were performed using Octet, a BioLayer Interferometry (BLI)-based method. Experimental steps for Octet generally included the following: Immobilization (capture of ligand or test article onto a biosensor); Association (dipping of ligand- or test article-coated biosensors into wells containing serial dilutions of the corresponding test article or ligand); and Dissociation (returning of biosensors to well containing buffer) in order to determine the affinity of the test articles. A reference well containing buffer alone was also included in the method for background correction during data processing. In particular, anti-human Fc (AHC) biosensors were used to capture the test articles and then dipped into multiple concentration of IL-2Rβ (R&D Systems, Minneapolis, Minn.) for KD determination. The affinity results and corresponding sensorgrams are depicted in FIGS. 17D, 18D, and 19D. Each of the three constructs showed high affinity binding (3-8 nM) for IL-1Rβ.
  • Stability of IL-15/Rα-Fc fusion proteins were evaluated using Differential Scanning Fluorimetry (DSF). DSF experiments were performed using a Bio-Rad CFX Connect Real-Time PCR Detection System. Proteins were mixed with SYPRO Orange fluorescent dye and diluted to 0.2 mg/mL in PBS. The final concentration of SYPRO Orange was 10×. After an initial 10 minute incubation period at 25° C., proteins were heated from 25 to 95° C. using a heating rate of 1° C./min. A fluorescence measurement was taken every 30 sec. Melting temperatures (Tm) were calculated using the instrument software. The stability results and corresponding melting curves are depicted in FIGS. 17E, 18E, and 19E. Each of the constructs showed favorable overall stability with Tm˜68° C.
    • D. Example 1D: Activity of IL-15/Rα-Fc Fusion Proteins in Cell Proliferation Assays
  • IL-15/Rα-Fc fusion proteins in the various formats as described above were tested in a cell proliferation assay. Human PBMCs were treated with the test articles at the indicated concentrations. 4 days after treatment, the PBMCs were stained with anti-CD8-FITC (RPA-T8), anti-CD4-PerCP/Cy5.5 (OKT4), anti-CD27-PE (M-T271), anti-CD56-BV421 (5.1H11), anti-CD16-BV421 (3G8), and anti-CD45RA-BV605 (Hi100) to gate for the following cell types: CD4+ T cells, CD8+ T cells, and NK cells (CD56+/CD16+). Ki67 is a protein strictly associated with cell proliferation, and staining for intracellular Ki67 was performed using anti-Ki67-APC (Ki-67) and Foxp3/Transcription Factor Staining Buffer Set (Thermo Fisher Scientific, Waltham, Mass.). The percentage of Ki67 on the above cell types was measured using FACS (depicted in FIGS. 20A-20C and 21A-21C).
  • The various IL-15/Rα-Fc fusion proteins induced strong proliferation of CD8+ T cells and NK cells. Notably, differences in proliferative activity were dependent on the linker length on the IL-15-Fc side. In particular, constructs having no linker (hinge only), including XENP21471, XENP21474, and XENP21475, demonstrated weaker proliferative activity.
    • E. Example 1E: Activity of IL-15/Rα-Fc Fusion Proteins in an SEB-Stimulated PBMC Assay
  • As described above, IL-15/Rα heterodimers can potently activate T cells. IL-15/Rα-Fc fusion proteins in the various formats as described above were tested in an SEB-stimulated PBMC assay. Staphylococcal Enterotoxin B (SEB) is a superantigen that causes T cell activation and proliferation in a manner similar to that achieved by activation via the T cell receptor (TCR). Stimulating human PBMC with SEB is a common method for assaying T cell activation and proliferation.
  • Human PBMCs from multiple donors were stimulated with 10 ng/mL of SEB for 72 hours in combination with 20 μg/mL of various IL-15/Rα-Fc fusion proteins or controls (PBS, an isotype control, and a bivalent anti-PD-1 antibody). After treatment, supernatant was collected and assayed for IL-2, data for which is depicted in FIG. 22. The data clearly show that the IL-15/Rα-Fc fusion proteins enhanced IL-2 secretion more than PBS and isotype control. Notably, a number of the IL-15/Rα-Fc fusion proteins have activity equivalent to or better than that of the anti-PD-1 antibody.
    • F. Example 1F: IL-15/Rα-Fc Fusion Proteins Enhance Engraftment and Disease Activity in Human PBMC-Engrafted NSG Mice
  • IL-15/Rα-Fc fusion protein XENP20818 was evaluated in a Graft-versus-Host Disease (GVHD) model conducted in female NSG (NOD-SCID-gamma) immunodeficient mice. When the NSG mice were injected with human PBMCs, the human PBMCs developed an autoimmune response against mouse cells. Treatment of NSG mice injected with human PBMCs followed with IL-15/Rα-Fc fusion proteins enhances proliferation of the engrafted T cells.
  • 10 million human PBMCs were engrafted into NSG mice via IV-OSP on Day 0 followed by dosing of XENP20818 (1 mg/kg on Day 1 and then weekly thereafter) and recombinant IL-15 (Biolegend; 0.17 mg/kg on Day 1 and then weekly thereafter). The survival curve is shown in FIG. 23. The data show that mice receiving the IL-15/Rα-Fc fusion protein demonstrated rapid morbidity and mortality (all dead by Day 10) compared with mice receiving recombinant IL-15 (all alive by Day 14). This is likely due to the expected longer half-life of the IL-15/Rα-Fc fusion protein.
  • In another experiment, 10 million human PBMCs were engrafted in NSG mice via IV-OSP on Day 0 followed by dosing of XENP20818 (1 mg/kg, 0.3 mg/kg, 0.1 mg/kg, or 0.03 mg/kg on Day 1 and then weekly thereafter) or PBS. Control groups in which mice were not engrafted with PBMCs were included to investigate any effect of XENP20818 on wild-type NSG mice. Blood was collected on Day 7 to measure IFNγ, data for which is depicted in FIG. 24, and to measure CD4+ T cell, CD8+ T cell, and CD45+ cell counts, data for which are depicted in FIG. 25. The data shows a clear dose response for XENP20818.
    • XI. Example 2: IL-15/Rα-Fc Heterodimeric Fusion Proteins with Engineered Disulfide Bonds
  • To further improve stability and prolong the half-life of IL-15/Rα-Fc fusion proteins, we engineered disulfide bonds into the IL-15/Rα interface.
    • A. Example 2A: Engineering and Characterization of IL-15/Rα Heterodimers with Engineered Disulfide Bonds
  • By examining the crystal structure of the IL-15/Rα complex, as well as by modeling using Molecular Operating Environment (MOE; Chemical Computing Group, Montreal, Quebec, Canada) software, we predicted residues at the IL-15/Rα interface that may be substituted with cysteine in order to form covalent disulfide bonds, as depicted in FIG. 26.
  • Plasmids coding for IL-15 or IL-15Rα(sushi) were constructed by standard gene synthesis, followed by subcloning into a pTT5 expression vector. The IL-15Rα(sushi) chain included a C-terminal polyhistidine tag. Residues identified as described above were substituted with cysteines by standard mutagenesis techniques. Additionally, up to three amino acids following the sushi domain in IL-15Rα were added to the C-terminus of IL-15Rα(sushi) as a scaffold for engineering cysteines (illustrative sequences for which are depicted in FIG. 27). Sequences for illustrative IL-15 and IL-15Rα(sushi) variants engineered with cysteines are respectively depicted in FIGS. 28 and 29.
  • Cartoon schematics of IL-15/Rα heterodimers with and without engineered disulfides are depicted in FIGS. 30A-C. Sequences for an illustrative ncIL-15/Rα heterodimer XENP21996 is depicted in FIG. 31. Sequences for illustrative dsIL-15/Rα heterodimers XENP22004, XENP22005, XENP22006, XENP22008, and XENP22494 are depicted in FIG. 32. Sequences for an illustrative scIL-15/Rα heterodimer are depicted in FIG. 33. “Wild-type” IL-15/Rα heterodimers, with additional residues at the C-terminus but without engineered cysteines, were generated as controls. Sequences for these control IL-15/Rα heterodimers are listed as XENPs 22001, 22002, and 22003 in the figures and the sequence listing. Proteins were produced by transient transfection in HEK293E cells and purified by Ni-NTA chromatography.
  • After the proteins were purified, they were characterized by capillary isoelectric focusing (CEF) for purity and homogeneity as generally described in Example 1B, gel images for which are depicted in FIGS. 34-35. The proteins were then screened for stability using DSF as generally described in Example 1C, data for which are depicted in FIGS. 36-38. Finally, the proteins were screened for binding to IL-2Rβ by Octet as generally described in Example 1C, data for which is depicted in FIG. 38.
  • Many of the disulfide bonds were correctly formed as indicated by denaturing non-reducing CEF, where the larger molecular weight of the covalent complex can be seen when compared to the controls without engineered disulfide bonds (FIGS. 34-35). The disulfide bonded IL-15/Rα heterodimers had increased thermostability of up to +13° C. (FIG. 38). Binding to IL-2Rβ was not affected by the inclusion of engineered disulfide bonds (FIG. 38). Favorite disulfide bonded pairs were XENP22005, XENP22006, XENP22008, and XENP22494 and were constructed as Fc fusion proteins as described below.
    • B. Example 2B: Characterization of IL-15/Rα-Fc Fusion Proteins with Engineered Disulfide Bonds
  • Plasmids coding for IL-15 or IL-15Rα sushi domain with the above-described mutations were subcloned into a pTT5 expression vector containing Fc fusion partners (e.g., constant regions as depicted in FIG. 8). Cartoon schematics of IL-15/Rα-Fc fusion proteins with engineered disulfide bonds are depicted in FIGS. 39A-D.
  • Disulfide-bonded IL-15/Rα heterodimeric Fc fusion or “dsIL-15/Rα-heteroFc” (FIG. 39A) is the same as “IL-15/Rα-heteroFc”, but wherein IL-15Rα(sushi) and IL-15 are further covalently linked as a result of engineered cysteines. Illustrative proteins of this format include XENP22013, XENP22014, XENP22015, and XENP22017, sequences for which are depicted in FIG. 40.
  • Disulfide-bonded IL-15/Rα Fc fusion or “dsIL-15/Rα-Fc” (FIG. 39B) is the same as “ncIL-15/Rα-Fc”, but wherein IL-15Rα(sushi) and IL-15 are further covalently linked as a result of engineered cysteines. Illustrative proteins of this format include XENP22357, XENP22358, XENP22359, XENP22684, and XENP22361, sequences for which are depicted in FIG. 41. Sequences for additional proteins of this format are listed as XENPs 22360, 22362, 22363, 22364, 22365, and 22366 in the figures and the sequence listing.
  • Bivalent disulfide-bonded IL-15/Rα-Fc or “bivalent dsIL-15/Rα-Fc” (FIG. 39C) is the same as “bivalent ncIL-15/Rα-Fc”, but wherein IL-15Rα(sushi) and IL-15 are further covalently linked as a result of engineered cysteines. Illustrative proteins of this format include XENP22634, XENP22635, and XENP22636, sequences for which are depicted in FIG. 42. Sequences for additional proteins of this format are listed as XENP22687 in the figures and the sequence listing.
  • Fc-disulfide-bonded IL-15/Rα fusion or “Fc-dsIL-15/Rα” (FIG. 39D) is the same as “Fc-ncIL-15/Rα”, but wherein IL-15Rα(sushi) and IL-15 are further covalently linked as a result of engineered cysteines. Illustrative proteins of this format include XENP22639 and XENP22640, sequences for which are depicted in FIG. 43.
  • “Wild-type” IL-15/Rα-Fc fusion proteins, with additional residues at the C-terminus but without engineered cysteines, were generated as controls. Sequences for these control IL-15/Rα-Fc fusion proteins are listed as XENPs 21988, 21989, 21990, 21991, 21992, 22354, 22355, and 22356 in the figures and the sequence listing.
  • Proteins were produced by transient transfection in HEK293E cells and were purified by a two-step purification process comprising protein A chromatography (GE Healthcare) and anion exchange chromatography (HiTrapQ 5 mL column with a 5-40% gradient of 50 mM Tris pH 8.5 and 50 mM Tris pH 8.5 with 1 M NaCl).
  • After the proteins were purified, they were characterized by capillary isoelectric focusing (CEF) for purity and homogeneity as generally described in Example 1B. As above, many of the disulfide bonds were correctly formed as indicated by denaturing non-reducing CEF, where the larger molecular weight of the covalent complex can be seen when compared to the controls without engineered disulfide bonds (FIG. 44).
  • The proteins were then tested in a cell proliferation assay. IL-15/Rα-Fc fusion proteins (with or without engineered disulfide bonds) or controls were incubated with PBMCs for 4 days. Following incubation, PBMCs were stained with anti-CD4-PerCP/Cy5.5 (RPA-T4), anti-CD8-FITC (RPA-T8), anti-CD45RA-BV510 (HI100), anti-CD16-BV421 (3G8), anti-CD56-BV421 (HCD56), anti-CD27-PE (0323), and anti-Ki67-APC (Ki-67) to mark various cell populations and analyzed by FACS as generally described in Example 1D. Proliferation of NK cells, CD4+ T cells, and CD8+ T cells as indicated by Ki67 expression are depicted in FIGS. 45A-C. Each of the IL-15/Rα-Fc fusion proteins and the IL-15 control induced strong proliferation of NK cells, CD8+ T cells, and CD4+ T cells.
    • XII. Example 3: IL-15/Rα-Fc Fusion Proteins Engineered for Lower Potency and Increased PK and Half-Life
  • In order to further improve PK and prolong half-life, we reasoned that decreasing the potency of IL-15 would decrease the antigen sink, and thus, increase the half-life.
    • A. Example 3A: Engineering and Production of Variant IL-15/Rα-Fc Fusion Proteins
  • By examining the crystal structure of the IL-15:IL-2RB and IL-15:common gamma chain interfaces, as well as by modeling using MOE software, we predicted residues at these interfaces that may be substituted in order to reduce potency. FIG. 46 depicts a structural model of the IL-15:receptor complexes showing locations of the predicted residues where we engineered isosteric substitutions (in order to reduce the risk of immunogenicity). Sequences for illustrative IL-15 variants engineered for reduced potency are depicted in FIG. 47.
  • Plasmids coding for IL-15 or IL-15Rα(sushi) were constructed by standard gene synthesis, followed by subcloning into a pTT5 expression vector containing Fc fusion partners (e.g., constant regions as depicted in FIG. 8). Substitutions identified as described above were incorporated by standard mutagenesis techniques. Sequences for illustrative IL-15/Rα-Fc fusion proteins of the “IL-15/Rα-heteroFc” format engineered for reduced potency are depicted in FIG. 48, with additional sequences listed as XENPs 22815, 22816, 22817, 22818, 22819, 22820, 22823, 22824, 22825, 22826, 22827, 22828, 22829, 22830, 22831, 22832, 22833, 22834, 23555, 23559, 23560, 24017, 24020, 24043, and 24048 in the figures and the sequence listing.
  • Sequences for illustrative IL-15/Rα-Fc fusion proteins of the “scIL-15/Rα-Fc” format engineered for lower potency are depicted in FIG. 49, with additional sequences listed as XENPs 24013, 24014, and 24016 in the figures and the sequence listing. Sequences for illustrative IL-15/Rα-Fc fusion proteins of the “ncIL-15/Rα-Fc” format engineered for lower potency are depicted in FIG. 50. Sequences for illustrative ncIL-15/Rα heterodimers engineered for lower potency are depicted in FIG. 51, with additional sequences listed as XENPs 22791, 22792, 22793, 22794, 22795, 22796, 22803, 22804, 22805, 22806, 22807, 22808, 22809, 22810, 22811, 22812, 22813, and 22814 in the figures and the sequence listing. Sequences for an illustrative IL-15/Rα-Fc fusion protein of the “bivalent ncIL-15/Rα-Fc” format engineered for lower potency are depicted in FIG. 52. Sequences for illustrative IL-15/Rα-Fc fusion proteins of the “dsIL-15/Rα-Fc” format engineered for lower potency are depicted in FIG. 53.
  • Proteins were produced by transient transfection in HEK293E cells and were purified by a two-step purification process comprising protein A chromatography (GE Healthcare) and anion exchange chromatography (HiTrapQ 5 mL column with a 5-40% gradient of 50 mM Tris pH 8.5 and 50 mM Tris pH 8.5 with 1 M NaCl).
    • B. Example 3B: In Vitro Activity of Variant IL-15/Rα-heteroFc and scIL-15/Rα-Fc Fusion Proteins Engineered for Decreased Potency
  • The variant IL-15/Rα-Fc fusion proteins were tested in a number of cell proliferation assays.
  • In a first cell proliferation assay, IL-15/Rα-Fc fusion proteins (with or without engineered substitutions) or control were incubated with PBMCs for 4 days. Following incubation, PBMCs were stained with anti-CD4-Evolve605 (SK-3), anti-CD8-PerCP/Cy5.5 (RPA-T8), anti-CD45RA-APC/Cγ7 (HI100), anti-CD16-eFluor450 (CB16), anti-CD56-eFluor450 (TULY56), anti-CD3-FITC (OKT3), and anti-Ki67-APC (Ki-67) to mark various cell populations and analyzed by FACS as generally described in Example 1D. Proliferation of NK cells, CD8+ T cells, and CD4+ T cells as indicated by Ki67 expression are depicted in FIGS. 54-55. Most of the IL-15/Rα-Fc fusion proteins induced proliferation of each cell population; however, activity varied depending on the particular engineered substitutions.
  • In a second cell proliferation assay, IL-15/Rα-Fc fusion proteins (with or without engineered substitutions) were incubated with PBMCs for 3 days. Following incubation, PBMCs were stained with anti-CD3-FITC (OKT3), anti-CD4-Evolve604 (SK-3), anti-CD8-PerCP/Cy5.5 (RPA-T8), anti-CD16-eFluor450 (CB16), anti-CD56-eFluor450 (TULY56), anti-CD27-PE (0323), anti-CD45RA-APC/Cγ7 (HI100) and anti-Ki67-APC (20Raj1) antibodies to mark various cell populations. FIGS. 56-57 depict selection of various cell populations following incubation with XENP22821 by FACS. Lymphocytes were first gated on the basis of side scatter (SSC) and forward scatter (FSC) (FIG. 56A). Lymphocytes were then gated based on CD3 expression (FIG. 56B). Cells negative for CD3 expression were further gated based on CD16 expression to identify NK cells (CD16+) (FIG. 56C). CD3+ T cells were further gated based on CD4 and CD8 expression to identify CD4+ T cells, CD8+ T cells, and γδ T cells (CD3+CD4−CD8−) (FIG. 57A). The CD4+ and CD8+ T cells were gated for CD45RA expression as shown respectively in FIGS. 57B-C. Finally, the proliferation of the various cell populations were determined based on percentage Ki67 expression, and the data are shown in FIGS. 59A-D. NK and CD8+ T cells are more sensitive than CD4+ T cells to IL-15/Rα-Fc fusion proteins, and as above, proliferative activity varied depending on the particular engineered substitutions. FIG. 59D shows the fold change in EC50 of various IL-15/Rα-Fc fusion proteins relative to control XENP20818. FIGS. 58A and B further depict the activation of lymphocytes following treatment with IL-15/Rα-Fc fusion proteins by gating for the expression of CD69 and CD25 (T cell activation markers) before and after incubation of PBMCs with XENP22821.
  • In a third experiment, additional variant IL-15/Rα-Fc fusion proteins were incubated with human PBMCs for 3 days at 37° C. Following incubation, PBMCs were stained with anti-CD3-FITC (OKT3), anti-CD4-SB600 (SK-3), anti-CD8-PerCP/Cy5.5 (RPA-T8), anti-CD45RA-APC/Cγ7 (HI100), anti-CD16-eFluor450 (CB16), anti-CD25-PE (M-A251), and anti-Ki67-APC (Ki-67) to mark various cell populations and analyzed by FACS as generally described in Example 1D. Proliferation of CD8+(CD45RA−) T cells, CD4+(CD45RA−) T cells, γδ T cells, and NK cells as indicated by Ki67 expression are depicted in FIGS. 60A-D.
  • In a fourth experiment, human PBMCs were incubated with the additional IL-15/Rα-Fc variants at the indicated concentrations for 3 days. Following incubation, PBMCs were stained with anti-CD3-FITC (OKT3), anti-CD4 (SB600), anti-CD8-PerCP/Cy5.5 (RPA-T8), anti-CD16-eFluor450 (CB16), anti-CD25-PE (M-A251), anti-CD45RA-APC/Cγ7 (HI100), and anti-Ki67-APC (Ki67) and analyzed by FACS as generally described in Example 1D. Percentage of Ki67 on CD8+ T cells, CD4+ T cells and NK cells following treatment are depicted in FIG. 61.
  • In a fifth experiment, variant IL-15/Rα-Fc fusion proteins were incubated with human PBMCs for 3 days at 37° C. Following incubation, cells were stained with anti-CD3-PE (OKT3), anti-CD4-FITC (RPA-T4), anti-CD8α-BV510 (SK1), anti-CD8β-APC (2ST8.5H7), anti-CD16-BV421 (3G8), anti-CD25-PerCP/Cy5.5 (M-A251), anti-CD45RA-APC/Cγ7 (HI100), anti-CD56-BV605 (NCAM16.2), and anti-Ki67-PE/Cγ7 (Ki-67) and analyzed by FACS as generally described in Example 1D. Percentage of Ki67 on CD8+ T cells, CD4+ T cells, γδ T cells, and NK cells are depicted in FIGS. 62A-E.
  • In a sixth experiment, variant IL-15/Rα-Fc fusion proteins were incubated with human PBMCs for 3 days at 37° C. Following incubation, cells were stained with anti-CD3-PE (OKT3), anti-CD4-FITC (RPA-T4), anti-CD8α-BV510 (SK1), anti-CD8β-APC (SIDI8BEE), anti-CD16-BV421 (3G8), anti-CD25-PerCP/Cy5.5 (M-A251), anti-CD45RA-APC/Cγ7 (HI100), anti-CD56-BV605 (NCAM16.2), and anti-Ki67-PE/Cγ7 (Ki-67) and analyzed by FACS as generally described in Example 1D. Percentage of Ki67 on CD8+ T cells, CD4+ T cells, γδ T cells, and NK cells are depicted in FIGS. 63A-E.
    • C. Example 3C: In Vitro Activity of Variant scIL-15/Rα-Fc Fusion Proteins Engineered for Decreased Potency with Different Linker Lengths Between IL-15 and IL-15Rα
  • IL-15/Rα-Fc fusion proteins with some of the substitutions described above, further with different lengths linkers between IL-15 and IL-15Rα (as depicted in Table 3) were incubated with human PBMCs at the indicated concentrations for 3 days at 37° C. Following incubation, PBMCs were stained with anti-CD3-PE (OKT3), anti-CD4-FITC (RPA-T4), anti-CD8-APC (RPA-T8), anti-CD16-BV605 (3G8), anti-CD25-PerCP/Cy5.5 (M-A251), anti-CD45RA-APC/Fire750 (HI100) and anti-Ki67-PE/Cγ7 (Ki-67) and analyzed by FACS as generally described in Example 1D. Percentage Ki67 on CD8+ T cells, CD4+ T cells, γδ T cells and NK (CD16+) cells are depicted in FIGS. 64A-D. The data show that the ncIL-15/Rα-Fc fusion protein XENP21479 is the most potent inducer of CD8+ T cell, CD4+ T cell, NK (CD16+) cell, and γδ T cell proliferation. Each of the scIL-15/Rα-Fc fusion proteins were less potent than XENP21479 in inducing proliferation, but differences were dependent on both the linker length, as well as the particular engineered substitutions.
  • TABLE 3
    Linker between IL- Mutation
    XENP Format
    15 and IL-15Rα
    24013 scIL-15/Rα-Fc (GGGGS)5 D61N
    (SEQ ID NO: 18)
    21014 scIL-15/Rα-Fc (GGGGS)5 N65D
    (SEQ ID NO: 18)
    24015 scIL-15/Rα-Fc (GGGGS)5 Q108E
    (SEQ ID NO: 18)
    24475 scIL-15/Rα-Fc (GGGGS)6 Q108E
    (SEQ ID NO: 19)
    24476 scIL-15/Rα-Fc (GGGGS)6 N4D/N65D
    (SEQ ID NO: 19)
    24478 scIL-15/Rα-Fc (GGGGS)7 Q108E
    (SEQ ID NO: 20)
    24479 scIL-15/Rα-Fc (GGGGS)7 N4D/N65D
    (SEQ ID NO: 20)
    24481 scIL-15/Rα-Fc 30AA-linker Q108E
    • D. Example 3D: In Vitro Activity of Variant IL-15/Rα-Fc Fusion Proteins Engineered for Decreased Potency in Additional Formats
  • Variant IL-15/Rα-Fc fusion proteins in different formats (as depicted in Table 4) were incubated with human PBMCs at the indicated concentrations for 3 days at 37° C. Following incubation, PBMCs were stained with anti-CD3-PE (OKT3), anti-CD4-FITC (RPA-T4), anti-CD8-APC (RPA-T8), anti-CD16-BV605 (3G8), anti-CD25-PerCP/Cy5.5 (M-A251), anti-CD45RA-APC/Fire750 (HI100) and anti-Ki67-PE/Cγ7 (Ki-67) and analyzed by FACS as generally described in Example 1D. Percentage Ki67 on CD8+ T cells, CD4+ T cells, γδ T cells and NK (CD16+) cells are respectively depicted in FIGS. 65A-D. As above, the data show that the ncIL-15/Rα-Fc fusion protein XENP21479 is the most potent inducer of CD8+ T cell, CD4+ T cell, NK (CD16+) cell, and γδ T cell proliferation. Notably, introduction of Q108E substitution into the ncIL-15/Rα-Fc format (XENP24349) drastically reduces its proliferative activity in comparison to wildtype (XENP21479).
  • TABLE 4
    XENP Format Mutation
    24351 Bivalent IL-15/Rα-Fc N4D/N65D
    21479 ncIL-15/Rα-Fc WT
    23472 dsIL-15/Rα-Fc N65D
    23557 IL-15/Rα-heteroFc N4D/N65D
    24349 ncIL-15/Rα-Fc Q108E
    • E. Example 3E: STATS Phosphorylation by Variant IL-15/Rα-Fc Fusion Proteins
  • Transpresentation of IL-15 and IL-15Rα drives phosphorylation of STATS and subsequent proliferation of NK and T cells (CD4+ and CD8+). Accordingly, CD8+ and CD4+ T cells were analyzed for STATS phosphorylation following 15 minutes incubation with the indicated IL-15/Rα-Fc test articles. PBMCs were stained with anti-CD4-BV421 (RPA-T4) and anti-CD8-A700 (SK1) for 30-45 minutes at room temperature. Cells were washed and incubated with pre-chilled (−20° C.) 90% methanol for 20-60 minutes. After incubation with methanol, cells were washed again and stained with anti-CD45RA-BV510 (HI100), anti-CD27-BV605 (L128), anti-CD25-PE (M-A251), anti-pSTAT5-Alexa647 (pY687), and anti-FoxP3-Alexa488 (259D) to mark various cell populations and STATS phosphorylation. FIGS. 66A-D depict selection of various cell populations following incubation with XENP22821. Lymphocytes were first gated on the basis of SSC and FSC (FIG. 66A). The lymphocytes were then gated based on CD4 and CD8 expression to identify CD4+ and CD8+ T cells (FIG. 66B). The CD4+ and CD8+ T cells were then further gated based on CD45RA and CD27 expression to identify further subpopulations depicted respectively in FIGS. 66C-D. Finally, the phosphorylation of STATS in the various cell populations was determined, and the data are shown in FIGS. 67A-C. STATS phosphorylation on T cells was induced in a dose dependent manner and also varied depending on the particular engineered substitutions. FIG. 67C shows the fold change in EC50 for STATS phosphorylation of the variant IL-15/Rα-Fc fusion proteins relative to control.
    • F. Example 3F: PK of Variant IL-15/Rα-Fc Fusion Proteins Engineered for Lower Potency
  • In order to investigate if IL-15/Rα-Fc fusion proteins engineered for reduced potency had improved half-life and PK, we examined these variants in a PK study in C57BL/6 mice. Two cohorts of mice (5 mice per test article per cohort) were dosed with 0.1 mg/kg of the indicated test articles via IV-TV on Day 0. Serum was collected 60 minutes after dosing and then on Days 2, 4, and 7 for Cohort 1 and Days 1, 3, and 8 for Cohort 2. Serum levels of IL-15/Rα-Fc fusion proteins were determined using anti-IL-15 and anti-IL-15Rα antibodies in a sandwich ELISA. The results are depicted in FIG. 68. FIG. 69 depicts the correlation between potency and half-life of the test articles.
  • As predicted, variants with reduced potency demonstrated substantially longer half-life. Notably, half-life was improved up to almost 9 days (see XENP22821 and XENP22822), as compared to 0.5 days for the wild-type control XENP20818.
    • G. Example 3G: Variant IL-15/Rα-Fc Fusion Proteins Enhance Engraftment and Disease Activity in Human PBMC-Engrafted NSG Mice
  • The variant IL-15/Rα-Fc fusion proteins were evaluated in a GVHD models conducted in female NSG immunodeficient mice as generally described in Example 1F.
  • In a first study, 10 million human PBMCs were engrafted into NSG mice via IV-OSP on Day 0 followed by dosing of IL-15/Rα-Fc fusion proteins at the indicated concentrations on Day 1. CD45+ proliferation correlates with decreased body weight (as shown in FIG. 70), and so CD45+ cells were measured on Days 4 and 8 as an indicator of disease activity in this study (FIG. 71A-B). The data show that each of the IL-15/Rα-Fc fusion proteins enhance proliferation of CD45+ cells in human PBMC-engrafted NSG mice as compared to control (PBS).
  • In another study, 10 million human PBMCs were engrafted into NSG mice via IV-OSP on Day 0 followed by dosing with IL-15/Rα-Fc fusion proteins at the indicated concentrations on Day 1. IFNγ levels and human NK cell, CD45+ lymphocytes, CD8+ T cell and CD4+ T cell counts were measured at days 4, 7, and 11 (FIGS. 72-76). The data show that the variant IL-15/Rα-Fc fusion proteins enhance IFNγ secretion and proliferation of human NK cell and T cells in a dose dependent manner. Notably, the observed activity is correlated to the in vitro potency of each variant.
  • In yet another study, 10 million human PBMCs were engrafted into NSG mice via IV-OSP on Day −8 followed by dosing with the indicated test articles at the indicated concentrations on Day 0. IFNγ levels and human NK cell, CD45+ lymphocytes, CD8+ T cell and CD4+ T cell counts were measured at Days 4, 7, and 11. FIG. 77 depicts IFNγ levels in mice serum on Days 4, 7, and 11. FIGS. 78A-C respectively depict CD8+ T cell counts on Days 4, 7, and 11. FIGS. 79A-C respectively depict CD4+ T cell counts on Days 4, 7, and 11. FIGS. 80A-C respectively depict CD45+ cell counts on Days 4, 7, and 11. Body weight of the mice were also measured on Days 4, 7, and 11 and depicted as percentage of initial body weight in FIG. 81.
    • H. Example 3H: IL-15/Rα-Fc Fusion Proteins are Active in Cynomolgus Monkeys
  • Cynomolgus monkeys were administered a single intravenous (i.v.) dose of XENP20818 (n=3), XENP22819 (n=1), XENP22821 (n=3), XENP22822 (n=3), XENP22834 (n=3), and XENP23343 (n=3). Lymphocyte counts (FIGS. 82, 84, 86, 88, 90, and 92) and proliferation (FIGS. 83, 85, 87, 89, 91, and 93) were assessed over time. The data show significant changes in CD56+ NK cells (FIG. 86A), CD16+ NK cells (FIG. 86B), γδ T cells (FIG. 86C), CD8+ T cells (CD45RA+) (FIG. 86D), CD8+ T cells (CD45RA−) (FIG. 86E), and CD4+ T cells (FIG. 86F) following treatment with XENP22821 peaking at Day 6 with subsequent recovery and normalizing. Finally, the Figures show significant expression of Ki67 on CD56+ NK cells (FIG. 87A), CD16+ NK cells (FIG. 87B), CD8+ T cells (CD45RA+) (FIG. 87C), CD8+ T cells (CD45RA−) (FIG. 87D), and CD4+ T cells (FIG. 87E) indicating proliferative activity following treatment with XENP22821. Similar proliferative activity was observed following treatment with XENP20818, XENP22819, XENP22822, and XENP23343, demonstrating that most of the IL-15/Rα-Fc fusion proteins of the invention are active in cynomolgus monkeys.
    • XIII. Example 4: IL-15/Rα-Fc Fusion Proteins Engineered with Xtend Fe
  • IL-15/Rα-Fc variants engineered for decreased potency as described above were further engineered with Xtend Fc (hereon referred to as “IL-15/Rα-XtendFc” fusion proteins) to further increase half-life by subcloning plasmids coding for IL-15 and/or IL-15Rα(sushi) into a pTT5 expression vector containing Fc fusion partners with M428L/N434S substitutions (see FIG. 8, Backbone 11). Sequences for illustrative IL-15/Rα-XtendFc are depicted in FIGS. 94-96 (see also Table 5).
  • TABLE 5
    XENP Format Mutation
    24306 IL-15/Rα-heteroFc D30N/E64Q/N65D
    24341 IL-15/Rα-heteroFc N1D/N65D
    24301 IL-15/Rα-heteroFc N4D/N65D
    24383 ncIL-15/Rα-Fc Q108E
    24346 Bivalent IL-15/Rα-Fc Q108E
    • A. Example 4A: In Vitro Activity of Additional IL-15/Rα-Fc Variants
  • Human PBMCs were incubated with the IL-15/Rα-XtendFc variants at the indicated concentrations for 3 days. Following incubation, PBMCs were stained with anti-CD3-FITC (OKT3), anti-CD4-PE (RPA-T4), anti-CD8-eFluor450 (SK-1), anti-CD45RA−PE/Cγ7 (HI100), anti-CD16-PerCP/Cy5.5 (3G8), anti-CD25-APC/Fire750 (M-A251), and anti-Ki67-APC (Ki-67) to mark various cell populations and analyzed by FACS as generally described in Example 1D. Proliferation of CD8+ T cells, CD4+ T cells and NK cells following treatment as indicated by Ki67 expression are depicted in FIG. 97.
  • As the Xtend variants were selected for investigating activity in cynomolgus monkeys, their ability to proliferate cynomolgus T cells was investigated. Cyno PBMCs were incubated with selected test articles at the indicated concentrations for 3 days. Following incubation, PBMCs were stained with anti-CD3-FITC (SP34), anti-CD4-PE/Cγ7 (OKT4), anti-CD8-APC (RPA-T8), anti-CD45RA-APC/Fire750 (HI100), anti-CD16-BV605 (3G8), anti-CD25-BV421 (M-A251), and anti-Ki67-PerCP/Cy5.5 (Ki-67) to mark various cell populations and analyzed by FACS as generally described in Example 1D. Proliferation of CD8+ T cells, CD4+ T cells and NK cells following treatment as indicated by Ki67 expression are depicted in FIG. 98.
    • B. Example 4B: In Vivo Activity of IL-15/Rα-XtendFc Variants in a GVHD Model
  • 10 million human PBMCs were engrafted into NSG mice via IV-OSP on Day −7 followed by dosing with the indicated test articles (0.3 mg/kg) on Day 0. Whole blood was collected on Day 4 and 7, and mice were sacrificed on Days 5-8 or 11 for their spleens to measure CD4+ T cell, CD8+ T cell, and CD45+ cell counts using FACS. FIGS. 99A-C respectively depict CD4+ T cell counts on Days 4 and 7 in whole blood and Day 8 in spleen. FIGS. 100A-C, respectively depict CD8+ T cell counts on Days 4 and 7 in whole blood and Day 8 in spleen. FIGS. 101A-C respectively depict CD4+ T cell counts on Days 4 and 7 in whole blood and Day 8 in spleen. Body weight of the mice were also measured on Day −8, −2, 1, 5, 8 and 11 as depicted in FIGS. 102A-102F. Each point represents one female NSG mouse.
    • C. Example 4C: In Vivo Activity of Variant IL-15/Rα-XtendFc Fusion Proteins in Cynomolgus Monkeys
  • Monkeys (n=3) were administered a single intravenous (i.v.) dose of indicated test articles (Day 1) and blood was collected daily. CD8+ T cell, CD4+ T cell and NK cell counts in blood were assessed over time as depicted respectively in FIGS. 103A-C. Each point is an average of 3 cynomolgus monkeys. The data show that each of the variants were active in proliferating immune cells indicating that the IL-15/Rα-Fc fusion proteins of the invention could be useful as therapeutics for cancer in humans.
  • The examples set forth above are provided to give those of ordinary skill in the art a complete disclosure and description of how to make and use the embodiments of the compositions, systems and methods of the invention, and are not intended to limit the scope of what the inventors regard as their invention. Modifications of the above-described modes for carrying out the invention that are obvious to persons of skill in the art are intended to be within the scope of the following claims. All patents and publications mentioned in the specification are indicative of the levels of skill of those skilled in the art to which the invention pertains. All references cited in this disclosure are incorporated by reference to the same extent as if each reference had been incorporated by reference in its entirety individually.
  • All headings and section designations are used for clarity and reference purposes only and are not to be considered limiting in any way. For example, those of skill in the art will appreciate the usefulness of combining various aspects from different headings and sections as appropriate according to the spirit and scope of the invention described herein.
  • All references cited herein are hereby incorporated by reference herein in their entireties and for all purposes to the same extent as if each individual publication or patent or patent application was specifically and individually indicated to be incorporated by reference in its entirety for all purposes.
  • Many modifications and variations of this application can be made without departing from its spirit and scope, as will be apparent to those skilled in the art. The specific embodiments and examples described herein are offered by way of example only, and the application is to be limited only by the terms of the appended claims, along with the full scope of equivalents to which the claims are entitled.

Claims (81)

What is claimed is:
1. A heterodimeric protein comprising:
a) a first fusion protein comprising a first protein domain and a first Fc domain, wherein said first protein domain is covalently attached to the N-terminus of said first Fc domain using a first domain linker;
b) a second fusion protein comprising a second protein domain and a second Fc domain, wherein said second protein domain is covalently attached to the N-terminus of said Fc domain using a seconddomain linker;
wherein said first and said second Fc domains have a set of amino acid substitutions selected from the group consisting of S267K/L368D/K370S: S267K/LS364K/E357Q; S364K/E357Q: L368D/K370S; L368D/K370S: S364K; L368E/K370S: S364K; T411T/E360E/Q362E: D401K; L368D/K370S: S364K/E357L and K370S: S364K/E357Q, according to EU numbering and wherein said first protein domain comprises an IL15 protein and said second protein domain comprises an IL15Rα protein.
2. The heterodimeric protein according to claim 1, wherein said first and/or said second Fc domains have an additional set of amino acid substitutions comprising Q295E/N384D/Q418E/N421D, according to EU numbering.
3. The heterodimeric protein according to claim 1 or 2, wherein said first and/or said second Fc domains have an additional set of amino acid substitutions consisting of G236R/L328R, E233P/L234V/L235A/G236del/S239K, E233P/L234V/L235A/G236del/S267K, E233P/L234V/L235A/G236del/S239K/A327G, E233P/L234V/L235A/G236del/S267K/A327G and E233P/L234V/L235A/G236del, according to EU numbering.
4. The heterodimeric protein according to any one of claims 1 to 3, wherein said IL15 protein has a polypeptide sequence selected from the group consisting of SEQ ID NO:1 (full-length human IL15) and SEQ ID NO:2 (truncated human IL15), and said IL15Rα protein has a polypeptide sequence selected from the group consisting of SEQ ID NO:3 (full-length human IL15Rα) and SEQ ID NO:4 (sushi domain of human IL15Rα).
5. The heterodimeric protein according to any one of claims 1 to 4, wherein said IL15 protein has one or more amino acid substitutions selected from the group consisting of N1D, N4D, D8N, D30N, D61N, E64Q, N65D, and Q108E.
6. The heterodimeric protein according to any one of claims 1 to 5, wherein said IL15 protein and said IL15Rα protein have a set of amino acid substitutions or additions selected from the group consisting of E87C: D96/P97/C98; E87C: D96/C97/A98; V49C: S40C; L52C: S40C; E89C: K34C; Q48C: G38C; E53C: L42C; C42S: A37C; and L45C: A37C, respectively.
7. The heterodimeric protein according to any one of claims 1 to 6, wherein said heterodimeric protein comprises:
i) said first fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP15902) and said second fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP15908),
ii) said first fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP15902) and said second fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP15909),
iii) said first fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP16479) and said second fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP15908),
iv) said first fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP15902) and said second fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP16481),
v) said first fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP15902) and said second fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP16483),
vi) said first fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP16479) and said second fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP15909),
vii) said first fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP16479) and said second fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP16481),
viii) said first fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP16480) and said second fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP16482),
ix) said first fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP16480) and said second fusion protein h having as a polypeptide sequence of SEQ ID NO:XX (XENP15909),
x) said first fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP17064) and said second fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP17038),
xi) said first fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP17064) and said second fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP17040), or
xii) said first fusion protein having a polypeptide sequence of SEQ ID NO:XX (17062) and said second fusion protein having a polypeptide sequence of SEQ ID NO:XX (17044),
xiii) said first fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP17686) and said second fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP15908),
xiv) said first fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP17687) and said second fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP15908),
xv) said first fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP17688) and said second fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP15908),
xvi) said first fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP17689) and said second fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP15908),
xvii) said first fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP17690) and said second fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP15908),
xviii) said first fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP17691) and said second fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP15908),
xix) said first fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP17692) and said second fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP15908),
xx) said first fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP17693) and said second fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP15908),
xxi) said first fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP17694) and said second fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP15908),
xxii) said first fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP17695) and said second fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP15908),
xxiii) said first fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP17696) and said second fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP15908),
xxiv) said first fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP17697) and said second fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP15908),
xxv) said first fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP17698) and said second fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP15908),
xxvi) said first fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP17699) and said second fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP15908),
xxvii) said first fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP17701) and said second fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP15908),
xxviii) said first fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP17691) and said second fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP15908),
xxix) said first fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP17702) and said second fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP15908),
xxx) said first fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP17703) and said second fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP15908),
xxxi) said first fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP17704) and said second fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP15908),
xxxii) said first fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP17705) and said second fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP15908),
xxxiii) said first fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP18295) and said second fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP17761),
xxxiv) said first fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP18783) and said second fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP15908),
xxxv) said first fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP18784) and said second fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP15908),
xxxvi) said first fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP18786) and said second fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP15908),
xxxvii) said first fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP18788) and said second fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP15908),
xxxviii) said first fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP19242) and said second fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP16481), or
xxxix) said first fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP19243) and said second fusion protein having a polypeptide sequence of SEQ ID NO:XX (XENP16481).
8. The heterodimeric protein according to any one of claims 1 to 7, wherein said first protein domain is covalently attached to the N-terminus of said first Fc domain directly and without using said first domain linker and/or said second protein domain is covalently attached to the N-terminus of said second Fc domain directly and without using said second domain linker.
9. The heterodimeric protein according to any one of claims 1 to 6, wherein said heterodimeric protein is selected from the group consisting of XENP20818, XENP20819, XENP21471, XENP21472, XENP21473, XENP21474, XENP21475, XENP21476, XENP21477, XENP22013, XENP22815, XENP22816, XENP22817, XENP22818, XENP22819, XENP22820, XENP22821, XENP22822, XENP22823, XENP22824, XENP22825, XENP22826, XENP22827, XENP22828, XENP22829, XENP22830, XENP22831, XENP22832, XENP22833, XENP22834, XENP23343, XENP23504, XENP23554, XENP23555, XENP23557, XENP23559, XENP24019, XENP24020, XENP24045, XENP24051, XENP24052, XENP24113, XENP24301, XENP24306, and XENP24341.
10. A nucleic acid composition encoding the first fusion protein of any one of claims 1 to 9.
11. A nucleic acid composition encoding the second fusion protein of any one of claims 1 to 10.
12. An expression vector comprising the nucleic acid composition of claim 10.
13. An expression vector comprising the nucleic acid composition of claim 11.
14. The expression vector of claim 13 further comprising the nucleic acid composition of claim 10.
15. A host cell comprising one or more expression vectors of any one of claims 12 to 14.
16. A heterodimeric protein comprising:
a) a fusion protein comprising a first protein domain, a second protein domain, and a first Fc domain, wherein said first protein domain is covalently attached to the N-terminus of said second protein domain using a first domain linker, and wherein said second protein domain is covalently attached to the N-terminus of said first Fc domain using a second domain linker;
b) a second Fc domain;
wherein said first and said second Fc domains have a set of amino acid substitutions selected from the group consisting of S267K/L368D/K370S: S267K/LS364K/E357Q; S364K/E357Q: L368D/K370S; L368D/K370S: S364K; L368E/K370S: S364K; T411T/E360E/Q362E: D401K; L368D/K370S: S364K/E357L and K370S: S364K/E357Q, according to EU numbering and wherein said first protein domain comprises an IL15Rα protein and said second protein domain comprises an IL15 protein.
17. The heterodimeric protein according to claim 16, wherein said first and/or said second Fc domains have an additional set of amino acid substitutions comprising Q295E/N384D/Q418E/N421D, according to EU numbering.
18. The heterodimeric protein according to claim 16 or 17, wherein said first and/or said second Fc domains have an additional set of amino acid substitutions consisting of G236R/L328R, E233P/L234V/L235A/G236del/S239K, E233P/L234V/L235A/G236del/S267K, E233P/L234V/L235A/G236del/S239K/A327G, E233P/L234V/L235A/G236del/S267K/A327G and E233P/L234V/L235A/G236del, according to EU numbering.
19. The heterodimeric protein according to any one of claims 16 to 18, wherein said IL15 protein has a polypeptide sequence selected from the group consisting of SEQ ID NO:1 (full-length human IL15) and SEQ ID NO:2 (truncated human IL15), and said IL15Rα protein has a polypeptide sequence selected from the group consisting of SEQ ID NO:3 (full-length human IL15Rα) and SEQ ID NO:4 (sushi domain of human IL15Rα).
20. The heterodimeric protein according to any one of claims 16 to 19, wherein said IL15 protein and said IL15Rα protein have a set of amino acid substitutions selected from the group consisting of E87C: D96/P97/C98; E87C: D96/C97/A98; V49C: 540C; L52C: 540C; E89C: K34C; Q48C: G38C; E53C: L42C; C42S: A37C; and L45C: A37C, respectively.
21. The heterodimeric protein according to any one of claims 16 to 20, wherein said first fusion protein has a polypeptide sequence of SEQ ID NO:XX (16478) and said Fc domain has a polypeptide sequence of SEQ ID NO:XX (8924).
22. The heterodimeric protein according to any one of claims 16 to 21, wherein said heterodimeric protein is XENP21478.
23. A nucleic acid composition encoding the fusion protein of any one of claims 16 to 22.
24. A nucleic acid composition encoding the second Fc domain of any one of claims 16 to 22.
25. An expression vector comprising the nucleic acid composition of claim 23.
26. An expression vector comprising the nucleic acid composition of claim 24.
27. The expression vector of claim 26, further comprising the nucleic acid composition of claim 23.
28. A host cell comprising one or two expression vectors of any one of claims 25 to 27.
29. A heterodimeric protein comprising:
a) a fusion protein comprising a first protein domain and a first Fc domain, wherein said first protein domain is covalently attached to the N-terminus of said first Fc domain using a domain linker;
b) a second Fc domain; and
c) a second protein domain noncovalently attached to said first protein domain;
wherein said first and said second Fc domains have a set of amino acid substitutions selected from the group consisting of S267K/L368D/K370S: S267K/LS364K/E357Q; S364K/E357Q: L368D/K370S; L368D/K370S: S364K; L368E/K370S: S364K; T411T/E360E/Q362E: D401K; L368D/K370S: S364K/E357L and K370S: S364K/E357Q, according to EU numbering and wherein said first protein domain comprises an IL15Rα and said second protein domain comprises an IL15 protein.
30. The heterodimeric protein according to claim 29, wherein said first and/or said second Fc domains have an additional set of amino acid substitutions comprising Q295E/N384D/Q418E/N421D, according to EU numbering.
31. The heterodimeric protein according to claim 29 or 30, wherein said first and/or said second Fc domains have an additional set of amino acid substitutions consisting of G236R/L328R, E233P/L234V/L235A/G236del/S239K, E233P/L234V/L235A/G236del/S267K, E233P/L234V/L235A/G236del/S239K/A327G, E233P/L234V/L235A/G236del/S267K/A327G and E233P/L234V/L235A/G236del, according to EU numbering.
32. The heterodimeric protein according to any one of claims 29 to 31, wherein said IL15 protein has a polypeptide sequence selected from the group consisting of SEQ ID NO:1 (full-length human IL15) and SEQ ID NO:2 (truncated human IL15), and said IL15Rα protein has a polypeptide sequence selected from the group consisting of SEQ ID NO:3 (full-length human IL15Rα) and SEQ ID NO:4 (sushi domain of human IL15Rα).
33. The heterodimeric protein according to any one of claims 29 to 32, wherein said IL15 protein and said IL15Rα protein have a set of amino acid substitutions selected from the group consisting of E87C: D96/P97/C98; E87C: D96/C97/A98; V49C: 540C; L52C: S40C; E89C: K34C; Q48C: G38C; E53C: L42C; C42S: A37C; and L45C: A37C, respectively.
34. The heterodimeric protein according to any one of claims 29 to 33, wherein said fusion protein has a polypeptide sequence selected from the group consisting of SEQ ID NO:XX (16481), SEQ ID NO:XX (17034), SEQ ID NO:XX (17038), SEQ ID NO:XX (17036), SEQ ID NO:XX (17039), SEQ ID NO:XX (17040), SEQ ID NO:XX (17044), SEQ ID NO:XX (17041), SEQ ID NO:XX (17043), SEQ ID NO:XX (17045), SEQ ID NO:XX (17042), SEQ ID NO:XX (15908), and SEQ ID NO:XX (17603).
35. The heterodimeric protein according to any one of claims 29 to 34, wherein said second Fc domain has a polypeptide sequence of SEQ ID NO:XX (8793) or SEQ ID NO:XX (8927).
36. The heterodimeric protein according to any one of claims 29 to 35, wherein said second protein domain has a polypeptide sequence selected from the group consisting of SEQ ID NO:XX (16484), SEQ ID NO:XX (17074), SEQ ID NO:XX (17071), SEQ ID NO:XX (17072), SEQ ID NO:XX (17075), SEQ ID NO:XX (17070), SEQ ID NO:XX (17073), and SEQ ID NO:XX (17083).
37. The heterodimeric protein according to any one of claims 29 to 36, wherein said heterodimer protein comprises
i) said fusion protein having a polypeptide sequence of SEQ ID NO:XX (16481), said second Fc domain having a polypeptide sequence of SEQ ID NO:XX (8793), and a second protein domain having a polypeptide sequence of SEQ ID NO:XX (16484);
ii) said fusion protein having a polypeptide sequence of SEQ ID NO:XX (17034), said second Fc domain having a polypeptide sequence of SEQ ID NO:XX (8793), and a second protein domain having a polypeptide sequence of SEQ ID NO:XX (16484);
iii) said fusion protein having a polypeptide sequence of SEQ ID NO:XX (17038), said second Fc domain having a polypeptide sequence of SEQ ID NO:XX (8793), and a second protein domain having a polypeptide sequence of SEQ ID NO:XX (16484);
iv) said fusion protein having a polypeptide sequence of SEQ ID NO:XX (17036), said second Fc domain having a polypeptide sequence of SEQ ID NO:XX (8793), and a second protein domain having a polypeptide sequence of SEQ ID NO:XX (16484);
v) said fusion protein having a polypeptide sequence of SEQ ID NO:XX (17038), said second Fc domain having a polypeptide sequence of SEQ ID NO:XX (8793), and a second protein domain having a polypeptide sequence of SEQ ID NO:XX (17074);
vi) said fusion protein having a polypeptide sequence of SEQ ID NO:XX (17039), said second Fc domain having a polypeptide sequence of SEQ ID NO:XX (8793), and a second protein domain having a polypeptide sequence of SEQ ID NO:XX (17074);
vii) said fusion protein having a polypeptide sequence of SEQ ID NO:XX (17040), said second Fc domain having a polypeptide sequence of SEQ ID NO:XX (8793), and a second protein domain having a polypeptide sequence of SEQ ID NO:XX (17074);
viii) said fusion protein having a polypeptide sequence of SEQ ID NO:XX (17044), said second Fc domain having a polypeptide sequence of SEQ ID NO:XX (8793), and a second protein domain having a polypeptide sequence of SEQ ID NO:XX (17071);
ix) said fusion protein having a polypeptide sequence of SEQ ID NO:XX (17044), said second Fc domain having a polypeptide sequence of SEQ ID NO:XX (8793), and a second protein domain having a polypeptide sequence of SEQ ID NO:XX (17072);
x) said fusion protein having a polypeptide sequence of SEQ ID NO:XX (17075), said second Fc domain having a polypeptide sequence of SEQ ID NO:XX (8793), and a second protein domain having a polypeptide sequence of SEQ ID NO:XX (17041);
xi) said fusion protein having a polypeptide sequence of SEQ ID NO:XX (17043), said second Fc domain having a polypeptide sequence of SEQ ID NO:XX (8793), and a second protein domain having a polypeptide sequence of SEQ ID NO:XX (17070);
xii) said fusion protein having a polypeptide sequence of SEQ ID NO:XX (17045), said second Fc domain having a polypeptide sequence of SEQ ID NO:XX (8793), and a second protein domain having a polypeptide sequence of SEQ ID NO:XX (17073);
xiii) said fusion protein having a polypeptide sequence of SEQ ID NO:XX (17042), said second Fc domain having a polypeptide sequence of SEQ ID NO:XX (8793), and a second protein domain having a polypeptide sequence of SEQ ID NO:XX (17083); or
xiv) said fusion protein having a polypeptide sequence of SEQ ID NO:XX (15908), said second Fc domain having a polypeptide sequence of SEQ ID NO:XX (8793), and a second protein domain having a polypeptide sequence of SEQ ID NO:XX (16484).
38. The heterodimeric protein according to any one of claims 29 to 37, wherein said heterodimer protein is selected from the group consisting of XENP21479, XENP22357, XENP22354, XENP22355, XENP22356, XENP22357, XENP22358, XENP22359, XENP22360, XENP22361, XENP22362, XENP22363, XENP22364, XENP22365, XENP22366, XENP22637, XENP24349, and XENP24383.
39. A nucleic acid composition encoding the fusion protein of any one of claims 29 to 38.
40. A nucleic acid composition encoding the second Fc domain of any one of claims 29 to 37.
41. An expression vector comprising the nucleic acid composition of claim 39.
42. An expression vector comprising the nucleic acid composition of claim 40.
43. The expression vector of claim 42, further comprising the nucleic acid composition of claim 39.
44. The expression vector of any one of claims 41 to 43, further comprising a nucleic acid composition encoding said second protein domain.
45. A host cell comprising one or more expression vectors of any one of claims 41 to 44.
46. A heterodimeric protein comprising:
a) a first fusion protein comprising a first protein domain and a first Fc domain, wherein said first protein domain is covalently attached to the N-terminus of said first Fc domain using a domain linker;
b) a second fusion protein comprising a second heavy chain comprising a second protein domain and a first second heavy chain comprising a second Fc domain, wherein said second protein domain is covalently attached to the C-terminus of said second Fc domain using a domain linker;
c) a third protein domain noncovalently attached to said first protein domain of said first fusion protein; and
d) a fourth protein domain noncovalently attached to said second protein domain of said second fusion protein,
wherein said first and said second Fc domains have a set of amino acid substitutions selected from the group consisting of S267K/L368D/K370S: S267K/LS364K/E357Q; S364K/E357Q: L368D/K370S; L368D/K370S: S364K; L368E/K370S: S364K; T411T/E360E/Q362E: D401K; L368D/K370S: S364K/E357L and K370S: S364K/E357Q, according to EU numbering and wherein said first protein domain and said second protein domain comprise an IL15Rα protein, and wherein said third protein domain and said fourth protein domain comprises an IL15 protein.
47. The heterodimeric protein according to claim 46, wherein said first and/or said second Fc domains have an additional set of amino acid substitutions comprising Q295E/N384D/Q418E/N421D, according to EU numbering.
48. The heterodimeric protein according to claim 46 or 47, wherein said first and/or said second Fc domains have an additional set of amino acid substitutions consisting of G236R/L328R, E233P/L234V/L235A/G236del/S239K, E233P/L234V/L235A/G236del/S267K, E233P/L234V/L235A/G236del/S239K/A327G, E233P/L234V/L235A/G236del/S267K/A327G and E233P/L234V/L235A/G236del, according to EU numbering.
49. The heterodimeric protein according to any one of claims 46 to 48, wherein said IL15 protein has a polypeptide sequence selected from the group consisting of SEQ ID NO:1 (full-length human IL15) and SEQ ID NO:2 (truncated human IL15), and said IL15Rα protein has a polypeptide sequence selected from the group consisting of SEQ ID NO:3 (full-length human IL15Rα) and SEQ ID NO:4 (sushi domain of human IL15Rα).
50. The heterodimeric protein according to any one of claims 46 to 49, wherein said IL15 protein and said IL15Rα protein have a set of amino acid substitutions selected from the group consisting of E87C: D96/P97/C98; E87C: D96/C97/A98; V49C: 540C; L52C: 540C; E89C: K34C; Q48C: G38C; E53C: L42C; C42S: A37C; and L45C: A37C, respectively.
51. The heterodimeric protein according to any one of claims 46 to 50, wherein said heterodimer protein comprises:
i) said first fusion protein has a polypeptide sequence of SEQ ID NO:XX (17023) said second fusion protein has a polypeptide sequence of SEQ ID NO:XX (17023), said third protein domain has a polypeptide sequence of SEQ ID NO:XX (16484), and said fourth protein domain has a polypeptide sequence of SEQ ID NO:XX (16484) or
ii) said first fusion protein has a polypeptide sequence of SEQ ID NO:XX (17581), said second fusion protein has a polypeptide sequence of SEQ ID NO:XX (17581), said third protein domain has a polypeptide sequence of SEQ ID NO:XX (17074), and said fourth protein domain has a polypeptide sequence of SEQ ID NO:XX (17074).
52. The heterodimeric protein according to any one of claims 46 to 51, wherein said heterodimeric protein is XENP21978, XENP22634, XENP24342, and XENP24306.
53. A nucleic acid composition encoding the first fusion protein of any one of claims 46 to 52.
54. A nucleic acid composition encoding the second fusion protein of any one of claims 46 to 53.
55. An expression vector comprising the nucleic acid composition of claim 39.
56. An expression vector comprising the nucleic acid composition of claim 55.
57. The expression vector of claim 56, further comprising the nucleic acid composition of claim 53.
58. The expression vector of any one of claims 55 to 57, further comprising a nucleic acid composition encoding said third protein domain.
59. The expression vector of any one of claims 55 to 58, further comprising a nucleic acid composition encoding said fourth protein domain.
60. A host cell comprising one or more expression vectors of any one of claims 56 to 59.
61. A heterodimeric protein comprising:
a) a first fusion protein comprising a first Fc domain and a first protein domain, wherein said first Fc domain is covalently attached to the N-terminus of said first protein domain using a domain linker;
b) a second Fc domain, and
c) a second protein domain noncovalently attached to said first protein domain of said first fusion protein;
wherein said first and said second Fc domains have a set of amino acid substitutions selected from the group consisting of S267K/L368D/K370S: S267K/LS364K/E357Q; S364K/E357Q: L368D/K370S; L368D/K370S: S364K; L368E/K370S: S364K; T411T/E360E/Q362E: D401K; L368D/K370S: S364K/E357L and K370S: S364K/E357Q, according to EU numbering and wherein said first protein domain comprises an IL15Rα protein and said second protein domain comprises an IL15 protein.
62. The heterodimeric protein according to claim 61, wherein said first and/or said second Fc domains have an additional set of amino acid substitutions comprising Q295E/N384D/Q418E/N421D, according to EU numbering.
63. The heterodimeric protein according to claim 61 or 62, wherein said first or said second Fc domains have an additional set of amino acid substitutions consisting of G236R/L328R, E233P/L234V/L235A/G236del/S239K, E233P/L234V/L235A/G236del/S267K, E233P/L234V/L235A/G236del/S239K/A327G, E233P/L234V/L235A/G236del/S267K/A327G and E233P/L234V/L235A/G236del, according to EU numbering.
64. The heterodimeric protein according to any one of claims 61 to 63, wherein said IL15 protein has a polypeptide sequence selected from the group consisting of SEQ ID NO:1 (full-length human IL15) and SEQ ID NO:2 (truncated human IL15), and said IL15Rα protein has a polypeptide sequence selected from the group consisting of SEQ ID NO:3 (full-length human IL15Rα) and SEQ ID NO:4 (sushi domain of human IL15Rα).
65. The heterodimeric protein according to any one of claims 61 to 64, wherein said IL15 protein and said IL15Rα protein have a set of amino acid substitutions selected from the group consisting of E87C: D96/P97/C98; E87C: D96/C97/A98; V49C: 540C; L52C: S40C; E89C: K34C; Q48C: G38C; E53C: L42C; C42S: A37C; and L45C: A37C, respectively.
66. The heterodimeric protein according to any one of claims 61 to 65, wherein heterodimeric protein comprises
i) said first fusion protein having a polypeptide sequence of SEQ ID NO: XX (17603), said second Fc domain having a polypeptide sequence of SEQ ID NO: XX (8927), and said second protein domain having a polypeptide sequence of SEQ ID NO: XX (16484); or
ii) said first fusion protein having a polypeptide sequence of SEQ ID NO: XX (17605), said second Fc domain having a polypeptide sequence of SEQ ID NO: XX (8927), and said second protein domain having a polypeptide sequence of SEQ ID NO: XX (17074).
67. The heterodimeric protein according to any one of claims 61 to 66, wherein said heterodimeric protein is XENP22637 or XENP22639.
68. A nucleic acid composition encoding the first fusion protein of any one of claims 61 to 67.
69. A nucleic acid composition encoding the second Fc domain of any one of claims 61 to 67.
70. An expression vector comprising the nucleic acid composition of claim 68.
71. An expression vector comprising the nucleic acid composition of claim 69.
72. The expression vector of claim 71, further comprising the nucleic acid composition of claim 68.
73. The expression vector of any one of claims 70 to 72, further comprising a nucleic acid composition encoding said second protein domain.
74. A host cell comprising one or more expression vectors of any one of claims 70 to 73.
75. A heterodimeric protein selected from the group consisting of XENP20818, XENP20819, XENP21471, XENP21472, XENP21473, XENP21474, XENP21475, XENP21476, XENP21477, XENP22013, XENP22815, XENP22816, XENP22817, XENP22818, XENP22819, XENP22820, XENP22821, XENP22822, XENP22823, XENP22824, XENP22825, XENP22826, XENP22827, XENP22828, XENP22829, XENP22830, XENP22831, XENP22832, XENP22833, XENP22834, XENP23343, XENP23504, XENP23554, XENP23555, XENP23557, XENP23559, XENP24019, XENP24020, XENP24045, XENP24051, XENP24052, XENP24113, XENP24301, XENP24306, XENP24341, XENP21478, XENP21479, XENP22357, XENP22354, XENP22355, XENP22356, XENP22357, XENP22358, XENP22359, XENP22360, XENP22361, XENP22362, XENP22363, XENP22364, XENP22365, XENP22366, XENP22637, XENP24349, XENP24383, XENP21978, XENP22634, XENP24342, XENP24306, XENP22637, and XENP22639.
76. A nucleic acid composition comprising one or more nucleic acids encoding a heterodimeric protein selected from the group consisting of XENP20818, XENP20819, XENP21471, XENP21472, XENP21473, XENP21474, XENP21475, XENP21476, XENP21477, XENP22013, XENP22815, XENP22816, XENP22817, XENP22818, XENP22819, XENP22820, XENP22821, XENP22822, XENP22823, XENP22824, XENP22825, XENP22826, XENP22827, XENP22828, XENP22829, XENP22830, XENP22831, XENP22832, XENP22833, XENP22834, XENP23343, XENP23504, XENP23554, XENP23555, XENP23557, XENP23559, XENP24019, XENP24020, XENP24045, XENP24051, XENP24052, XENP24113, XENP24301, XENP24306, XENP24341, XENP21478, XENP21479, XENP22357, XENP22354, XENP22355, XENP22356, XENP22357, XENP22358, XENP22359, XENP22360, XENP22361, XENP22362, XENP22363, XENP22364, XENP22365, XENP22366, XENP22637, XENP24349, XENP24383, XENP21978, XENP22634, XENP24342, XENP24306, XENP22637, and XENP22639.
77. An expression vector composition comprising one or more expression vectors each comprising a nucleic acid such that the one or more expression vectors encode a heterodimeric protein selected from the group consisting of XENP20818, XENP20819, XENP21471, XENP21472, XENP21473, XENP21474, XENP21475, XENP21476, XENP21477, XENP22013, XENP22815, XENP22816, XENP22817, XENP22818, XENP22819, XENP22820, XENP22821, XENP22822, XENP22823, XENP22824, XENP22825, XENP22826, XENP22827, XENP22828, XENP22829, XENP22830, XENP22831, XENP22832, XENP22833, XENP22834, XENP23343, XENP23504, XENP23554, XENP23555, XENP23557, XENP23559, XENP24019, XENP24020, XENP24045, XENP24051, XENP24052, XENP24113, XENP24301, XENP24306, XENP24341, XENP21478, XENP21479, XENP22357, XENP22354, XENP22355, XENP22356, XENP22357, XENP22358, XENP22359, XENP22360, XENP22361, XENP22362, XENP22363, XENP22364, XENP22365, XENP22366, XENP22637, XENP24349, XENP24383, XENP21978, XENP22634, XENP24342, XENP24306, XENP22637, and XENP22639.
78. A host cell comprising the nucleic acid composition of claim 76.
79. A host cell comprising the expression vector composition of claim 77.
80. A method of producing the heterodimeric protein of claim 75 comprising culturing the host cell claim 78 or 79 under suitable conditions wherein said heterodimeric protein is expressed, and recovering said protein.
81. A method of treating cancer in a patient in need thereof comprising administering a therapeutically effective amount of the heterodimeric protein of claim 75 to said patient.
US16/660,028 2016-10-14 2019-10-22 IL15/IL15Ralpha HETERODIMERIC Fc-FUSION PROTEINS Abandoned US20200040083A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US16/660,028 US20200040083A1 (en) 2016-10-14 2019-10-22 IL15/IL15Ralpha HETERODIMERIC Fc-FUSION PROTEINS
US17/692,755 US20220195048A1 (en) 2016-10-14 2022-03-11 IL15/IL15Ralpha HETERODIMERIC Fc-FUSION PROTEINS

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662408655P 2016-10-14 2016-10-14
US201662416087P 2016-11-01 2016-11-01
US201762443465P 2017-01-06 2017-01-06
US201762477926P 2017-03-28 2017-03-28
US15/785,401 US10501543B2 (en) 2016-10-14 2017-10-16 IL15/IL15Rα heterodimeric Fc-fusion proteins
US16/660,028 US20200040083A1 (en) 2016-10-14 2019-10-22 IL15/IL15Ralpha HETERODIMERIC Fc-FUSION PROTEINS

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US15/785,401 Continuation US10501543B2 (en) 2016-10-14 2017-10-16 IL15/IL15Rα heterodimeric Fc-fusion proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/692,755 Continuation US20220195048A1 (en) 2016-10-14 2022-03-11 IL15/IL15Ralpha HETERODIMERIC Fc-FUSION PROTEINS

Publications (1)

Publication Number Publication Date
US20200040083A1 true US20200040083A1 (en) 2020-02-06

Family

ID=60452718

Family Applications (6)

Application Number Title Priority Date Filing Date
US15/785,393 Active US10550185B2 (en) 2016-10-14 2017-10-16 Bispecific heterodimeric fusion proteins containing IL-15-IL-15Rα Fc-fusion proteins and PD-1 antibody fragments
US15/785,401 Active 2038-01-11 US10501543B2 (en) 2016-10-14 2017-10-16 IL15/IL15Rα heterodimeric Fc-fusion proteins
US16/660,028 Abandoned US20200040083A1 (en) 2016-10-14 2019-10-22 IL15/IL15Ralpha HETERODIMERIC Fc-FUSION PROTEINS
US16/718,072 Active 2038-09-23 US11584794B2 (en) 2016-10-14 2019-12-17 Bispecific heterodimeric fusion proteins containing IL-15-IL-15Ralpha Fc-fusion proteins and immune checkpoint antibody fragments
US17/692,755 Pending US20220195048A1 (en) 2016-10-14 2022-03-11 IL15/IL15Ralpha HETERODIMERIC Fc-FUSION PROTEINS
US18/065,462 Pending US20230220081A1 (en) 2016-10-14 2022-12-13 BISPECIFIC HETERODIMERIC FUSION PROTEINS CONTAINING IL-15 - IL-15Ralpha Fc-FUSION PROTEINS AND IMMUNE CHECKPOINT ANTIBODY FRAGMENTS

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US15/785,393 Active US10550185B2 (en) 2016-10-14 2017-10-16 Bispecific heterodimeric fusion proteins containing IL-15-IL-15Rα Fc-fusion proteins and PD-1 antibody fragments
US15/785,401 Active 2038-01-11 US10501543B2 (en) 2016-10-14 2017-10-16 IL15/IL15Rα heterodimeric Fc-fusion proteins

Family Applications After (3)

Application Number Title Priority Date Filing Date
US16/718,072 Active 2038-09-23 US11584794B2 (en) 2016-10-14 2019-12-17 Bispecific heterodimeric fusion proteins containing IL-15-IL-15Ralpha Fc-fusion proteins and immune checkpoint antibody fragments
US17/692,755 Pending US20220195048A1 (en) 2016-10-14 2022-03-11 IL15/IL15Ralpha HETERODIMERIC Fc-FUSION PROTEINS
US18/065,462 Pending US20230220081A1 (en) 2016-10-14 2022-12-13 BISPECIFIC HETERODIMERIC FUSION PROTEINS CONTAINING IL-15 - IL-15Ralpha Fc-FUSION PROTEINS AND IMMUNE CHECKPOINT ANTIBODY FRAGMENTS

Country Status (21)

Country Link
US (6) US10550185B2 (en)
EP (2) EP3526240A1 (en)
JP (4) JP7142630B2 (en)
KR (3) KR102562519B1 (en)
CN (2) CN110214147A (en)
AU (4) AU2017342559B2 (en)
BR (2) BR112019007288A2 (en)
CA (2) CA3039930A1 (en)
CL (4) CL2019001001A1 (en)
CO (2) CO2019003943A2 (en)
CR (2) CR20190227A (en)
IL (2) IL265997A (en)
MA (2) MA46533A (en)
MX (2) MX2019004327A (en)
PE (2) PE20191033A1 (en)
PH (2) PH12019500781A1 (en)
RU (1) RU2019114175A (en)
SA (1) SA519401562B1 (en)
SG (2) SG11201903304YA (en)
WO (2) WO2018071918A1 (en)
ZA (2) ZA201902383B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021188835A1 (en) * 2020-03-18 2021-09-23 City Of Hope Multivalent chemokine receptor binding complexes
US20220227867A1 (en) * 2020-12-24 2022-07-21 Xencor, Inc. ICOS TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND ICOS ANTIGEN BINDING DOMAINS

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
CA3211863A1 (en) 2013-01-14 2014-07-17 Xencor, Inc. Novel heterodimeric proteins
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
HUE049281T2 (en) * 2013-09-13 2020-09-28 Beigene Switzerland Gmbh Anti-pd1 antibodies and their use as therapeutics and diagnostics
US11040111B2 (en) * 2014-03-03 2021-06-22 Academia Sinica Bi-specific antibodies and uses thereof
AU2015237184B2 (en) 2014-03-28 2020-11-26 Xencor, Inc. Bispecific antibodies that bind to CD38 and CD3
WO2016000619A1 (en) 2014-07-03 2016-01-07 Beigene, Ltd. Anti-pd-l1 antibodies and their use as therapeutics and diagnostics
CU24597B1 (en) 2014-11-26 2022-05-11 Xencor Inc HETERODIMERIC BIESPECIFIC ANTIBODIES THAT BIND CD3 AND CD20
TN2017000222A1 (en) 2014-11-26 2018-10-19 Xencor Inc Heterodimeric antibodies that bind cd3 and cd38
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
LT3283508T (en) 2015-04-17 2021-07-12 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities
CA3007030A1 (en) 2015-12-07 2017-06-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and psma
SG11201808783XA (en) 2016-04-15 2018-11-29 Alpine Immune Sciences Inc Cd80 variant immunomodulatory proteins and uses thereof
CA3024509A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Mrna combination therapy for the treatment of cancer
WO2017218707A2 (en) * 2016-06-14 2017-12-21 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
KR20190020341A (en) 2016-06-28 2019-02-28 젠코어 인코포레이티드 Heterozygous antibodies that bind to somatostatin receptor 2
EP3481393B1 (en) 2016-07-05 2021-04-14 Beigene, Ltd. Combination of a pd-1 antagonist and a raf inhibitor for treating cancer
US11834490B2 (en) 2016-07-28 2023-12-05 Alpine Immune Sciences, Inc. CD112 variant immunomodulatory proteins and uses thereof
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
US10696722B2 (en) 2016-08-10 2020-06-30 Ajou University Industry-Academic Cooperation Foundation Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same
FI3500299T3 (en) 2016-08-19 2024-02-14 Beigene Switzerland Gmbh Combination of zanubrutinib with an anti-cd20 or an anti-pd-1 antibody for use in treating cancer
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
JP7142630B2 (en) 2016-10-14 2022-09-27 ゼンコア インコーポレイテッド IL15/IL15Rα heterodimeric FC-fusion protein
AR110414A1 (en) 2016-12-21 2019-03-27 Cephalon Inc ANTIBODIES THAT SPECIFICALLY JOIN HUMAN IL-15 AND USES OF THESE
US11555038B2 (en) 2017-01-25 2023-01-17 Beigene, Ltd. Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
NZ756395A (en) * 2017-03-16 2024-01-26 Alpine Immune Sciences Inc Cd80 variant immunomodulatory proteins and uses thereof
WO2018170023A1 (en) 2017-03-16 2018-09-20 Alpine Immune Sciences, Inc. Pd-l2 variant immunomodulatory proteins and uses thereof
JOP20190260A1 (en) 2017-05-02 2019-10-31 Merck Sharp & Dohme Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
US11597768B2 (en) 2017-06-26 2023-03-07 Beigene, Ltd. Immunotherapy for hepatocellular carcinoma
US11084863B2 (en) 2017-06-30 2021-08-10 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains
CA3198255A1 (en) 2017-10-10 2019-04-18 Alpine Immune Sciences, Inc. Ctla-4 variant immunomodulatory proteins and uses thereof
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
US11312770B2 (en) 2017-11-08 2022-04-26 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
US11786529B2 (en) 2017-11-29 2023-10-17 Beigene Switzerland Gmbh Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors
WO2019125732A1 (en) 2017-12-19 2019-06-27 Xencor, Inc. Engineered il-2 fc fusion proteins
SG11202007518RA (en) 2018-02-28 2020-09-29 Pfizer Il-15 variants and uses thereof
EP3773911A2 (en) 2018-04-04 2021-02-17 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
CA3097741A1 (en) * 2018-04-18 2019-10-24 Xencor, Inc. Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
CN113195534A (en) 2018-04-18 2021-07-30 Xencor股份有限公司 LAG-3 targeting heterodimeric fusion proteins comprising an IL-15/IL-15RA FC fusion protein and a LAG-3 antigen binding domain
TW202011984A (en) * 2018-04-18 2020-04-01 美商山可爾股份有限公司 Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof
JP2021521784A (en) 2018-04-18 2021-08-30 ゼンコア インコーポレイテッド PD-1 targeted heterodimer fusion proteins containing IL-15 / IL-15RaFc fusion proteins and PD-1 antigen binding domains and their use
CN110437339B (en) * 2018-05-04 2021-08-13 免疫靶向有限公司 Fusion protein type prodrug with interleukin 15 as active component
ES2955511T3 (en) 2018-05-14 2023-12-04 Werewolf Therapeutics Inc Activatable interleukin 2 polypeptides and methods of use thereof
AU2019271149B2 (en) 2018-05-14 2023-07-13 Werewolf Therapeutics, Inc. Activatable interleukin 12 polypeptides and methods of use thereof
TW202015726A (en) 2018-05-30 2020-05-01 瑞士商諾華公司 Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
US11634467B2 (en) 2018-06-22 2023-04-25 Cugene Inc. Cytokine-based bioactivatable drugs and methods of uses thereof
WO2020069398A1 (en) 2018-09-27 2020-04-02 Akrevia Therapeutics Inc. Masked cytokine polypeptides
CN113195523A (en) 2018-10-03 2021-07-30 Xencor股份有限公司 IL-12 heterodimer Fc fusion proteins
MA53862A (en) * 2018-10-12 2022-01-19 Xencor Inc FC FUSION PROTEINS OF IL-15/IL-15RALPHA TARGETTING PD-1 AND USES IN COMBINATION THERAPIES INVOLVING THE SAME
PE20211279A1 (en) 2018-10-23 2021-07-19 Dragonfly Therapeutics Inc HETERODIMERIC PROTEINS FUSED WITH FC
CN109627342B (en) * 2018-12-10 2022-12-06 苏州近岸蛋白质科技股份有限公司 Protein and culture medium formula combination applied to NK cell culture and preparation method
WO2020123980A1 (en) * 2018-12-14 2020-06-18 Proviva Therapeutics (Hong Kong) Limited Il-15 compositions and methods of use thereof
WO2020132646A1 (en) * 2018-12-20 2020-06-25 Xencor, Inc. Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d antigen binding domains
EP3908314A4 (en) * 2019-01-11 2023-05-10 Memorial Sloan Kettering Cancer Center Multimerization of il-15/il-15r-alpha-fc complexes to enhance immunotherapy
CN111100210B (en) * 2019-01-30 2022-04-19 武汉九州钰民医药科技有限公司 Fc fusion protein and application thereof
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
CN113811549A (en) * 2019-02-21 2021-12-17 Xencor股份有限公司 Non-targeted and targeted IL-10 FC fusion proteins
WO2020180726A1 (en) 2019-03-01 2020-09-10 Xencor, Inc. Heterodimeric antibodies that bind enpp3 and cd3
WO2020200941A1 (en) * 2019-03-29 2020-10-08 F. Hoffmann-La Roche Ag Spr-based binding assay for the functional analysis of multivalent molecules
WO2020231855A1 (en) 2019-05-10 2020-11-19 Nant Holdings Ip, Llc Nogapendekin alfa-inbakicept for immune stimulant therapies and treatment of viral infections
JP2022532217A (en) 2019-05-14 2022-07-13 ウェアウルフ セラピューティクス， インコーポレイテッド Separation part and how to use it
JP2022533222A (en) 2019-05-20 2022-07-21 サイチューン ファーマ IL-2 / IL-15Rβγ agonist dosing regimen for treating cancer or infectious diseases
JP2022536898A (en) * 2019-06-12 2022-08-22 アスクジーン・ファーマ・インコーポレイテッド NOVEL IL-15 PRODRUGS AND METHODS OF USE THEREOF
AU2019456283B2 (en) 2019-07-08 2023-06-08 Immunitybio, Inc. Mononuclear cell derived NK cells
US11453862B2 (en) 2019-07-08 2022-09-27 Immunitybio, Inc. Mononuclear cell derived NK cells
CA3146341A1 (en) 2019-07-30 2021-02-04 Aaron L. Kurtzman Bispecific anti lrrc15 and cd3epsilun antibudies
EP4019536A4 (en) * 2019-08-19 2023-09-06 Nantong Yichen Biopharma. Co. Ltd. Immunocytokine, preparation for same, and uses thereof
CN116574183A (en) * 2019-08-22 2023-08-11 盛禾(中国)生物制药有限公司 Multifunctional antibodies, their preparation and use
CN112409484B (en) * 2019-08-22 2023-03-21 盛禾(中国)生物制药有限公司 Multifunctional antibodies, their preparation and uses
US20220348651A1 (en) 2019-09-18 2022-11-03 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
RU2753282C2 (en) * 2019-09-19 2021-08-12 Закрытое Акционерное Общество "Биокад" IMMUNOCYTOKIN INCLUDING A HETERODIMERIC PROTEIN COMPLEX BASED ON ОСНОВЕ IL-15/IL-15Rα AND ITS APPLICATION
US20210130495A1 (en) * 2019-09-27 2021-05-06 Agenus Inc. Heterodimeric proteins
US11851466B2 (en) * 2019-10-03 2023-12-26 Xencor, Inc. Targeted IL-12 heterodimeric Fc-fusion proteins
TW202128757A (en) 2019-10-11 2021-08-01 美商建南德克公司 Pd-1 targeted il-15/il-15ralpha fc fusion proteins with improved properties
WO2021092719A1 (en) * 2019-11-11 2021-05-20 王盛典 Fusion protein that targets antigen-specific t cells to induce differentiation thereof into memory stem cells
CN111690068B (en) * 2019-11-13 2022-04-19 中国科学技术大学 IL-15/SuIL-15R alpha-dFc-gamma 4 complex protein and construction method and application thereof
CN111690069B (en) * 2019-11-13 2022-04-19 中国科学技术大学 IL-15/SuIL-15R alpha-mFc-gamma 4 complex protein and construction method and application thereof
US11692020B2 (en) 2019-11-20 2023-07-04 Anwita Biosciences, Inc. Cytokine fusion proteins, and their pharmaceutical compositions and therapeutic applications
CA3164337A1 (en) * 2019-12-13 2021-06-17 Cugene Inc. Novel interleukin-15 (il-15) fusion proteins and uses thereof
TW202136318A (en) 2020-01-28 2021-10-01 美商建南德克公司 Il15/il15r alpha heterodimeric fc-fusion proteins for the treatment of cancer
CN113321738A (en) * 2020-02-27 2021-08-31 启愈生物技术(上海)有限公司 Tumor-targeting, anti-CD 3 and T cell activation tri-functional fusion protein and application thereof
EP4119571A4 (en) * 2020-03-12 2024-04-03 Sl Metagen Novel bispecific protein and use thereof
BR112022020440A2 (en) 2020-04-10 2022-12-27 Cytomx Therapeutics Inc ACTIVATIVE CYTOKINE CONSTRUCTS AND RELATED COMPOSITIONS AND METHODS
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
US20230192797A1 (en) * 2020-05-18 2023-06-22 Jiangsu Simcere Pharmaceutical Co., Ltd. Human il-15 mutant and uses thereof
MX2023001440A (en) * 2020-08-07 2023-03-06 Genentech Inc Flt3 ligand fusion proteins and methods of use.
US11919958B2 (en) 2020-08-19 2024-03-05 Xencor, Inc. Anti-CD28 compositions
WO2022048563A1 (en) * 2020-09-01 2022-03-10 Wuxi Biologics (Shanghai) Co. Ltd. Long-acting il-15 and uses thereof
CN112898436A (en) * 2020-10-23 2021-06-04 广州医科大学附属肿瘤医院 Expression of mouse PD1 and mouse IL-15 gene fusion protein with targeting function and application thereof
JP2023550685A (en) 2020-10-26 2023-12-05 サイチューン ファーマ IL-2/IL-15Rβγ agonist for treating squamous cell carcinoma
EP4232068A1 (en) 2020-10-26 2023-08-30 Cytune Pharma IL-2/IL-15RBetaGamma AGONIST FOR TREATING NON-MELANOMA SKIN CANCER
CN114437228B (en) * 2020-10-30 2024-02-06 中国科学院生物物理研究所 Double-function fusion protein composed of IL-2 and antibody subunit
US11459372B2 (en) 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
EP4271798A1 (en) 2020-12-30 2023-11-08 CRISPR Therapeutics AG Compositions and methods for differentiating stem cells into nk cells
CN114712494A (en) * 2021-01-06 2022-07-08 盛禾(中国)生物制药有限公司 Composition of multifunctional antibody targeting PD-1
CN114712495A (en) * 2021-01-06 2022-07-08 盛禾(中国)生物制药有限公司 Multifunctional antibody composition
WO2022192403A1 (en) 2021-03-09 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
KR20230154311A (en) 2021-03-10 2023-11-07 젠코어 인코포레이티드 Heterodimeric antibodies binding to CD3 and GPC3
TW202304958A (en) 2021-03-16 2023-02-01 美商Ｃｙｔｏｍｘ生物製藥公司 Masked activatable cytokine constructs and related compositions and methods
WO2022232321A1 (en) * 2021-04-28 2022-11-03 Minotaur Therapeutics, Inc. Humanized chimeric bovine antibodies and methods of use
CN116655771A (en) * 2021-05-28 2023-08-29 苏州复融生物技术有限公司 Development and application of novel interleukin 15 mutant polypeptide
CA3220418A1 (en) 2021-06-23 2022-12-29 Guy Luc Michel De Martynoff Interleukin 15 variants
CA3221886A1 (en) * 2021-06-23 2022-12-29 Cytune Pharma Interleukin-15 based immunocytokines
IL310372A (en) 2021-07-28 2024-03-01 Genentech Inc Il15/il15r alpha heterodimeric fc-fusion proteins for the treatment of blood cancers
WO2023015198A1 (en) 2021-08-04 2023-02-09 Genentech, Inc. Il15/il15r alpha heterodimeric fc-fusion proteins for the expansion of nk cells in the treatment of solid tumours
AU2022325498A1 (en) 2021-08-13 2024-02-01 Cytune Pharma Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer
KR20230044131A (en) * 2021-09-24 2023-04-03 바이오엔시스템스 주식회사 Fusion protein dimer comprising pd-1 and il-15 and use thereof
KR102595699B1 (en) 2021-11-03 2023-10-31 주식회사 드론위더스 Drone shelter
US20230151095A1 (en) 2021-11-12 2023-05-18 Xencor, Inc. Bispecific antibodies that bind to b7h3 and nkg2d
WO2023088354A1 (en) * 2021-11-18 2023-05-25 江苏先声药业有限公司 Il-15 mutant fusion protein pharmaceutical composition
US20240025968A1 (en) 2022-04-07 2024-01-25 Xencor, Inc. LAG-3 TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND LAG-3 ANTIGEN BINDING DOMAINS
WO2023222886A1 (en) 2022-05-20 2023-11-23 Depth Charge Ltd Antibody-cytokine fusion proteins
WO2024011179A1 (en) 2022-07-07 2024-01-11 Genentech, Inc. Combinations of il15/il15r alpha heterodimeric fc-fusion proteins and fcrh5xcd3 bispecific antibodies for the treatment of blood cancers
KR20240008802A (en) * 2022-07-11 2024-01-19 주식회사 지뉴브 Cytokine fusion protein
US20240076353A1 (en) * 2022-08-31 2024-03-07 Suzhou Forlong Biotechnology Co., Ltd. Agonistic Interleiukin 15 Complexes and Uses Thereof
CN116178546A (en) * 2022-10-13 2023-05-30 深圳市百士通科技开发有限公司 Multifunctional recombinant antibody and preparation method and application thereof
CN116162171A (en) * 2022-10-13 2023-05-26 深圳市百士通科技开发有限公司 Use of antibody mutation methods in therapeutic antibody drugs

Family Cites Families (385)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CU22545A1 (en) 1994-11-18 1999-03-31 Centro Inmunologia Molecular OBTAINING A CHEMICAL AND HUMANIZED ANTIBODY AGAINST THE RECEPTOR OF THE EPIDERMAL GROWTH FACTOR FOR DIAGNOSTIC AND THERAPEUTIC USE
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4169888A (en) 1977-10-17 1979-10-02 The Upjohn Company Composition of matter and process
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS6023084B2 (en) 1979-07-11 1985-06-05 味の素株式会社 blood substitute
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
US4364935A (en) 1979-12-04 1982-12-21 Ortho Pharmaceutical Corporation Monoclonal antibody to a human prothymocyte antigen and methods of preparing same
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
EP0272253A4 (en) 1986-03-07 1990-02-05 Massachusetts Inst Technology Method for enhancing glycoprotein stability.
WO1987006265A1 (en) 1986-04-17 1987-10-22 Kyowa Hakko Kogyo Co., Ltd. Novel compounds dc-88a and dc-89a1 and process for their preparation
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
JP3040121B2 (en) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド Methods of treating tumor cells by inhibiting growth factor receptor function
FI102355B1 (en) 1988-02-11 1998-11-30 Bristol Myers Squibb Co A method for preparing anthracycline immunoconjugates having a linking spacer
US5084468A (en) 1988-08-11 1992-01-28 Kyowa Hakko Kogyo Co., Ltd. Dc-88a derivatives
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP2598116B2 (en) 1988-12-28 1997-04-09 協和醗酵工業株式会社 New substance DC113
US5187186A (en) 1989-07-03 1993-02-16 Kyowa Hakko Kogyo Co., Ltd. Pyrroloindole derivatives
JP2510335B2 (en) 1989-07-03 1996-06-26 協和醗酵工業株式会社 DC-88A derivative
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
JPH05507080A (en) 1990-05-03 1993-10-14 スクリップス　クリニック　アンド　リサーチ　ファウンデーション Intermediates for the formation of calicheamycin and esperamycin oligosaccharides
US5968509A (en) 1990-10-05 1999-10-19 Btp International Limited Antibodies with binding affinity for the CD3 antigen
CZ282603B6 (en) 1991-03-06 1997-08-13 Merck Patent Gesellschaft Mit Beschränkter Haftun G Humanized and chimeric monoclonal antibody, expression vector and pharmaceutical preparation
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
LU91067I2 (en) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab and its variants and immunochemical derivatives including immotoxins
US5264586A (en) 1991-07-17 1993-11-23 The Scripps Research Institute Analogs of calicheamicin gamma1I, method of making and using the same
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
ES2149768T3 (en) 1992-03-25 2000-11-16 Immunogen Inc CONJUGATES OF BINDING AGENTS OF CELLS DERIVED FROM CC-1065.
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
US6329507B1 (en) 1992-08-21 2001-12-11 The Dow Chemical Company Dimer and multimer forms of single chain polypeptides
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
AU690528B2 (en) 1992-12-04 1998-04-30 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
DE69327229T2 (en) 1992-12-11 2000-03-30 Dow Chemical Co Multivalent single chain antibodies
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5767237A (en) 1993-10-01 1998-06-16 Teikoku Hormone Mfg. Co., Ltd. Peptide derivatives
GB9401182D0 (en) 1994-01-21 1994-03-16 Inst Of Cancer The Research Antibodies to EGF receptor and their antitumour effect
ATE271557T1 (en) 1994-04-22 2004-08-15 Kyowa Hakko Kogyo Kk DC-89 DERIVATIVE
JPH07309761A (en) 1994-05-20 1995-11-28 Kyowa Hakko Kogyo Co Ltd Method for stabilizing duocamycin derivative
US5945311A (en) 1994-06-03 1999-08-31 GSF--Forschungszentrumfur Umweltund Gesundheit Method for producing heterologous bi-specific antibodies
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5550246A (en) 1994-09-07 1996-08-27 The Scripps Research Institute Calicheamicin mimics
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
JPH11507535A (en) 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド Antibodies and antibody fragments that suppress tumor growth
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US7696338B2 (en) 1995-10-30 2010-04-13 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin fusion proteins and means for expression thereof
EP0871490B1 (en) 1995-12-22 2003-03-19 Bristol-Myers Squibb Company Branched hydrazone linkers
WO1997041232A1 (en) 1996-04-26 1997-11-06 Beth Israel Deaconess Medical Center Antagonists of interleukin-15
US6451308B1 (en) 1996-04-26 2002-09-17 Beth Israel Deaconess Medical Center Antagonists of interleukin-15
WO1998048032A2 (en) 1997-04-21 1998-10-29 Donlar Corporation POLY-(α-L-ASPARTIC ACID), POLY-(α-L-GLUTAMIC ACID) AND COPOLYMERS OF L-ASP AND L-GLU, METHOD FOR THEIR PRODUCTION AND THEIR USE
JP4213224B2 (en) 1997-05-02 2009-01-21 ジェネンテック，インコーポレーテッド Method for producing multispecific antibody having heteromultimer and common component
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
ATE283364T1 (en) 1998-01-23 2004-12-15 Vlaams Interuniv Inst Biotech MULTIPURPOSE ANTIBODIES DERIVATIVES
ES2340112T3 (en) 1998-04-20 2010-05-28 Glycart Biotechnology Ag ANTIBODY GLICOSILATION ENGINEERING FOR THE IMPROVEMENT OF DEPENDENT CELLULAR CYTOTOXICITY OF ANTIBODIES.
EP1071752B1 (en) 1998-04-21 2003-07-09 Micromet AG CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF
US6455677B1 (en) 1998-04-30 2002-09-24 Boehringer Ingelheim International Gmbh FAPα-specific antibody with improved producibility
US7074405B1 (en) 1998-06-22 2006-07-11 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
GB9815909D0 (en) 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6723538B2 (en) 1999-03-11 2004-04-20 Micromet Ag Bispecific antibody and chemokine receptor constructs
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US6939545B2 (en) 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
ATE316982T1 (en) 1999-08-09 2006-02-15 Lexigen Pharm Corp MULTIPLE CYTOKINE ANTIBODIES COMPLEXES
CA2385528C (en) 1999-10-01 2013-12-10 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US7303749B1 (en) 1999-10-01 2007-12-04 Immunogen Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
JP4668498B2 (en) 1999-10-19 2011-04-13 協和発酵キリン株式会社 Method for producing polypeptide
US6716410B1 (en) 1999-10-26 2004-04-06 The Regents Of The University Of California Reagents and methods for diagnosing, imaging and treating atherosclerotic disease
US7129332B2 (en) 2000-02-25 2006-10-31 The United States Of America As Represented By The Department Of Health And Human Services Anti-EGFRvIII scFvs with improved cytotoxicity and yield, immunotoxins based thereon, and methods of use thereof
US7449443B2 (en) 2000-03-23 2008-11-11 California Institute Of Technology Method for stabilization of proteins using non-natural amino acids
US20010035606A1 (en) 2000-03-28 2001-11-01 Schoen Alan H. Set of blocks for packing a cube
EP1278778A2 (en) 2000-05-03 2003-01-29 Amgen Inc., Modified peptides, comprising an fc domain, as therapeutic agents
AU2001258567A1 (en) 2000-05-19 2001-11-26 Scancell Limited Humanised antibodies to the epidermal growth factor receptor
JP2004511430A (en) 2000-05-24 2004-04-15 イムクローン　システムズ　インコーポレイティド Bispecific immunoglobulin-like antigen binding protein and production method
US6586207B2 (en) 2000-05-26 2003-07-01 California Institute Of Technology Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues
AU2001283496A1 (en) 2000-07-25 2002-02-05 Immunomedics, Inc. Multivalent target binding protein
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
DE10043437A1 (en) 2000-09-04 2002-03-28 Horst Lindhofer Use of trifunctional bispecific and trispecific antibodies for the treatment of malignant ascites
PL218428B1 (en) 2000-10-06 2014-12-31 Kyowa Hakko Kogyo Kk Cells producing antibody compositions
AU2001294175A1 (en) 2000-10-06 2002-04-22 Kyowa Hakko Kogyo Co. Ltd. Method of purifying antibody
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
AU2002251913A1 (en) 2001-02-02 2002-08-19 Millennium Pharmaceuticals, Inc. Hybrid antibodies and uses thereof
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
CA2442801A1 (en) 2001-04-02 2002-10-10 Idec Pharmaceutical Corporation Recombinant antibodies coexpressed with gntiii
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
CN1463270A (en) 2001-05-31 2003-12-24 梅达莱克斯公司 Disulfide prodrugs and linkers and stablizers useful therefore
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
CN100497389C (en) 2001-06-13 2009-06-10 根马布股份公司 Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
CA2452058A1 (en) 2001-06-26 2003-01-09 Imclone Systems Incorporated Bispecific antibodies that bind to vegf receptors
WO2003035835A2 (en) 2001-10-25 2003-05-01 Genentech, Inc. Glycoprotein compositions
WO2003073238A2 (en) 2002-02-27 2003-09-04 California Institute Of Technology Computational method for designing enzymes for incorporation of amino acid analogs into proteins
US20080219974A1 (en) 2002-03-01 2008-09-11 Bernett Matthew J Optimized antibodies that target hm1.24
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US7332580B2 (en) 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
NZ554740A (en) 2002-05-24 2009-01-31 Schering Corp Neutralizing human anti-IGFR antibody
ES2544527T3 (en) 2002-07-31 2015-09-01 Seattle Genetics, Inc. Drug conjugates and their use to treat cancer, an autoimmune disease or an infectious disease
US8946387B2 (en) 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US20060235208A1 (en) 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
US7820166B2 (en) 2002-10-11 2010-10-26 Micromet Ag Potent T cell modulating molecules
AU2003282624A1 (en) 2002-11-14 2004-06-03 Syntarga B.V. Prodrugs built as multiple self-elimination-release spacers
UA90082C2 (en) 2002-11-15 2010-04-12 Дженмаб А/С Isolated monoclonal antibody which binds to and inhibits human cd25
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US7610156B2 (en) 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
CN101186613B (en) 2003-05-20 2014-09-17 伊缪诺金公司 Cytotoxic agents comprising new maytansinoids
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
AU2004242846A1 (en) 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders
NZ543202A (en) 2003-05-31 2008-04-30 Micromet Ag Pharmaceutical composition comprising a bispecific antibody for epcam
US7888134B2 (en) 2003-06-05 2011-02-15 Oakland University Immunosensors: scFv-linker design for surface immobilization
ES2356154T3 (en) 2003-07-21 2011-04-05 Transgene S.A. MULTIFUNCTIONAL CYTOKINS.
US20150071948A1 (en) 2003-09-26 2015-03-12 Gregory Alan Lazar Novel immunoglobulin variants
US20060134105A1 (en) 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
ES2831379T3 (en) 2003-10-09 2021-06-08 Ambrx Inc Polymeric derivatives for selective protein modification
US20050176028A1 (en) 2003-10-16 2005-08-11 Robert Hofmeister Deimmunized binding molecules to CD3
ZA200603619B (en) 2003-11-06 2008-10-29 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
EP1701979A2 (en) 2003-12-03 2006-09-20 Xencor, Inc. Optimized antibodies that target the epidermal growth factor receptor
WO2005056759A2 (en) 2003-12-04 2005-06-23 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
PT1718677E (en) 2003-12-19 2012-07-18 Genentech Inc Monovalent antibody fragments useful as therapeutics
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
US8778880B2 (en) 2004-02-02 2014-07-15 Ambrx, Inc. Human growth hormone modified at position 35
ES2367027T3 (en) 2004-02-27 2011-10-27 Inserm (Institut National De La Santé Et De La Recherche Medicale) IL-15 BINDING SITE FOR IL-15RALFA AND SPECIFIC IL-15 MUTANTS THAT HAVE AGONIST / ANTAGONIST ACTIVITY.
AU2005227326B2 (en) 2004-03-24 2009-12-03 Xencor, Inc. Immunoglobulin variants outside the Fc region
NZ550934A (en) 2004-05-19 2010-05-28 Medarex Inc Chemical linkers and conjugates thereof
US7691962B2 (en) 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
EP1753783B1 (en) 2004-06-03 2014-08-06 Novimmune SA Anti-cd3 antibodies and methods of use thereof
WO2006004910A2 (en) 2004-06-28 2006-01-12 Transtarget Inc. Improved bispecific antibodies
WO2006020258A2 (en) 2004-07-17 2006-02-23 Imclone Systems Incorporated Novel tetravalent bispecific antibody
ZA200701783B (en) 2004-09-02 2009-10-28 Genentech Inc Anti-Fc-gamma RIIB receptor antibody and uses therefor
CU23472A1 (en) 2004-09-17 2009-12-17 Ct Ingenieria Genetica Biotech ANTAGONIST PEPTIDE OF INTERLEUCINE-15
NZ580115A (en) 2004-09-23 2010-10-29 Genentech Inc Cysteine engineered antibody light chains and conjugates
AU2005289685B2 (en) 2004-09-24 2009-07-16 Amgen Inc. Modified Fc molecules
US7632497B2 (en) 2004-11-10 2009-12-15 Macrogenics, Inc. Engineering Fc Antibody regions to confer effector function
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8066989B2 (en) 2004-11-30 2011-11-29 Trion Pharma Gmbh Method of treating tumor growth and metastasis by using trifunctional antibodies to reduce the risk for GvHD in allogeneic antitumor cell therapy
WO2006063974A2 (en) 2004-12-13 2006-06-22 Cytos Biotechnology Ag Il-15 antigen arrays and uses thereof
DE602006005200D1 (en) 2005-01-05 2009-04-02 F Star Biotech Forsch & Entw Synthetic immunoglobulin domains with modified binding properties in regions of the molecule other than the complementarity determining regions
JP4986633B2 (en) 2005-01-12 2012-07-25 協和発酵キリン株式会社 Stabilized human IgG2 and IgG3 antibodies
ES2592271T3 (en) 2005-03-31 2016-11-29 Chugai Seiyaku Kabushiki Kaisha Polypeptide production methods by regulating the association of polypeptides
US7714016B2 (en) 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
US20060257361A1 (en) 2005-04-12 2006-11-16 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services Novel form of interleukin-15, Fc-IL-15, and methods of use
US9284375B2 (en) 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
EP3805245A1 (en) 2005-05-17 2021-04-14 University of Connecticut Compositions and methods for immunomodulation in an organism
EP1907592B1 (en) 2005-07-01 2011-03-09 Dako Denmark A/S Monomeric and polymeric linkers useful for conjugating biological molecules and other substances
US8309690B2 (en) 2005-07-01 2012-11-13 Medimmune, Llc Integrated approach for generating multidomain protein therapeutics
AU2006272597A1 (en) 2005-07-25 2007-02-01 Emergent Product Development Seattle Llc Single dose use of CD20-specific binding molecules
PL1912675T3 (en) 2005-07-25 2014-10-31 Emergent Product Dev Seattle B-cell reduction using cd37-specific and cd20-specific binding molecules
JP2009509918A (en) 2005-08-05 2009-03-12 シンタルガ・ビーブイ Triazole-containing releasable linkers, their conjugates, and production methods
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20100209437A1 (en) 2005-09-12 2010-08-19 Greg Elson Anti-CD3 Antibody Fromulations
CA2624189A1 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
ES2616316T3 (en) 2005-10-11 2017-06-12 Amgen Research (Munich) Gmbh Compositions comprising specific antibodies for different species and uses thereof
KR20080073293A (en) 2005-10-14 2008-08-08 메디뮨 엘엘씨 Cell display of antibody libraries
WO2007047829A2 (en) 2005-10-19 2007-04-26 Laboratoires Serono S.A. Novel heterodimeric proteins and uses thereof
EP1777294A1 (en) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
TW200732350A (en) 2005-10-21 2007-09-01 Amgen Inc Methods for generating monovalent IgG
WO2007059404A2 (en) 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
US7820165B2 (en) 2005-11-21 2010-10-26 Merck Serono, S.A. Compositions and methods of producing hybrid antigen binding molecules and uses thereof
JP2009521474A (en) 2005-12-21 2009-06-04 メディミューン，エルエルシー EphA2BiTE molecules and uses thereof
NZ596494A (en) * 2006-01-13 2013-07-26 Us Gov Nat Inst Health Codon optimized il-15 and il-15r-alpha genes for expression in mammalian cells
US8940784B2 (en) 2006-02-02 2015-01-27 Syntarga B.V. Water-soluble CC-1065 analogs and their conjugates
EP1820513A1 (en) 2006-02-15 2007-08-22 Trion Pharma Gmbh Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies
EP1829895A1 (en) 2006-03-03 2007-09-05 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies
GEP20135917B (en) 2006-03-17 2013-09-10 Biogen Idec Inc Stabilized polypeptide compositions
ES2395969T3 (en) 2006-03-24 2013-02-18 Merck Patent Gmbh Genetically modified heterodimeric protein domains
WO2007114325A1 (en) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
EP4001409A1 (en) 2006-03-31 2022-05-25 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
WO2007113648A2 (en) 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
EA200802289A1 (en) 2006-05-08 2009-04-28 Филоджен Спа DIRECTED TO TARGET WITH ANTIBODIES OF CYTOKINES FOR THERAPY
JP2009541275A (en) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス Production of bispecific antibodies
AT503861B1 (en) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw METHOD FOR MANIPULATING T-CELL RECEPTORS
AT503902B1 (en) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw METHOD FOR MANIPULATING IMMUNE LOBULINS
AT503889B1 (en) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F MULTIVALENT IMMUNE LOBULINE
WO2008042754A2 (en) 2006-10-02 2008-04-10 Sea Lane Biotechnologies, Llc Design and construction of diverse synthetic peptide and polypeptide libraries
CA2680237C (en) 2007-03-27 2018-11-06 Sea Lane Biotechnologies, Llc Constructs and libraries comprising antibody surrogate light chain sequences
EP1975178A1 (en) 2007-03-30 2008-10-01 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Transcytotic modular antibody
PT2520590T (en) 2007-04-03 2018-11-14 Amgen Res Munich Gmbh Cross-species-specific binding domain
WO2008119566A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific bispecific binders
WO2008124858A2 (en) 2007-04-11 2008-10-23 F-Star Biotechnologische Forschungs- Und Entwicklungsges. M.B.H. Targeted receptor
US8629245B2 (en) 2007-05-01 2014-01-14 Research Development Foundation Immunoglobulin Fc libraries
DK2160401T3 (en) 2007-05-11 2014-10-20 Altor Bioscience Corp Fusion Molecules and IL-15 Variants
NZ581395A (en) 2007-05-14 2012-08-31 Biogen Idec Inc Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
DK2176298T3 (en) 2007-05-30 2018-02-12 Xencor Inc Methods and compositions for inhibiting CD32B-expressing cells
US20100267934A1 (en) 2007-05-31 2010-10-21 Genmab A/S Stable igg4 antibodies
CA2691322A1 (en) 2007-06-12 2008-12-24 Wyeth Anti-cd20 therapeutic compositions and methods
CN101802006B (en) 2007-06-26 2013-08-14 F-星生物技术研究与开发有限公司 Display of binding agents
EP2724727A1 (en) 2007-06-27 2014-04-30 The United States of America, as Represented by The Secretary, Department of Health and Human Services Complexes of IL-15 and IL-15R alpha and uses thereof
CA2695382A1 (en) 2007-08-01 2009-02-05 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health Of Human Services, National Institutes Of A fold-back diabody diphtheria toxin immunotoxin and methods of use
AU2007357156B2 (en) 2007-08-01 2013-01-10 Syntarga B.V. Substituted CC-1065 analogs and their conjugates
CN101842116A (en) 2007-08-28 2010-09-22 比奥根艾迪克Ma公司 Compositions that bind multiple epitopes of IGF-1R
EP2033657A1 (en) 2007-09-04 2009-03-11 Trion Pharma Gmbh Intraoperative trifunctional antibody application for prophylatic intraperitonal tumour cell dissemination
JP5963341B2 (en) 2007-09-14 2016-08-10 アムジエン・インコーポレーテツド Homogeneous antibody population
MX342551B (en) 2007-09-26 2016-10-04 Chugai Pharmaceutical Co Ltd Modified antibody constant region.
EP2195341B1 (en) 2007-09-26 2017-03-22 UCB Biopharma SPRL Dual specificity antibody fusions
CN101874042B9 (en) 2007-09-26 2019-01-01 中外制药株式会社 Method for changing isoelectric point of antibody by using amino acid substitution of CDR
EP4098661A1 (en) 2007-12-26 2022-12-07 Xencor, Inc. Fc variants with altered binding to fcrn
ES2774337T3 (en) 2008-01-07 2020-07-20 Amgen Inc Method for manufacturing heterodimeric Fc molecules of antibodies using electrostatic conduction effects
WO2009106096A1 (en) 2008-02-27 2009-09-03 Fresenius Biotech Gmbh Treatment of resistant tumors with trifunctional antibodies
WO2009126944A1 (en) 2008-04-11 2009-10-15 Trubion Pharmaceuticals, Inc. Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
WO2009129538A2 (en) 2008-04-18 2009-10-22 Xencor, Inc. Human equivalent monoclonal antibodies engineered from nonhuman variable regions
JP5624535B2 (en) 2008-05-02 2014-11-12 シアトル ジェネティクス，インコーポレーテッド Methods and compositions for preparing antibodies and antibody derivatives having low core fucosylation
RU2010153580A (en) 2008-06-03 2012-07-20 Эбботт Лэборетриз (Us) IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND THEIR APPLICATION
US9273136B2 (en) 2008-08-04 2016-03-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fully human anti-human NKG2D monoclonal antibodies
WO2010028796A1 (en) 2008-09-10 2010-03-18 F. Hoffmann-La Roche Ag Trispecific hexavalent antibodies
US20170247470A9 (en) 2008-09-17 2017-08-31 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
EP2796469B1 (en) 2008-09-17 2019-05-08 Xencor, Inc. Novel compositions and methods for treating ige-mediated disorders
MX2011003133A (en) 2008-09-26 2011-04-21 Roche Glycart Ag Bispecific anti-egfr/anti-igf-1r antibodies.
US10981998B2 (en) 2008-10-01 2021-04-20 Amgen Research (Munich) Gmbh Cross-species-specific single domain bispecific single chain antibody
PT2352763E (en) 2008-10-01 2016-06-02 Amgen Res (Munich) Gmbh Bispecific single chain antibodies with specificity for high molecular weight target antigens
NZ591134A (en) 2008-10-01 2012-08-31 Micromet Ag Cross-species-specific (human and primate) bispecific single chain antibody that binds both cd3 (epsilon) epitope and prostate specific membrane antigen (pmsa)
NZ591087A (en) 2008-10-01 2012-08-31 Micromet Ag Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody
EA032828B1 (en) 2008-10-10 2019-07-31 Аптево Рисёрч Энд Девелопмент Ллс Tcr complex immunotherapeutics
CN102317283A (en) 2008-11-03 2012-01-11 辛塔佳股份有限公司 Novel cc-1065 analogs and their conjugates
US8057507B2 (en) 2009-01-16 2011-11-15 Novate Medical Limited Vascular filter
EP2389192A4 (en) 2009-01-23 2013-01-16 Biogen Idec Inc Stabilized fc polypeptides with reduced effector function and methods of use
CA2754528A1 (en) 2009-03-06 2010-09-10 Genetech, Inc. Antibody formulation
EP2233500A1 (en) 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
AU2010230563A1 (en) 2009-04-02 2011-09-22 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain Fab fragments
EP2417159A1 (en) 2009-04-07 2012-02-15 Roche Glycart AG Bispecific anti-erbb-3/anti-c-met antibodies
BRPI1014449A2 (en) 2009-04-07 2017-06-27 Roche Glycart Ag bispecific antibodies anti-erbb-2 / anti-c-met.
US20100256340A1 (en) 2009-04-07 2010-10-07 Ulrich Brinkmann Trivalent, bispecific antibodies
EP2241576A1 (en) 2009-04-17 2010-10-20 Trion Pharma Gmbh Use of trifunctional bispecific antibodies for the treatment of tumors associated with CD133+/EpCAM+ cancer stem cells
MX2011011925A (en) 2009-05-27 2011-12-06 Hoffmann La Roche Tri- or tetraspecific antibodies.
TWI560271B (en) 2009-06-26 2016-12-01 Sealane Biotechnologies Llc Expression of surrogate light chains
CN102471378B (en) 2009-06-26 2014-04-02 瑞泽恩制药公司 Readily isolated bispecific antibodies with native immuneoglobulin format
CN102549016B (en) 2009-06-30 2015-05-06 研究发展基金会 Immunoglobulin FC polypeptides
EP2451840B1 (en) 2009-07-08 2018-12-26 Amgen Inc. Design of stable and aggregation free antibody fc molecules through ch3 domain interface engineering
EP3135294B1 (en) 2009-08-14 2020-06-03 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Use of il-15-il-15 receptor heterodimers to treat lymphopenia
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
DE102009045006A1 (en) 2009-09-25 2011-04-14 Technische Universität Dresden Anti-CD33 antibodies and their use for immuno-targeting in the treatment of CD33-associated diseases
JP2013511281A (en) 2009-11-23 2013-04-04 アムジェン インコーポレイテッド Monomeric antibody Fc
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
CA2782218C (en) 2009-11-30 2018-07-31 Janssen Biotech, Inc. Antibody fc mutants with ablated effector functions
PL2522724T3 (en) 2009-12-25 2020-07-13 Chugai Seiyaku Kabushiki Kaisha Polypeptide modification method for purifying polypeptide multimers
CN105693861A (en) 2009-12-29 2016-06-22 新兴产品开发西雅图有限公司 Heterodimer binding protein and application thereof
US20130129723A1 (en) 2009-12-29 2013-05-23 Emergent Product Development Seattle, Llc Heterodimer Binding Proteins and Uses Thereof
US20110189178A1 (en) 2010-02-04 2011-08-04 Xencor, Inc. Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions
CA2794745A1 (en) 2010-03-29 2011-10-06 Zymeworks, Inc. Antibodies with enhanced or suppressed effector function
TWI667346B (en) 2010-03-30 2019-08-01 中外製藥股份有限公司 Antibodies with modified affinity to fcrn that promote antigen clearance
AU2011244282A1 (en) 2010-04-20 2012-11-15 Genmab A/S Heterodimeric antibody Fc-containing proteins and methods for production thereof
TWI586806B (en) 2010-04-23 2017-06-11 建南德克公司 Production of heteromultimeric proteins
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
DK2580243T3 (en) 2010-06-09 2020-01-13 Genmab As ANTIBODIES AGAINST HUMAN CD38
CA2802344C (en) 2010-06-18 2023-06-13 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
EP3029066B1 (en) 2010-07-29 2019-02-20 Xencor, Inc. Antibodies with modified isoelectric points
EP2601216B1 (en) 2010-08-02 2018-01-03 MacroGenics, Inc. Covalent diabodies and uses thereof
CN103068846B9 (en) 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 Bispecific antibodies comprising disulfide-stabilized Fv fragments
WO2012032080A1 (en) 2010-09-07 2012-03-15 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H Stabilised human fc
EP2918607B1 (en) 2010-09-21 2017-11-08 Altor BioScience Corporation Multimeric il-15 soluble fusion molecules and methods of making and using same
AU2011325833C1 (en) 2010-11-05 2017-07-13 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
HUE032782T2 (en) 2010-11-10 2017-10-30 Amgen Res (Munich) Gmbh Prevention of adverse effects caused by cd3 specific binding domains
LT3489255T (en) 2011-02-10 2021-08-25 Roche Glycart Ag Mutant interleukin-2 polypeptides
EP2681245B1 (en) 2011-03-03 2018-05-09 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
AU2012229251A1 (en) 2011-03-11 2013-09-12 Amgen Inc. Method of correlated mutational analysis to improve therapeutic antibodies
US20140112926A1 (en) 2011-03-16 2014-04-24 Amgen Inc. Fc VARIANTS
NZ608724A (en) 2011-03-25 2015-12-24 Glenmark Pharmaceuticals Sa Hetero-dimeric immunoglobulins
TWI743461B (en) 2011-03-28 2021-10-21 法商賽諾菲公司 Dual variable region antibody-like binding proteins having cross-over binding region orientation
MX354359B (en) 2011-03-29 2018-02-28 Roche Glycart Ag Antibody fc variants.
EP3753572A1 (en) 2011-04-28 2020-12-23 Amgen Research (Munich) GmbH Dosage regimen for administering a cd19xcd3 bispecific antibody to patients at risk for potential adverse effects
EA201892619A1 (en) 2011-04-29 2019-04-30 Роше Гликарт Аг IMMUNOCONJUGATES CONTAINING INTERLEUKIN-2 MUTANT POLYPETIPS
EP2714733B1 (en) 2011-05-21 2019-01-23 MacroGenics, Inc. Cd3-binding molecules capable of binding to human and non-human cd3
CA2834589A1 (en) 2011-05-25 2012-11-29 Merck Sharp & Dohme Corp. Method for preparing fc-containing polypeptides having improved properties
EP2537933A1 (en) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
RU2641256C2 (en) 2011-06-30 2018-01-16 Чугаи Сейяку Кабусики Кайся Heterodimerizated polypeptide
WO2013006544A1 (en) 2011-07-06 2013-01-10 Medimmune, Llc Methods for making multimeric polypeptides
EP2736928B1 (en) 2011-07-28 2019-01-09 i2 Pharmaceuticals, Inc. Sur-binding proteins against erbb3
WO2013022855A1 (en) 2011-08-05 2013-02-14 Xencor, Inc. Antibodies with modified isoelectric points and immunofiltering
UA116192C2 (en) 2011-08-23 2018-02-26 Рош Глікарт Аг Bispecific t cell activating antigen binding molecules
EP2748197A2 (en) 2011-08-26 2014-07-02 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
WO2013047748A1 (en) 2011-09-30 2013-04-04 中外製薬株式会社 Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
US20140335089A1 (en) 2011-09-30 2014-11-13 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for promoting elimination of antigens
DK2766392T3 (en) 2011-10-10 2019-10-07 Xencor Inc PROCEDURE FOR CLEANING ANTIBODIES
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
WO2013056851A2 (en) 2011-10-20 2013-04-25 Esbatech - A Novartis Company Llc Stable multiple antigen-binding antibody
CN104011207B (en) 2011-10-31 2018-09-18 中外制药株式会社 Control the antigen binding molecules of the association of heavy chain and light chain
KR102052774B1 (en) 2011-11-04 2019-12-04 자임워크스 인코포레이티드 Stable heterodimeric antibody design with mutations in the fc domain
WO2013096828A1 (en) 2011-12-22 2013-06-27 Sea Lane Biotechnologies, Llc Surrogate binding proteins
US9492562B2 (en) 2012-01-20 2016-11-15 Vib Vzw Targeted human-interferon fusion proteins
SG10201805584YA (en) 2012-02-24 2018-08-30 Chugai Pharmaceutical Co Ltd ANTIGEN-BINDING MOLECULE FOR PROMOTING DISAPPEARANCE OF ANTIGEN VIA FcγRIIB
EA035344B1 (en) 2012-04-20 2020-05-29 Мерюс Н.В. Method for producing two antibodies from a single host cell
US20150353630A1 (en) 2012-05-30 2015-12-10 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for eliminating aggregated antigens
US9499634B2 (en) 2012-06-25 2016-11-22 Zymeworks Inc. Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
US20140154253A1 (en) 2012-07-13 2014-06-05 Zymeworks Inc. Bispecific Asymmetric Heterodimers Comprising Anti-CD3 Constructs
IN2015DN01299A (en) 2012-07-23 2015-07-03 Zymeworks Inc
JOP20200236A1 (en) 2012-09-21 2017-06-16 Regeneron Pharma Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
EP2904016B1 (en) 2012-10-08 2018-11-14 Roche Glycart AG Fc-free antibodies comprising two fab-fragments and methods of use
CA2892059C (en) 2012-11-21 2023-02-14 Wuhan Yzy Biopharma Co., Ltd. Bispecific antibody
US20140377269A1 (en) 2012-12-19 2014-12-25 Adimab, Llc Multivalent antibody analogs, and methods of their preparation and use
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
CA3211863A1 (en) 2013-01-14 2014-07-17 Xencor, Inc. Novel heterodimeric proteins
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
AU2014207549B2 (en) 2013-01-15 2018-12-06 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
CN113045660B (en) 2013-03-13 2023-09-01 伊麦吉纳博公司 Antigen binding constructs to CD8
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
US10544187B2 (en) 2013-03-15 2020-01-28 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
KR102561553B1 (en) 2013-03-15 2023-07-31 젠코어 인코포레이티드 Heterodimeric proteins
CA2909576C (en) 2013-04-19 2023-07-18 Cytune Pharma Cytokine derived treatment with reduced vascular leak syndrome
WO2014209804A1 (en) 2013-06-24 2014-12-31 Biomed Valley Discoveries, Inc. Bispecific antibodies
US10202433B2 (en) 2013-06-27 2019-02-12 Inserm (Institut National De La Sante Et De La Recherche Medicale) IL-15 mutant polypeptides as IL-15 antagonists and encoding nucleic acids
EP3022088B1 (en) 2013-07-19 2019-02-06 Firefly Medical, Inc. Devices for mobility assistance and infusion management
EP4269441A3 (en) 2013-08-08 2024-01-24 Cytune Pharma Il-15 and il-15ralpha sushi domain based on modulokines
DK3030262T3 (en) 2013-08-08 2019-12-02 Cytune Pharma COMBINED PHARMACEUTICAL COMPOSITION
EP2839842A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
EP3066133A1 (en) 2013-11-04 2016-09-14 Glenmark Pharmaceuticals S.A. Production of t cell retargeting hetero-dimeric immunoglobulins
US20150210772A1 (en) 2013-12-17 2015-07-30 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
PE20210107A1 (en) 2013-12-17 2021-01-19 Genentech Inc ANTI-CD3 ANTIBODIES AND METHODS OF USE
US10519251B2 (en) 2013-12-30 2019-12-31 Epimab Biotherapeutics, Inc. Fabs-in-tandem immunoglobulin and uses thereof
CN105189562B (en) * 2014-01-08 2019-08-16 上海恒瑞医药有限公司 IL-15 heterodimeric body protein and application thereof
EP2915569A1 (en) 2014-03-03 2015-09-09 Cytune Pharma IL-15/IL-15Ralpha based conjugates purification method
TWI754319B (en) 2014-03-19 2022-02-01 美商再生元醫藥公司 Methods and antibody compositions for tumor treatment
AU2015237184B2 (en) 2014-03-28 2020-11-26 Xencor, Inc. Bispecific antibodies that bind to CD38 and CD3
EP3137105A4 (en) 2014-04-30 2017-12-27 President and Fellows of Harvard College Combination vaccine devices and methods of killing cancer cells
SG10201913680PA (en) 2014-05-29 2020-03-30 Macrogenics Inc Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
US20150351275A1 (en) 2014-05-30 2015-12-03 Johanson Manufacturing Corporation Thin-Film Radio Frequency Power Terminator
WO2015195163A1 (en) 2014-06-20 2015-12-23 R-Pharm Overseas, Inc. Pd-l1 antagonist fully human antibody
ES2899890T3 (en) 2014-06-30 2022-03-15 Altor Bioscience Corp IL-15-based molecules and methods of using the same
WO2016014984A1 (en) 2014-07-24 2016-01-28 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
JO3663B1 (en) 2014-08-19 2020-08-27 Merck Sharp & Dohme Anti-lag3 antibodies and antigen-binding fragments
MY189028A (en) 2014-08-19 2022-01-20 Novartis Ag Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
US9763705B2 (en) 2014-10-03 2017-09-19 Globus Medical, Inc. Orthopedic stabilization devices and methods for installation thereof
CN107001438A (en) 2014-10-14 2017-08-01 阿尔莫生物科技股份有限公司 Interleukin 15 composition and application thereof
BR112017008666A2 (en) 2014-11-05 2018-01-30 Genentech, Inc. anti-fgfr2 / 3 antibodies and methods of use
SI3789402T1 (en) 2014-11-20 2022-10-28 F. Hoffmann-La Roche Ag Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
CU24597B1 (en) * 2014-11-26 2022-05-11 Xencor Inc HETERODIMERIC BIESPECIFIC ANTIBODIES THAT BIND CD3 AND CD20
TN2017000222A1 (en) 2014-11-26 2018-10-19 Xencor Inc Heterodimeric antibodies that bind cd3 and cd38
US20160176969A1 (en) 2014-11-26 2016-06-23 Xencor, Inc. Heterodimeric antibodies including binding to cd8
US10905743B2 (en) 2014-12-19 2021-02-02 Jiangsu Hengrui Medicine Co., Ltd. Interleukin 15 protein complex
ES2881484T3 (en) 2014-12-22 2021-11-29 Pd 1 Acquisition Group Llc Anti-PD-1 antibodies
US10428155B2 (en) 2014-12-22 2019-10-01 Xencor, Inc. Trispecific antibodies
US10227411B2 (en) * 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
EP3064507A1 (en) 2015-03-06 2016-09-07 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof
EP4059514A1 (en) 2015-05-08 2022-09-21 Xencor, Inc. Heterodimeric antibodies that bind cd3 and tumor antigens
KR20180093127A (en) 2015-07-30 2018-08-20 마크로제닉스, 인크. PD-1-Binding Molecules and Methods of Use Thereof
JP2018532729A (en) 2015-09-25 2018-11-08 アルター・バイオサイエンス・コーポレーション Interleukin-15 superagonist significantly enhances graft versus tumor activity
EA201891428A1 (en) 2015-12-22 2018-12-28 Регенерон Фармасьютикалз, Инк. COMBINATION OF ANTIBODIES TO PD-1 AND BISPECIFIC ANTIBODIES TO CD20 / CD3 FOR THE TREATMENT OF MALIGNANT TUMOR
WO2017210443A1 (en) 2016-06-01 2017-12-07 Xencor, Inc. Bispecific antibodies that bind cd123 and cd3
US20170349657A1 (en) 2016-06-01 2017-12-07 Xencor, Inc. Bispecific antibodies that bind cd20 and cd3
EP3252078A1 (en) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
BR112018075198A2 (en) 2016-06-07 2019-03-19 Macrogenics, Inc. method for treating cancer or a pathogen-associated disease, pharmaceutical composition, and kit
WO2017218707A2 (en) 2016-06-14 2017-12-21 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
US20190256454A1 (en) 2016-07-05 2019-08-22 Novartis Ag New process for early sacubitril intermediates
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
JP7142630B2 (en) 2016-10-14 2022-09-27 ゼンコア インコーポレイテッド IL15/IL15Rα heterodimeric FC-fusion protein
KR102392142B1 (en) 2016-10-21 2022-04-28 알토 바이오사이언스 코포레이션 Mutimeric IL-15-Based Molecules
EA201991214A1 (en) 2016-11-18 2019-10-31 ANTIBODIES AGAINST PD-1 AND THEIR COMPOSITION
US11084863B2 (en) 2017-06-30 2021-08-10 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
WO2019157340A1 (en) 2018-02-08 2019-08-15 Amgen Inc. Low ph pharmaceutical antibody formulation
SG11202007518RA (en) 2018-02-28 2020-09-29 Pfizer Il-15 variants and uses thereof
TW202011984A (en) 2018-04-18 2020-04-01 美商山可爾股份有限公司 Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof
JP2021521784A (en) 2018-04-18 2021-08-30 ゼンコア インコーポレイテッド PD-1 targeted heterodimer fusion proteins containing IL-15 / IL-15RaFc fusion proteins and PD-1 antigen binding domains and their use
MA53862A (en) 2018-10-12 2022-01-19 Xencor Inc FC FUSION PROTEINS OF IL-15/IL-15RALPHA TARGETTING PD-1 AND USES IN COMBINATION THERAPIES INVOLVING THE SAME
WO2020132646A1 (en) 2018-12-20 2020-06-25 Xencor, Inc. Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d antigen binding domains
US20220135682A1 (en) 2019-03-11 2022-05-05 Jounce Therapeutics, Inc. Anti-ICOS Antibodies for the Treatment of Cancer

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021188835A1 (en) * 2020-03-18 2021-09-23 City Of Hope Multivalent chemokine receptor binding complexes
US20220227867A1 (en) * 2020-12-24 2022-07-21 Xencor, Inc. ICOS TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND ICOS ANTIGEN BINDING DOMAINS

Also Published As

Publication number Publication date
US20180118805A1 (en) 2018-05-03
PE20191034A1 (en) 2019-08-05
PH12019500782A1 (en) 2019-06-03
AU2022203782B2 (en) 2024-02-22
US20220195048A1 (en) 2022-06-23
JP7273453B2 (en) 2023-05-15
AU2022203820A1 (en) 2022-06-23
KR20190065346A (en) 2019-06-11
AU2017342560A1 (en) 2019-05-02
KR102649972B1 (en) 2024-03-22
AU2017342559B2 (en) 2022-03-24
US10501543B2 (en) 2019-12-10
JP2022180450A (en) 2022-12-06
US20200123259A1 (en) 2020-04-23
RU2019114175A (en) 2020-11-16
JP2019533444A (en) 2019-11-21
MX2019004328A (en) 2019-09-18
CO2019003945A2 (en) 2019-04-30
MX2019004327A (en) 2019-10-14
US10550185B2 (en) 2020-02-04
US20180118828A1 (en) 2018-05-03
MA46533A (en) 2019-08-21
JP7142630B2 (en) 2022-09-27
CL2022000097A1 (en) 2022-10-14
BR112019007281A2 (en) 2019-07-09
KR102562519B1 (en) 2023-08-02
PE20191033A1 (en) 2019-08-05
CR20230179A (en) 2023-06-12
IL265998A (en) 2019-06-30
KR20240038176A (en) 2024-03-22
RU2019114268A (en) 2020-11-16
SG11201903304YA (en) 2019-05-30
EP3526241A1 (en) 2019-08-21
CA3040504A1 (en) 2018-04-19
SA519401562B1 (en) 2023-02-14
ZA201902383B (en) 2020-08-26
EP3526240A1 (en) 2019-08-21
KR20190060821A (en) 2019-06-03
RU2019114268A3 (en) 2021-02-19
CL2021003547A1 (en) 2022-09-20
CL2019001000A1 (en) 2020-03-27
JP2023106405A (en) 2023-08-01
CA3039930A1 (en) 2018-04-19
AU2017342559A1 (en) 2019-05-02
ZA201902380B (en) 2020-08-26
RU2019114175A3 (en) 2021-02-19
US20230220081A1 (en) 2023-07-13
WO2018071919A1 (en) 2018-04-19
BR112019007288A2 (en) 2019-07-09
WO2018071918A1 (en) 2018-04-19
CO2019003943A2 (en) 2019-04-30
MA46534A (en) 2019-08-21
CR20190227A (en) 2019-08-29
JP2019533443A (en) 2019-11-21
CL2019001001A1 (en) 2020-03-27
CN110214148A (en) 2019-09-06
CN110214147A (en) 2019-09-06
AU2022203782A1 (en) 2022-06-23
SG11201903302UA (en) 2019-05-30
US11584794B2 (en) 2023-02-21
AU2017342560B2 (en) 2022-03-17
PH12019500781A1 (en) 2019-06-03
IL265997A (en) 2019-06-30

Similar Documents

Publication Publication Date Title
US20220195048A1 (en) IL15/IL15Ralpha HETERODIMERIC Fc-FUSION PROTEINS
JP2023159173A (en) ENGINEERED IL-2 Fc FUSION PROTEINS
US20230331813A1 (en) TIM-3 TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND TIM-3 ANTIGEN BINDING DOMAINS
US20230279071A1 (en) LAG-3 TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND LAG-3 ANTIGEN BINDING DOMAINS
US11512122B2 (en) IL-7-FC-fusion proteins
US20220227867A1 (en) ICOS TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND ICOS ANTIGEN BINDING DOMAINS
US20240025968A1 (en) LAG-3 TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND LAG-3 ANTIGEN BINDING DOMAINS
US20230146665A1 (en) Il-18-fc fusion proteins
RU2779938C2 (en) HETERODIMERIC FC-FUSED PROTEINS IL15/IL15Rα

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

AS Assignment

Owner name: XENCOR, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BERNETT, MATTHEW;RASHID, RUMANA;DESJARLAIS, JOHN;AND OTHERS;SIGNING DATES FROM 20190325 TO 20190327;REEL/FRAME:052447/0470

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION